ANNUAL REPORT
FY 2023 — Form 10-K
FY 2023PDF · 225 pages1.7 MB
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023 or
☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission file number 1-8002
THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its charter)
Delaware 04-2209186
(State of incorporation) (I.R.S. Employer Identification No.)
168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 622-1000
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $1.00 par value TMO New York Stock Exchange
0.750% Notes due 2024 TMO 24A New York Stock Exchange
0.125% Notes due 2025 TMO 25B New York Stock Exchange
2.000% Notes due 2025 TMO 25 New York Stock Exchange
3.200% Notes due 2026 TMO 26B New York Stock Exchange
1.400% Notes due 2026 TMO 26A New York Stock Exchange
1.450% Notes due 2027 TMO 27 New York Stock Exchange
1.750% Notes due 2027 TMO 27B New York Stock Exchange
0.500% Notes due 2028 TMO 28A New York Stock Exchange
1.375% Notes due 2028 TMO 28 New York Stock Exchange
1.950% Notes due 2029 TMO 29 New York Stock Exchange
0.875% Notes due 2031 TMO 31 New York Stock Exchange
2.375% Notes due 2032 TMO 32 New York Stock Exchange
3.650% Notes due 2034 TMO 34 New York Stock Exchange
2.875% Notes due 2037 TMO 37 New York Stock Exchange
1.500% Notes due 2039 TMO 39 New York Stock Exchange
1.875% Notes due 2049 TMO 49 New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§
232.405 of this chapter) during the preceding 12 months. Yes ☒ No ☐
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange
Act. Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the
correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of June 30, 2023, the aggregate market value of the voting stock held by nonaffiliates of the Registrant was approximately $201,176,616,000 (based on the last reported sale
of common stock on the New York Stock Exchange Composite Tape reporting system on June 30, 2023).
As of February 3, 2024, the Registrant had 381,312,268 shares of Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Sections of Thermo Fisher’s definitive Proxy Statement for the 2024 Annual Meeting of Shareholders (the “Proxy Statement”) are incorporated by reference into Part III of this
report.
-- 1 of 225 --
THERMO FISHER SCIENTIFIC INC.
ANNUAL REPORT ON FORM 10-K
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
TABLE OF CONTENTS
Page
PART I
Item 1. Business 3
Item 1A. Risk Factors 9
Item 1B. Unresolved Staff Comments 17
Item 1C. Cybersecurity 17
Item 2. Properties 18
Item 3. Legal Proceedings 18
Item 4. Mine Safety Disclosures 18
PART II
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 19
Item 6. Reserved 19
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations 19
Item 7A. Quantitative and Qualitative Disclosures About Market Risk 28
Item 8. Financial Statements and Supplementary Data 29
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 73
Item 9A. Controls and Procedures 73
Item 9B. Other Information 73
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 74
PART III
Item 10. Directors, Executive Officers and Corporate Governance 74
Item 11. Executive Compensation 74
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 74
Item 13. Certain Relationships and Related Transactions, and Director Independence 74
Item 14. Principal Accountant Fees and Services 74
PART IV
Item 15. Exhibits and Financial Statement Schedules 74
Item 16. Form 10-K Summary 78
2
-- 2 of 225 --
THERMO FISHER SCIENTIFIC INC.
PART I
Forward-looking Statements
Forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934 (the Exchange Act), are made throughout this Annual
Report on Form 10-K. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including
without limitation statements regarding: projections of revenues, expenses, earnings, margins, tax rates, tax provisions, cash flows, pension and benefit
obligations and funding requirements, and our liquidity position; cost reductions, restructuring activities, new product and service developments, competitive
strengths or market position, acquisitions or divestitures; growth, declines and other trends in markets we sell into; new or modified laws, regulations and
accounting pronouncements; outstanding claims, legal proceedings, tax audits and assessments and other contingent liabilities; foreign currency exchange rates
and fluctuations in those rates; general economic and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the
foregoing; the COVID-19 pandemic; and any other statements that address events or developments that Thermo Fisher intends or believes will or may occur in
the future. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to
identify forward-looking statements, although not all forward-looking statements are accompanied by such words. While the company may elect to update
forward-looking statements in the future, it specifically disclaims any obligation to do so, even if the company’s estimates change, and readers should not rely
on those forward-looking statements as representing the company’s views as of any date subsequent to the date of the filing of this report. A number of
important factors could cause the results of the company to differ materially from those indicated by such forward-looking statements, including those detailed
under the heading, “Risk Factors” in Part I, Item 1A.
Item 1. Business
Description of Business
Thermo Fisher Scientific Inc. (also referred to in this document as “Thermo Fisher,” “we,” the “company,” or the “registrant”) is the world leader in serving
science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. We serve customers working in pharmaceutical and biotech
companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial, research and
development, quality and process control settings. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and
pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab
Services, Patheon and PPD.
We continuously increase our depth of capabilities across our broad portfolio of innovative products and services and leverage our extensive global channels to
address our customers’ needs. We do this through organic investments in research and development, capacity and capabilities and through acquisitions. Our
goal is to enable our customers to be more productive in an increasingly competitive business environment, enable them to accelerate innovation, solve their
challenges and advance their important work.
Business Segments and Products
We report our business in four segments – Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma
Services.
Life Sciences Solutions Segment
Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical
research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers
in pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Life Sciences Solutions includes three primary
businesses – Biosciences, Genetic Sciences, and BioProduction.
Our biosciences business includes reagents, instruments and consumables that help our customers conduct biological and medical research in areas such as
molecular biology and protein biology, discover new drugs and vaccines, and enable the diagnosis of infection and disease. Our genetic sciences business
combines a wide variety of instruments and related reagents used to provide high-value genomic solutions to assist customer decisions in the research, clinical,
healthcare and applied markets. Our bioproduction business supports developers and manufacturers of biological-based therapeutics and vaccines with a
portfolio of premium solutions and services focused on upstream cell culture, downstream purification, analytics for detection and quantitation of
process/product impurities, and a suite of single-use solutions spanning the biologics workflow.
3
-- 3 of 225 --
THERMO FISHER SCIENTIFIC INC.
Analytical Instruments Segment
Through our Analytical Instruments segment, we provide a broad offering of instruments and the supporting consumables, software and services that are used
for a range of applications. These products and services are used by customers in pharmaceutical, biotechnology, academic, government, environmental and
other research and industrial markets, as well as the clinical laboratory. This segment includes three primary businesses – Chromatography and Mass
Spectrometry, Chemical Analysis, and Electron Microscopy.
Our chromatography and mass spectrometry business develops and provides analytical instrumentation for organic and inorganic sample analysis across both
applied technologies and scientific research. Our chemical analysis products fall into three main categories: production, process and analytics; field and safety
instruments; and environmental and process instruments. Our electron microscopy business serves customers in the life sciences, materials sciences, and
semiconductor markets providing leading research tools; and also, in the semiconductor market provides integrated workflows that power research
development and production solutions.
Specialty Diagnostics Segment
Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers
in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of
diagnoses, which improves patient care in a more cost-efficient manner. This segment has five primary businesses – Clinical Diagnostics, ImmunoDiagnostics,
Microbiology, Transplant Diagnostics and our Healthcare Market Channel.
Our clinical diagnostics products include a broad offering of liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein
detection assays, and instruments. Such products are used for, among other things, drugs-of-abuse testing, therapeutic drug monitoring, thyroid hormone
testing, sepsis screening, serum toxicity, first trimester screening, tumor markers testing, and the diagnosis and monitoring of multiple myeloma. Our
immunodiagnostics offerings include developing, manufacturing and marketing complete blood-test systems to support the clinical diagnosis and monitoring of
allergy, asthma and autoimmune diseases. Our microbiology offerings include dehydrated and prepared culture media, collection and transport systems,
instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products and associated products for
the microbiology laboratory. Our transplant diagnostics products include human leukocyte antigen typing and testing for the organ transplant market. Our
healthcare market channel offerings include a broad array of consumables, diagnostic kits and reagents, equipment, instruments, solutions and services for
hospitals, clinical laboratories, reference laboratories, physicians’ offices and other clinical testing facilities.
Laboratory Products and Biopharma Services Segment
Our Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Our unique combination of self-manufactured
and sourced products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive
and cost-efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug
development, clinical research, clinical trials services and commercial drug manufacturing. We serve the pharmaceutical, biotechnology, academic, government
and other research and industrial markets, as well as the clinical laboratory market through four key businesses: Laboratory Products, Research and Safety
Market Channel, Pharma Services and Clinical Research.
Our laboratory products include lab consumables, equipment and chemicals that are used for life science research and drug discovery and development to
advance the prevention and cure of diseases and enhance quality of life. Our research and safety market channel offers a mix of products that are manufactured
by Thermo Fisher, by third parties for us on a private-label basis, and by third parties under their brands but offered for sale through us. Our pharma services
business provides the entire spectrum of development, manufacturing and clinical trials services for both small-molecule and large-molecule pharmaceuticals.
Our clinical research business offers comprehensive, integrated clinical development and analytical services including all phases of development (i.e., Phases I-
IV), peri- and post-approval and site and patient access services.
Sales and Marketing
We market and sell our products and services through a direct sales force, customer-service professionals, electronic commerce and third-party distributors. Our
global team delivers a combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands,
including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
We have approximately 14,000 sales personnel including highly trained technical specialists who enable us to better meet the needs of our more technical end-
users. We also provide customers with product standardization and other supply-chain-management services to reduce procurement costs.
4
-- 4 of 225 --
THERMO FISHER SCIENTIFIC INC.
New Products and Research and Development
Our business includes the development and introduction of new products and may include entry into new business segments. We anticipate that we will
continue to make significant expenditures for research and development as we seek to provide a continuing flow of innovative products to maintain and
improve our competitive position.
Resources
Raw Materials
Our management team believes that we have a readily available supply of raw materials for all of our significant products from various sources. No single
supplier is material, although for reasons of quality assurance, regulatory requirements, cost effectiveness, availability or uniqueness of design, certain
materials components may be sourced from a single supplier or a limited number of suppliers that can readily provide such materials or components.
Raw material and fuel prices are subject to fluctuations due to market conditions. We employ many strategies, including the use of alternative materials, to
mitigate the effect of these fluctuations on our results.
Patents, Licenses and Trademarks
Patents are important in many aspects of our business. No particular patent, or related group of patents, is so important, however, that its loss would
significantly affect our operations as a whole. Where appropriate, we seek patent protection for inventions and developments made by our personnel that are
incorporated into our products or otherwise fall within our fields of interest. Patent rights resulting from work sponsored by outside parties do not always
accrue exclusively to the company and may be limited by agreements or contracts.
We protect some of our technology as trade secrets and, where appropriate, we use trademarks or register trademarks used in connection with products. We also
enter into license agreements with others to grant and/or receive rights to intellectual property rights.
All trademarks, trade names, product names, graphics and logos of Thermo Fisher contained herein are trademarks or registered trademarks of Thermo Fisher
or its subsidiaries, as applicable, in the United States and/or other countries. Solely for convenience, we may refer to trademarks in this Annual Report on Form
10-K without the ™ and ® symbols. Such references are not intended to indicate, in any way, that we will not assert, to the fullest extent permitted by law, our
rights to our trademarks. To the extent other trademarks appear in this Annual Report on Form 10-K, they are the property of their respective owners.
Seasonal Influences
Revenues in the fourth quarter are historically stronger than in other quarters due to the capital spending patterns of industrial, pharmaceutical and government
customers. Sales of seasonal products, such as allergy and flu tests and related diagnostic products, vary quarter to quarter and year to year.
Competition
The company encounters aggressive and able competition in virtually all of the markets we serve. Because of the diversity of our products and services, we
face many different types of competitors and competition. Our competitors include a broad range of manufacturers, third-party distributors and service
providers. Competitive climates in many of the markets we serve are characterized by changing technology and customer demands that require continuing
research and development. Our success primarily depends on the following factors:
• technical performance and advances in technology that result in new products and improved price/performance ratios;
• product differentiation, availability and reliability;
• the depth of our capabilities;
• our reputation among customers as a quality provider of products and services;
• customer service and support;
• active research and application-development programs; and
• relative prices of our products and services.
5
-- 5 of 225 --
THERMO FISHER SCIENTIFIC INC.
Government Regulation
Environmental Regulations
We are subject to various laws and governmental regulations concerning environmental matters and employee safety and health in the United States and other
countries. U.S. federal environmental legislation that affects us includes the Toxic Substances Control Act, the Resource Conservation and Recovery Act, the
Clean Air Act, the Clean Water Act, the Safe Drinking Water Act, and the Comprehensive Environmental Response Compensation and Liability Act
(CERCLA). We are also subject to regulation by the Occupational Safety and Health Administration (OSHA) concerning employee safety and health matters.
The United States Environmental Protection Agency (USEPA), OSHA, and other federal agencies have the authority to promulgate regulations that have an
effect on our operations.
In addition to these federal laws and regulations, various states have been delegated certain authority under the aforementioned federal statutes and have
authority over these matters under state laws. Many state and local governments have adopted environmental and employee safety and health laws and
regulations, some of which are similar to federal requirements.
A number of our operations involve the handling, manufacturing, use or sale of substances that are or could be classified as toxic or hazardous materials within
the meaning of applicable laws. Consequently, some risk of environmental harm is inherent in our operations and products, as it is with other companies
engaged in similar businesses.
Our expenses for environmental requirements are incurred generally for ongoing compliance and historical remediation matters. Based on current information,
we believe that these compliance costs are not material. For historical remediation obligations, our expenditures relate primarily to the cost of permitting,
installing, and operating and maintaining groundwater-treatment systems and other remedial measures.
Our Fair Lawn and Somerville, New Jersey facilities entered into administrative consent orders with the New Jersey Department of Environmental Protection
in 1984 to maintain groundwater-remediation activities at these sites, and are currently under the State’s Licensed Site Remediation Professional Program. As
the owner of the Fair Lawn facility, we are listed as a potentially responsible party for remediation within an area called the Fair Lawn Wellfields Superfund
Site, and, in 2008, the company and certain other parties entered into a consent order with the USEPA to complete a Remedial Investigation/Feasibility Study.
In 2018, the USEPA issued a Record of Decision, setting forth the scope of required remediation work at the site, which includes upgrading a water treatment
plant to address constituents such as chlorinated organic compounds, 1,4-dioxane, and perfluorooctanoic acid/perfluorooctane sulfonate (PFOA/PFOS). In
2020, the court approved a consent decree that requires the company and another responsible party to finance and perform the required remediation work with
USEPA oversight. In 2023, the design of a groundwater treatment plant was fully approved by USEPA. Construction is expected to commence in 2024, and the
plant is expected to be fully operating by April 2025.
In 2011, our Life Technologies subsidiary entered into a consent decree with the USEPA and other responsible parties to implement a groundwater remedy at
the former Davis Landfill Superfund site in Smithfield, Rhode Island. After years of additional study, in September, 2020, USEPA revised its cleanup plan by
selecting an interim remedial approach that includes groundwater treatment followed by additional monitoring of site conditions. Depending on the results of
these treatment and monitoring activities over the next several years, USEPA anticipates selecting a final groundwater remedy for the site. In November 2021,
the 2011 consent decree was amended to reflect the parties’ obligations to implement USEPA’s interim remedy, for which pre-design work commenced during
2022 and is ongoing.
We record accruals for environmental liabilities based on current interpretations of environmental laws and regulations when it is probable that a liability has
been incurred and the amount of such liability can be reasonably estimated. We calculate estimates based upon several factors, including reports prepared by
environmental specialists and management’s knowledge and experience with these environmental matters. We include in these estimates potential costs for
investigation, remediation and operation and maintenance of cleanup sites. Accrued liabilities for environmental matters totaled $75 million at December 31,
2023.
These environmental liabilities do not include third-party recoveries to which we may be entitled. We believe that our accrual is adequate for the environmental
liabilities we currently expect to incur. As a result we believe that our ultimate liability with respect to environmental matters will not have a material adverse
effect on our financial position, results of operations or cash flows. However, we may be subject to remedial or compliance costs due to future events, such as
changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies, changes in the
conduct of our operations, and the effect of changes in accounting rules, which could have a material adverse effect on our financial position, results of
operations or cash flows. For a discussion of the environmental laws and regulations that the Company’s operations, products and services are subject to and
other environmental contingencies, refer to Note 12 to our Consolidated Financial Statements.
6
-- 6 of 225 --
THERMO FISHER SCIENTIFIC INC.
Other Laws and Regulations
Our operations, and some of the products and services we offer, are subject to a number of complex and stringent laws and regulations governing the
development, testing, approval, production, handling, transportation and distribution of chemicals, drugs and other similar products, including the operating
and security standards of the Food and Drug Administration, the Drug Enforcement Administration, the Bureau of Alcohol, Tobacco, Firearms and Explosives,
and various state boards of pharmacy as well as comparable state and foreign agencies. As Thermo Fisher’s businesses also include export and import
activities, we are subject to pertinent laws enforced by the U.S. Departments of Commerce, State and Treasury. In addition, our logistics activities must comply
with the rules and regulations of the Department of Transportation, the Federal Aviation Administration and similar foreign agencies. While we believe we are
in compliance in all material respects with such laws and regulations, any noncompliance could result in substantial fines or otherwise restrict our ability to
provide competitive distribution services and thereby have an adverse effect on our financial condition. To date, no such laws or regulations have had a material
impact on our operations.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government contracts
could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our products to
government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government. We are also
subject to investigation for compliance with the regulations governing government contracts. A failure to comply with these regulations could also result in
suspension of these contracts, criminal, civil and administrative penalties or debarment.
For a discussion of risks related to changes in governmental regulations, refer to “Risk Factors” in Part I, Item 1A.
Human Capital
The success of Thermo Fisher is fueled by colleagues who are highly engaged and feel empowered to achieve their goals. Everything we do starts with our
Mission – to enable our customers to make the world healthier, cleaner and safer. Our colleagues understand the role they play in fulfilling that Mission and
that inspires them to bring their best to work each day. Our Mission is not only a differentiator for us externally, but a motivator for us internally.
Our culture is rooted in our 4i Values of Integrity, Intensity, Innovation and Involvement. Within this framework, we strive to create a safe, fair and positive
working environment for our colleagues around the world. We want our teams to feel they have a stake in our success, a voice in our direction and to be
empowered to make a difference for the key stakeholders we serve.
Every year, we conduct an Employee Involvement Survey to solicit direct feedback from our colleagues on what we’re doing well and where we need to
improve. We then compile the feedback to measure our progress using three key indices: Leadership, Involvement and Inclusion. Our continued focus on
enhancing our culture helps position our company to be an even better place to work.
We are committed to maintaining the strongest team in our industry, focusing on developing and retaining our colleagues, while leveraging our leadership to
attract new colleagues to our company. As of December 31, 2023, we employed approximately 122,000 colleagues globally, with an approximate regional
distribution as follows: 61,000 based in the Americas, 20,000 in the Asia Pacific region, and nearly 41,000 in Europe, the Middle East and Africa (EMEA).
Culture of Inclusion
We recognize that the future aspirations outlined in our Vision for 2030, which serves as our long-term roadmap, will only be achievable if we have a culture
that values diversity of backgrounds, experiences and viewpoints. When differences among colleagues are welcomed and supported, we create an inclusive
workplace that unlocks the true benefits of diversity and promotes conditions for sustained success.
Diversity and Inclusion (D&I) is not an initiative at Thermo Fisher. It’s woven into the fabric of our culture, and our ways of working, embedded in every stage
of our colleague lifecycle - from recruiting to onboarding, training, development and longer-term career planning. Our colleagues are encouraged to openly
share the wide range of perspectives they represent. Progress is measured and reviewed on a range of D&I factors to help inform our efforts and initiatives,
including those related to diversity within our workforce. We understand the critical role diversity plays in sustained business success, so we strive to have a
workforce that represents the customers we serve. Further, to provide additional transparency to our U.S. workforce demographics, following our report
submission to the U.S. Equal Employment Opportunity Commission, we disclose our EEO-1 report on our website each year.
Our inclusive culture is a competitive advantage, and we prioritize colleague engagement and empowerment to contribute, collaborate and innovate. For
example, in 2023, Thermo Fisher was recognized as a Top Company for Women and Best Employer for Diversity by Forbes, a Best Place to Work for
Disability Inclusion, and a top scorer on the Human Rights
7
-- 7 of 225 --
THERMO FISHER SCIENTIFIC INC.
Campaign’s Corporate Equality Index for LGBTQ inclusion. Establishing this kind of environment is critical for our colleagues, where they can contribute
their best ideas and bring their true selves to work each day.
We are also committed to ensuring our colleagues have access to resources, awareness training and internal networks that offer support and guidance. Our D&I
strategy is greatly enabled by our Business Resource Groups (BRGs), which bring together individuals with similar interests to share experiences, learn from
each other and collaborate to identify solutions to business challenges. Our BRGs reinforce that all colleagues can make a difference for our customers, for
each other and for our company. As of December 31, 2023, we had 9 global BRGs, with more than 230 local BRG chapters.
Talent Development
Our overarching goal from a talent perspective is to create opportunities for our colleagues to achieve their full potential and career aspirations here at Thermo
Fisher. We focus on the entire lifecycle of a colleague’s career, from their initial recruitment, to onboarding, through ongoing development. We encourage and
support colleagues to enhance their skills so they are in the best position to deliver on their goals and achieve their career objectives.
In today’s environment, we know talent is a key differentiator, and that building the strongest team in the industry is critical to our future. From our colleague
referral program, summer internships, university relations, to our Graduate Leadership Development Program, we continue to build strong internal and external
sourcing channels.
Once on board, talent development at Thermo Fisher is a key organizational capability. We continue to make significant investments to support our colleagues
along every step of their career journey to help support their success. Our talent development framework incorporates a multi-faceted approach, including
formal and self-paced training, networking opportunities, on-the-job stretch learning, coaching, mentoring and manager training utilizing contemporary
technology solutions to support the broad needs of our workforce.
We provide multiple programs at all career levels, from online learning for all colleagues through Thermo Fisher University, to focused trainings for managers
at various experience levels, to our Global Leadership Program for executives. We also support our colleagues’ career advancement through our tuition
reimbursement program.
In a company our size, we can also actively manage our talent through rotational opportunities across our businesses, functions and geographies that help our
colleagues gain new experiences, share knowledge and broaden their skills. Our executives and leaders participate in frequent talent discussions as well as
formal reviews, leveraging workforce data and predictive analytics to better anticipate the talent requirements of our business based on our growth
opportunities and market demand.
Thermo Fisher is dedicated to talent development to meet our evolving business needs and to provide our colleagues with opportunities for long and fulfilling
careers. Our colleagues are passionate about our company, and their role in our success, and it’s our responsibility to help them reach their full potential.
Total Rewards
We offer a comprehensive total rewards package that we regularly evaluate and measure against established benchmarks to ensure its effectiveness in recruiting
and retention, and to position Thermo Fisher as an employer of choice.
Our health and wellness programs provide competitive, flexible programs that our global colleagues and their families can count on. For example, for U.S.
colleagues, we offer a choice of comprehensive national medical, dental and vision plans; a wellness program, including valuable health incentive opportunities
and tax-advantaged savings and spending accounts; as well as commuter benefits, employee assistance programs, optional group legal coverage, and company-
paid disability, accident and life insurance. We also offer a company-paid proprietary program for cancer care called the Impact Program, which gives our
colleagues and their families access to personalized support and direct lines of communication to experts in cancer genetics and genomics. Similar benefits are
available in all countries around the world where we operate.
We also invest in our colleagues’ financial health, helping them to grow and protect their savings, plan for the future and share in the success of the company
they are helping to build. We deliver comprehensive rewards, including competitive base pay, and also provide a variety of incentive and equity programs that,
by design, directly link the impact of colleague contributions to the company’s overall success.
Available Information
The company files annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission (SEC) under the
Exchange Act. The SEC maintains a website that contains reports, proxy and information statements and other information that issuers, including the company,
file electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov. We also make available free of charge on or
through our own website at www.thermofisher.com our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on
8
-- 8 of 225 --
THERMO FISHER SCIENTIFIC INC.
Form 8-K and, if applicable, amendments to those reports filed or furnished pursuant to Section 13(a) of the Exchange Act as soon as reasonably practicable
after we electronically file such material with, or furnish it to, the SEC. In addition, paper copies of these documents may be obtained free of charge by writing
to the company care of its Investor Relations Department at our principal executive office located at 168 Third Avenue, Waltham, Massachusetts 02451.
Information about Our Executive Officers
As of February 22, 2024, our executive officers were:
Name Age
Present Title
(Fiscal Year First Became Executive Officer) Other Positions Held
Marc N. Casper 55 Chairman, President and Chief Executive Officer (2001) President and Chief Executive Officer (2009-2020)
Chief Operating Officer (2008-2009)
Executive Vice President (2006-2009)
Stephen Williamson 57 Senior Vice President and Chief Financial Officer (2015) Vice President, Financial Operations (2008-2015)
Michel Lagarde 50 Executive Vice President and Chief Operating Officer (2017) Executive Vice President (2019-2021)
Senior Vice President and President, Pharma Services (2017-2019)
President and Chief Operating Officer, Patheon N.V. (2016-2017)
Gianluca Pettiti 45 Executive Vice President (2021) Senior Vice President and President, Specialty Diagnostics (2019-
2021)
President, Biosciences (2018-2019)
President, China (2015-2017)
Michael A. Boxer 62 Senior Vice President and General Counsel (2018) Senior Vice President, General Counsel and Secretary (2021-2022)
Lisa P. Britt 55 Senior Vice President and Chief Human Resources Officer
(2017)
Joseph R. Holmes 45 Vice President and Chief Accounting Officer (2021) Senior Director, Technical Accounting (2017-2021)
Item 1A. Risk Factors
Set forth below are the risks, some of which have occurred and any of which may occur in the future, that we believe are material to our investors. This section
contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements in Item 1.
Business under the caption “Forward-looking Statements”.
Industry and Economic Risks
Our growth would suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality. Our
growth depends in part on the growth of the markets which we serve. Any decline or lower than expected growth in our served markets would diminish
demand for our products and services, which would adversely affect our financial statements. Certain of our businesses operate in industries that may
experience periodic, cyclical downturns.
Our business is affected by general economic conditions and related uncertainties affecting markets in which we operate. Our business is affected by
general economic conditions, both inside and outside the U.S. Both domestic and international markets experienced significant inflationary pressures in 2023
and inflation rates in the U.S., as well as in other countries in which we operate, continue at elevated levels. If the global economy and financial markets, or
economic conditions in Europe, the U.S. or other key markets, continue to be unstable, they could adversely affect the business, results of operations and
financial condition of the company and its customers, distributors, and suppliers, having the effect of:
• reducing demand for some of our products;
• increasing the rate of order cancellations or delays;
• increasing the risk of excess and obsolete inventories;
• increasing pressure on the prices for our products and services;
• causing supply interruptions, which could disrupt our ability to produce our products; and
• creating longer sales cycles, and greater difficulty in collecting sales proceeds and slower adoption of new technologies.
9
-- 9 of 225 --
THERMO FISHER SCIENTIFIC INC.
Economic, political, foreign currency and other risks associated with international sales and operations could adversely affect our results of
operations. International markets contribute a substantial portion of our revenues, and we intend to continue expanding our presence in these regions. The
exposure to fluctuations in currency exchange rates takes on different forms. International revenues and costs are subject to the risk that fluctuations in
exchange rates could adversely affect our reported revenues and profitability when translated into U.S. dollars for financial reporting purposes. These
fluctuations could also adversely affect the demand for products and services provided by us. As a multinational corporation, our businesses occasionally
invoice third-party customers in currencies other than the one in which they primarily do business (which we refer to as the functional currency). Movements in
the invoiced currency relative to the functional currency could adversely impact our cash flows and our results of operations. As our international sales grow,
exposure to fluctuations in currency exchange rates could have a larger effect on our financial results. In 2023, currency translation had an unfavorable effect of
$0.02 billion on revenues due to the strengthening of the U.S. dollar relative to other currencies in which the company sells products and services.
Some emerging market countries may be particularly vulnerable to periods of global and local political, legal, regulatory and financial instability, including
issues of geopolitical relations, the imposition of international sanctions in response to certain state actions and/or sovereign debt issues, and may have a higher
incidence of corruption and fraudulent business practices. As a result of these and other factors, our strategy to grow in emerging markets may not be
successful, and growth rates in these markets may not be sustainable.
In addition, many of our employees, contract manufacturers, suppliers, job functions, outsourcing activities and manufacturing facilities are located outside the
U.S. Accordingly, our future results could be harmed by a variety of factors, including:
• interruption to transportation flows for delivery of parts to us and finished goods to our customers;
• changes in a specific country's or region's political, economic, social or other conditions;
• changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade
embargoes and sanctions and other trade barriers;
• tariffs imposed by the U.S. on goods from other countries and tariffs imposed by other countries on U.S. goods, including the tariffs adopted by the
U.S. government on various imports from China and by the Chinese government on certain U.S. goods;
• the impact of public health emergencies, pandemics, epidemics or other health outbreaks on the global economy, such as the COVID-19 pandemic;
• uncertainties regarding the collectability of accounts receivable;
• the imposition of governmental controls;
• diverse data privacy and protection requirements;
• supply interruptions, which could disrupt our ability to produce our products;
• increases in materials, energy, labor or other manufacturing-related costs or higher supply chain logistics costs;
• negative consequences from changes in or interpretation of laws and regulations, including those related to tax and import/export;
• difficulty in staffing and managing widespread operations;
• differing labor regulations;
• differing protection of intellectual property;
• unexpected changes in regulatory requirements; and
• geopolitical uncertainty or turmoil, including terrorism and war.
Demand for some of our products depends on capital spending policies of our customers and on government funding policies. Our customers include
pharmaceutical and chemical companies, laboratories, universities, healthcare providers, government agencies and public and private research institutions.
Many factors, including public policy spending priorities, available resources, and product and economic cycles, have a significant effect on the capital
spending policies of these entities. Spending by some of these customers fluctuates based on budget allocations and the timely passage of the annual federal
budget. An impasse in federal government budget decisions could lead to substantial delays or reductions in federal spending.
10
-- 10 of 225 --
THERMO FISHER SCIENTIFIC INC.
We are subject to risks associated with public health emergencies, pandemics, epidemics, or other health outbreaks. Our global operations expose us to
risks associated with public health emergencies, epidemics, pandemics and other health outbreaks, including the COVID-19 pandemic. COVID-19 had an
adverse impact on certain of our operations, supply chains and distribution systems, and we may experience unpredictable reductions in supply and demand for
certain of our products and services. National, state and local governments have implemented and may continue to implement safety precautions, including
quarantines, border closures, increased border controls, travel restrictions, shelter in place orders and shutdowns and other measures. These measures may
disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide. Our ability to continue to
manufacture products is highly dependent on our ability to maintain the safety and health of our factory employees. The ability of our employees to work may
be significantly impacted by future epidemics and pandemics. In addition, the duration and extent of future revenues from sales of products related to the
COVID-19 response are uncertain and dependent primarily on customer testing demand as well as therapy and vaccine demand.
Business Risks
We must develop new products, adapt to rapid and significant technological change, respond to introductions of new products by competitors and
maintain quality to remain competitive. Our growth strategy includes significant investment in and expenditures for product development. We sell our
products in several industries that are characterized by rapid and significant technological changes, frequent new product and service introductions and
enhancements and evolving industry standards. Competitive factors include technological innovation, price, service and delivery, breadth of product line,
customer support, e-business capabilities and the ability to meet the special requirements of customers. Our competitors may adapt more quickly to new
technologies and changes in customers’ requirements than we can. Without the timely introduction of new products, services and enhancements, our products
and services will likely become technologically obsolete over time, in which case our revenues and operating results would suffer.
Many of our existing products and those under development are technologically innovative and require significant planning, design, development and testing at
the technological, safety, quality, product and manufacturing-process levels. Our customers use many of our products to develop, test and manufacture their
own products. As a result, we must anticipate industry trends and develop products in advance of the commercialization of our customers’ products. If we fail
to adequately develop products or predict our customers’ needs and future activities, we may invest heavily in research and development of products and
services that do not lead to significant revenues.
It may be difficult for us to implement our strategies for improving internal growth. Our growth depends in part on the growth of the markets which we
serve. Any decline or lower than expected growth in our served markets could diminish demand for our products and services, which would adversely affect
our results of operations and financial condition. To address this issue, we are pursuing a number of strategies to improve our internal growth, including:
• strengthening our presence in selected geographic markets;
• allocating research and development funding to products with higher growth prospects;
• developing new applications for our technologies;
• expanding our service offerings;
• continuing key customer initiatives;
• combining sales and marketing operations in appropriate markets to compete more effectively;
• finding new markets for our products; and
• continuing the development of commercial tools and infrastructure to increase and support cross-selling opportunities of products and services to take
advantage of our depth in product offerings.
We may not be able to successfully implement these strategies, and these strategies may not result in the expected growth of our business.
Because we compete directly with certain of our larger customers and product suppliers, our results of operations could be adversely affected in the
short term if these customers or suppliers abruptly discontinue or significantly modify their relationship with us. Our largest customer in the laboratory
products business is also a significant competitor. Our business may be harmed in the short term if our competitive relationship in the marketplace with certain
of our large customers results in a discontinuation of their purchases from us. In addition, we manufacture products that compete directly with products that we
source from third-party suppliers. We also source competitive products from multiple suppliers. Our business could be adversely affected in the short term if
any of our large third-party suppliers abruptly discontinues selling products to us.
11
-- 11 of 225 --
THERMO FISHER SCIENTIFIC INC.
Our inability to complete any pending acquisitions or to successfully integrate any new or previous acquisitions could have a material adverse effect
on our business. Our business strategy includes the acquisition of technologies and businesses that complement or augment our existing products and services.
Certain acquisitions may be difficult to complete for a number of reasons, including the need for antitrust and/or other regulatory approvals, as well as disputes
or litigation. Any acquisition we may complete may be made at a substantial premium over the fair value of the net identifiable assets of the acquired company.
Further, we may not be able to integrate acquired businesses successfully into our existing businesses, make such businesses profitable, or realize anticipated
cost savings or synergies, if any, from these acquisitions, which could adversely affect our business.
Moreover, we have acquired many companies and businesses. As a result of these acquisitions, we recorded significant goodwill and indefinite-lived intangible
assets (primarily tradenames) on our balance sheet, which amount to approximately $44.02 billion and $1.24 billion, respectively, as of December 31, 2023. In
addition, we have definite-lived intangible assets totaling $15.44 billion as of December 31, 2023. We assess the realizability of goodwill and indefinite-lived
intangible assets annually as well as whenever events or changes in circumstances indicate that these assets may be impaired. We assess the realizability of
definite-lived intangible assets whenever events or changes in circumstances indicate that these assets may be impaired. These events or circumstances would
generally include operating losses or a significant decline in earnings associated with the acquired business or asset. Our ability to realize the value of the
goodwill and intangible assets will depend on the future cash flows of these businesses. These cash flows in turn depend in part on how well we have integrated
these businesses. If we are not able to realize the value of the goodwill and intangible assets, we may be required to incur material charges relating to the
impairment of those assets.
Operational Risks
Our reliance upon sole or limited sources of supply for certain materials or components could cause production interruptions, delays and
inefficiencies. Some of our businesses purchase certain materials from sole or limited source suppliers for reasons of quality assurance, regulatory
requirements, cost effectiveness, availability or uniqueness of design. If these or other suppliers encounter financial, operating or other difficulties, or if our
relationship with them changes, we might not be able to quickly establish or qualify replacement sources of supply. The supply chains for our businesses could
also be disrupted by supplier capacity constraints, bankruptcy or exiting of the business for other reasons, decreased availability or increased cost of key raw
materials or commodities, such as energy, and external events such as global economic downturns and macroeconomic trends, natural disasters, pandemic
health issues such as COVID-19, war, terrorist actions, governmental actions and legislative or regulatory changes. Any of these factors could result in
production interruptions, delays, extended lead times and inefficiencies.
A significant cyber-attack or other disruption in, or breach in security of, our information technology systems could adversely harm our operating
results and financial condition, damage our reputation or otherwise materially harm our business. We rely on information technology systems to process,
transmit and store electronic information (including sensitive data such as confidential business information, medical information, financial data and personally
identifiable data relating to employees, customers and other business partners) and to manage or support a variety of critical business processes and activities
(such as interacting with suppliers, selling our products and services, fulfilling orders and billing, collecting and making payments, shipping products,
providing services and support to customers, tracking customer activity, fulfilling contractual obligations and otherwise conducting business). We use a risk-
based approach to implementing security controls, reviewing the security controls of certain key business partners and third-party service providers and
conducting due diligence on companies we propose to acquire. Despite our efforts, any particular system we operate or use may be susceptible to compromise
of a vulnerability or a privileged account, damage or interruption from natural disasters, power loss, telecommunication failures, data center failure, third party
provider failures (including failures at cloud services), hardware and software failures, human error or sabotage, terrorist attacks, geopolitical events, computer
hackers, computer viruses, ransomware, phishing, computer denial-of-service attacks, unauthorized access to customer or employee data or company trade
secrets, and other attempts to harm our systems and access our information.
We and our third-party providers experience cyber-attacks and other attempts to gain unauthorized access to our products, services, and systems and data on a
regular basis, and we anticipate continuing to be subject to such attempts as cyber-attacks become increasingly sophisticated and more difficult to predict and
protect against, particularly with the advancement of artificial intelligence. Despite our and our third-party providers’ implementation of security measures, our
products, services, and systems and data, are vulnerable to cyber-attacks, data breaches, malware, inadvertent error, disruptions, tampering or other theft or
misuse, including by employees, contingent workers, malicious actors, or nation-states or their agents. Although most of our systems leverage data backups,
our disaster recovery planning is not sufficient for every eventuality. In addition, our customers rely upon our products (i.e. instruments, etc.) within their
environments, which may be at risk of compromise. Risks affecting our products may include those associated with remote access solutions, system
vulnerabilities, or delay of security updates, which may require customers to take action such as network isolation, password change, or manual update.
12
-- 12 of 225 --
THERMO FISHER SCIENTIFIC INC.
Cyber-attacks, disruptions or other incidents described above, or breaches of security in our networks, in our customers’ or third-party providers’ networks, in
third-party products we use, or in cloud-based services provided to us, regardless of whether the breach is attributable to a vulnerability in our products or
services, a privileged account compromise, or a failure to maintain the digital security infrastructure or security tools that protect the integrity of our products,
services, and systems and data, could materially interrupt our operations or our customer’s operations, delay production and shipments, impact quality, result in
theft of our and our customers’ intellectual property and trade secrets, damage our reputation or key relationships, result in defective products or services, legal
claims and proceedings, liability and penalties under privacy laws and increased cost for security and remediation, in each case resulting in an adverse effect on
our business and financial results.
A violation of data privacy laws could adversely harm our operating results and financial condition, damage our reputation or otherwise materially
harm our business. If we are unable to maintain reliable information technology systems and appropriate controls with respect to global data privacy and
security requirements, we may suffer regulatory consequences in addition to business consequences. As a global organization, we are subject to data privacy
and security laws, regulations, and customer-imposed controls in numerous jurisdictions as a result of producing, collecting, processing, storing and
transmitting confidential, personal and/or sensitive data in the course of our business. For example, in the U.S., individual states regulate data breach and
security requirements and multiple governmental bodies assert authority over aspects of the protection of personal privacy. European laws require us to have an
approved legal mechanism to transfer personal data out of Europe, and the EU General Data Protection Regulation imposes significantly stricter requirements
in how we collect and process personal data. Several countries, such as China, have passed laws that require personal data relating to their citizens to be
maintained on local servers and impose additional data transfer restrictions. Government enforcement actions can be costly and interrupt the regular operation
of our business, and data breaches or violations of data privacy laws can result in fines, reputational damage and civil lawsuits, any of which may adversely
affect our business, reputation and financial statements.
Our success is largely dependent upon our ability to attract and retain a highly qualified workforce, comprised of scientific, technical, clinical, and
management talent. We have in the past, and may in the future, have difficulty in attracting and retaining such talent. Our success in doing so is largely
dependent upon various factors, including a highly competitive market, sought-after skills, management changes, competitor recruitment, and maintaining an
attractive workplace culture. Macroeconomic shifts such as increased competition for employees and wage inflation, have previously and could in the future
affect our talent retention, turnover rates and operational costs. We cannot ensure that we will be able to hire or retain the personnel necessary for our
operations or that the departure of any personnel will not have a material impact on our financial condition and results of operations.
We may incur unexpected costs from increases in fuel and raw material prices, which could reduce our earnings and cash flows. Our primary
commodity exposures are for fuel, petroleum-based resins and steel. The costs for these commodities, as well as the costs of transportation, construction and
services necessary for the production and distribution of our products, continue to increase and be volatile. While we may seek to minimize the impact of price
increases through higher prices to customers and various cost-saving measures, our earnings and cash flows could be adversely affected in the event these
measures are insufficient to cover our costs.
Because we rely heavily on third-party package-delivery services, a significant disruption in these services or significant increases in prices may
disrupt our ability to ship products, increase our costs and lower our profitability. We ship a significant portion of our products to our customers through
independent package delivery companies, such as Federal Express in the U.S. and DHL in Europe. We also maintain a small fleet of vehicles dedicated to the
delivery of our products and ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S.
Postal Service. If one or more of these third-party package-delivery providers were to experience a major work stoppage, preventing our products from being
delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our
relationships with certain of our customers could be adversely affected. In addition, if one or more of these third-party package-delivery providers were to
increase prices, and we were not able to find comparable alternatives or make adjustments in our delivery network, our profitability could be adversely
affected.
Natural disasters, public health crises, political crises, and other catastrophic events or other events outside of our control may disrupt our facilities or
the facilities of third parties on which we depend, and could impact customer spending. We have significant operations in California, near major
earthquake faults, which make us susceptible to earthquake risk. An earthquake or other natural disaster (including the effects of climate change such as sea
level rise, drought, flooding, wildfires and more intense weather events), could disrupt our operations, including the ability to fulfill supply obligations to our
customers, or impair our critical systems. Any of these disruptions or other events outside of our control, such as strikes or other labor unrest, could have an
adverse effect on our results of operations. In addition, if any of our facilities, including our manufacturing or warehouse facilities, or the facilities of our
suppliers, third-party service providers, or customers, is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, fires, floods
or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict, or other
events
13
-- 13 of 225 --
THERMO FISHER SCIENTIFIC INC.
outside of our control, such as trade protectionism, strikes or other labor unrest, our results of operations could be adversely affected. Moreover, these types of
events could negatively impact customer spending in the impacted regions or depending upon the severity, globally, which could also adversely impact our
operating results.
Increasing attention to environmental, social and governance matters may impact our business, financial results, stock price or reputation. We face
increasing scrutiny from stakeholders related to our environmental, social and governance (ESG) practices and disclosures, including practices and disclosures
related to climate change, diversity and inclusion and governance standards. Investor advocacy groups, certain institutional investors, lenders, investment funds
and other influential investors are also increasingly focused on ESG practices and disclosures and in recent years have placed increasing importance on the
implications and social cost of their investments. In addition, government organizations are enhancing or advancing legal and regulatory requirements specific
to ESG matters. The heightened stakeholder focus on ESG issues related to our business requires the continuous monitoring of various and evolving laws,
regulations, standards and expectations and the associated reporting requirements. A failure to adequately meet evolving stakeholder expectations may result in
noncompliance, the loss of business, reputational impacts, diluted market valuation, an inability to attract customers and an inability to attract and retain top
talent. In addition, if legislation or regulations are enacted or promulgated in the U.S. or in any other jurisdiction in which we do business that impose more
stringent restrictions and requirements than our current legal or regulatory obligations, we and companies in our supply chain may experience increased
compliance burdens and costs to meet the regulatory obligations, which could cause disruption in the sourcing, manufacturing and distribution of our products
and adversely affect our business, financial condition or results of operations. In addition, our adoption of certain standards or mandated compliance to certain
requirements could necessitate additional investments that could impact our profitability.
Legal, Quality and Regulatory Risks
New governmental regulations or changes in existing governmental regulations may reduce demand for our products or increase our expenses. We
compete in many markets in which we and our customers must comply with federal, state, local and international regulations, such as environmental, health
and safety and food and drug regulations. We develop, configure and market our products to meet customer needs created by those regulations. Any significant
change in regulations, such as the Inflation Reduction Act of 2022 (IRA), which contains drug price negotiation provisions, or change in the interpretation of
existing regulations, could reduce demand for our products or increase our expenses. For example, we manufacture pharmaceuticals and many of our
instruments are marketed to the pharmaceutical industry for use in discovering and developing drugs. Changes in the U.S. Food and Drug Administration’s (the
FDA) regulation of the drug discovery and development process could have an adverse effect on the demand for these products, and increased FDA regulation
of laboratory-developed tests could delay and add to the cost of commercialization of these products, as well as subject us to additional regulatory controls.
We are subject to laws and regulations governing government contracts, and failure to address these laws and regulations or comply with government
contracts could harm our business by leading to a reduction in revenues associated with these customers. We have agreements relating to the sale of our
products to government entities and, as a result, we are subject to various statutes and regulations that apply to companies doing business with the government.
The laws governing government contracts differ from the laws governing private contracts and government contracts may contain pricing terms and conditions
that are not applicable to private contracts. We are also subject to investigation for compliance with the regulations governing government contracts. A failure
to comply with these regulations could result in suspension of these contracts, criminal, civil and administrative penalties or debarment.
Our pharma services offerings are highly complex, and if we are unable to provide quality and timely offerings to our customers, our business could
suffer. Our pharma services offerings are highly exacting and complex, due in part to strict quality and regulatory requirements. Our operating results in this
business depend on our ability to execute and, when necessary, improve our quality management strategy and systems, and our ability to effectively train and
maintain our employee base with respect to quality management. A failure of our quality control systems could result in problems with facility operations or
preparation or provision of products. In each case, such problems could arise for a variety of reasons, including equipment malfunction, failure to follow
specific protocols and procedures, problems with raw materials or environmental factors and damage to, or loss of, manufacturing operations. Such problems
could affect production of a particular batch or series of batches of products, requiring the destruction of such products or a halt of facility production
altogether.
In addition, our failure to meet required quality standards may result in our failure to timely deliver products to our customers, which in turn could damage our
reputation for quality and service. Any such failure could, among other things, lead to increased costs, lost revenues, reimbursement to customers for lost drug
product, registered intermediates, registered starting materials, and active pharmaceutical ingredients, other customer claims, damage to and possibly
termination of existing customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other
batches or products. Production problems in our drug and biologic manufacturing operations could be particularly
14
-- 14 of 225 --
THERMO FISHER SCIENTIFIC INC.
significant because the cost of raw materials for such manufacturing is often high. If problems in preparation or manufacture of a product or failures to meet
required quality standards for that product are not discovered before such product is released to the market, we may be subject to adverse regulatory actions,
including product recalls, product seizures, injunctions to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary
sanctions, and criminal actions. In addition, such problems or failures could subject us to litigation claims, including claims from our customers for
reimbursement for the cost of lost or damaged active pharmaceutical ingredients, the cost of which could be significant.
We are subject to product and other liability risks for which we may not have adequate insurance coverage. We may be named as a defendant in product
liability or errors and omissions lawsuits, which may allege that products or services we have provided have resulted or could result in an unsafe condition,
property damage or injury to end users or financial loss for consumers. Additionally, products currently or previously sold by our environmental and process
instruments and radiation measurement and security instruments businesses include fixed and portable instruments used for chemical, radiation and trace
explosives detection. These products are used in airports, embassies, cargo facilities, border crossings and other high-threat facilities for the detection and
prevention of terrorist acts. If any of these products were to malfunction, it is possible that explosive or radioactive material could fail to be detected by our
product, which could lead to product liability claims. In addition, patients involved in our clinical services trials conducted by our clinical development services
business or taking drugs approved on the basis of those trials may also bring personal injury claims against us. There are also many other factors beyond our
control that could lead to liability claims, such as the reliability and competence of the customers’ operators and the training of such operators.
Any such product liability claims brought against us could be significant and any adverse determination may result in liabilities subject to insurance policy
exclusions where insurance would not respond or in excess of our insurance coverage. Although we carry product liability and errors and omissions insurance,
we cannot be certain that our current insurance will be sufficient to cover these claims or that it can be maintained on acceptable terms, if at all.
We are required to comply with a wide variety of laws and regulations, and are subject to regulation by various federal, state and foreign agencies. We
are subject to various local, state, federal, foreign and transnational laws and regulations, which include the operating and security standards of the FDA, the
U.S. Drug Enforcement Agency (the DEA), various state boards of pharmacy, state health departments, the U.S. Department of Health and Human Services
(the DHHS), the European Medicines Agency (the EMA), the EU member states and other comparable agencies and, in the future, any changes to such laws
and regulations could adversely affect us. In particular, we are subject to laws and regulations concerning current good manufacturing practices and drug safety.
Our subsidiaries may be required to register for permits and/or licenses with, and may be required to comply with the laws and regulations of, the DEA, the
FDA, the DHHS, foreign agencies including the EMA, and other various state boards of pharmacy, state health departments and/or comparable state agencies
as well as certain accrediting bodies depending upon the type of operations and location of product distribution, manufacturing and sale.
The manufacture, distribution and marketing of many of our products and services, including medical devices, and our pharma and clinical development
services, are subject to extensive ongoing regulation by the FDA, the DEA, the EMA, and other equivalent local, state, federal and non-U.S. regulatory
authorities. In addition, we are subject to inspections by these regulatory authorities. Failure by us or by our customers to comply with the requirements of
these regulatory authorities, including without limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities, could
result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution, restrictions on our operations, civil or
criminal sanctions, or withdrawal of existing or denial of pending approvals, including those relating to products or facilities. In addition, such a failure could
expose us to contractual or product liability claims, contractual claims from our customers, including claims for reimbursement for lost or damaged active
pharmaceutical ingredients or personal injury, as well as ongoing remediation and increased compliance costs, any or all of which could be significant. We are
the sole manufacturer of a number of pharmaceuticals for many of our customers and a negative regulatory event could impact our customers’ ability to provide
products to their customers.
We are also subject to a variety of federal, state, local and international laws and regulations that govern, among other things, the handling, transportation and
manufacture of substances that could be classified as hazardous, and we are required to comply with various import laws and export control and economic
sanctions laws, which may affect our transactions with certain customers. In certain circumstances, export control and economic sanctions regulations may
prohibit the export of certain products, services and technologies. In other circumstances, we may be required to obtain an export license before exporting the
controlled item. Compliance with the various import laws that apply to our businesses can restrict our access to, and increase the cost of obtaining, certain
products and at times can interrupt our supply of imported inventory. Any noncompliance by us with applicable laws and regulations or the failure to maintain,
renew or obtain necessary permits and licenses could result in criminal, civil and administrative penalties and could have an adverse effect on our results of
operations.
15
-- 15 of 225 --
THERMO FISHER SCIENTIFIC INC.
Our reputation, ability to do business and financial statements may be impaired by improper conduct by any of our employees, agents, business
partners or other third parties. We have internal controls and compliance systems to protect the company against acts committed by employees, agents or
businesses that we acquire that would violate U.S. and/or non-U.S. laws, including the laws governing payments to government officials, bribery, fraud,
kickbacks and false claims, pricing, sales and marketing practices, conflicts of interest, competition, employment practices and workplace behavior, export and
import compliance, money laundering and data privacy, but these controls and systems may not be sufficient to prevent every such wrongful act. In particular,
the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act 2010 and similar anti-bribery laws in other jurisdictions generally prohibit companies and their
intermediaries from making improper payments to government officials for the purpose of obtaining or retaining business, and we operate in many parts of the
world that have experienced governmental corruption to some degree. Any such improper actions or allegations of such acts could damage our reputation and
subject us to civil or criminal investigations in the U.S. and in other jurisdictions and related shareholder lawsuits, could lead to substantial civil and criminal,
monetary and nonmonetary penalties and could cause us to incur significant legal and investigatory fees. In addition, the government may seek to hold us liable
for violations committed by companies which we acquire. We also rely on our suppliers to adhere to our supplier standards of conduct, and material violations
of such standards of conduct could occur that could have a material effect on our business, reputation and financial statements. In addition, any allegations of
issues resulting from the misuse of our products could, even if untrue, adversely affect our reputation and our customers’ willingness to purchase products from
us. Any such allegations could cause us to lose customers and divert our resources from other tasks, which could materially and adversely affect our business
and operating results.
Our inability to protect our intellectual property could have a material adverse effect on our business. In addition, third parties may claim that we
infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result. We place considerable emphasis on
obtaining patent and trade secret protection for significant new technologies, products and processes because of the length of time and expense associated with
bringing new products through the development process and into the marketplace. Our success depends in part on our ability to develop patentable products
and obtain, defend and enforce patent protection for our products both in the U.S. and in other countries. We own numerous U.S. and foreign patents, and we
intend to file additional applications, as appropriate, for patents covering our products. Patents may not be issued for any pending or future patent applications
owned by or licensed to us, and the claims allowed under any issued patents may not be sufficiently broad to protect our technology. Any issued patents owned
by or licensed to us may be challenged, invalidated or circumvented, and the rights under these patents may not provide us with competitive advantages. In
addition, competitors may design around our technology or develop competing technologies. Intellectual property rights may also be unavailable or limited in
some foreign countries, which could make it easier for competitors to capture increased market position. We could incur substantial costs to defend ourselves in
suits brought against us or in suits in which we may assert our patent rights against others. An unfavorable outcome of any such litigation could materially
adversely affect our business and results of operations.
We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with our
collaborators, employees and consultants. These agreements may not adequately protect our trade secrets and other proprietary rights. These agreements may
be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently
developed by our competitors.
We also depend in part on our trademarks and the strength of our proprietary brands, which we consider important to our business. If we are unable to protect
or preserve the value of our intellectual property rights for any reason, including our inability to successfully defend against counterfeit, knock offs, grey-
market, infringing or otherwise unauthorized products, our brand and reputation could be damaged, and our business may be harmed.
Third parties may assert claims against us to the effect that we are infringing on their intellectual property rights. In the event that a claim relating to intellectual
property is asserted against us, or third parties not affiliated with us hold pending or issued patents that relate to our products or technology, we may seek
licenses to such intellectual property or challenge those patents. However, we may be unable to obtain these licenses on commercially reasonable terms, if at
all, and our challenge of the patents may be unsuccessful. Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or
distribution of our products and, therefore, could have a material adverse effect on our business, financial condition and results of operations.
Risks Relating to Financial Profile
Fluctuations in our effective tax rate may adversely affect our results of operations and cash flows. As a global company, we are subject to taxation in
numerous countries, states and other jurisdictions. In preparing our financial statements, we record the amount of tax that is payable in each of the countries,
states and other jurisdictions in which we operate. Our future effective tax rate, however, may be lower or higher than experienced in the past due to numerous
factors, including a change in the mix of our profitability from country to country, changes in accounting for income taxes, the results of examinations and
audits of
16
-- 16 of 225 --
THERMO FISHER SCIENTIFIC INC.
our tax filings and recently enacted and future changes in tax laws in jurisdictions in which we operate. Any of these factors could cause us to experience an
effective tax rate significantly different from previous periods or our current expectations, which could have an adverse effect on our business, results of
operations and cash flows.
In December 2021, the Organization for Economic Cooperation and Development (“OECD”) published a proposal for the establishment of a global minimum
tax rate of 15% (the “Pillar Two rule”). The OECD has recommended that the Pillar Two rule become effective for fiscal years beginning after January 1, 2024.
To date, member states are in various stages of implementation and the OECD continues to refine technical guidance. We are closely monitoring developments
of the Pillar Two rule and are currently evaluating the potential impacts in each of the countries in which we operate; however, we currently do not expect the
Pillar Two rule to have a material impact on our effective tax rate.
Our existing and future indebtedness may restrict our investment opportunities or limit our activities and negatively impact our credit ratings. As of
December 31, 2023, we had approximately $34.92 billion in outstanding indebtedness. In addition, we have availability to borrow under a revolving credit
facility that provides for up to $5.00 billion of unsecured multi-currency revolving credit (the Facility). We may also obtain additional long-term debt and lines
of credit to meet future financing needs, which would have the effect of increasing our total leverage.
Our leverage could have negative consequences, including increasing our vulnerability to adverse economic and industry conditions, limiting our ability to
obtain additional financing and limiting our ability to acquire new products and technologies through strategic acquisitions.
Our ability to make scheduled payments, refinance our obligations or obtain additional financing will depend on our future operating performance and on
economic, financial, competitive and other factors beyond our control. Our business may not generate sufficient cash flow to meet our obligations. If we are
unable to service our debt, refinance our existing debt or obtain additional financing, we may be forced to delay strategic acquisitions, capital expenditures or
research and development expenditures.
Additionally, the agreements governing our debt require that we maintain a financial ratio, and contain affirmative and negative covenants that restrict our
activities by, among other limitations, limiting our ability to incur additional indebtedness, merge or consolidate with other entities and create liens. The
covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are
defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is
outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage
Ratio of 3.5:1.0 as of the last day of any fiscal quarter.
Our ability to comply with these financial restrictions and covenants is dependent on our future performance, which is subject to prevailing economic
conditions and other factors, including factors that are beyond our control such as the impact of foreign exchange rates and interest rates. Our failure to comply
with any of these restrictions or covenants may result in an event of default under the applicable debt instrument, which could permit acceleration of the debt
under that instrument and require us to prepay that debt before its scheduled due date. Also, an acceleration of the debt under certain of our debt instruments
would trigger an event of default under other of our debt instruments.
Item 1B. Unresolved Staff Comments
None.
Item 1C. Cybersecurity
Cybersecurity Risk Management and Strategy
As is the case for most large global companies, we are regularly subject to cyberattacks and other cybersecurity incidents and, therefore, we incorporate
cybersecurity into our overall risk management process. Our commitment to cybersecurity emphasizes using a risk-based, “defense in depth” approach to
assess, educate, block, identify, respond to and recover from cybersecurity threats. Recognizing that no single technology, process or control can effectively
prevent or mitigate all risks, we employ a strategy of technologies, processes and controls, all working independently but as part of a cohesive strategy to
manage or reduce risk.
Our cybersecurity program assists in the management of risks associated with the confidentiality, integrity and availability of data and systems within the
company environment to effectively support our business objectives and customer expectations. The program provides guidance to business stakeholders on
cybersecurity risks as input into their risk management processes that balance cybersecurity risk with other important risks that may include strategic,
regulatory, economic and financial considerations.
17
-- 17 of 225 --
THERMO FISHER SCIENTIFIC INC.
We seek to routinely refine our cybersecurity approach to adapt to changes in the threat landscape and manage emerging security risks. In order to evaluate
risks from cybersecurity threats associated with the company’s use of certain third-party technology providers, we have incorporated a risk-based assessment
into the corporate information technology (IT) procurement process designed to assess the security risk of certain third parties providing new technology
solutions to our environment.
We believe cybersecurity is the responsibility of every employee, and regularly educate and share best practices with our employees to raise awareness of
cybersecurity threats through a security awareness training program, including regular exercises, periodic cyber-event simulations and annual attestation to our
Technology Acceptable Use Policy.
We do not reasonably believe there are currently any cybersecurity incidents that have materially affected or are reasonably likely to materially affect the
company or its business strategy, results of operations or financial condition. For more information on the risks related to our IT systems, see “A significant
disruption in, or breach in security of, our IT systems or violation of data privacy laws could adversely affect our business or customers that use our products”
under the heading “Risk Factors” in Part I, Item 1A.
Cybersecurity Governance and Oversight
The Board of Directors has delegated the oversight of cybersecurity risks to the Audit Committee. Our cybersecurity program is led by the company’s senior
vice president, chief information officer, along with our vice president, chief information security officer. Management provides an operational update to the
Audit Committee each quarter. In addition, the Audit Committee and our full Board of Directors receive an annual overview of the cybersecurity program,
cybersecurity threat landscape, investments, and opportunities to enhance the company’s systems and security of products and operations.
The company’s corporate IT security team leads the company-wide cybersecurity strategy and advocates to protect the company systems, its employees and
customers against cybersecurity risks. Through annual internal and external audits, we maintain an ISO/IEC 27001:2013 certification for the management of
our cybersecurity program consisting of the following areas:
• cybersecurity program management and governance including risk management;
• cybersecurity operations including security operation centers;
• product security;
• security investigations;
• cybersecurity architecture and engineering; and
• security awareness and training.
Our senior vice president, chief information officer, vice president, chief information security officer (CISO), and vice president, chief product security officer
have each served in various roles in IT and information security for over 20 years. These individuals’ knowledge and experience along with the culture and
talent of the corporate IT security team organization are instrumental in developing and executing our cybersecurity strategies. The CISO meets with senior
leadership to review and discuss the cybersecurity program, including emerging cybersecurity risks, threats and industry trends.
Cybersecurity is integrated into the risk management process for the company through various corporate mechanisms, including quarterly business reviews,
annual budget planning, and targeted risk-based engagements.
Item 2. Properties
The company owns and leases office, engineering, laboratory, production and warehouse space throughout the world.
Item 3. Legal Proceedings
There are various lawsuits and claims against the company involving product liability, intellectual property, employment and commercial issues. See Note 12 to
our Consolidated Financial Statements – “Commitments and Contingencies”.
Item 4. Mine Safety Disclosures
Not applicable.
18
-- 18 of 225 --
THERMO FISHER SCIENTIFIC INC.
PART II
Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Price of Common Stock
Our common stock is traded on the New York Stock Exchange under the symbol TMO.
Holders of Common Stock
As of February 3, 2024, the company had 2,337 holders of record of its common stock. This does not include holdings in street or nominee names.
Issuer Purchases of Equity Securities
There was no share repurchase activity for the company’s fourth quarter of 2023. On November 14, 2023, the Board of Directors announced that it replaced the
existing authorization to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to repurchase up to $4.00
billion of the company’s common stock. Early in the first quarter of 2024, the company repurchased $3.00 billion (5.5 million shares) of the company's
common stock. At February 22, 2024, $1.00 billion was available for future repurchases of the company’s common stock under this authorization.
Item 6. Reserved
Not applicable.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Reference is made throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations to Notes to the Consolidated
Financial Statements, which begin on page 29 of this report. Management’s Discussion and Analysis of Financial Condition and Results of Operations for 2021
is included in Item 7 of the company’s 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission.
The company refers to various amounts or measures not prepared in accordance with generally accepted accounting principles (non-GAAP measures). These
non-GAAP measures are further described and reconciled to their most directly comparable amount or measure under the section “Non-GAAP Measures” later
in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Overview
Thermo Fisher Scientific Inc. enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex
analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing
therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics. The
company’s operations fall into four segments (Note 4): Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics and Laboratory Products and
Biopharma Services.
Consolidated Results
(Dollars in millions except per share amounts) 2023 2022 Change
Revenues $ 42,857 $ 44,915 (5) %
GAAP operating income $ 6,859 $ 8,393 (18) %
GAAP operating income margin 16.0 % 18.7 % (2.7) pt
Adjusted operating income (non-GAAP measure) $ 9,810 $ 10,985 (11) %
Adjusted operating income margin (non-GAAP measure) 22.9 % 24.5 % (1.6) pt
GAAP diluted earnings per share attributable to Thermo Fisher Scientific Inc. $ 15.45 $ 17.63 (12) %
Adjusted earnings per share (non-GAAP measure) $ 21.55 $ 23.24 (7) %
19
-- 19 of 225 --
THERMO FISHER SCIENTIFIC INC.
Organic Revenue Growth
Revenue growth (5)%
Impact of acquisitions 1 %
Impact of currency translation 0 %
Organic revenue growth* (non-GAAP measure) (5)%
* Results may not sum due to rounding.
Since 2020, the Life Sciences Solutions and Specialty Diagnostics segments as well as the laboratory products business have supported COVID-19 diagnostic
testing, scaling and evolving their molecular diagnostics solutions and plastic consumables businesses to respond to the COVID-19 pandemic. The biosciences
and bioproduction businesses have expanded their capacity to meet the needs of pharma and biotech customers as they have expanded their own production
volumes to meet global vaccine manufacturing requirements. Additionally, our pharma services business has provided our pharma and biotech customers with
the services they needed to develop and produce vaccines and therapies globally. Since the company’s acquisition of PPD in December 2021, the clinical
research business has continued to play a leading role in supporting the clinical trials for COVID-19 vaccines and therapies. These positive impacts continued
at much lower levels in 2023 as customer testing as well as therapy and vaccine demand declined. Sales of products related to COVID-19 testing were $0.33
billion and $3.11 billion in 2023 and 2022, respectively.
During 2023, growth from pharma and biotech customers slightly declined. Over the past few years, the company has played a meaningful role in the
production of COVID-19 vaccines and therapies. In 2023, reduced demand for our products and services that support COVID-19 vaccines and therapies was
partially offset through strong commercial execution as a result of our trusted partner status with customers in this market. We saw broad based strength across
the academic and government market as we saw the benefits of our accelerated investments into high impact innovation with great customer adoption and
strong demand globally. The industrial and applied market was strong, driven by the relevance of our analytical instrument technologies serving our
semiconductor and materials science customers. The diagnostics and healthcare market declined due to decreased demand for COVID-19 testing products.
During 2023, sales growth in all major regions declined due to decreased demand for COVID-19 related products, as well as a challenging macroeconomic
environment and low economic activity in China. Contributions to organic revenue during 2023 from the Analytical Instruments and Laboratory Products and
Biopharma Services segments were more than offset by declines in the Life Sciences Solutions and Specialty Diagnostics segments.
The company continues to execute its proven growth strategy which consists of three pillars:
• High-impact innovation,
• Our trusted partner status with customers, and
• Our unparalleled commercial engine.
GAAP operating income margin and adjusted operating income margin decreased in 2023 due primarily to lower COVID-19 related revenue. This was
partially offset by strong productivity improvements and strong pricing realization to address higher inflation. GAAP operating income margin in 2023 was
also impacted by restructuring and other charges incurred for headcount reductions and facility consolidations in an effort to streamline operations and limit the
impact of expected lower revenue (Note 16). We estimate that restructuring actions resulting in charges of approximately $0.2 billion in 2023 will realize
annual cost savings of approximately $0.5 billion, primarily due to reduced employee expenses.
The company’s references to strategic growth investments generally refer to targeted spending for enhancing commercial capabilities, including expansion of
geographic sales reach and e-commerce platforms, marketing initiatives, expanded service and operational infrastructure, research and development projects
and other expenditures to enhance the customer experience, as well as incentive compensation and recognition for employees. The company’s references
throughout this discussion to productivity improvements generally refer to improved cost efficiencies from its Practical Process Improvement (PPI) business
system including reduced costs resulting from implementing continuous improvement methodologies, global sourcing initiatives, a lower cost structure
following restructuring actions including headcount reductions and consolidation of facilities, and low cost region manufacturing.
Notable Recent Acquisitions
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic
assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s
portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma.
20
-- 20 of 225 --
THERMO FISHER SCIENTIFIC INC.
On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of
regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of
highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development.
Segment Results
The company’s management evaluates segment operating performance using operating income before certain charges/credits as defined in Note 4. Accordingly,
the following segment data are reported on this basis.
(Dollars in millions) 2023 2022
Revenues
Life Sciences Solutions $ 9,977 $ 13,532
Analytical Instruments 7,263 6,624
Specialty Diagnostics 4,405 4,763
Laboratory Products and Biopharma Services 23,041 22,511
Eliminations (1,829) (2,515)
Consolidated revenues $ 42,857 $ 44,915
Life Sciences Solutions
Organic* (non-
GAAP measure) (Dollars in millions) 2023 2022
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues $ 9,977 $ 13,532 (26) % 0 % 0 % (26)%
Segment income 3,420 5,582 (39) %
Segment income margin 34.3 % 41.2 % (6.9) pt
The decrease in organic revenues in 2023 was primarily due to moderation in COVID-19 related revenue. The decrease in segment income margin resulted
primarily from significantly lower COVID-19 related revenue and unfavorable volume pull-through, partially offset by exceptionally strong productivity
improvements and favorable price realization.
Analytical Instruments
Organic* (non-
GAAP measure) (Dollars in millions) 2023 2022
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues $ 7,263 $ 6,624 10 % (1)% 0 % 10 %
Segment income 1,908 1,507 27 %
Segment income margin 26.3 % 22.8 % 3.5 pt
The increase in organic revenues in 2023 was due to increased demand across all the segment’s businesses, with particular strength in the electron microscopy
and chromatography and mass spectrometry businesses. The increase in segment income margin resulted primarily from strong productivity, strong pricing
realization to address higher inflation and strong volume pull-through, offset in part by the effects of currency translation and strategic growth investments.
Specialty Diagnostics
Organic* (non-
GAAP measure) (Dollars in millions) 2023 2022
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues $ 4,405 $ 4,763 (8) % 0 % 5 % (13)%
Segment income 1,124 1,024 10 %
Segment income margin 25.5 % 21.5 % 4.0 pt
The decrease in organic revenues in 2023 was due to decreased demand, primarily driven by products addressing diagnosis of COVID-19, partially offset by
underlying growth in the immunodiagnostics, microbiology, and transplant diagnostics businesses. The increase in segment income margin was due to
favorable business mix, strong pricing realization to address higher inflation, and strong productivity improvements, partially offset by the impact of lower
COVID-19 testing volume.
21
-- 21 of 225 --
THERMO FISHER SCIENTIFIC INC.
Laboratory Products and Biopharma Services
Organic* (non-
GAAP measure) (Dollars in millions) 2023 2022
Total
Change
Currency
Translation
Acquisitions/
Divestitures
Revenues $ 23,041 $ 22,511 2 % 0 % 0 % 2 %
Segment income 3,358 2,872 17 %
Segment income margin 14.6 % 12.8 % 1.8 pt
The increase in organic revenues in 2023 was primarily due to higher sales in the clinical research and pharma services businesses. The increase in segment
income margin was primarily due to very strong productivity improvements and strong pricing realization to address higher inflation.
* Results may not sum due to rounding
Non-operating Items
(Dollars in millions) 2023 2022
Net interest expense $ 496 $ 454
GAAP other income/(expense) (65) (104)
Adjusted other income/(expense) (non-GAAP measure) (15) 13
GAAP tax rate 4.5 % 9.0 %
Adjusted tax rate (non-GAAP measure) 10.0 % 13.0 %
Weighted average diluted shares 388 394
Net interest expense (interest expense less interest income) increased due primarily to the increase in debt for general corporate purposes and the company’s
capital deployment initiatives, which included financing stock buybacks, paying dividends and acquiring The Binding Site Group and CorEvitas, LLC (Note
2). These increases were partially offset by higher cash and cash equivalents balances as well as higher interest rates on these balances when compared to 2022.
See additional discussion under the caption “Liquidity and Capital Resources” below. In 2023 and 2022 the company’s net interest expense was reduced by
approximately $116 million and $16 million, respectively, as a result of its interest rate swap and cross-currency interest rate swap arrangements (Note 14).
GAAP other income/(expense) and adjusted other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities,
and net periodic pension benefit cost/income, excluding the service cost component. GAAP other income/(expense) in 2023 also includes $45 million of net
losses on investments. GAAP other income/(expense) in 2022 also includes $160 million of net losses on investments and $26 million of losses on the early
extinguishment of debt (Note 10), partially offset by $67 million of net gains on derivative instruments to address certain foreign currency risks.
The GAAP and adjusted tax rates in 2023 were impacted by changes in valuation allowances, including a $183 million release in a jurisdiction where the
deferred tax assets are now expected to be realized, and, to a lesser extent, by a decrease in pre-tax earnings compared to 2022. The company’s GAAP and
adjusted tax rates in 2023 were also impacted by tax planning initiatives, including a tax benefit of $127 million for U.S. tax credits and the revaluation of net
operating loss carryforwards due to higher tax rates as a result of its tax return resubmissions, a tax benefit of $91 million, net of related tax expenses, from a
foreign exchange loss on an intercompany debt refinancing transaction, and $233 million of tax benefits resulting from intra-entity transactions. The company’s
GAAP and adjusted tax rates in 2022 were impacted by releases of valuation allowances of $189 million in jurisdictions where the deferred tax assets are now
expected to be realized. The company’s 2022 GAAP tax rate was also impacted by a net benefit of $208 million resulting from tax audit settlements (Note 8).
The effective tax rates in both 2023 and 2022 were also affected by relatively significant earnings in lower tax jurisdictions. Due primarily to the non-
deductibility of intangible asset amortization for tax purposes, the company’s cash payments for income taxes were higher than its income tax expense for
financial reporting purposes. See additional discussion under the caption “Liquidity and Capital Resources” below.
The company expects its GAAP effective tax rate in 2024 will be between 4% and 6% based on currently forecasted rates of profitability in the countries in
which the company conducts business and expected generation of foreign tax credits. The effective tax rate can vary significantly from period to period as a
result of discrete income tax factors and events. The company expects its adjusted tax rate will be approximately 10.5% in 2024.
The company has operations and a taxable presence in approximately 70 countries outside the U.S. Some of these countries have lower tax rates than the U.S.
The company’s ability to obtain a benefit from lower tax rates outside the U.S. is dependent on its relative levels of income in countries outside the U.S. and on
the statutory tax rates in those countries. Based on the
22
-- 22 of 225 --
THERMO FISHER SCIENTIFIC INC.
dispersion of the company’s non-U.S. income tax provision among many countries, the company believes that a change in the statutory tax rate in any
individual country is not likely to materially affect the company’s income tax provision or net income, aside from any resulting one-time adjustment to the
company’s deferred tax balances to reflect a new rate.
Weighted average diluted shares decreased in 2023 compared to 2022 due to share repurchases, net of option dilution.
Liquidity and Capital Resources
The company’s proven growth strategy has enabled it to generate free cash flow as well as access the capital markets. The company deploys its capital
primarily via mergers and acquisitions and secondarily via share buybacks and dividends.
December 31, December 31,
(In millions) 2023 2022
Cash and cash equivalents $ 8,077 $ 8,524
Total debt 34,917 34,488
Approximately half of the company’s cash balances and cash flows from operations are from outside the U.S. The company uses its non-U.S. cash for needs
outside of the U.S. including acquisitions, capacity expansion, and repayment of third-party foreign debt by foreign subsidiaries. In addition, the company also
transfers cash to the U.S. using non-taxable intercompany transactions, including loans and returns of capital, as well as dividends where the related U.S.
dividend received deduction or foreign tax credit equals any tax cost arising from the dividends. As a result of using such means of transferring cash to the
U.S., the company does not expect any material adverse liquidity effects from its significant non-U.S. cash balances for the foreseeable future.
The company believes that its existing cash and cash equivalents and its future cash flow from operations together with available borrowing capacity under its
revolving credit agreement will be sufficient to meet the cash requirements of its existing businesses for the foreseeable future, including at least the next 24
months.
As of December 31, 2023, the company’s short-term debt totaled $3.61 billion. The company has a revolving credit facility with a bank group that provides up
to $5.00 billion of unsecured multi-currency revolving credit (Note 10). If the company borrows under this facility, it intends to leave undrawn an amount
equivalent to outstanding commercial paper to provide a source of funds in the event that commercial paper markets are not available. As of December 31,
2023, no borrowings were outstanding under the company’s revolving credit facility, although available capacity was reduced by immaterial outstanding letters
of credit.
(In millions) 2023 2022
Net cash provided by operating activities $ 8,406 $ 9,154
Net cash used in investing activities (5,142) (2,159)
Net cash used in financing activities (3,622) (2,810)
Free cash flow (non-GAAP measure) 7,014 6,935
Operating Activities
During 2023, cash provided by income was offset in part by investments in working capital. A decrease in inventories provided cash of $0.60 billion. A
decrease in accounts payable used cash of $0.50 billion, and changes in other assets and other liabilities used cash of $0.80 billion primarily due to the timing
of payments for compensation and income taxes. Cash payments for income taxes were $1.48 billion during 2023.
During 2022, cash provided by income was offset in part by investments in working capital. Increases in accounts receivable and inventories used cash of $0.43
billion and $0.83 billion, respectively, primarily to support growth in sales. An increase in accounts payable provided cash of $0.65 billion. Cash payments for
income taxes were $1.23 billion during 2022.
The company is contingently liable with respect to certain legal proceedings and related matters. An unfavorable outcome that differs materially from current
accrual estimates, if any, for one or more of the matters described under the heading “Product Liability, Workers Compensation and Other Personal Injury
Matters” in Note 12 could have a material adverse effect on the company’s financial position as well as its results of operations and cash flows.
23
-- 23 of 225 --
THERMO FISHER SCIENTIFIC INC.
Investing Activities
During 2023, acquisitions of The Binding Site Group and CorEvitas, LLC used cash of $2.70 billion and $0.91 billion, respectively. The company’s investing
activities also included purchases of $1.48 billion of property, plant and equipment for capacity and capability investments.
During 2022 the company’s investing activities were principally for the purchase of property, plant and equipment for capacity and capability investments.
The company expects that for all of 2024, expenditures for property, plant and equipment, net of disposals, will be between $1.3 billion and $1.5 billion.
Financing Activities
During 2023, issuance of senior notes provided $5.94 billion of cash. Repayment of senior notes and net commercial paper activity used cash of $5.78 billion
and $0.32 billion, respectively. The company’s financing activities also included the repurchase of $3.00 billion of the company’s common stock (5.2 million
shares) and the payment of $0.52 billion in cash dividends. On November 14, 2023, the Board of Directors announced that it replaced the existing authorization
to repurchase the company’s common stock, of which $1.00 billion was remaining, with a new authorization to repurchase up to $4.00 billion of the company’s
common stock.
Early in the first quarter of 2024, the company repurchased $3.00 billion (5.5 million shares) of the company's common stock. At February 22, 2024, $1.00
billion was available for future repurchases of the company’s common stock under this authorization.
During 2022, issuance of senior notes provided $3.19 billion of cash. Repayment of senior notes and net commercial paper activity used cash of $0.38 billion
and $2.16 billion, respectively. The company’s financing activities also included the repurchase of $3.00 billion of the company's common stock (5.3 million
shares) and the payment of $0.46 billion in cash dividends.
In addition to the obligations on the balance sheet at December 31, 2023, which include, but are not limited to pension obligations (Note 7), unrecognized tax
benefits (Note 8), debt (Note 10), operating leases (Note 11), and contingent consideration (Note 14), the company has also entered into an agreement to
acquire Olink (Note 2). The company also has unconditional purchase obligations in the ordinary course of business that include agreements to purchase goods,
services or fixed assets, pay royalties, and fund capital commitments pursuant to investments held by the company (Note 12).
Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial
measures such as organic revenue growth, which is reported revenue growth, excluding the impacts of revenues from acquired/divested businesses and the
effects of currency translation. We report organic revenue growth because Thermo Fisher management believes that in order to understand the company’s short-
term and long-term financial trends, investors may wish to consider the impact of acquisitions/divestitures and foreign currency translation on revenues.
Thermo Fisher management uses organic revenue growth to forecast and evaluate the operational performance of the company as well as to compare revenues
of current periods to prior periods.
We report adjusted operating income, adjusted operating income margin, adjusted other income/(expense), adjusted tax rate, and adjusted EPS. We believe that
the use of these non-GAAP financial measures, in addition to GAAP financial measures, helps investors to gain a better understanding of our core operating
results and future prospects, consistent with how management measures and forecasts the company’s core operating performance, especially when comparing
such results to previous periods, forecasts, and to the performance of our competitors. Such measures are also used by management in their financial and
operating decision-making and for compensation purposes. To calculate these measures we exclude, as applicable:
• Certain acquisition-related costs, including charges for the sale of inventories revalued at the date of acquisition, significant transaction/acquisition-
related costs, including changes in estimates of contingent acquisition-related consideration, and other costs associated with obtaining short-term
financing commitments for pending/recent acquisitions. We exclude these costs because we do not believe they are indicative of our normal operating
costs.
• Costs/income associated with restructuring activities and large-scale abandonments of product lines, such as reducing overhead and consolidating
facilities. We exclude these costs because we believe that the costs related to restructuring activities and large-scale abandonment of product lines are
not indicative of our normal operating costs.
• Equity in earnings/losses of unconsolidated entities; impairments of long-lived assets; and certain other gains and losses that are either isolated or
cannot be expected to occur again with any predictability, including gains/losses on
24
-- 24 of 225 --
THERMO FISHER SCIENTIFIC INC.
investments, the sale of businesses, product lines, and real estate, significant litigation-related matters, curtailments/settlements of pension plans, and
the early retirement of debt. We exclude these items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast
accurately for future periods.
• The expense associated with the amortization of acquisition-related intangible assets because a significant portion of the purchase price for
acquisitions may be allocated to intangible assets that have lives of up to 20 years. Exclusion of the amortization expense allows comparisons of
operating results that are consistent over time for both our newly acquired and long-held businesses and with both acquisitive and non-acquisitive peer
companies.
• The noncontrolling interest and tax impacts of the above items and the impact of significant tax audits or events (such as changes in deferred taxes
from enacted tax rate/law changes), the latter of which we exclude because they are outside of our normal operations and difficult to forecast
accurately for future periods.
We report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate
cash for use in acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company.
Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that
are not deducted from the measure.
The non-GAAP financial measures of the company’s results of operations and cash flows included in this Form 10-K are not meant to be considered superior to
or a substitute for the company’s results of operations prepared in accordance with GAAP. Reconciliations of such non-GAAP financial measures to the most
directly comparable GAAP financial measures are set forth within the “Consolidated Results” and “Segment Results” sections and below.
(Dollars in millions except per share amounts) 2023 2022
Reconciliation of adjusted operating income and adjusted operating income margin
GAAP operating income $ 6,859 16.0 % $ 8,393 18.7 %
Cost of revenues adjustments (a) 95 0.2 % 46 0.1 %
Selling, general and administrative expenses adjustments (b) 59 0.1 % 37 0.1 %
Restructuring and other costs (c) 459 1.1 % 114 0.3 %
Amortization of acquisition-related intangible assets 2,338 5.5 % 2,395 5.3 %
Adjusted operating income (non-GAAP measure) $ 9,810 22.9 % $ 10,985 24.5 %
Reconciliation of adjusted other income/(expense)
GAAP other income/(expense) $ (65) $ (104)
Adjustments (d) 50 117
Adjusted other income/(expense) (non-GAAP measure) $ (15) $ 13
Reconciliation of adjusted tax rate
GAAP tax rate 4.5 % 9.0 %
Adjustments (e) 5.5 % 4.0 %
Adjusted tax rate (non-GAAP measure) 10.0 % 13.0 %
Reconciliation of adjusted earnings per share
GAAP diluted earnings per share (EPS) attributable to Thermo Fisher Scientific Inc. $ 15.45 $ 17.63
Cost of revenues adjustments (a) 0.24 0.12
Selling, general and administrative expenses adjustments (b) 0.15 0.09
Restructuring and other costs (c) 1.18 0.29
Amortization of acquisition-related intangible assets 6.03 6.07
Other income/expense adjustments (d) 0.13 0.30
Provision for income taxes adjustments (e) (1.66) (1.70)
Equity in earnings/losses of unconsolidated entities 0.15 0.44
Noncontrolling interests adjustments (f) (0.12) —
Adjusted EPS (non-GAAP measure) $ 21.55 $ 23.24
25
-- 25 of 225 --
THERMO FISHER SCIENTIFIC INC.
(Dollars in millions except per share amounts) 2023 2022
Reconciliation of free cash flow
GAAP net cash provided by operating activities $ 8,406 $ 9,154
Purchases of property, plant and equipment (1,479) (2,243)
Proceeds from sale of property, plant and equipment 87 24
Free cash flow (non-GAAP measure) $ 7,014 $ 6,935
(a) Adjusted results in 2023 and in 2022 exclude charges for the sale of inventories revalued at the date of acquisition and charges for inventory write-downs associated with
large-scale abandonment of product lines. Adjusted results in 2023 also exclude $13 million of accelerated depreciation on manufacturing assets to be abandoned due to
facility consolidations.
(b) Adjusted results in 2023 and 2022 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in
estimates of contingent acquisition consideration, and charges associated with product liability litigation.
(c) Adjusted results in 2023 and 2022 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, charges for environmental-
related matters, abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $26 million of contract
termination costs associated with facility closures, $19 million of net charges for pre-acquisition litigation and other matters, and $11 million of gains on the sale of real
estate. Adjusted results in 2022 also exclude $14 million of gain on the sale of intellectual property.
(d) Adjusted results exclude net gains/losses on investments. Adjusted results in 2022 also exclude $67 million of net gains on derivative instruments to address certain foreign
currency risks and $26 million of losses on the early extinguishment of debt.
(e) Adjusted results in 2023 and 2022 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of
tax rate/law changes and the tax impacts from audit settlements (including a $658 million benefit from an audit settlement in 2022). Adjusted results in 2023 also exclude
$14 million of charges for pre-acquisition matters. Adjusted results in 2022 also exclude a $423 million charge for the impact of deferred tax realizability assessments as a
result of audit settlements.
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests.
Critical Accounting Policies and Estimates
The company’s discussion and analysis of its financial condition and results of operations is based upon its financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management
to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent liabilities.
On an on-going basis, management evaluates its estimates, including those related to acquisition-related measurements and income taxes. Management
believes the most complex and sensitive judgments, because of their significance to the consolidated financial statements, result primarily from the need to
make estimates about the effects of matters that are inherently uncertain. Management bases its estimates on historical experience, current market and
economic conditions and other assumptions that management believes are reasonable. The results of these estimates form the basis for judgments about the
carrying value of assets and liabilities where the values are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions.
The company believes the following represent its critical accounting policies and estimates used in the preparation of its financial statements:
Acquisition-related Measurements
Business Combinations
The company uses assumptions and estimates in determining the fair value of assets acquired and liabilities assumed in a business combination. The
determination of the fair value of intangible assets, which represent a significant portion of the purchase price in many of the company’s acquisitions, requires
the use of significant judgment with regard to (i) the fair value and (ii) whether such intangibles are amortizable or non-amortizable and, if the former, the
period and the method by which the intangible asset will be amortized. The company estimates the fair value of acquisition-related intangible assets principally
based on projections of cash flows that will arise from identifiable intangible assets of acquired businesses, which include estimates of customer attrition and
technology obsolescence rates. The projected cash flows are discounted to determine the present value of the assets at the dates of acquisition. See Note 2 for
additional information about our recent business combinations.
26
-- 26 of 225 --
THERMO FISHER SCIENTIFIC INC.
Goodwill and Indefinite-lived Intangible Assets
The company evaluates goodwill and indefinite-lived intangible assets for impairment annually and when events occur or circumstances change that would
more likely than not reduce the fair value of an asset below its carrying amount. Events or circumstances that might require an interim evaluation include
unexpected adverse business conditions, economic factors, unanticipated technological changes or competitive activities, loss of key personnel and acts by
governments and courts, among others. Goodwill and indefinite-lived intangible assets totaled $44.02 billion and $1.24 billion, respectively, at December 31,
2023 (see Note 1 for additional information). Estimates of discounted future cash flows require assumptions related to revenue and operating income growth
rates, discount rates and other factors. For the goodwill impairment tests, the company also considers (i) peer revenues and earnings trading multiples from
companies that have operational and financial characteristics that are similar to the respective reporting units and (ii) estimated weighted average costs of
capital. Different assumptions from those made in the company’s analysis could materially affect projected cash flows and the company’s evaluation of
goodwill and indefinite-lived intangible assets for impairment.
The company performed the quantitative goodwill impairment test for all of its reporting units and indefinite-lived intangible assets. Determinations of fair
value based on projections of discounted cash flows, which decreased from the prior year projections primarily due to higher discount rates, and based on peer
revenues and earnings trading multiples, which also decreased from the prior year, were sufficient to conclude that no impairments of goodwill or indefinite-
lived intangible assets existed at the end of the tenth fiscal month of 2023, the date of the company’s annual impairment testing. There were no interim
impairments of goodwill or indefinite-lived intangible assets in 2023. There can be no assurance, however, that adverse events or conditions will not cause the
fair values of these assets to decline. Should the fair values of the company’s reporting units or indefinite-lived intangible assets decline because of reduced
operating performance, market declines, or other indicators of impairment, or as a result of changes in the discount rates, charges for impairment may be
necessary.
During its annual 2023 goodwill impairment assessments, the company determined that the excess of fair value over carrying value for one of the clinical
research business’s reporting units had increased to 4%. Despite this favorable increase, given that the fair value of the reporting unit was not substantially in
excess of its carrying value as of the annual 2023 assessment date, relatively small decreases in future cash flows versus anticipated results, decreases in peer
trading multiples and/or increases in weighted average costs of capital could result in impairment of goodwill. The reporting unit had $3.95 billion of goodwill,
and an overall carrying value of $5.54 billion as of December 31, 2023.
Definite-lived Intangible Assets
Definite-lived intangible assets totaled $15.44 billion at December 31, 2023 (see Note 1 for additional information). Certain definite-lived intangible assets
have largely independent cash flows. The company reviews these definite-lived intangible assets for impairment individually when indication of potential
impairment exists, such as a significant reduction in cash flows associated with the assets. Actual cash flows arising from a particular intangible asset could
vary from projected cash flows, which could imply different carrying values from those established at the dates of acquisition and which could result in
impairment of such asset. Most of the company’s definite-lived intangible assets are used in conjunction with other assets, such as property, plant and
equipment and operating lease right-of-use assets. In these situations, the company considers the asset groups to be the units of account for impairment testing.
The company recorded definite-lived intangible asset impairments of $0.01 billion and $0.12 billion in 2023 and 2021, respectively (Note 16).
Income Taxes
Unrecognized Tax Benefits
In the ordinary course of business there is inherent uncertainty in quantifying the company’s income tax positions. The company assesses income tax positions
and records tax benefits for all years subject to examination based upon management’s evaluation of the facts, circumstances and information available at the
reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the company has recorded the largest amount of tax
benefit with a greater than 50 percent likelihood of being realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant
information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, no tax benefit has been recognized in the
financial statements. Should tax return positions that the company expects are sustainable not be sustained upon audit, the company could be required to record
an incremental tax provision for such taxes. The company’s liability for these unrecognized tax benefits totaled $0.54 billion at December 31, 2023, compared
to $0.57 billion at December 31, 2022, primarily as a result of an audit settlement (Note 8).
The company operates in numerous countries under many legal forms and, as a result, is subject to the jurisdiction of numerous domestic and non-U.S. tax
authorities, as well as to tax agreements and treaties among these governments. Determination of taxable income in any jurisdiction requires the company to
interpret the related tax laws and regulations and the use of estimates and assumptions regarding significant future events, such as the amount, timing and
character of deductions, permissible
27
-- 27 of 225 --
THERMO FISHER SCIENTIFIC INC.
revenue recognition methods under the tax law and the sources and character of income and tax credits. Changes in tax laws, regulations, agreements and
treaties, currency exchange restrictions or the company’s level of operations or profitability in each taxing jurisdiction could have an impact upon the amount
of current and deferred tax balances and hence the company’s net income.
Valuation Allowances
The company estimates the degree to which tax assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation
allowance for tax assets that it believes will more likely than not go unused. In situations in which the company has been able to determine that its deferred tax
assets will be realized, that determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it
becomes more likely than not that a tax asset will be used, the company reverses the related valuation allowance. Any such reversals are recorded as a reduction
of the company’s tax provision. The company’s tax valuation allowance totaled $1.32 billion at both December 31, 2023 and December 31, 2022 (Note 8).
Should the company’s actual future taxable income by tax jurisdiction vary from estimates, additional allowances or reversals thereof may be necessary.
Recent Accounting Pronouncements
A description of recently issued accounting standards is included under the heading “Recent Accounting Pronouncements” in Note 1.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
The company is exposed to market risk from changes in interest rates and currency exchange rates, which could affect its future results of operations and
financial condition. The company manages its exposure to these risks through its regular operating and financing activities. The company has periodically
hedged interest rate risks of fixed-rate instruments with offsetting interest rate swaps. Additionally, the company uses short-term forward and option contracts
primarily to hedge certain balance sheet and operational exposures resulting from changes in currency exchange rates. Such exposures result from purchases,
sales, cash and intercompany loans that are denominated in currencies other than the functional currencies of the respective operations. The currency-exchange
contracts principally hedge transactions denominated in euro, British pounds sterling, Canadian dollars, Singapore dollars, Czech koruna, Hong Kong dollars
and Swedish krona. Income and losses arising from these derivative contracts are recognized as offsets to losses and income resulting from the underlying
exposure being hedged. The company does not enter into speculative derivative agreements.
Interest Rates
The company is exposed to changes in interest rates while conducting normal business operations as a result of ongoing investing and financing activities,
which affect the company’s debt as well as cash and cash equivalents. As of December 31, 2023, the company’s debt portfolio was comprised primarily of
fixed rate borrowings. The fair market value of the company’s fixed interest rate debt is subject to interest rate risk. Generally, the fair market value of fixed
interest rate debt will increase as interest rates fall and decrease as interest rates rise. The total estimated fair value of the company’s debt at December 31, 2023
was $32.27 billion (Note 14). Fair values were determined from available market prices using current interest rates and terms to maturity. If interest rates were
to decrease by 100 basis points, the fair value of the company’s debt at December 31, 2023 would increase by approximately $2.33 billion. If interest rates were
to increase by 100 basis points, the fair value of the company’s debt at December 31, 2023 would decrease by approximately $2.05 billion.
In addition, the fair value of the company’s cross-currency interest rate swap arrangements is subject to interest rate risk. If interest rates were to decrease by
100 basis points, the fair value of the company’s cross-currency interest rate swaps at December 31, 2023 would decrease by approximately $0.39 billion. If
interest rates were to increase by 100 basis points, the fair value of the company’s cross-currency interest rate swaps at December 31, 2023 would increase by
approximately $0.53 billion.
Currency Exchange Rates
The company views its investments in international subsidiaries with a functional currency other than the U.S. dollar as permanent. The company’s investment
in international subsidiaries is sensitive to fluctuations in currency exchange rates. The functional currencies of the company’s international subsidiaries are
principally denominated in British pounds sterling, euro, Swedish krona, Canadian dollars, Norwegian kroner and Danish kroner. The effect of a change in the
period ending currency exchange rates on the company’s net investment in international subsidiaries is reflected in the “accumulated other comprehensive
items” component of shareholders’ equity. The company also uses foreign currency-denominated debt to partially hedge its net investments in foreign
operations against adverse movements in exchange rates. A 10% depreciation in year-end 2023 functional currencies, relative to the U.S. dollar, would result in
a reduction of shareholders’ equity of approximately $1.26 billion.
28
-- 28 of 225 --
THERMO FISHER SCIENTIFIC INC.
The fair value of forward currency-exchange contracts is sensitive to changes in currency exchange rates. The fair value of forward currency-exchange
contracts is the estimated amount that the company would pay or receive upon termination of the contract, taking into account the change in currency exchange
rates. A 10% depreciation in year-end 2023 non-functional currency exchange rates related to the company’s contracts would result in an unrealized loss on
forward currency-exchange contracts of $43 million. A 10% appreciation in year-end 2023 non-functional currency exchange rates related to the company’s
contracts would result in an additional unrealized gain on forward currency-exchange contracts of $49 million. The unrealized gains or losses on forward
currency-exchange contracts resulting from changes in currency exchange rates are expected to approximately offset losses or gains on the exposures being
hedged.
Certain of the company’s cash and cash equivalents are denominated in currencies other than the functional currency of the depositor and are sensitive to
changes in currency exchange rates. A 10% depreciation in the related year-end 2023 non-functional currency exchange rates applied to such cash balances
would result in a negative impact of $13 million on the company’s net income.
Item 8. Financial Statements and Supplementary Data
INDEX OF CONSOLIDATED FINANCIAL STATEMENTS
Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 238) 30
Consolidated Balance Sheets as of December 31, 2023 and 2022 33
Consolidated Statements of Income for the years ended December 31, 2023, 2022 and 2021 34
Consolidated Statements of Comprehensive Income for the years ended December 31, 2023, 2022 and 2021 35
Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 36
Consolidated Statements of Redeemable Noncontrolling Interest and Equity for the years ended December 31, 2023, 2022 and 2021 37
Notes to Consolidated Financial Statements
Note 1. Nature of Operations and Summary of Significant Accounting Policies 38
Note 2. Acquisitions 44
Note 3. Revenues and Contract-related Balances 48
Note 4. Business Segment and Geographical Information 49
Note 5. Other Income/(Expense) 51
Note 6. Stock-based Compensation Expense 51
Note 7. Pension and Other Postretirement Benefit Plans 53
Note 8. Income Taxes 58
Note 9. Earnings per Share 61
Note 10. Debt and Other Financing Arrangements 61
Note 11. Leases 64
Note 12. Commitments and Contingencies 65
Note 13. Comprehensive Income/(Loss) and Shareholders' Equity 67
Note 14. Fair Value Measurements and Fair Value of Financial Instruments 67
Note 15. Supplemental Cash Flow Information 70
Note 16. Restructuring and Other Costs 71
29
-- 29 of 225 --
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Thermo Fisher Scientific Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Thermo Fisher Scientific Inc. and its subsidiaries (the “Company”) as of December 31, 2023
and 2022, and the related consolidated statements of income, of comprehensive income, of redeemable noncontrolling interest and equity and of cash flows for
each of the three years in the period ended December 31, 2023, including the related notes (collectively referred to as the “consolidated financial statements”).
We also have audited the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control -
Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of
December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023 in
conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material
respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control - Integrated Framework
(2013) issued by the COSO.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and
for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Annual Report on Internal Control Over Financial
Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's
internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable
assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal
control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and
significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control
over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and
testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other
procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over
financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect
the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being
made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or
timely
30
-- 30 of 225 --
detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated
or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements
and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our
opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate
opinion on the critical audit matter or on the accounts or disclosures to which it relates.
Income taxes
As described in Note 8 to the consolidated financial statements, the Company’s provision for income taxes for the year ended December 31, 2023 was $284
million. The Company has deferred tax liabilities, net, of $1,091 million (including a valuation allowance of $1,317 million) and unrecognized tax benefits of
$540 million as of December 31, 2023. As disclosed by management, the Company operates in numerous countries under many legal forms and, as a result, is
subject to the jurisdiction of numerous domestic and non-U.S. tax authorities, as well as to tax agreements and treaties among these governments.
Determination of taxable income in any jurisdiction requires management to interpret the related tax laws and regulations and to use estimates and assumptions
regarding significant future events, such as the amount, timing and character of deductions, permissible revenue recognition methods under the tax law and the
sources and character of income and tax credits. Management assesses income tax positions and records tax benefits for all years subject to examination based
upon management’s evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where it is more likely than
not that a tax benefit will be sustained, management has recorded the largest amount of tax benefit with a greater than 50 percent likelihood of being realized
upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where it is not more likely
than not that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Management estimates the degree to which tax
assets will result in a benefit, after consideration of all positive and negative evidence, and provides a valuation allowance for tax assets that it believes will
more likely than not go unused. In situations in which management has been able to determine that the Company’s deferred tax assets will be realized, that
determination generally relies on future reversals of taxable temporary differences and expected future taxable income. If it becomes more likely than not that a
tax asset will be used, management reverses the related valuation allowance.
The principal considerations for our determination that performing procedures relating to income taxes is a critical audit matter are (i) the significant judgment
by management when interpreting the numerous and complex tax laws and regulations as it relates to determining the provision for income taxes, deferred tax
assets and liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits, (ii) a high degree of auditor judgment, subjectivity, and
effort in performing procedures and evaluating audit evidence related to the provision for income taxes, deferred tax assets and liabilities, including the
valuation allowance, and liabilities for unrecognized tax benefits, and (iii) the audit effort involved the use of professionals with specialized skill and
knowledge.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated
financial statements. These procedures included testing the effectiveness of controls relating to the provision for income taxes, deferred tax assets and
liabilities, including the valuation allowance, and liabilities for unrecognized tax benefits. These procedures also included, among others (i) testing the accuracy
of the provision for income taxes, including the rate reconciliation and permanent and temporary differences, (ii) evaluating whether the data utilized in the
calculations of the provision for income taxes, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits were appropriate and consistent
with evidence obtained in other areas of the audit, (iii) evaluating management’s assessment of the realizability of deferred tax assets on a jurisdictional basis,
(iv) evaluating the identification of liabilities for unrecognized tax benefits and the reasonableness of the more likely than not
31
-- 31 of 225 --
determination in consideration of court decisions, legislative actions, statutes of limitations, and developments in tax examinations by jurisdiction, (v) testing
the calculation of the liability for unrecognized tax benefits by jurisdiction, including estimates of the amount of income tax benefit expected to be sustained,
and (vi) evaluating the adequacy of the Company’s disclosures. Professionals with specialized skill and knowledge were used to assist in evaluating the
reasonableness of management’s judgments and estimates related to the application of foreign and domestic tax laws and regulations.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 22, 2024
We have served as the Company’s auditor since 2002.
32
-- 32 of 225 --
THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED BALANCE SHEETS
December 31, December 31,
(In millions except share and per share amounts) 2023 2022
Assets
Current assets:
Cash and cash equivalents $ 8,077 $ 8,524
Accounts receivable, less allowances of $193 and $189 8,221 8,115
Inventories 5,088 5,634
Contract assets, net 1,443 1,312
Other current assets 1,760 1,644
Total current assets 24,589 25,229
Property, plant and equipment, net 9,448 9,280
Acquisition-related intangible assets, net 16,670 17,442
Other assets 3,999 4,007
Goodwill 44,020 41,196
Total assets $ 98,726 $ 97,154
Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations $ 3,609 $ 5,579
Accounts payable 2,872 3,381
Accrued payroll and employee benefits 1,596 2,095
Contract liabilities 2,689 2,601
Other accrued expenses 3,246 3,354
Total current liabilities 14,012 17,010
Deferred income taxes 1,922 2,849
Other long-term liabilities 4,642 4,238
Long-term obligations 31,308 28,909
Commitments and contingencies (Note 12)
Redeemable noncontrolling interest 118 116
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued
Common stock, $1 par value, 1,200,000,000 shares authorized; 442,188,634 and 440,668,112 shares issued 442 441
Capital in excess of par value 17,286 16,743
Retained earnings 47,364 41,910
Treasury stock at cost, 55,541,290 and 50,157,275 shares (15,133) (12,017)
Accumulated other comprehensive income/(loss) (3,224) (3,099)
Total Thermo Fisher Scientific Inc. shareholders’ equity 46,735 43,978
Noncontrolling interests (11) 54
Total equity 46,724 44,032
Total liabilities, redeemable noncontrolling interest and equity $ 98,726 $ 97,154
The accompanying notes are an integral part of these consolidated financial statements.
33
-- 33 of 225 --
THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENTS OF INCOME
Year Ended
December 31, December 31, December 31,
(In millions except per share amounts) 2023 2022 2021
Revenues
Product revenues $ 25,243 $ 28,548 $ 30,361
Service revenues 17,614 16,367 8,850
Total revenues 42,857 44,915 39,211
Costs and operating expenses:
Cost of product revenues 13,168 14,247 13,594
Cost of service revenues 12,589 11,697 5,979
Selling, general and administrative expenses 8,445 8,993 8,007
Research and development expenses 1,337 1,471 1,406
Restructuring and other costs 459 114 197
Total costs and operating expenses 35,998 36,522 29,183
Operating income 6,859 8,393 10,028
Interest income 879 272 43
Interest expense (1,375) (726) (536)
Other income/(expense) (65) (104) (694)
Income before income taxes 6,298 7,835 8,841
Provision for income taxes (284) (703) (1,109)
Equity in earnings/(losses) of unconsolidated entities (59) (172) (4)
Net income 5,955 6,960 7,728
Less: net (losses) income attributable to noncontrolling interests and redeemable noncontrolling
interest (40) 10 3
Net income attributable to Thermo Fisher Scientific Inc. $ 5,995 $ 6,950 $ 7,725
Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic $ 15.52 $ 17.75 $ 19.62
Diluted $ 15.45 $ 17.63 $ 19.46
Weighted average shares
Basic 386 392 394
Diluted 388 394 397
The accompanying notes are an integral part of these consolidated financial statements.
34
-- 34 of 225 --
THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Year Ended
December 31, December 31, December 31,
(In millions) 2023 2022 2021
Comprehensive income
Net income $ 5,955 $ 6,960 $ 7,728
Other comprehensive income/(loss):
Currency translation adjustment:
Currency translation adjustment (net of tax provision (benefit) of $(134), $173 and $231) (69) (822) 373
Unrealized gains and losses on hedging instruments:
Reclassification adjustment for losses included in net income (net of tax benefit of $2, $1
and $17) 5 2 56
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net
of tax provision (benefit) of $(22), $9 and $11) (69) 38 36
Amortization of net loss and prior service benefit included in net periodic pension cost (net
of tax benefit of $1, $3 and $6) — 5 13
Total other comprehensive income/(loss) (133) (777) 478
Comprehensive income 5,822 6,183 8,206
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable
noncontrolling interest (48) 3 2
Comprehensive income attributable to Thermo Fisher Scientific Inc. $ 5,870 $ 6,180 $ 8,204
The accompanying notes are an integral part of these consolidated financial statements.
35
-- 35 of 225 --
THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
Year Ended
December 31, December 31, December 31,
(In millions) 2023 2022 2021
Operating activities
Net income $ 5,955 $ 6,960 $ 7,728
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment 1,068 986 831
Amortization of acquisition-related intangible assets 2,338 2,395 1,761
Change in deferred income taxes (1,300) (995) (647)
Stock-based compensation 278 307 230
Loss on early extinguishment of debt — 26 767
Other non-cash expenses 604 524 190
Changes in assets and liabilities, excluding the effects of acquisitions:
Accounts receivable (43) (430) (204)
Inventories 598 (825) (1,065)
Contract assets/liabilities 252 (354) 221
Accounts payable (500) 648 479
Contributions to retirement plans (42) (41) (34)
Other (802) (47) (945)
Net cash provided by operating activities 8,406 9,154 9,312
Investing activities
Acquisitions, net of cash acquired (3,660) (39) (19,395)
Purchase of property, plant and equipment (1,479) (2,243) (2,523)
Proceeds from sale of property, plant and equipment 87 24 20
Proceeds from cross-currency interest rate swap interest settlements 70 15 8
Other investing activities, net (160) 84 (42)
Net cash used in investing activities (5,142) (2,159) (21,932)
Financing activities
Net proceeds from issuance of debt 5,942 3,193 18,137
Repayment of debt (5,782) (375) (11,738)
Proceeds from issuance of commercial paper 1,620 1,526 2,512
Repayments of commercial paper (1,935) (3,690) —
Purchases of company common stock (3,000) (3,000) (2,000)
Dividends paid (523) (455) (395)
Other financing activities, net 56 (9) 65
Net cash (used in) provided by financing activities (3,622) (2,810) 6,581
Exchange rate effect on cash (82) (139) 194
(Decrease) increase in cash, cash equivalents and restricted cash (440) 4,046 (5,845)
Cash, cash equivalents and restricted cash at beginning of year 8,537 4,491 10,336
Cash, cash equivalents and restricted cash at end of year $ 8,097 $ 8,537 $ 4,491
The accompanying notes are an integral part of these consolidated financial statements.
36
-- 36 of 225 --
THERMO FISHER SCIENTIFIC INC.
CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY
Redeemable
Noncontrolling
Interest
Common Stock Capital in
Excess of
Par Value Retained
Earnings
Treasury Stock
Accumulated
Other
Comprehensive
Items
Total
Thermo Fisher
Scientific Inc.
Shareholders’
Equity Noncontrolling
Interests Total Equity (In millions) Shares Amount Shares Amount
Balance at December 31, 2020 $ — 437 $ 437 $ 15,579 $ 28,116 40 $ (6,818) $ (2,807) $ 34,507 $ 10 $ 34,517
Issuance of shares under stock
plans — 2 2 324 — 1 (104) — 222 — 222
Stock-based compensation — — — 230 — — — — 230 — 230
Purchases of company common
stock — — — — — 4 (2,000) — (2,000) — (2,000)
Dividends declared ($1.04 per
share) — — — — (410) — — — (410) — (410)
Recognition upon acquisition 122 — — — — — — — — — —
Net income/(loss) 1 — — — 7,725 — — — 7,725 2 7,727
Other comprehensive
income/(loss) (1) — — — — — — 478 478 — 478
Contributions from (distributions
to) noncontrolling interests — — — — — — — — — 50 50
Other — — — 41 — — — — 41 — 41
Balance at December 31, 2021 122 439 439 16,174 35,431 45 (8,922) (2,329) 40,793 62 40,855
Issuance of shares under stock
plans — 2 2 262 — — (95) — 169 — 169
Stock-based compensation — — — 307 — — — — 307 — 307
Purchases of company common
stock — — — — — 5 (3,000) — (3,000) — (3,000)
Dividends declared ($1.20 per
share) — — — — (471) — — — (471) — (471)
Net income/(loss) 15 — — — 6,950 — — — 6,950 (5) 6,945
Other comprehensive
income/(loss) (6) — — — — — — (770) (770) (1) (771)
Contributions from (distributions
to) noncontrolling interests (15) — — — — — — — — (2) (2)
Balance at December 31, 2022 116 441 441 16,743 41,910 50 (12,017) (3,099) 43,978 54 44,032
Issuance of shares under stock
plans — 1 1 265 — 1 (88) — 178 — 178
Stock-based compensation — — — 278 — — — — 278 — 278
Purchases of company common
stock — — — — — 5 (3,000) — (3,000) — (3,000)
Dividends declared ($1.40 per
share) — — — — (541) — — — (541) — (541)
Net income/(loss) 19 — — — 5,995 — — — 5,995 (59) 5,936
Other comprehensive
income/(loss) (3) — — — — — — (125) (125) (5) (130)
Contributions from (distributions
to) noncontrolling interests (14) — — — — — — — — (1) (1)
Excise tax from stock
repurchases — — — — — — (28) — (28) — (28)
Balance at December 31, 2023 $ 118 442 $ 442 $ 17,286 $ 47,364 56 $ (15,133) $ (3,224) $ 46,735 $ (11) $ 46,724
The accompanying notes are an integral part of these consolidated financial statements.
37
-- 37 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1. Nature of Operations and Summary of Significant Accounting Policies
Nature of Operations
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life
sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development
and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as
healthcare and diagnostics.
Principles of Consolidation
The accompanying financial statements include the accounts of the company and its wholly and majority-owned subsidiaries. All material intercompany
accounts and transactions have been eliminated. The company accounts for investments in businesses using the equity method when it has the ability to
exercise significant influence but not control (generally between 20% and 50% ownership), is not the primary beneficiary and has not elected the fair value
option. At December 31, 2023 and 2022, the company had such investments with carrying amounts of $489 million and $369 million, respectively. The
company has elected the fair value option of accounting for certain of its investments with readily determinable fair values that would otherwise be accounted
for under the equity method. At December 31, 2023 and 2022, the fair value of such investments was $5 million and $7 million, respectively.
Redeemable Noncontrolling Interest
The company owns 60% of its consolidated subsidiary PPD-SNBL K.K. The 40% ownership interest held by a third party is classified as a redeemable
noncontrolling interest on the consolidated balance sheet due to certain put options under which the third party may require the company to purchase the
remaining ownership interest at a premium upon the occurrence of certain events.
Presentation
Certain reclassifications of prior year amounts have been made to conform to the current year presentation.
Revenue Recognition
Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer,
which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at
a point in time in a manner similar to consumables. Service revenues (primarily clinical research, pharmaceutical, and instrument and enterprise services) are
recognized over time as customers receive and consume the benefits of such services. For revenues recognized over time, the company generally uses costs
accumulated relative to total estimated costs to measure progress as this method approximates satisfaction of the performance obligation. For contracts that
contain multiple performance obligations, the company allocates the consideration to which it expects to be entitled (i.e., the transaction price) to each
performance obligation based on relative standalone selling prices and recognizes the related revenues when or as control of each individual performance
obligation is transferred to customers. The company exercises judgment in determining the timing of revenue by analyzing the point in time or the period over
which the customer has the ability to direct the use of and obtain substantially all of the remaining benefits of the asset. The company immediately expenses
contract costs that would otherwise be capitalized and amortized over a period of less than one year.
Changes to the scope of services contracts generally also include changes in the transaction price. Typically, these contract modifications are not distinct from
existing services provided under the contract, and result in cumulative adjustments to revenue on the modification date. However, some modifications are
distinct from existing services provided under the contract and recognized prospectively.
Payments from customers for most instruments and consumables are typically due in a fixed number of days after shipment or delivery of the product. Service
arrangements commonly call for payments in advance of performing the work (e.g., extended service contracts), upon completion of the service (e.g.,
pharmaceutical services) or a mix of both. Some arrangements include variable amounts of consideration that arise from discounts, rebates, and other programs
and practices. In such arrangements, the company estimates the amount by which to reduce the stated contract amount to reflect the transaction price. The
company records reimbursement for third-party pass-through and out-of-pocket costs as revenues and the related expenses as costs of revenues.
38
-- 38 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Contract-related Balances
Accounts receivable include unconditional rights to consideration from customers, which generally represent billings that do not bear interest. The company
maintains allowances for doubtful accounts for estimates of expected losses resulting from the inability of its customers to pay amounts due. The allowance for
doubtful accounts is the company’s best estimate of the amount of probable credit losses in existing accounts receivable. The company determines the
allowance based on history of similarly aged receivables, the creditworthiness of the customer, reasons for delinquency, current economic conditions,
expectations associated with future events and circumstances where reasonable and supportable forecasts are available and any other information that is
relevant to the judgment. Receivables from academic and government customers as well as large, well-capitalized commercial customers have historically
experienced less collectability risk. Account balances are charged off against the allowance when the company believes it is probable the receivable will not be
recovered. The company does not have any off-balance-sheet credit exposure related to customers.
Contract assets include revenues recognized in advance of billings where the company’s right to bill includes something other than the passage of time. Such
amounts are recorded net of estimated losses resulting from the inability to invoice customers, which is primarily due to risk associated with the company’s
performance. Contract assets are classified as current or noncurrent based on the amount of time expected to lapse until the company's right to consideration
becomes unconditional.
Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenues on
service contracts. Contract liabilities are classified as current or noncurrent based on the periods over which remaining performance obligations are expected to
be transferred to customers. Contract assets and liabilities are presented on a net basis in the consolidated balance sheet if they arise from different performance
obligations in the same contract.
Warranty Obligations
The company provides for the estimated cost of standard product warranties, primarily from historical information, in cost of product revenues at the time
product revenues are recognized. The liability for warranties is included in other accrued expenses in the accompanying balance sheet. Extended warranty
agreements are considered service contracts, which are discussed above. Costs of service contracts are recognized as incurred.
Leases
Operating leases that have commenced are included in other assets, other accrued expenses and other long-term liabilities in the consolidated balance sheet.
Finance leases that have commenced are included in property, plant and equipment, net, current maturities of long-term obligations and long-term obligations
in the consolidated balance sheet. Classification of lease liabilities as either current or noncurrent is based on the expected timing of payments due under the
company’s obligations.
Right-of-use (ROU) assets represent the company’s right to use an underlying asset for the lease term and lease liabilities represent the company’s obligation to
make lease payments arising from the lease. Lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of
lease payments over the lease term. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. The company
recognizes operating lease expense on a straight-line basis over the lease term. Finance lease expense includes depreciation, which is recognized on a straight-
line basis over the expected life of the leased asset, and an immaterial amount of interest expense.
Because most of the company’s leases do not provide an implicit interest rate, the company estimates incremental borrowing rates based on the information
available at the commencement date in determining the present value of lease payments. The company uses the implicit rate when readily determinable. Lease
terms include the effect of options to extend or terminate the lease when it is reasonably certain that the company will exercise that option.
As a lessee, the company accounts for the lease and non-lease components as a single lease component.
Research and Development
The company conducts research and development activities to increase its depth of capabilities in technologies, software and services. Research and
development costs include employee compensation and benefits, consultants, facilities related costs, material costs, depreciation and travel. Research and
development costs are expensed as incurred.
Restructuring Costs
Accounting for the timing and amount of termination benefits provided by the company to employees is determined based on whether: (a) the company has a
substantive plan to provide such benefits, (b) the company has a written employment contract with the affected employees that includes a provision for such
benefits, (c) the termination benefits are due to the occurrence of
39
-- 39 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
an event specified in an existing plan or agreement, or (d) the termination benefits are a one-time benefit. In certain circumstances, employee termination
benefits may meet more than one of the characteristics listed above and therefore, may have individual elements that are subject to different accounting models.
From time to time when executing a restructuring or exit plan, the company also incurs costs other than termination benefits, such as lease termination costs,
that are not associated with or will not be incurred to provide economic benefits to the company. These include costs that represent amounts under contractual
obligations that exist prior to the restructuring plan communication date and will either continue after the restructuring plan is completed with no economic
benefit or result in a penalty to cancel a contractual obligation. Such costs are recognized when incurred, which generally occurs at the contract termination or
over the period from when a plan to abandon a leased facility is approved through the cease-use date but charges may continue over the remainder of the
original contractual period.
Income Taxes
The company recognizes deferred income taxes based on the expected future tax consequences of differences between the financial statement basis and the tax
basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences are expected to be reflected in the tax return. A
valuation allowance is provided for tax assets that will more likely than not go unused.
The financial statements reflect expected future tax consequences of uncertain tax positions that the company has taken or expects to take on a tax return
presuming the taxing authorities’ full knowledge of the positions and all relevant facts, but without discounting for the time value of money.
Earnings per Share
Basic earnings per share has been computed by dividing net income attributable to Thermo Fisher Scientific Inc. by the weighted average number of shares
outstanding during the year. Except where the result would be antidilutive to net income attributable to Thermo Fisher Scientific Inc., diluted earnings per share
has been computed using the treasury stock method for outstanding stock options and restricted units.
Cash and Cash Equivalents
Cash equivalents consists principally of money market funds, commercial paper and other marketable securities purchased with an original maturity of three
months or less. These investments are carried at cost, which approximates market value.
Inventories
Inventories are valued at the lower of cost or net realizable value, cost being determined by the first-in, first-out (FIFO) method. As discussed below, prior to
the third quarter of 2021 certain of the company's businesses utilized the last-in, first-out (LIFO) method. The company periodically reviews quantities of
inventories on hand and compares these amounts to the expected use of each product or product line. In addition, the company has certain inventory that is
subject to fluctuating market pricing. The company records a charge to cost of sales for the amount required to reduce the carrying value of inventory to net
realizable value. Costs associated with the procurement of inventories, such as inbound freight charges, purchasing and receiving costs, and internal transfer
costs, are included in cost of revenues in the accompanying statement of income. The components of inventories are as follows:
December 31, December 31,
(In millions) 2023 2022
Raw materials $ 2,057 $ 2,405
Work in process 705 660
Finished goods 2,326 2,569
Inventories $ 5,088 $ 5,634
Prior to the third quarter of 2021, certain of the company’s businesses utilized the LIFO method of accounting for inventories. During the third quarter of 2021,
these businesses, which comprised approximately 5% of consolidated inventories, changed from the LIFO method to the FIFO method. The company believes
this change is preferable as it will provide a consistent, uniform costing method for all inventories across the company, better reflect the current value of
inventories, and improve comparability with peers. Prior financial statements have not been retrospectively adjusted due to immateriality. The cumulative pre-
tax effect of this change in accounting principle of $33 million was recorded as an increase to inventories and a decrease to cost of product revenues in the third
quarter of 2021. This change was recorded in the Laboratory Products and Biopharma
40
-- 40 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Services ($20 million) and Specialty Diagnostics ($13 million) segments. Reductions to cost of revenues as a result of the liquidation of LIFO inventories were
nominal during the first half of 2021.
Property, Plant and Equipment
Property, plant and equipment are recorded at cost. The costs of additions and improvements are capitalized, while maintenance and repairs are charged to
expense as incurred. The company generally provides for depreciation and amortization using the straight-line method over the estimated useful lives of the
property as follows: buildings and improvements, 25 to 40 years; machinery and equipment (including software), 3 to 10 years; and leasehold improvements,
the shorter of the term of the lease or the life of the asset. When assets are retired or otherwise disposed of, the assets and related accumulated depreciation are
eliminated from the accounts and the resulting gain or loss is reflected in the accompanying statement of income. Property, plant and equipment consists of the
following:
December 31, December 31,
(In millions) 2023 2022
Land $ 458 $ 454
Buildings and improvements 3,593 3,153
Machinery, equipment and leasehold improvements 9,235 7,967
Construction in progress 2,238 2,695
Property, plant and equipment, at cost 15,524 14,269
Less: Accumulated depreciation and amortization 6,076 4,989
Property, plant and equipment, net $ 9,448 $ 9,280
Acquisition-related Intangible Assets
Acquisition-related intangible assets include the costs of acquired customer relationships, product technology, tradenames, backlog and other specifically
identifiable intangible assets, and are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years. The
company reviews these intangible assets for impairment when indication of potential impairment exists, such as a significant reduction in cash flows associated
with the assets. When impairment indicators exist, the company determines whether the carrying value of its intangible assets exceeds the related undiscounted
cash flows. In these situations, the carrying value is written down to fair value.
In addition, the company has tradenames that have indefinite lives and which are not amortized. Intangible assets with indefinite lives are reviewed for
impairment annually or whenever events or changes in circumstances indicate they may be impaired. The company may perform an optional qualitative
assessment. If the company determines that the fair value of the indefinite-lived intangible asset is more likely than not greater than its carrying amount, no
additional testing is necessary. If not, or if the company bypasses the optional qualitative assessment, it writes the carrying value down to the fair value, if
applicable.
Acquisition-related intangible assets are as follows:
Balance at December 31, 2023 Balance at December 31, 2022
(In millions) Gross Accumulated
Amortization Net Gross Accumulated
Amortization Net
Definite lived:
Customer relationships $ 22,762 $ (9,410) $ 13,352 $ 21,792 $ (8,330) $ 13,462
Product technology 5,894 (4,591) 1,303 5,882 (4,360) 1,522
Tradenames 1,634 (1,079) 555 1,635 (1,008) 627
Backlog 1,084 (859) 225 1,038 (442) 596
31,374 (15,939) 15,435 30,347 (14,140) 16,207
Indefinite lived:
Tradenames 1,235 N/A 1,235 1,235 N/A 1,235
Acquisition-related intangible assets $ 32,609 $ (15,939) $ 16,670 $ 31,582 $ (14,140) $ 17,442
41
-- 41 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The estimated future amortization expense of acquisition-related intangible assets with definite lives as of December 31, 2023 is as follows:
(In millions)
2024 $ 1,931
2025 1,630
2026 1,460
2027 1,430
2028 1,398
2029 and thereafter 7,586
Estimated future amortization expense of definite-lived intangible assets $ 15,435
Other Assets
Other assets in the accompanying balance sheet include operating lease right-of-use assets, investments, deferred tax assets, pension assets, insurance recovery
receivables related to product liability matters, certain intangible assets and other assets.
At December 31, 2023 and 2022, the company had $37 million and $36 million, respectively, of intangible assets not derived from acquisitions, net of
accumulated amortization, which are being amortized using the straight-line method over their estimated useful lives, which range up to 20 years.
Equity investments that do not have readily determinable fair values and are not eligible for the net asset value (NAV) practical expedient are measured at cost
minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investments of the
same issuer. The company performs qualitative assessments to identify impairments of these investments. At December 31, 2023 and 2022, the company had
such investments with carrying amounts of $12 million and $55 million, respectively, and investments measured at NAV of $28 million and $22 million,
respectively, which are included in other assets.
Goodwill
The company assesses goodwill for impairment at the reporting unit level annually and whenever events occur or circumstances change that would more likely
than not reduce the fair value of a reporting unit below its carrying amount. Such events or circumstances generally include the occurrence of operating losses
or a significant decline in earnings associated with one or more of the company’s reporting units. The company is permitted to first assess qualitative factors to
determine whether the quantitative goodwill impairment test is necessary. If the qualitative assessment results in a determination that the fair value of a
reporting unit is more likely than not less than its carrying amount, the company performs a quantitative goodwill impairment test. The company may bypass
the qualitative assessment for the reporting unit in any period and proceed directly to the goodwill impairment test. The company estimates the fair value of its
reporting units by using forecasts of discounted future cash flows and peer market multiples. The company would record an impairment charge based on the
excess of a reporting unit’s carrying amount over its fair value (limited to the amount of goodwill). The company determined that no impairments existed in
2023, 2022 or 2021.
The changes in the carrying amount of goodwill by segment are as follows:
(In millions) Life Sciences
Solutions Analytical
Instruments Specialty
Diagnostics
Laboratory
Products and
Biopharma Services Total
Balance at December 31, 2021 $ 10,143 $ 5,043 $ 3,277 $ 23,461 $ 41,924
Acquisitions — 24 — — 24
Finalization of purchase price allocations for
2021 acquisitions 9 — — 168 177
Currency translation (6) (102) (186) (635) (929)
Balance at December 31, 2022 10,146 4,965 3,091 22,994 41,196
Acquisitions — 31 1,741 627 2,399
Currency translation 5 55 91 274 425
Balance at December 31, 2023 $ 10,151 $ 5,051 $ 4,923 $ 23,895 $ 44,020
42
-- 42 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Loss Contingencies
Accruals are recorded for various contingencies, including legal proceedings, environmental, workers’ compensation, product, general and auto liabilities, self-
insurance and other claims that arise in the normal course of business. The accruals are based on management’s judgment, historical claims experience, the
probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarial estimates. Additionally, the
company records receivables from third-party insurers up to the amount of the loss when recovery has been determined to be probable. Certain liabilities
acquired in acquisitions have been recorded at readily determinable fair values and, as such, were discounted to present value at the dates of acquisition.
Currency Translation
All assets and liabilities of the company’s subsidiaries operating in non-U.S. dollar currencies are translated at period-end exchange rates. Resulting translation
adjustments are reflected in the “accumulated other comprehensive items” component of shareholders’ equity. Revenues and expenses are translated at average
exchange rates for the period. Currency transaction gains/(losses) are included in the accompanying statement of income and in aggregate were $(67) million,
$62 million and $25 million in 2023, 2022 and 2021, respectively.
Derivative Contracts
The company is exposed to certain risks relating to its ongoing business operations including changes to interest rates and currency exchange rates. The
company uses derivative instruments primarily to manage currency exchange and interest rate risks. The company recognizes derivative instruments as either
assets or liabilities and measures those instruments at fair value. If a derivative is a hedge, depending on the nature of the hedge, changes in the fair value of the
derivative are either offset against the change in fair value of the hedged item through earnings or recognized in other comprehensive items until the hedged
item is recognized in earnings. Derivatives that are not designated as hedges are recorded at fair value through earnings.
The company uses short-term forward and option currency exchange contracts primarily to hedge certain balance sheet and operational exposures resulting
from changes in currency exchange rates, predominantly intercompany loans and cash balances that are denominated in currencies other than the functional
currencies of the respective operations. The currency-exchange contracts principally hedge transactions denominated in euro, British pounds sterling, Canadian
dollars, Singapore dollars, Czech koruna, Hong Kong dollars and Swedish krona. The company does not hold or engage in transactions involving derivative
instruments for purposes other than risk management.
Cash flow hedges. For derivative instruments that are designated and qualify as a cash flow hedge, the gain or loss on the derivative is reported as a
component of other comprehensive items and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings
and is presented in the same income statement line item as the earnings effect of the hedged item.
Fair value hedges. For derivative instruments that are designated and qualify as a fair value hedge, the gain or loss on the derivative, as well as the
offsetting loss or gain on the hedged item attributable to the hedged risk, are recognized in earnings.
Net investment hedges. The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest
rate swaps to partially hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-
denominated senior notes, certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are
effective as, economic hedges of part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate
fluctuations on the euro-denominated debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-
currency interest rate swaps, excluding interest accruals, are included in currency translation adjustment within other comprehensive items and
shareholders’ equity.
Government Assistance
From time to time, the company receives assistance from various governmental agencies generally in the form of cash or non-income tax credits. These
programs help offset the costs of certain research and development activities, facility construction and expansion efforts, or hiring objectives. When the
company believes that it is probable that it will meet the conditions tied to the assistance, it offsets the associated expense in the consolidated income statement.
Such amounts were not material to the consolidated financial statements as of and for the years ended December 31, 2023 and 2022.
43
-- 43 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period.
The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and
businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.
Recent Accounting Pronouncements
The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material
impact on the company's financial statements or disclosures.
Standard Description
Effective date for Thermo Fisher
and adoption approach
Impact of adoption
or other significant
matters
Standards recently adopted
Accounting Standards Update
(ASU) No. 2021-05, Leases (Topic
842): Lessors-Certain Leases with
Variable Lease Payments
Amended guidance to require lessors to classify leases as operating
leases if they have certain variable lease payment structures and would
have selling losses if they were classified as sales-type or direct
financing leases.
Third quarter of 2021 using a
prospective method Not material
ASU No. 2021-10, Government
Assistance (Topic 832):
Disclosures by Business Entities
about Government Assistance
New guidance to disclose information about certain types of
government assistance they receive, including cash grants and tax
credits. Among other things, the new guidance requires expanded
disclosure regarding the qualitative and quantitative characteristics of
the nature, amount, timing, and significant terms and conditions of
transactions with a government arising from a grant or other forms of
assistance accounted for under a contribution model.
Fourth quarter of 2022 using a
prospective method
Not material
ASU No. 2022-04, Liabilities-
Supplier Finance Programs
(Subtopic 405-50): Disclosure of
Supplier Finance Program
Obligations
New guidance to disclose information about supplier finance programs.
Among other things, the new guidance requires expanded disclosure
about key program terms, payment terms, and amounts outstanding for
obligations under supplier finance programs for each period presented.
Some aspects adopted in 2023 using a
retrospective method and will adopt
other aspects in 2024 using a
prospective method
Not material
Standards not yet adopted
ASU No. 2023-07, Segment
Reporting (Topic 280): Improving
Reportable Segment Disclosures
Among other things, new guidance to disclose significant segment
expenses and other items by reportable segment as well as information
about the chief operating decision maker.
2024 annual report and interim periods
thereafter using a retrospective method
Will increase
disclosures in Note 4
ASU No. 2023-09, Income Taxes
(Topic 740): Improvements to
Income Tax Disclosures
Among other things, new guidance to disclose additional information
about the tax rate reconciliation and income taxes paid.
2025 annual report and interim periods
thereafter using a prospective or
retrospective method
Will increase
disclosures in Note 8
Note 2. Acquisitions
The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill,
primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled
workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to
expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand
sales of company products and services.
44
-- 44 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying
financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as
incurred.
2023
On January 3, 2023, the company acquired, within the Specialty Diagnostics segment, The Binding Site Group, a U.K.-based provider of specialty diagnostic
assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders. The acquisition expands the segment’s
portfolio with the addition of pioneering innovation in diagnostics and monitoring for multiple myeloma. The goodwill recorded as a result of this business
combination is not tax deductible.
On August 14, 2023, the company acquired, within the Laboratory Products and Biopharma Services segment, CorEvitas, LLC, a U.S.-based provider of
regulatory-grade, real-world evidence for approved medical treatments and therapies. The acquisition expands the segment’s portfolio with the addition of
highly complementary real-world evidence solutions to enhance decision-making as well as the time and cost of drug development. The goodwill recorded as a
result of this business combination is not tax deductible.
The components of the purchase price and net assets acquired are as follows:
(In millions) The Binding Site CorEvitas
Purchase price
Cash paid $ 2,412 $ 730
Debt settled 307 184
Cash acquired (20) (4)
$ 2,699 $ 910
Net assets acquired
Definite-lived intangible assets
Customer relationships $ 868 $ 260
Product technology 162 47
Tradenames 42 —
Backlog — 46
Goodwill 1,741 627
Net tangible assets 174 (2)
Deferred tax assets (liabilities) (288) (68)
$ 2,699 $ 910
In addition, in 2023, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Raman-based spectroscopy solutions for in-
line measurement.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2023 are 18 years for customer relationships, 14 years for product
technology, 15 years for tradenames, and 13 years for backlog. The weighted-average amortization period for definite-lived intangible assets acquired in 2023
is 17 years.
Proposed Acquisition
On October 17, 2023, the company entered into a purchase agreement to acquire all of the issued and outstanding shares of Olink Holding AB (publ) at a price
of $26.00 per share, or approximately $3.1 billion. Olink is a leading provider of next-generation proteomics solutions that will expand the company’s
capabilities in this field. The company has commenced a tender offer to acquire all of the American Depositary Shares and common shares of Olink. The
transaction is expected to close by mid-year 2024, subject to the satisfaction of customary closing conditions including receipt of applicable regulatory
approvals, and completion of the tender offer. Upon completion, Olink will become part of the Life Sciences Solutions segment. The company intends to
finance the purchase price with cash on hand and the net proceeds from issuances of debt.
2022
In 2022, the company acquired, within the Analytical Instruments segment, a U.S.-based developer of Fourier-transform infrared gas analysis technologies.
45
-- 45 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
2021
On January 15, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, the Belgium-based European viral vector
manufacturing business of Groupe Novasep SAS. The European viral vector manufacturing business provides manufacturing services for vaccines and
therapies to biotechnology companies and large biopharma customers. The acquisition expands the segment’s capabilities for cell and gene vaccines and
therapies. The goodwill recorded as a result of this business combination is not tax deductible.
On February 25, 2021, the company acquired, within the Life Sciences Solutions segment, Mesa Biotech, Inc., a U.S.-based molecular diagnostic company.
Mesa Biotech has developed and commercialized a polymerase chain reaction (PCR) based rapid point-of-care testing platform available for detecting
infectious diseases including COVID-19. The acquisition enables the company to accelerate the availability of reliable and accurate advanced molecular
diagnostics at the point of care. The goodwill recorded as a result of this business combination is not tax deductible.
On September 30, 2021, the company assumed operating responsibility, within the Laboratory Products and Biopharma Services segment, of a new state-of-
the-art biologics manufacturing facility in Lengnau, Switzerland from CSL Limited to perform pharma services for CSL with capacity to serve other customers
as well. The goodwill recorded as a result of this business combination is not tax deductible.
On December 8, 2021, the company acquired, within the Laboratory Products and Biopharma Services segment, PPD, Inc., a U.S.-based global provider of
clinical research services to the pharma and biotech industry. The addition of PPD’s clinical research services enhances our offering to biotech and pharma
customers by enabling them to accelerate innovation and increase their productivity within the drug development process. The goodwill recorded as a result of
this business combination is not tax deductible.
On December 30, 2021, the company acquired, within the Life Sciences Solutions segment, PeproTech, Inc., a U.S.-based developer and manufacturer of
recombinant proteins. PeproTech provides bioscience reagents known as recombinant proteins, including cytokines and growth factors. The acquisition
expands the segment’s bioscience offerings. The goodwill recorded as a result of this business combination is not tax deductible.
In addition, in 2021, the company acquired, within the Life Sciences Solutions segment, cell sorting technology assets, an Ireland-based life sciences distributor
and a developer of a digital PCR platform; within the Analytical Instruments segment, a Belgium-based developer of micro-chip based technology for liquid
chromatography columns; and within the Specialty Diagnostics segment, a transplant diagnostics information system provider.
46
-- 46 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The components of the purchase price and net assets acquired for 2021 acquisitions are as follows:
(In millions) PPD PeproTech European Viral
Vector Business Mesa Biotech
Lengnau biologics
manufacturing
facility Other
Purchase price
Cash paid $ 17,237 $ 1,946 $ 848 $ 421 $ 17 $ 298
Fair value of equity awards
exchanged 43 — — — — —
Fair value of contingent
consideration — — — 65 1 117
Cash acquired (1,244) (83) (18) (14) — (12)
$ 16,036 $ 1,863 $ 830 $ 472 $ 18 $ 403
Net assets acquired
Current assets $ 2,477 $ 58 $ 39 $ 54 $ — $ 12
Property, plant and equipment 527 18 59 2 93 2
Definite-lived intangible assets:
Customer relationships 6,257 510 302 — — 2
Product technology — 282 25 279 — 224
Tradenames 594 — — 2 — 2
Backlog 1,038 — — — — —
Goodwill 13,949 1,198 600 237 18 198
Other assets 1,060 11 3 3 364 2
Contract liabilities (1,539) — (59) — — (1)
Deferred tax assets (liabilities) (1,782) (192) (80) (72) — (27)
Finance lease liabilities (90) — (24) — (82) —
Debt assumed (4,299) — — — — —
Other liabilities assumed (2,034) (22) (35) (33) (375) (11)
Redeemable noncontrolling interest (122) — — — — —
$ 16,036 $ 1,863 $ 830 $ 472 $ 18 $ 403
During 2022, we finalized the allocations of the purchase price for the Lengnau biologics manufacturing facility, PPD, Inc. and PeproTech, Inc., largely with
respect to definite-lived intangible assets, property, plant and equipment, contract liabilities, equity method investments, asset retirement obligations, defined
benefit pension plans, assumed contingent consideration and the related deferred taxes. The adjustments to the income statement recorded during 2022 were not
material.
The weighted-average amortization periods for definite-lived intangible assets acquired in 2021 are 17 years for customer relationships, 11 years for product
technology, 7 years for tradenames and 3 years for backlog. The weighted average amortization period for all definite-lived intangible assets acquired in 2021
is 14 years.
Unaudited Pro Forma Information
The following unaudited pro forma information provides the effect of the company's 2021 acquisition of PPD as if the acquisition had occurred on January 1,
2020:
47
-- 47 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Year Ended
December 31,
(In millions) 2021
Revenues $ 44,886
Net income attributable to Thermo Fisher Scientific Inc. $ 7,369
The historical consolidated financial information of the company and PPD has been adjusted in the pro forma information to give effect to pro forma events
that are directly attributable to the acquisitions and related financing arrangements and are factually supportable.
To reflect the acquisition of PPD as if it had occurred on January 1, 2020, the unaudited pro forma results include adjustments to reflect, among other things,
the incremental intangible asset amortization to be incurred based on the values of each identifiable intangible asset and the interest expense from debt
financings obtained to partially fund the cash consideration transferred. Pro forma adjustments were tax effected at the company's historical statutory rates in
effect for the respective periods. The unaudited pro forma amounts are not necessarily indicative of the combined results of operations that would have been
realized had the acquisitions and related financings occurred on the aforementioned dates nor are they meant to be indicative of any anticipated combined
results of operations that the company will experience after the transaction. In addition, the amounts do not include any adjustments for actions that may be
taken following the completion of the transaction, such as expected cost savings, operating synergies, or revenue enhancements that may be realized
subsequent to the transaction.
Pro forma net income attributable to Thermo Fisher Scientific Inc. for the year ended December 31, 2021, excludes $312 million of transaction costs, initial
restructuring costs, and debt extinguishment costs directly attributable to the PPD acquisition that were included in the determination of net income attributable
to Thermo Fisher Scientific Inc. for that period.
The company’s results would not have been materially different from its pro forma results had the company’s other 2021 acquisitions occurred at the beginning
of 2020.
PPD’s revenues and losses attributable to Thermo Fisher Scientific Inc. in 2021, subsequent to the acquisition date, were $378 million and $(60) million,
respectively. The loss includes non-recurring transaction and compensation costs.
Note 3. Revenues and Contract-related Balances
Disaggregated Revenues
Revenues by type are as follows:
(In millions) 2023 2022 2021
Revenues
Consumables $ 17,597 $ 20,624 $ 22,608
Instruments 7,646 7,924 7,753
Services 17,614 16,367 8,850
Consolidated revenues $ 42,857 $ 44,915 $ 39,211
Revenues by geographic region based on customer location are as follows:
(In millions) 2023 2022 2021
Revenues
North America $ 22,764 $ 24,594 $ 19,659
Europe 10,741 10,762 11,134
Asia-Pacific 7,873 8,115 7,218
Other regions 1,479 1,444 1,200
Consolidated revenues $ 42,857 $ 44,915 $ 39,211
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions. See Note 4 for
revenues by reportable segment and other geographic data.
48
-- 48 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Remaining Performance Obligations
The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2023 was
$26.92 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 53% of which is expected to occur
within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty
service agreements, which typically have durations of three to five years.
Contract-related Balances
Noncurrent contract assets and noncurrent contract liabilities are included within other assets and other long-term liabilities in the accompanying balance sheet,
respectively. Contract asset and liability balances are as follows:
December 31, December 31,
(In millions) 2023 2022
Current contract assets, net $ 1,443 $ 1,312
Noncurrent contract assets, net 4 7
Current contract liabilities 2,689 2,601
Noncurrent contract liabilities 1,499 1,179
Substantially all of the current contract liabilities balance at December 31, 2022 and 2021 was recognized in revenues during 2023 and 2022, respectively.
Noncurrent contract liabilities increased during 2023 primarily due to advanced payments from a customer.
Note 4. Business Segment and Geographical Information
The company’s financial performance is reported in four segments. A description of each segment follows.
Life Sciences Solutions: provides an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and
production of new drugs and vaccines as well as diagnosis of infection and disease. These products and services are used by customers in pharmaceutical,
biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Analytical Instruments: provides a broad offering of instruments and the supporting consumables, software and services that are used for a range of
applications in the laboratory and in the field. These products and services are used by customers in pharmaceutical, biotechnology, academic, government,
environmental and other research and industrial markets, as well as the clinical laboratory.
Specialty Diagnostics: offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare,
clinical, pharmaceutical, industrial, and food safety laboratories. Our healthcare products are used to increase the speed and accuracy of diagnoses, which
improves patient care in a more cost-efficient manner.
Laboratory Products and Biopharma Services: offers virtually everything needed for the laboratory. Our unique combination of self-manufactured and sourced
products and extensive service offering enables our customers to focus on their core activities and helps them to be more innovative, productive and cost-
efficient. The segment also includes a comprehensive offering of outsourced services used by the pharmaceutical and biotech industries for drug development,
clinical research, clinical trials services and commercial drug manufacturing.
The company’s management evaluates segment operating performance based on operating income before certain charges/credits to cost of revenues and
selling, general and administrative expenses, principally associated with acquisition accounting; restructuring and other costs/income including costs arising
from facility consolidations such as severance and abandoned lease expense and gains and losses from the sale of real estate and product lines as well as from
significant litigation-related matters; and amortization of acquisition-related intangible assets. The company uses this measure because it helps management
understand and evaluate the segments’ core operating results and facilitates comparison of performance for determining compensation.
49
-- 49 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Business Segment Information
(In millions) 2023 2022 2021
Revenues
Life Sciences Solutions $ 9,977 $ 13,532 $ 15,631
Analytical Instruments 7,263 6,624 6,069
Specialty Diagnostics 4,405 4,763 5,659
Laboratory Products and Biopharma Services 23,041 22,511 14,862
Eliminations (1,829) (2,515) (3,010)
Consolidated revenues 42,857 44,915 39,211
Segment Income
Life Sciences Solutions 3,420 5,582 7,817
Analytical Instruments 1,908 1,507 1,197
Specialty Diagnostics 1,124 1,024 1,280
Laboratory Products and Biopharma Services 3,358 2,872 1,844
Subtotal reportable segments 9,810 10,985 12,138
Cost of revenues adjustments (95) (46) (8)
Selling, general and administrative expenses adjustments (59) (37) (144)
Restructuring and other costs (459) (114) (197)
Amortization of acquisition-related intangible assets (2,338) (2,395) (1,761)
Consolidated operating income 6,859 8,393 10,028
Interest income 879 272 43
Interest expense (1,375) (726) (536)
Other income/(expense) (65) (104) (694)
Consolidated income before taxes $ 6,298 $ 7,835 $ 8,841
Depreciation
Life Sciences Solutions $ 220 $ 214 $ 197
Analytical Instruments 93 83 83
Specialty Diagnostics 86 75 128
Laboratory Products and Biopharma Services 669 614 423
Consolidated depreciation $ 1,068 $ 986 $ 831
Cost of revenues charges included in the above table consist of charges for the sale of inventories revalued at the date of acquisition, inventory write-downs
associated with large-scale abandonments of product lines, and accelerated depreciation on fixed assets to estimated salvage value in connection with the
consolidation of operations. Selling, general and administrative charges/credits included in the above table consist of significant transaction/integration costs
(including reimbursement thereof) related to recent/terminated acquisitions, charges/credits for changes in estimates of contingent acquisition consideration,
and charges related to product liability litigation.
50
-- 50 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(In millions) 2023 2022 2021
Total assets
Life Sciences Solutions $ 20,191 $ 21,848 $ 22,751
Analytical Instruments 10,247 10,019 9,692
Specialty Diagnostics 8,636 5,542 6,010
Laboratory Products and Biopharma Services 51,091 51,281 52,639
Corporate/other (a) 8,561 8,464 4,031
Consolidated total assets $ 98,726 $ 97,154 $ 95,123
Capital expenditures
Life Sciences Solutions $ 178 $ 490 $ 810
Analytical Instruments 87 140 79
Specialty Diagnostics 121 112 167
Laboratory Products and Biopharma Services 1,013 1,403 1,327
Corporate/other 80 98 140
Consolidated capital expenditures $ 1,479 $ 2,243 $ 2,523
(a) Corporate assets consist primarily of cash and cash equivalents and property and equipment at the company's corporate offices.
Geographical Information
(In millions) 2023 2022 2021
Revenues (b)
United States $ 22,013 $ 23,820 $ 18,907
Other 20,844 21,095 20,304
Consolidated revenues $ 42,857 $ 44,915 $ 39,211
Long-lived Assets (c)
United States $ 6,352 $ 6,308 $ 5,578
Other 4,652 4,565 4,286
Consolidated long-lived assets $ 11,004 $ 10,873 $ 9,864
(b) Revenues are attributed to countries based on customer location.
(c) Includes property, plant and equipment, net, and operating lease ROU assets.
Note 5. Other Income/(Expense)
In all periods, other income/(expense) includes currency transaction gains/losses on non-operating monetary assets and liabilities and net periodic pension
benefit cost/income, excluding the service cost component, which is included in operating expenses on the accompanying statements of income. In 2023, other
income/(expense) includes $46 million of net losses on investments.
In 2022, other income/(expense) includes $161 million of net losses on investments, $67 million of net gains on derivative instruments to address certain
foreign currency risks, and $26 million of losses on the early extinguishment of debt (Note 10).
In 2021, other income/(expense) includes $767 million of losses on the early extinguishment of debt (Note 10), $36 million of financing costs associated with
obtaining bridge financing commitments in connection with the agreement to acquire PPD (Note 2), offset in part by $66 million of net gains on investments.
The company had a cash outlay of $36 million in 2021 associated with obtaining the bridge financing commitments, included in other financing activities, net,
in the accompanying statement of cash flows.
Note 6. Stock-based Compensation Expense
The company has stock-based compensation plans for its key employees, directors and others. These plans permit the grant of a variety of stock and stock-
based awards, including restricted stock units, stock options or performance-based shares, as determined by the compensation committee of the company’s
Board of Directors or, for certain non-officer grants, by the company’s employee equity committee, which consists of its chief executive officer. The company
generally issues new shares of its common stock to satisfy option exercises and restricted unit vesting. Grants of stock options and restricted units generally
51
-- 51 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
provide that in the event of both a change in control of the company and a qualifying termination of an option or unit holder’s employment, all options and
service-based restricted unit awards held by the recipient become immediately vested (unless an employment or other agreement with the employee provides
for different treatment).
Compensation cost is based on the grant-date fair value and is recognized ratably over the requisite vesting period or to the date based on qualifying retirement
eligibility, if earlier, and is primarily included in selling, general and administrative expenses.
Stock Options
The company’s practice is to grant stock options at fair market value. Options vest over 3-5 years with terms of 7-10 years, assuming continued employment
with certain exceptions. Vesting of the option awards is contingent upon meeting certain service conditions. The fair value of most option grants is estimated
using the Black-Scholes option pricing model. For option grants that require the achievement of both service and market conditions, a lattice model is used to
estimate fair value. The fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting
period. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. Expected volatility is calculated
based on the historical volatility of the company’s stock. Historical data on exercise patterns is the basis for estimating the expected life of an option. The risk-
free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term which approximates the expected life assumed at the date of grant. The
expected annual dividend rate is calculated by dividing the company’s annual dividend, based on the most recent quarterly dividend rate, by the closing stock
price on the grant date. The compensation expense recognized for all stock-based awards is net of estimated forfeitures. Forfeitures are estimated based on an
analysis of actual option forfeitures.
The weighted average assumptions used in the Black-Scholes option pricing model are as follows:
2023 2022 2021
Expected stock price volatility 25 % 26 % 26 %
Risk free interest rate 4.2 % 2.0 % 0.8 %
Expected life of options (years) 4.7 4.7 4.3
Expected annual dividend 0.3 % 0.2 % 0.2 %
The weighted average per share grant-date fair values of options granted during 2023, 2022 and 2021 were $159.32, $135.07 and $123.97, respectively. The
total intrinsic value of options exercised during the same periods was $320 million, $336 million and $501 million, respectively. The intrinsic value is the
difference between the market value of the shares on the exercise date and the exercise price of the option.
A summary of the company’s option activity for the year ended December 31, 2023 is presented below:
Shares
(in millions) Weighted average
exercise price
Weighted average
remaining
contractual term
(in years)
Aggregate intrinsic
value
(in millions)
Outstanding at December 31, 2022 5.6 $ 359.27
Granted 0.7 546.94
Exercised (1.0) 218.82
Canceled/expired (0.3) 543.25
Outstanding at December 31, 2023 5.0 $ 401.30 3.9 $ 714
Vested and unvested expected to vest at December 31, 2023 4.8 $ 396.20 3.9 $ 712
Exercisable at December 31, 2023 2.8 $ 316.88 2.7 $ 635
As of December 31, 2023, there was $162 million of total unrecognized compensation cost related to unvested stock options granted. The cost is expected to be
recognized through 2027 with a weighted average amortization period of 2.2 years.
Restricted Share/Unit Awards
Awards of restricted units convert into an equivalent number of shares of common stock. The awards generally vest over 3-4 years, assuming continued
employment, with some exceptions. Vesting of the awards is contingent upon meeting certain service conditions and may also be contingent upon meeting
certain performance and/or market conditions. The fair market value of the award at the time of the grant is amortized to expense over the requisite service
period of the award, which is
52
-- 52 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
generally the vesting period. Recipients of restricted units have no voting rights but are entitled to accrue dividend equivalents. The fair value of service- and
performance-based restricted unit awards is determined based on the number of units granted and the market value of the company’s shares on the grant date.
For awards with market-based vesting conditions, the company uses a lattice model to estimate the grant-date fair value of the award.
A summary of the company’s restricted unit activity for the year ended December 31, 2023 is presented below:
Units
(in millions)
Weighted
average
grant-date
fair value
Unvested at December 31, 2022 0.7 $ 495.39
Granted 0.4 545.73
Vested (0.4) 480.45
Forfeited (0.1) 528.59
Unvested at December 31, 2023 0.6 $ 533.65
The weighted average per share grant-date fair values of restricted units granted during 2022 and 2021 were $520.83 and $444.61, respectively. The total fair
value of shares vested during 2023, 2022 and 2021 was $207 million, $163 million and $151 million, respectively.
As of December 31, 2023, there was $179 million of total unrecognized compensation cost related to unvested restricted stock unit awards. The cost is
expected to be recognized through 2027 with a weighted average amortization period of 1.9 years.
Employee Stock Purchase Plans
Qualifying employees are eligible to participate in an employee stock purchase plan sponsored by the company. Shares may be purchased under the program
at 95% of the fair market value at the end of the purchase period and the shares purchased are not subject to a holding period. Shares are purchased through
payroll deductions of up to 10% of each participating employee’s qualifying gross wages. The company issued 0.1 million, 0.2 million and 0.1 million shares,
respectively, of its common stock in 2023, 2022 and 2021 under the employee stock purchase plan.
Note 7. Pension and Other Postretirement Benefit Plans
401(k) Savings Plan and Other Defined Contribution Plans
The company’s 401(k) savings and other defined contribution plans cover the majority of the company’s eligible U.S. and certain non-U.S. employees.
Contributions to the plans are made by both the employee and the company. Company contributions are based on the level of employee contributions, and are
based on formulas determined by the company. In 2023, 2022 and 2021, the company charged to expense $468 million, $402 million and $299 million,
respectively, related to its defined contribution plans.
Defined Benefit Pension Plans
Employees of a number of the company’s non-U.S. and certain U.S. subsidiaries participate in defined benefit pension plans covering substantially all full-time
employees at those subsidiaries. Some of the plans are unfunded, as permitted under the plans and applicable laws. The company also maintains postretirement
healthcare programs at several acquired businesses where certain employees are eligible to participate. The liabilities and costs associated with the company’s
postretirement healthcare programs are generally funded on a self-insured and insured-premium basis and are not material for any period presented.
The company recognizes the funded status of defined benefit pension and other postretirement benefit plans as an asset or liability. This amount is defined as
the difference between the fair value of plan assets and the benefit obligation. The company is required to recognize as a component of other comprehensive
items, net of tax, the actuarial gains/losses and prior service costs/credits that arise but were not previously required to be recognized as components of net
periodic benefit cost. Other comprehensive items is adjusted as these amounts are later recognized in income as components of net periodic benefit cost.
When a company with a pension plan is acquired, any excess of projected benefit obligation over the plan assets is recognized as a liability and any excess of
plan assets over the projected benefit obligation is recognized as an asset. The recognition of a new liability or a new asset results in the elimination of (a)
previously existing unrecognized net gain or loss and (b) unrecognized prior service cost or credits.
53
-- 53 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The company funds annually, at a minimum, the statutorily required minimum amount as actuarially determined. Contributions to the plans included in the
following table are estimated at between $30 million and $50 million for 2024.
The following table provides a reconciliation of benefit obligations and plan assets of the company’s domestic and non-U.S. pension plans:
Domestic pension benefits Non-U.S. pension benefits
(In millions) 2023 2022 2023 2022
Accumulated benefit obligation $ 1,005 $ 995 $ 1,166 $ 1,016
Change in projected benefit obligations
Projected benefit obligation at beginning of year $ 995 $ 1,260 $ 1,069 $ 1,552
Acquisitions — — 15 51
Service costs — — 26 34
Interest costs 47 27 42 20
Settlements — — (37) (31)
Plan participants' contributions — — 9 9
Actuarial (gains) losses 42 (210) 65 (447)
Benefits paid (79) (82) (25) (19)
Currency translation and other — — 57 (100)
Projected benefit obligation at end of year $ 1,005 $ 995 $ 1,221 $ 1,069
Change in fair value of plan assets
Fair value of plan assets at beginning of year $ 937 $ 1,226 $ 868 $ 1,302
Acquisitions — — 15 14
Actual return on plan assets 84 (212) 29 (347)
Employer contributions 5 5 36 36
Settlements — — (37) (31)
Plan participants' contributions — — 9 9
Benefits paid (79) (82) (25) (19)
Currency translation and other — — 49 (96)
Fair value of plan assets at end of year $ 947 $ 937 $ 944 $ 868
Funded status $ (58) $ (58) $ (277) $ (201)
Amounts recognized in balance sheet
Noncurrent assets $ — $ — $ 65 $ 81
Current liability (6) (6) (11) (11)
Noncurrent liabilities (52) (52) (331) (271)
Net amount recognized $ (58) $ (58) $ (277) $ (201)
Amounts recognized in accumulated other comprehensive items
Net actuarial loss $ 217 $ 200 $ 151 $ 74
Prior service credits — — (5) (4)
Net amount recognized $ 217 $ 200 $ 146 $ 70
For domestic pension plans, actuarial losses experienced in 2023 were driven by decreases in the weighted average discount rates used to determine the
projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset
returns. For non-U.S. pension plans, actuarial losses experienced in 2023 were principally driven by decreases in the weighted average discount rates used to
determine the projected benefit obligation.
For domestic pension plans, actuarial gains experienced in 2022 were driven by increases in the weighted average discount rates used to determine the
projected benefit obligation, as well as differences between actual and expected returns on plan assets for certain portions of plan benefits indexed to asset
returns. For non-U.S. pension plans, actuarial gains experienced in 2022 were principally driven by increases in the weighted average discount rates used to
determine the projected benefit obligation.
54
-- 54 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The actuarial assumptions used to compute the funded status for the plans are based upon information available as of December 31, 2023 and 2022 and are as
follows:
Domestic pension benefits Non-U.S. pension benefits
2023 2022 2023 2022
Weighted average assumptions used to determine projected
benefit obligations
Discount rate for determining benefit obligation 4.82 % 5.01 % 3.47 % 3.91 %
Interest crediting rate for cash balance plans 4.76 % 4.96 % 2.06 % 2.19 %
Average rate of increase in employee compensation N/A N/A 2.64 % 2.78 %
The actuarial assumptions used to compute the net periodic pension benefit cost (income) are based upon information available as of the beginning of the year,
as presented in the following table:
Domestic pension benefits Non-U.S. pension benefits
2023 2022 2021 2023 2022 2021
Weighted average assumptions used to
determine net benefit cost (income)
Discount rate - service cost N/A N/A N/A 3.62 % 1.00 % 0.65 %
Discount rate - interest cost 5.01 % 2.70 % 2.33 % 3.95 % 1.36 % 0.80 %
Average rate of increase in employee
compensation N/A N/A N/A 2.77 % 2.73 % 2.30 %
Expected long-term rate of return on assets 6.25 % 4.75 % 4.25 % 4.33 % 2.33 % 2.02 %
The discount rate reflects the rate the company would have to pay to purchase high-quality investments that would provide cash sufficient to settle its current
pension obligations. The discount rate is determined based on a range of factors, including the rates of return on high-quality, fixed-income corporate bonds
and the related expected duration of the obligations or, in certain instances, the company has used a hypothetical portfolio of high quality instruments with
maturities that mirror the benefit obligation in order to accurately estimate the discount rate relevant to a particular plan.
The company utilizes a full yield curve approach in the estimation of these components by applying the specific spot-rates along the yield curve used in the
determination of the benefit obligation to the relevant projected cash flows.
The expected long-term rate of return on plan assets reflects the average rate of earnings expected on the funds invested, or to be invested, to provide for the
benefits included in the projected benefit obligations. In determining the expected long-term rate of return on plan assets, the company considers the relative
weighting of plan assets, the historical performance of total plan assets and individual asset classes and economic and other indicators of future performance. In
addition, the company may consult with and consider the opinions of financial and other professionals in developing appropriate return benchmarks.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market risk and providing adequate liquidity
to meet immediate and future benefit payment requirements.
The expected rate of compensation increase reflects the long-term average rate of salary increases and is based on historic salary increase experience and
management’s expectations of future salary increases.
The projected benefit obligation and fair value of plan assets for the company’s qualified and non-qualified pension plans with projected benefit obligations in
excess of plan assets are as follows:
Pension plans
(In millions) 2023 2022
Pension plans with projected benefit obligations in excess of plan assets
Projected benefit obligation $ 1,752 $ 1,636
Fair value of plan assets 1,352 1,296
55
-- 55 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The accumulated benefit obligation and fair value of plan assets for the company's qualified and non-qualified pension plans with accumulated benefit
obligations in excess of plan assets are as follows:
Pension plans
(In millions) 2023 2022
Pension plans with accumulated benefit obligations in excess of plan assets
Accumulated benefit obligation $ 1,695 $ 1,583
Fair value of plan assets 1,349 1,294
The measurement date used to determine benefit information is December 31 for all plan assets and benefit obligations.
The net periodic pension benefit cost (income) includes the following components:
Domestic pension benefits Non-U.S. pension benefits
(In millions) 2023 2022 2021 2023 2022 2021
Components of net benefit cost (income)
Service cost $ — $ — $ — $ 26 $ 34 $ 27
Interest cost on benefit obligation 47 27 23 42 20 11
Expected return on plan assets (59) (45) (40) (37) (26) (19)
Amortization of actuarial net loss — 4 7 2 7 12
Amortization of prior service cost (benefit) — — — (1) (1) —
Settlement/curtailment loss (gain) — — — 1 (2) —
Net periodic benefit cost (income) $ (12) $ (14) $ (10) $ 33 $ 32 $ 31
Expected benefit payments are estimated using the same assumptions used in determining the company’s benefit obligation at December 31, 2023. Benefit
payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any
of these factors could significantly affect these estimated future benefit payments. Estimated future benefit payments during the next five years and in the
aggregate for the five fiscal years thereafter, are as follows:
(In millions) Domestic pension benefits Non-U.S. pension benefits
Expected benefit payments
2024 $ 81 $ 52
2025 79 55
2026 80 59
2027 79 60
2028 79 65
2029-2033 374 354
Domestic Pension Plan Assets
The company’s overall objective is to manage the assets in a liability framework where investments are selected that are expected to have similar changes in
fair value as the related liabilities will have upon changes in interest rates. The company invests in a portfolio of both return-seeking and liability-hedging
assets, primarily through the use of institutional collective funds, to achieve long-term growth and to insulate the funded position from interest rate volatility.
The strategic asset allocation uses a combination of risk controlled and index strategies in fixed income and global equities. The target allocations for the
investments are approximately 10% to funds investing in U.S. equities, approximately 10% to funds investing in international equities and approximately 80%
to funds investing in fixed income securities. The portfolio maintains enough liquidity at all times to meet the near-term benefit payments.
Non-U.S. Pension Plan Assets
The company maintains specific plan assets for many of the individual pension plans outside the U.S. The investment strategy of each plan has been uniquely
established based on the country specific standards and characteristics of the plans. Several of the plans have contracts with insurance companies whereby the
market risks of the benefit obligations are borne by the insurance companies. When assets are held directly in investments, generally the objective is to invest in
a portfolio of diversified assets with a variety of fund managers. The investments may include equity funds, fixed income funds, hedge funds,
56
-- 56 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
multi-asset funds, alternative investments and derivative funds with the target asset allocations ranging from approximately 0% - 25% for equity funds, 30% -
90% for fixed income funds, 0% - 40% for multi-asset funds, 0% - 4% for alternative investments, 0% - 4% for real estate funds and 0% - 45% for funds
holding derivatives. The derivatives held by the funds are primarily interest rate swaps intended to match the movements in the plan liabilities. Each plan
maintains enough liquidity at all times to meet the near-term benefit payments.
The fair values of the company’s plan assets at December 31, 2023 and 2022, by asset category are as follows:
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs Not subject to
leveling (a) (In millions) 2023 (Level 1) (Level 2) (Level 3)
Domestic pension plan assets
U.S. equity funds $ 93 $ — $ — $ — $ 93
International equity funds 93 — — — 93
Fixed income funds 739 — — — 739
Money market funds 22 — — — 22
Total domestic pension plans $ 947 $ — $ — $ — $ 947
Non-U.S. pension plan assets
Equity funds $ 7 $ — $ — $ — $ 7
Fixed income funds 346 9 — — 337
Multi-asset funds 66 — — — 66
Derivative funds 184 — — — 184
Alternative investments 1 — — — 1
Insurance contracts 333 — 333 — —
Real estate funds 1 — — — 1
Cash / money market funds 6 4 — — 2
Total non-U.S. pension plans $ 944 $ 13 $ 333 $ — $ 598
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs Not subject to
leveling (a) (In millions) 2022 (Level 1) (Level 2) (Level 3)
Domestic pension plan assets
U.S. equity funds $ 89 $ — $ — $ — $ 89
International equity funds 91 — — — 91
Fixed income funds 739 — — — 739
Money market funds 18 — — — 18
Total domestic pension plans $ 937 $ — $ — $ — $ 937
Non-U.S. pension plan assets
Equity funds $ 8 $ — $ — $ — $ 8
Fixed income funds 299 — — — 299
Multi-asset funds 56 — — — 56
Derivative funds 190 — — — 190
Insurance contracts 306 — 306 — —
Cash / money market funds 9 4 — — 5
Total non-U.S. pension plans $ 868 $ 4 $ 306 $ — $ 558
(a) Investments measured at the net asset value per share (or its equivalent) practical expedient have not been classified in the fair value hierarchy.
57
-- 57 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The tables above present the fair value of the company’s plan assets in accordance with the fair value hierarchy (Note 14). Certain investments that are
measured at fair value using the net asset value per share practical expedient have not been classified in the fair value hierarchy. The fair value amounts of
these investments presented in the above tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension
plan assets. These investments were also redeemable at the balance sheet date or within limited time restrictions.
Note 8. Income Taxes
The components of income before provision for income taxes are as follows:
(In millions) 2023 2022 2021
U.S. $ 2,431 $ 3,859 $ 3,340
Non-U.S. 3,867 3,976 5,501
Income before income taxes $ 6,298 $ 7,835 $ 8,841
The components of the provision for income taxes are as follows:
(In millions) 2023 2022 2021
Current income tax provision
Federal $ 228 $ 813 $ 446
Non-U.S. 1,206 633 1,148
State 150 254 160
1,584 1,700 1,754
Deferred income tax provision (benefit)
Federal $ (551) $ (611) $ (227)
Non-U.S. (647) (314) (399)
State (102) (72) (19)
(1,300) (997) (645)
Provision for income taxes $ 284 $ 703 $ 1,109
The provision for income taxes in the accompanying statement of income differs from the provision calculated by applying the statutory federal income tax rate
to income before income taxes due to the following:
(In millions) 2023 2022 2021
Statutory federal income tax rate 21 % 21 % 21 %
Provision for income taxes at statutory rate $ 1,323 $ 1,645 $ 1,857
Increases (decreases) resulting from:
Foreign rate differential (223) (329) (255)
Income tax credits (276) (202) (315)
Global intangible low-taxed income 113 96 76
Foreign-derived intangible income (108) (149) (119)
Excess tax benefits from stock options and restricted stock units (69) (80) (124)
Provision for (reversal of) tax reserves, net 13 (544) (17)
Intra-entity transfers (233) (18) (284)
Foreign exchange loss on inter-company debt refinancing (112) — —
Provision for (reversal of) valuation allowances, net (32) 344 36
Withholding taxes 33 84 164
Tax return reassessments and settlements (187) (210) 1
State income taxes, net of federal tax 70 111 82
Other, net (28) (45) 7
Provision for income taxes $ 284 $ 703 $ 1,109
58
-- 58 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the
U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the
U.S. federal statutory rate.
During 2023, the company released valuation allowances of $32 million in jurisdictions where the deferred tax assets are now expected to be realized. In 2023
the company also recorded a tax benefit of $127 million for U.S. tax credits and the revaluation of net operating loss carryforwards due to higher tax rates as a
result of its tax return resubmissions, a $91 million tax benefit, net of related tax expenses, from a foreign exchange loss on an intercompany debt refinancing
transaction, and $233 million of tax benefits resulting from intra-entity transactions.
During 2022, the company settled an IRS audit relating to the 2017 and 2018 tax years. The company recorded a $208 million net tax benefit primarily from
this settlement and related impacts, which resulted in a decrease in the company’s unrecognized tax benefits of $658 million. The company recorded $49
million of charges for expired tax credits and other related components of the settlement. The company recorded a charge of $395 million to establish a
valuation allowance against certain U.S. foreign tax credits which the company believes will more likely than not expire unutilized. The company also recorded
$101 million of additional net unrecognized tax benefit liabilities related to other tax audits.
During 2021, the company recorded a $188 million income tax benefit related to the deferred tax implications of an intra-entity transfer of assets. Also in 2021,
the company recorded a $96 million income tax benefit related to a capital loss resulting from certain intra-entity transactions.
The company generally receives a tax deduction upon the exercise of non-qualified stock options by employees, or the vesting of restricted stock units held by
employees, for the difference between the exercise price and the market price of the underlying common stock on the date of exercise. The company uses the
incremental tax benefit approach for utilization of tax attributes. These excess tax benefits reduce the tax provision. In 2023, 2022 and 2021, the company's tax
provision was reduced by $69 million, $80 million and $124 million, respectively, of such benefits.
Net deferred tax asset/(liability) in the accompanying balance sheet consists of the following:
(In millions) 2023 2022
Deferred tax asset/(liability)
Depreciation and amortization $ (4,286) $ (4,277)
Net operating loss and credit carryforwards 2,385 1,951
Reserves and accruals 157 140
Accrued compensation 299 259
Inventory basis difference 275 364
Deferred interest 753 445
Research and development and other capitalized costs 380 220
Unrealized (gains) losses on hedging instruments (66) (199)
Other, net 329 435
Deferred tax assets/(liabilities), net before valuation allowance 226 (662)
Less: Valuation allowance 1,317 1,322
Deferred tax assets/(liabilities), net $ (1,091) $ (1,984)
The company estimates the degree to which tax assets, losses and credit carryforwards will result in a benefit based on expected profitability by tax jurisdiction
and provides a valuation allowance for tax assets and loss and credit carryforwards that it believes will more likely than not expire unutilized. At December 31,
2023, all of the company’s valuation allowance relates to deferred tax assets, primarily net operating losses and disallowed interest expense carryforward, for
which any subsequently recognized tax benefits will reduce income tax expense.
59
-- 59 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The changes in the valuation allowance are as follows:
Year Ended December 31,
(In millions) 2023 2022 2021
Beginning balance $ 1,322 $ 968 $ 933
Additions (reductions) charged to income tax provision, net (32) 344 24
Additions due to acquisitions 4 14 30
Currency translation and other 23 (4) (19)
Ending balance $ 1,317 $ 1,322 $ 968
At December 31, 2023, the company had net federal, state and non-U.S. net operating loss carryforwards of $70 million, $93 million and $1.42 billion,
respectively. Use of the carryforwards is limited based on the future income of certain subsidiaries. Of the federal net operating loss carryforwards, $30 million
expire in the years 2024 through 2037, and the remainder do not expire. Of the state net operating loss carryforwards, $83 million expire in the years 2024
through 2042, and the remainder do not expire. Of the net non-U.S. net operating loss carryforwards, $435 million expire in the years 2026 through 2043, and
the remainder do not expire.
At December 31, 2023, the company had foreign tax credit carryforwards of $648 million and deferred interest carryforwards of $753 million. The foreign tax
credit carryforwards will expire in the years 2025 through 2032. Of the deferred interest carryforwards, $149 million expire in the years 2025 through 2033 and
the remainder do not expire.
U.S. federal taxes have been recorded on approximately $34 billion of undistributed foreign earnings as of December 31, 2023. A provision has not been made
for certain U.S. state income taxes or additional non-U.S. taxes that would be due when cash is repatriated to the U.S. as the company’s undistributed foreign
earnings are intended to be reinvested outside of the U.S. indefinitely. The determination of the amount of the unrecognized deferred tax liability related to the
undistributed foreign earnings is not practicable due to the uncertainty in the manner in which these earnings will be distributed. The company’s intent is to
only make distributions from non-U.S. subsidiaries in the future when they can be made at no net tax cost.
Unrecognized Tax Benefits
As of December 31, 2023, the company had $0.54 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax
rate.
A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:
(In millions) 2023 2022 2021
Beginning balance $ 572 $ 1,124 $ 1,091
Additions due to acquisitions — 15 26
Additions for tax positions of current year 4 104 32
Additions for tax positions of prior years 34 24 60
Reductions for tax positions of prior years (43) (659) (5)
Closure of tax years (6) (4) (27)
Settlements (21) (32) (53)
Ending balance $ 540 $ 572 $ 1,124
Substantially all of the unrecognized tax benefits are classified as long-term liabilities. The company does not expect its unrecognized tax benefits to change
significantly over the next twelve months.
During 2023, the company’s unrecognized tax benefits decreased by $12 million as a result of uncertain tax positions relating to foreign tax positions and
decreased $19 million relating to U.S. federal and state tax positions.
During 2022, the company’s unrecognized tax benefits increased by $143 million as a result of uncertain tax positions relating to foreign tax positions and
decreased $610 million relating to U.S. federal and state tax positions which included $658 million from the settlement of the IRS audit of the 2017 and 2018
tax years. The company also assumed $15 million of uncertain tax benefits as part of the acquisition of PPD.
During 2021, the company’s unrecognized tax benefits increased by $80 million as a result of uncertain tax positions relating to foreign tax positions and
decreased $75 million relating to U.S. federal and state tax positions. The company also assumed $26 million of uncertain tax benefits as part of the acquisition
of PPD.
60
-- 60 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The company classified interest and penalties related to unrecognized tax benefits as income tax expense. The total amount of interest and penalties related to
uncertain tax positions and recognized in the balance sheet as of December 31, 2023 and 2022 was $95 million and $74 million, respectively.
The company conducts business globally and, as a result, Thermo Fisher or one or more of its subsidiaries files income tax returns in the U.S. federal
jurisdiction and various state and foreign jurisdictions. In the normal course of business, the company is subject to examination by taxing authorities throughout
the world, including such major jurisdictions as Australia, Canada, China, Denmark, Finland, France, Germany, Japan, Singapore, Sweden, the United
Kingdom and the United States. With few exceptions, the company is no longer subject to U.S. state and local or non-U.S. income tax examinations for years
before 2012 and no longer subject to U.S. federal income tax examinations for years before 2019.
Note 9. Earnings per Share
(In millions except per share amounts) 2023 2022 2021
Net income attributable to Thermo Fisher Scientific Inc. $ 5,995 $ 6,950 $ 7,725
Basic weighted average shares 386 392 394
Plus effect of: stock options and restricted stock units 2 2 3
Diluted weighted average shares 388 394 397
Basic earnings per share $ 15.52 $ 17.75 $ 19.62
Diluted earnings per share $ 15.45 $ 17.63 $ 19.46
Antidilutive stock options excluded from diluted weighted average shares 2 2 1
Note 10. Debt and Other Financing Arrangements
Effective interest rate at
December 31, December 31, December 31,
(Dollars in millions) 2023 2023 2022
Commercial Paper $ — $ 310
Floating Rate (SOFR + 0.35%) 1.5-Year Senior Notes, Due 4/18/2023 — 1,000
Floating Rate (SOFR + 0.39%) 2-Year Senior Notes, Due 10/18/2023 — 500
0.797% 2-Year Senior Notes, Due 10/18/2023 — 1,350
Floating Rate (EURIBOR + 0.20%) 2-Year Senior Notes Due 11/18/2023 (euro-denominated) — 1,819
0.000% 2-Year Senior Notes Due 11/18/2023 (euro-denominated) — 589
0.75% 8-Year Senior Notes, Due 9/12/2024 (euro-denominated) 0.93 % 1,104 1,071
Floating Rate (SOFR + 0.53%) 3-Year Senior Notes, Due 10/18/2024 — 500
1.215% 3-Year Senior Notes, Due 10/18/2024 1.42 % 2,500 2,500
0.125% 5.5-Year Senior Notes, Due 3/1/2025 (euro-denominated) 0.41 % 883 857
2.00% 10-Year Senior Notes, Due 4/15/2025 (euro-denominated) 2.10 % 706 686
0.853% 3-Year Senior Notes, Due 10/20/2025 (yen-denominated) 1.05 % 158 170
0.000% 4-Year Senior Notes Due 11/18/2025 (euro-denominated) 0.15 % 607 589
3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated) 3.39 % 552 535
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated) 1.53 % 773 749
4.953% 3-Year Senior Notes, Due 8/10/2026 5.19 % 600 —
5.000% 3-Year Senior Notes due 12/5/2026 5.00 % 1,000 —
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated) 1.65 % 552 535
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated) 1.97 % 662 642
1.054% 5-Year Senior Notes, Due 10/20/2027 (yen-denominated) 1.18 % 205 221
4.80% 5-Year Senior Notes, Due 11/21/2027 5.00 % 600 600
61
-- 61 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Effective interest rate at
December 31, December 31, December 31,
(Dollars in millions) 2023 2023 2022
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated) 0.77 % 883 857
0.77% 5-Year Senior Notes, Due 9/6/2028 (yen-denominated) 0.90 % 206 —
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated) 1.46 % 662 642
1.750% 7-Year Senior Notes, Due 10/15/2028 1.89 % 700 700
5.000% 5-Year Senior Notes due 1/31/2029 5.00 % 1,000 —
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated) 2.08 % 773 749
2.60% 10-Year Senior Notes, Due 10/1/2029 2.74 % 900 900
1.279% 7-Year Senior Notes, Due 10/19/2029 (yen-denominated) 1.44 % 33 36
4.977% 7-Year Senior Notes, Due 8/10/2030 5.12 % 750 —
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated) 0.89 % 1,932 1,873
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated) 1.13 % 993 963
2.00% 10-Year Senior Notes, Due 10/15/2031 2.23 % 1,200 1,200
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated) 2.55 % 662 642
1.49% 10-Year Senior Notes, Due 10/20/2032 (yen-denominated) 1.60 % 45 48
4.95% 10-Year Senior Notes, Due 11/21/2032 5.09 % 600 600
5.086% 10-Year Senior Notes, Due 8/10/2033 5.20 % 1,000 —
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated) 1.20 % 1,656 1,606
5.200% 10-Year Senior Notes due 1/31/2034 5.20 % 500 —
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated) 3.76 % 828 803
1.50% 12-Year Senior Notes, due 9/6/2035 (yen-denominated) 1.58 % 152 —
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated) 2.94 % 773 749
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated) 1.73 % 993 963
2.80% 20-Year Senior Notes, Due 10/15/2041 2.90 % 1,200 1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated) 1.77 % 1,380 1,339
2.069% 20-Year Senior Notes, Due 10/20/2042 (yen-denominated) 2.13 % 104 111
5.404% 20-Year Senior Notes, due 8/10/2043 5.50 % 600 —
2.02% 20-Year Senior Notes, due 9/6/2043 (yen-denominated) 2.06 % 206 —
5.30% 30-Year Senior Notes, Due 2/1/2044 5.37 % 400 400
4.10% 30-Year Senior Notes, Due 8/15/2047 4.23 % 750 750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated) 1.98 % 1,104 1,071
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated) 2.07 % 828 803
2.382% 30-Year Senior Notes, Due 10/18/2052 (yen-denominated) 2.43 % 236 254
Other 77 79
Total borrowings at par value 35,028 34,561
Unamortized discount (113) (112)
Unamortized debt issuance costs (188) (171)
Total borrowings at carrying value 34,727 34,278
Finance lease liabilities 190 210
Less: Short-term obligations and current maturities 3,609 5,579
Long-term obligations $ 31,308 $ 28,909
SOFR - Secured Overnight Financing Rate
EURIBOR - Euro Interbank Offered Rate
62
-- 62 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any
debt issuance costs.
See Note 14 for fair value information pertaining to the company’s long-term borrowings.
As of December 31, 2023, the annual repayment requirements for debt obligations are as follows:
(In millions) Borrowings Finance Lease
Liabilities
2024 $ 3,604 $ 5
2025 2,356 13
2026 2,925 12
2027 2,020 10
2028 2,451 8
2029 and thereafter 21,672 142
$ 35,028 $ 190
In addition to available borrowings under the company’s revolving credit agreements, discussed below, the company had unused lines of credit of $69 million
as of December 31, 2023. These unused lines of credit generally provide for short-term unsecured borrowings at various interest rates.
Credit Facilities
The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit.
The Facility expires on January 7, 2027. The revolving credit agreement calls for interest at either a Term SOFR, a EURIBOR-based rate (for funds drawn in
euro) or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial
covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio
(Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as
any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the
Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of December 31, 2023, no
borrowings were outstanding under the Facility, although available capacity was reduced by immaterial outstanding letters of credit.
Commercial Paper Programs
The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S.
program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in
the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not
exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under
both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and
bear varying interest rates on a fixed or floating basis.
Senior Notes
Interest is payable quarterly on the floating rate senior notes, annually on the euro-denominated fixed rate senior notes and semi-annually on all other senior
notes. Each of the U.S. dollar, euro-denominated fixed rate senior notes and yen-denominated private placement notes may be redeemed at a redemption price
of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of yen-
denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative
covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to
pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants at December 31, 2023.
In 2022 the company completed the full allocation of an amount equal to the net proceeds from the 0.000% senior notes due 2025 to finance or refinance, in
whole or in part, certain COVID-19 response projects.
In 2022, the company redeemed all of its 3.650% Senior Notes due 2025. In connection with the redemption, the company incurred $26 million of losses on the
early extinguishment of debt included in other income/(expense) on the accompanying statement of income.
63
-- 63 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
In 2021, the company redeemed some of its existing senior notes. In connection with these redemptions, the company incurred $767 million of losses on the
early extinguishment of debt included in other income/(expense) on the accompanying statement of income. Upon redemption of the senior notes, the company
terminated the related fixed to floating rate interest rate swap arrangements and received $22 million, included in other financing activities, net, in the
accompanying statement of cash flows.
Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes
outstanding as of December 31, 2023, included in the table above (collectively, the “Euronotes”) in registered public offerings: the 0.00% Senior Notes due
2025, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The
company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s
other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined
in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the
Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of
Thermo Fisher International are consolidated in the financial statements of the company.
Note 11. Leases
As a lessee, the company leases certain logistics, office, and manufacturing facilities, as well as vehicles, copiers, and other equipment. These operating leases
generally have remaining lease terms between 1 month and 30 years, and some include options to extend (generally for 1 to 10 years) or have options to
terminate the arrangement within 1 year.
The company has guaranteed the residual value of three leased operating facilities with lease terms ending in 2024, 2025 and 2028. The company has agreed
with the lessor to comply with certain financial covenants consistent with its other debt arrangements (Note 10). The aggregate maximum guarantee under
these three lease arrangements is $147 million. Operating lease ROU assets and lease liabilities for these lease arrangements are recorded on the consolidated
balance sheet as of December 31, 2023, but exclude any amounts for residual value guarantees.
As a lessee, the consolidated financial statements include the following relating to operating leases:
(Dollars in millions) 2023 2022 2021
Statement of income
Operating lease costs $ 355 $ 351 $ 254
Variable lease costs 115 109 66
Statement of cash flows
Cash used in operating activities for payments of amounts included in the measurement of operating
lease liabilities $ 410 $ 289 $ 288
Operating lease ROU assets obtained in exchange for new operating lease liabilities 234 430 293
Balance sheet
ROU assets - included in other assets $ 1,556 $ 1,593
Operating lease liabilities - included in other accrued expenses 263 272
Operating lease liabilities - included in other long-term liabilities 1,244 1,313
Weighted average at end of year
Remaining operating lease term 9.2 years 9.4 years
Discount rate 4.0 % 3.2 %
Lease costs arising from finance leases, short-term leases, and sublease income are not material. See Note 10 for additional information relating to finance
leases.
64
-- 64 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
As of December 31, 2023, future payments of operating lease liabilities are as follows:
(In millions)
2024 $ 294
2025 288
2026 242
2027 172
2028 131
2029 and thereafter 723
Total lease payments 1,850
Less: imputed interest 343
Total operating lease liability $ 1,507
As a lessor, operating leases, sales-type leases and direct financing leases are not material.
Note 12. Commitments and Contingencies
Purchase Obligations
The company has entered into unconditional purchase obligations, in the ordinary course of business, that include agreements to purchase goods, services or
fixed assets and to pay royalties that are enforceable and legally binding and that specify all significant terms including: fixed or minimum quantities to be
purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are
cancelable at any time without penalty. The aggregate amount of the company’s unconditional purchase obligations totaled $2.53 billion at December 31, 2023,
the majority of which are expected to be settled during 2024.
Letters of Credit, Guarantees and Other Commitments
Outstanding letters of credit and bank guarantees totaled $315 million at December 31, 2023. Substantially all of these letters of credit and guarantees expire
before 2040.
Outstanding surety bonds and other guarantees totaled $93 million at December 31, 2023. The expiration of these bonds and guarantees ranges through 2025.
The letters of credit, bank guarantees and surety bonds principally secure performance obligations, and allow the holder to draw funds up to the face amount of
the letter of credit, bank guarantee or surety bond if the applicable business unit does not perform as contractually required.
The company has funding commitments totaling $164 million at December 31, 2023, related to investments.
The company is a guarantor of pension plan obligations of a divested business. The purchaser of the divested business has agreed to pay for the pension
benefits, however the company was required to guarantee payment of these pension benefits should the purchaser fail to do so. The amount of the guarantee at
December 31, 2023 was $24 million.
In connection with the sale of businesses of the company, the buyers have assumed certain contractual obligations of such businesses and have agreed to
indemnify the company with respect to those assumed liabilities. In the event a third-party to a transferred contract does not recognize the transfer of
obligations or a buyer defaults on its obligations under the transferred contract, the company could be liable to the third-party for such obligations. However, in
such event, the company would be entitled to seek indemnification from the buyer.
Indemnifications
In conjunction with certain transactions, primarily divestitures, the company has agreed to indemnify the other parties with respect to certain liabilities related
to the businesses that were sold or leased properties that were abandoned (e.g., retention of certain environmental, tax, employee and product liabilities). The
scope and duration of such indemnity obligations vary from transaction to transaction. Where probable, an obligation for such indemnifications is recorded as a
liability. Generally, a maximum obligation cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, historically
the company has not made significant payments for these indemnifications.
In connection with the company’s efforts to reduce the number of facilities that it occupies, the company has vacated some of its leased facilities or sublet them
to third parties. When the company sublets a facility to a third-party, it remains the primary obligor under the master lease agreement with the owner of the
facility. As a result, if a third-party vacates the sublet facility,
65
-- 65 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
the company would be obligated to make lease or other payments under the master lease agreement. The company believes that the financial risk of default by
sublessors is individually and in the aggregate not material to the company’s financial position or results of operations.
In connection with the sale of products in the ordinary course of business, the company often makes representations affirming, among other things, that its
products do not infringe on the intellectual property rights of others and agrees to indemnify customers against third-party claims for such infringement. The
company has not been required to make material payments under such provisions.
Environmental Matters
The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all
potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the
required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the
company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment
systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material
in any period presented. The company records accruals for environmental remediation liabilities, based on current interpretations of environmental laws and
regulations, when it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. The company calculates
estimates based upon several factors, including input from environmental specialists and management’s knowledge of and experience with these environmental
matters. The company includes in these estimates potential costs for investigation, remediation and operation and maintenance of cleanup sites. At
December 31, 2023, the company’s total environmental liability was approximately $75 million. While management believes the accruals for environmental
remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future
events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or
changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and
cash flows.
Litigation and Related Contingencies
The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that
arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and
commercial issues. The company determines the probability and range of possible loss based on the current status of each of these matters. A liability is
recorded in the financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The
company establishes a liability that is an estimate of amounts expected to be paid in the future for events that have already occurred. The company accrues the
most likely amount or at least the minimum of the range of probable loss when a range of probable loss can be estimated. The accrued liabilities are based on
management’s judgment as to the probability of losses for asserted and unasserted claims and, where applicable, actuarially determined estimates. Accrual
estimates are adjusted as additional information becomes known or payments are made. The amount of ultimate loss may differ from these estimates. Due to
the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation
or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable
outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed below, nor are material losses
deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any,
for one or more of the matters described below could have a material adverse effect on the company’s results of operations, financial position and cash flows.
Product Liability, Workers Compensation and Other Personal Injury Matters
The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other
personal injury matters. The range of probable loss for product liability, workers compensation and other personal injury matters of the company’s continuing
operations at December 31, 2023, was approximately $222 million to $379 million. The company’s accrual for these matters totaled $224 million at
December 31, 2023. The accrual includes estimated defense costs and is gross of estimated amounts due from insurers of $88 million at December 31, 2023
that are included in other assets in the accompanying balance sheet. In addition, as of December 31, 2023, the company had a product liability accrual of $20
million relating to divested businesses.
66
-- 66 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Although the company believes that the amounts accrued and estimated recoveries are probable and appropriate based on available information, including
actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and
the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows.
Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers
is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment
history as well as the financial condition and ratings of its insurers on an ongoing basis.
Note 13. Comprehensive Income/(Loss) and Shareholders' Equity
Comprehensive Income (Loss)
Changes in each component of accumulated other comprehensive items, net of tax are as follows:
(In millions)
Currency
translation
adjustment
Unrealized
losses on
hedging
instruments
Pension and
other
postretirement
benefit
liability
adjustment Total
Balance at December 31, 2022 $ (2,880) $ (33) $ (186) $ (3,099)
Other comprehensive income/(loss) before reclassifications (69) — (69) (138)
Amounts reclassified from accumulated other comprehensive
income/(loss) 8 5 — 13
Net other comprehensive income/(loss) (61) 5 (69) (125)
Balance at December 31, 2023 $ (2,941) $ (28) $ (255) $ (3,224)
Shareholders’ Equity
At December 31, 2023, the company had reserved 39 million unissued shares of its common stock for possible issuance under stock-based compensation plans.
Early in the first quarter of 2024, the company repurchased $3.00 billion of the company's common stock (5.5 million shares).
Note 14. Fair Value Measurements and Fair Value of Financial Instruments
Fair Value Measurements
The company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2023. The
company’s financial assets and liabilities carried at fair value are primarily comprised of investments in publicly traded securities, insurance contracts,
investments in derivative contracts, mutual funds holding publicly traded securities and other investments in unit trusts held as assets to satisfy outstanding
deferred compensation and retirement liabilities; and acquisition-related contingent consideration.
Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
Level 1: Quoted market prices in active markets for identical assets or liabilities that the company has the ability to access.
Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data such as quoted prices, interest rates and yield curves.
Level 3: Inputs are unobservable data points that are not corroborated by market data.
67
-- 67 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 2023 (Level 1) (Level 2) (Level 3)
Assets
Cash equivalents $ 5,021 $ 5,021 $ — $ —
Bank time deposits 3 3 — —
Investments 20 20 — —
Insurance contracts 210 — 210 —
Derivative contracts 8 — 8 —
Total assets $ 5,262 $ 5,044 $ 218 $ —
Liabilities
Derivative contracts $ 290 $ — $ 290 $ —
Contingent consideration 87 — — 87
Total liabilities $ 377 $ — $ 290 $ 87
December 31,
Quoted
prices in
active
markets
Significant
other
observable
inputs
Significant
unobservable
inputs
(In millions) 2022 (Level 1) (Level 2) (Level 3)
Assets
Cash equivalents $ 5,804 $ 5,804 $ — $ —
Investments 25 25 — —
Warrants 12 — 12 —
Insurance contracts 162 — 162 —
Derivative contracts 79 — 79 —
Total assets $ 6,082 $ 5,829 $ 253 $ —
Liabilities
Derivative contracts $ 101 $ — $ 101 $ —
Contingent consideration 174 — — 174
Total liabilities $ 275 $ — $ 101 $ 174
The company uses the Black-Scholes model to value its warrants. The company determines the fair value of its insurance contracts by obtaining the cash
surrender value of the contracts from the issuer. The fair value of derivative contracts is the estimated amount that the company would receive/pay upon
liquidation of the contracts, taking into account the change in interest rates and currency exchange rates. The company initially measures the fair value of
acquisition-related contingent consideration based on amounts expected to be transferred (probability-weighted) discounted to present value. Changes to the
fair value of contingent consideration are recorded in selling, general and administrative expense.
The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones,
as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration.
(In millions) 2023 2022
Contingent consideration
Beginning balance $ 174 $ 317
Acquisitions (including assumed balances) 1 (18)
Payments (63) (66)
Changes in fair value included in earnings (25) (59)
Ending balance $ 87 $ 174
68
-- 68 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Derivative Contracts
The following table provides the aggregate notional value of outstanding derivative contracts.
December 31, December 31,
(In millions) 2023 2022
Cross-currency interest rate swaps designated as net investment hedge - euro $ 1,000 $ 900
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen 4,650 1,200
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc 2,500 —
Currency exchange contracts 1,567 2,434
While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the
balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.
Fair value – assets Fair value – liabilities
December 31, December 31, December 31, December 31,
(In millions) 2023 2022 2023 2022
Derivatives designated as hedging instruments
Cross-currency interest rate swaps (a) $ 5 $ 77 $ 287 $ 85
Derivatives not designated as hedging instruments
Currency exchange contracts (b) 3 2 3 16
Total derivatives $ 8 $ 79 $ 290 $ 101
(a) The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheet under the caption other assets or other long-term liabilities.
(b) The fair value of the currency exchange contracts is included in the accompanying balance sheet under the captions other current assets or other accrued expenses.
Gain (loss) recognized
(In millions) 2023 2022 2021
Fair value hedging relationships
Cross-currency interest rate swaps
Hedged long-term obligations - included in other income/(expense) $ — $ 77 $ —
Derivatives designated as hedging instruments - included in other income/(expense) — (81) —
Interest rate swaps
Hedged long-term obligations - included in other income/(expense) — — 25
Derivatives designated as hedging instruments - included in other income/(expense) — — (3)
Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive items to interest expense (4) — —
Amount reclassified from accumulated other comprehensive items to other income/(expense) (3) (3) (73)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in currency translation adjustment within other comprehensive items (356) 695 922
Cross-currency interest rate swaps
Included in currency translation adjustment within other comprehensive items (222) 52 71
Included in interest expense 120 19 8
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues 1 6 12
Included in other income/(expense) (29) 102 162
69
-- 69 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Gains and losses recognized on currency exchange contracts and the interest rate swaps designated as fair value hedges are included in the accompanying
statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.
The company uses foreign currency-denominated debt, certain foreign currency-denominated payables, and cross-currency interest rate swaps to partially
hedge its net investments in foreign operations against adverse movements in exchange rates. A portion of the company’s euro-denominated senior notes,
certain foreign currency-denominated payables, and its cross-currency interest rate swaps have been designated as, and are effective as, economic hedges of
part of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated
debt instruments and certain foreign currency-denominated payables, and contract fair value changes on the cross-currency interest rate swaps, excluding
interest accruals, are included in currency translation adjustment within other comprehensive items and shareholders’ equity.
See Note 1 and Note 10 for additional information on the company’s risk management objectives and strategies.
Cash Flow Hedge Arrangements
During 2021, in connection with the extinguishment of debt (Note 10), the company reclassified $65 million from accumulated other comprehensive
income/(loss) to other income/(expense).
Fair Value of Other Financial Instruments
The carrying value and fair value of the company’s debt instruments are as follows:
December 31, 2023 December 31, 2022
Carrying Fair Carrying Fair
(In millions) value value value value
Senior notes $ 34,650 $ 32,191 $ 33,889 $ 29,901
Commercial paper — — 310 310
Other 77 77 79 79
$ 34,727 $ 32,268 $ 34,278 $ 30,290
The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the
company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally
developed pricing models and unobservable inputs, which represent level 3 measurements.
Note 15. Supplemental Cash Flow Information
(In millions) 2023 2022 2021
Cash paid for:
Interest $ 1,385 $ 667 $ 555
Income taxes 1,482 1,234 2,182
Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment 296 393 379
Fair value of equity awards exchanged — — 43
Fair value of acquisition contingent consideration — — 183
Finance lease ROU assets obtained in exchange for new finance lease liabilities 2 33 15
Declared but unpaid dividends 137 119 104
Issuance of stock upon vesting of restricted stock units 234 241 265
Excise tax from stock repurchases 28 — —
70
-- 70 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
Cash, cash equivalents and restricted cash is included in the consolidated balance sheet as follows:
December 31, December 31,
(In millions) 2023 2022
Cash and cash equivalents $ 8,077 $ 8,524
Restricted cash included in other current assets 6 12
Restricted cash included in other assets 14 1
Cash, cash equivalents and restricted cash $ 8,097 $ 8,537
Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees and incoming cash in China awaiting government
administrative clearance.
Note 16. Restructuring and Other Costs
Restructuring and other costs in 2023 primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline
operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2023, severance actions
associated with facility consolidations and cost reduction measures affected approximately 5% of the company’s workforce.
Restructuring and other costs in 2022 primarily included impairment of long-lived assets and continuing charges for headcount reductions and facility
consolidations in an effort to streamline operations. In 2022, severance actions associated with facility consolidations and cost reduction measures affected less
than 2% of the company’s workforce.
Restructuring and other costs in 2021 primarily included charges for impairments of an acquired technology asset and a tradename asset, and, to a lesser extent,
compensation due to employees at acquired businesses on the date of acquisition. In 2021, severance actions associated with facility consolidations and cost
reduction measures affected less than 1% of the company’s workforce.
As of February 22, 2024, the company has identified restructuring actions that will result in additional charges of approximately $70 million, primarily in 2024,
and expects to identify additional actions in future periods which will be recorded when specified criteria are met, such as communication of benefit
arrangements or when the costs have been incurred.
Restructuring and other costs by segment are as follows:
(In millions) 2023 2022 2021
Life Sciences Solutions $ 105 $ 30 $ 129
Analytical Instruments 33 1 6
Specialty Diagnostics 11 68 18
Laboratory Products and Biopharma Services 295 12 35
Corporate 15 3 9
$ 459 $ 114 $ 197
71
-- 71 of 225 --
THERMO FISHER SCIENTIFIC INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
The following table summarizes the changes in the company’s accrued restructuring balance. Other amounts reported as restructuring and other costs in the
accompanying statement of income have been summarized in the notes to the table. Accrued restructuring costs are included in other accrued expenses in the
accompanying balance sheet.
(In millions) Total (a)
Balance at December 31, 2020 $ 21
Net restructuring charges incurred in 2021 (b) 37
Payments (40)
Currency translation (1)
Balance at December 31, 2021 17
Net restructuring charges incurred in 2022 (c) 68
Payments (44)
Balance at December 31, 2022 41
Net restructuring charges incurred in 2023 (d) (e) 194
Payments (175)
Balance at December 31, 2023 $ 60
(a) The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b) Excludes $160 million of charges, principally $122 million for impairments of an acquired technology asset and a tradename asset in the Life Sciences Solutions and
Laboratory Products and Biopharma Services segments, principally resulting from a reduction in expected cash flows, and $35 million of charges for compensation
contractually due to employees of acquired businesses at the date of acquisition in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
(c) Excludes $46 million of net charges, primarily charges for impairment of long-lived assets in the Specialty Diagnostic segment.
(d) Excludes $264 million of net charges, principally $126 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services and Life
Sciences Solutions segments, $26 million of contract termination costs associated with facility closures in the Laboratory Products and Biopharma Services segment, and
$19 million of net charges for pre-acquisition litigation and other matters in the Laboratory Products and Biopharma Services segment.
(e) Excludes $93 million of charges in the Laboratory Products and Biopharma Services segment for impairments of a disposal group that was held for sale beginning in the
third quarter of 2023. The loss attributable to Thermo Fisher Scientific Inc. was reduced by $46 million attributable to a noncontrolling interest.
The company expects to pay accrued restructuring costs primarily through 2024.
72
-- 72 of 225 --
THERMO FISHER SCIENTIFIC INC.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Not applicable.
Item 9A. Controls and Procedures
Management’s Evaluation of Disclosure Controls and Procedures
The company’s management, with the participation of the company’s chief executive officer and chief financial officer, has evaluated the effectiveness of the
company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period
covered by this report. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable
assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and
procedures. Based on such evaluation, the company’s chief executive officer and chief financial officer concluded that, as of the end of such period, the
company’s disclosure controls and procedures were effective at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There have been no changes in the company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the
fiscal quarter ended December 31, 2023, that have materially affected or are reasonably likely to materially affect the company’s internal control over financial
reporting.
Management’s Annual Report on Internal Control Over Financial Reporting
The company’s management, including the company’s chief executive officer and chief financial officer, is responsible for establishing and maintaining
adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company. Internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles. The company’s management conducted an assessment of the effectiveness of
the company’s internal control over financial reporting as of December 31, 2023 based on criteria established in Internal Control - Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment, the company’s management
concluded that, as of December 31, 2023, the company’s internal control over financial reporting was effective.
The company’s independent registered public accounting firm, PricewaterhouseCoopers LLP, has audited the effectiveness of the company’s internal control
over financial reporting as of December 31, 2023, as stated in their report that appears on page 30 of this Annual Report on Form 10-K.
Item 9B. Other Information
Amendment and Restatement of By-Laws
On February 21, 2024, the Board of Directors of the company amended and restated the company’s By-Laws, effective immediately, to remove the
supermajority voting requirement for amending Article II or Article VI of the By-laws. Specifically, the amendments to the By-laws eliminate Article VI,
Section 3 to remove the supermajority voting requirement, and update Article VI, Section 2 to remove the reference to Article VI, Section 3. The foregoing
description of the amendments to the By-laws does not purport to be complete and is qualified in its entirety by reference to the full text of the By-laws, as
amended and restated, a copy of which is attached as Exhibit 3.4 and incorporated by reference herein.
Director and Officer Trading Arrangements
On December 13, 2023, Michael A. Boxer, our senior vice president, general counsel, adopted a trading plan intended to satisfy the conditions under Rule
10b5-1(c) of the Exchange Act. Mr. Boxer’s plan is for the exercise of vested stock options and the associated sale of up to 20,566 shares of company common
stock through December 13, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan
terminates on the earlier of the date all the shares under the plan are sold and December 13, 2024.
On December 12, 2023, Lisa P. Britt, our senior vice president, chief human resources officer, adopted a trading plan intended to satisfy the conditions under
Rule 10b5-1(c) of the Exchange Act. Ms. Britt’s plan is for the exercise of vested stock options and the associated sale of up to 14,345 shares of company
common stock through November 11, 2024. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and
such plan terminates on the earlier of the date all the shares under the plan are sold and November 12, 2024.
On November 10, 2023, Marc N. Casper, our chairman, president and chief executive officer, adopted a trading plan intended to satisfy the conditions under
Rule 10b5-1(c) of the Exchange Act. Mr. Casper’s plan is for the exercise of vested stock options
73
-- 73 of 225 --
THERMO FISHER SCIENTIFIC INC.
and the associated sale of up to 202,150 shares of company common stock through November 1, 2024. The foregoing exercises or sales will be made in
accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and
November 4, 2024.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
PART III
Item 10. Directors, Executive Officers and Corporate Governance
The information with respect to directors required by this Item will be contained in our Proxy Statement to be filed with the SEC not later than 120 days after
the close of business of the fiscal year including under “Corporate governance,” and is incorporated in this report by reference.
The information with respect to executive officers required by this Item is included in Item 1 of Part I of this report.
The other information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and is incorporated in this
report by reference.
Item 11. Executive Compensation
The information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and “Executive compensation,” and
is incorporated in this report by reference.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item will be contained in our Proxy Statement including under “Information about stock ownership,” and is incorporated in
this report by reference.
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this Item will be contained in our Proxy Statement including under “Corporate governance,” and is incorporated in this report by
reference.
Item 14. Principal Accountant Fees and Services
The information required by this Item will be contained in our Proxy Statement including under “Audit matters,” and is incorporated in this report by reference.
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a) The following documents are filed as part of this report:
(1) Consolidated Financial Statements (see Index on page 29 of this report)
(2) All schedules are omitted because they are not applicable or not required, or because the required information is included either in the consolidated
financial statements or in the notes thereto.
(b) Exhibits
Exhibit
Number Description of Exhibit
2.1 Agreement and Plan of Merger, dated as of April 15, 2021, by and among Thermo Fisher Scientific Inc., Powder Acquisition Corp. and PPD, Inc. (filed as
Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed April 16, 2021 [File No. 1-8002] and incorporated in this document by reference).
3.1 Amended and Restated Certificate of Incorporation of the Registrant (filed as Exhibit 3.1 to the Registrant’s Annual Report on Form 10-K for the year ended
December 31, 2005 [File No. 1-8002] and incorporated in this document by reference).
3.2 Amendment to Thermo Fisher Scientific Inc.’s Third Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Registrant’s Current Report
on Form 8-K filed November 14, 2006 [File No. 1-8002] and incorporated in this document by reference).
3.3 Certificate of Elimination of the Series B Junior Participating Preferred Stock of the Company, dated November 13, 2015 (filed as Exhibit 3.1 to the
Registrant’s Current Report on Form 8-K filed November 16, 2015 [File No. 1-8002] and incorporated in this document by reference).
74
-- 74 of 225 --
THERMO FISHER SCIENTIFIC INC.
Exhibit
Number Description of Exhibit
3.4 Amended and Restated By-Laws of the Registrant, as amended and effective as of February 21, 2024
The Registrant agrees, pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, to furnish to the Commission, upon request, a copy of each instrument with respect
to long-term debt of the Registrant or its consolidated subsidiaries.
4.1 Indenture dated as of November 20, 2009 between the Company and The Bank of New York Mellon Trust Company, N.A. (filed as Exhibit 99.1 to the
Registrant’s Current Report on Form 8-K filed November 20, 2009 [File No. 1-8002] and incorporated in this document by reference).
4.2 Sixth Supplemental Indenture, dated as of December 11, 2013, between the Company and The Bank of New York Mellon Trust Company, N.A. (filed as
Exhibit 99.2 to the Registrant’s Current Report on Form 8-K filed December 11, 2013 [File No. 1-8002] and incorporated in this document by reference).
4.3 Eighth Supplemental Indenture, dated as of November 24, 2014, among the Company, The Bank of New York Mellon Trust Company, N.A., as trustee, and
The Bank of New York Mellon, London Branch, as paying agent (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 24, 2014
[File No. 1-8002] and incorporated in this document by reference).
4.4 Thirteenth Supplemental Indenture, dated as of September 12, 2016, between the Company and The Bank of New York Mellon Trust Company, N.A., as
trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 12, 2016 [File No. 1-8002] and incorporated in this document by
reference).
4.5 Fifteenth Supplemental Indenture, dated as of March 16, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee
(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed March 16, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.6 Sixteenth Supplemental Indenture, dated as of July 24, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (filed
as Exhibit 4.2 to the Registrant's Current Report on Form 8-K filed July 24, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.7 Seventeenth Supplemental Indenture, dated as of August 14, 2017, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee
(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 14, 2017 [File No. 1-8002] and incorporated in this document by reference).
4.8 Eighteenth Supplemental Indenture, dated as of September 30, 2019, between the Company, and The Bank of New York Mellon Trust Company, N.A., as
trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed September 30, 2019 [File No. 1-8002] and incorporated in this document by
reference).
4.9 Nineteenth Supplemental Indenture, dated as of October 8, 2019, between the Company, and the Bank of New York Mellon Trust Company, N.A., as trustee
(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 8, 2019 [File No. 1-8002] and incorporated in this document by reference).
4.10 Twenty-First Supplemental Indenture, dated as of April 2, 2020, between the Company, and The Bank of New York Mellon Trust Company, N.A., as trustee
(filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed April 2, 2020 [File No. 1-8002] and incorporated in this document by reference).
4.11 Twenty-Second Supplemental Indenture, dated as of August 23, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as
trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 23, 2021 [File No. 1-8002] and incorporated in this document by
reference).
4.12 Twenty-Third Supplemental Indenture, dated as of October 22, 2021, between the Company, and The Bank of New York Mellon Trust Company, N.A., as
trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 22, 2021 [File No. 1-8002] and incorporated in this document by
reference).
4.13 Twenty-Fourth Supplemental Indenture, dated as of October 20, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company,
N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 20, 2022 [File No. 1-8002] and incorporated in this
document by reference).
4.14 Twenty-Fifth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company,
N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this
document by reference).
4.15 Twenty-Sixth Supplemental Indenture, dated as of November 21, 2022, between the Company, as issuer, and The Bank of New York Mellon Trust Company,
N.A., as trustee (filed as Exhibit 4.3 to the Registrant’s Current Report on Form 8-K filed November 21, 2022 [File No. 1-8002] and incorporated in this
document by reference).
4.16 Twenty-Seventh Supplemental Indenture, dated as of August 10, 2023, between the Company, as issuer, and The Bank of New York Mellon Trust Company,
N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed August 10, 2023 [File No. 1-8002] and incorporated in this document
by reference).
4.17 Twenty-Eighth Supplemental Indenture, dated as of December 5, 2023, between the Company, as issuer, and The Bank of New York Mellon Trust Company,
N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K December 5, 2023 [File No. 1-8002] and incorporated in this document by
reference).
4.18 Indenture, dated as of August 9, 2016, among Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), as issuer, the Company, as guarantor,
and The Bank of New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K filed August 9, 2016
[File No. 1-8002] and incorporated in this document by reference).
75
-- 75 of 225 --
THERMO FISHER SCIENTIFIC INC.
Exhibit
Number Description of Exhibit
4.19 Third Supplemental Indenture, dated as of October 18, 2021, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of New
York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed October 18, 2021 [File No. 1-8002]
and incorporated in this document by reference).
4.20 Fourth Supplemental Indenture, dated as of November 18, 2021, among Thermo Fisher International, as issuer, the Company, as guarantor, and The Bank of
New York Mellon Trust Company, N.A., as trustee (filed as Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 18, 2021 [File No. 1-
8002] and incorporated in this document by reference).
4.21 Description of the Registrant’s Securities (filed as Exhibit 4.19 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022
[File No. 1-8002] and incorporated in this document by reference).
10.1 Thermo Fisher Scientific Inc. Deferred Compensation Plan for Directors of the Registrant, as amended and restated effective February 21, 2024.*
10.2 Thermo Electron Corporation Deferred Compensation Plan, effective November 1, 2001 (filed as Exhibit 10.13 to the Registrant’s Annual Report on Form 10-
K for the fiscal year ended December 29, 2001 [File No. 1-8002] and incorporated in this document by reference).*
10.3 Form of Amended and Restated Indemnification Agreement between the Registrant and its directors and officers (filed as Exhibit 10.2 to the Registrant’s
Registration Statement on Form S-4 [Reg. No. 333-90661] and incorporated in this document by reference).*
10.4 Summary of Thermo Fisher Scientific Inc. Annual Non-Management Director Compensation (filed as Exhibit 10.1 to the Registrant’s Current Report on
Form 8-K filed February 24, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.5 Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers, effective as of January 1, 2009 (filed as
Exhibit 10.25 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2009 [File No. 1-8002] and incorporated in this document by
reference).*
10.6 Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.12 to Fisher Scientific International Inc.’s Annual
Report on Form 10-K for the year ended December 31, 1992 [File No. 1-10920] and incorporated in this document by reference).*
10.7 First Amendment to the Fisher Scientific International Inc. Retirement Plan for Non-Employee Directors (filed as Exhibit 10.04 to Fisher Scientific
International Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005 [File No. 1-10920] and incorporated in this document by reference).*
10.8 Amendment to Retirement Plan for Non-Employee Directors of Fisher Scientific International Inc. (filed as Exhibit 10.02 to Fisher Scientific International
Inc.’s Current Report on Form 8-K filed March 7, 2006 [File No. 1-10920] and incorporated in this document by reference).*
10.9 Thermo Fisher Scientific Inc. Amended and Restated 2005 Deferred Compensation Plan, effective January 1, 2020 (filed as Exhibit 10.1 to the Registrant’s
Quarterly Report on Form 10-Q for the quarter ended June 27, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.10 2009 Restatement of Executive Severance Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.5 to the
Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.11 Executive Change In Control Retention Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.6 to the
Registrant’s Current Report on Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.12 Noncompetition Agreement, between Marc N. Casper and the Registrant, dated November 21, 2009 (filed as Exhibit 10.7 to the Registrant’s Current Report on
Form 8-K filed November 25, 2009 [File No. 1-8002] and incorporated in this document by reference).*
10.13 Amendment No. 1 to 2009 Restatement of Executive Severance Agreement, dated February 25, 2010, between the Registrant and Marc N. Casper (filed as
Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed February 25, 2010 [File No. 1-8002] and incorporated in this document by reference).*
10.14 Amendment No. 2 to 2009 Restatement of Executive Severance Agreement, dated November 30, 2010, between the Registrant and Marc N. Casper (filed as
Exhibit 10.55 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by
reference).*
10.15 Amendment No. 1 to Executive Change In Control Retention Agreement, dated November 30, 2010, between Marc N. Casper and the Registrant (filed as
Exhibit 10.56 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2010 [File No. 1-8002] and incorporated in this document by
reference).*
10.16 Amendment No. 2 to Executive Change in Control Retention Agreement, dated March 16, 2018, between Marc N. Casper and the Registrant (filed as Exhibit
10.3 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 [File No. 1-8002] and incorporated in this document by
reference).*
10.17 Form of Executive Change in Control Retention Agreement for Officers (other than Marc N. Casper) (filed as Exhibit 10.7 to the Registrant's Quarterly Report
on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.18 Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement for Directors (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-
Q for the quarter ended April 2, 2011 [File No. 1-8002] and incorporated in this document by reference).*
76
-- 76 of 225 --
THERMO FISHER SCIENTIFIC INC.
Exhibit
Number Description of Exhibit
10.19 Thermo Fisher Scientific Inc. Amended and Restated 2013 Stock Incentive Plan (filed as Exhibit 99.1 to the Registrant’s Form S-8 filed on May 24, 2023 [File
No. 333-272173] and incorporated in this document by reference).*
10.20 Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement for Officers (filed as Exhibit 10.44 to the Registrant's Annual Report on Form
10-K for the year ended December 31, 2016 [File No. 1-8002] and incorporated in this document by reference).*
10.21 Patheon N.V. 2016 Omnibus Incentive Plan (filed as Exhibit 10.2 to the Current Report on Form 8-K filed by Patheon N.V. on July 26, 2016 [File No. 001-
37837] and incorporated in this document by reference).*
10.22 Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated March 7, 2017 (filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-8
filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.23 Amendment to Patheon N.V. 2016 Omnibus Incentive Plan, dated August 23, 2017 (filed as Exhibit 4.6 to the Registrant's Registration Statement on Form S-8
filed August 29, 2017 [File No. 1-8002] and incorporated in this document by reference).*
10.24 Credit Agreement, dated January 7, 2022, among Thermo Fisher Scientific Inc., certain Subsidiaries of Thermo Fisher Scientific Inc. from time to time party
thereto, Bank of America, N.A., as Administrative Agent and each lender from time to time party thereto (filed as Exhibit 10.1 to the Registrant’s Current
Report on Form 8-K filed January 7, 2022 [File No. 1-8002] and incorporated in this document by reference).
10.25 Letter Agreement between the Registrant and Michel Lagarde dated August 28, 2017 (filed as Exhibit 10.39 to the Registrant’s Annual Report on Form 10-K
for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.26 Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated July 20, 2016 (filed as Exhibit
10.40 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by
reference).*
10.27 Option Agreement Under the Patheon N.V. 2016 Omnibus Incentive Plan between Patheon N.V. and Michel Lagarde dated March 23, 2017 (filed as Exhibit
10.42 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by
reference).*
10.28 Thermo Fisher Scientific Inc. Executive Severance Policy (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June
29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.29 Form of Noncompetition Agreement between the Registrant and certain key employees and executive officers (filed as Exhibit 10.2 to the Registrant’s
Quarterly Report on Form 10-Q for the quarter ended June 29, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.30 Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement effective as of February 25, 2020 (filed as Exhibit 10.45 to the
Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.31 Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement effective as of February 25, 2020 (filed as Exhibit 10.46 to the Registrant’s Annual
Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.32 Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement for Officers effective as of February 25, 2020 (filed as Exhibit 10.47 to the
Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.33 Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as
Exhibit 10.48 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by
reference).*
10.34 Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit 10.49
to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by reference).*
10.35 Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 25, 2020 (filed as Exhibit
10.50 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2019 [File No. 1-8002] and incorporated in this document by
reference).*
10.36 Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.47 to the Registrant’s Annual Report
on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.37 Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.48 to the Registrant’s
Annual Report on Form 10-K for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.38 Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement (filed as Exhibit 10.49 to the Registrant’s Annual Report on Form 10-K
for the year ended December 31, 2020 [File No. 1-8002] and incorporated in this document by reference).*
10.39 PPD, Inc. 2020 Omnibus Incentive Plan (filed as Exhibit 10.38 to PPD Inc.’s Form S-1/A filed January 27, 2020 [File No. 333-235860] and incorporated in
this document by reference).*
77
-- 77 of 225 --
THERMO FISHER SCIENTIFIC INC.
Exhibit
Number Description of Exhibit
10.40 Amendment to Nonstatutory Stock Option Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.45 to the Registrant’s
Annual Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.41 Amendment to Restricted Stock Unit Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.46 to the Registrant’s Annual
Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.42 Amendment to Performance Restricted Stock Unit Agreements between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.47 to the
Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022 [File No. 1-8002] and incorporated in this document by reference).*
10.43 Form of Thermo Fisher Scientific Inc.’s Nonstatutory Stock Option Agreement effective as of February 22, 2023 (filed as Exhibit 10.3 to the Registrant’s
Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.44 Form of Thermo Fisher Scientific Inc.’s Restricted Stock Unit Agreement (filed as Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the
quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.45 Form of Thermo Fisher Scientific Inc.’s Performance Restricted Stock Unit Agreement (filed as Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-
Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.46 Form of Nonstatutory Stock Option Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper effective as of February 22, 2023 (filed as Exhibit
10.6 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by
reference).*
10.47 Form of Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.5 to the Registrant’s Quarterly
Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.48 Form of Performance Restricted Stock Unit Agreement between Thermo Fisher Scientific Inc. and Marc N. Casper (filed as Exhibit 10.4 to the Registrant’s
Quarterly Report on Form 10-Q for the quarter ended April 1, 2023 [File No. 1-8002] and incorporated in this document by reference).*
10.49 Thermo Fisher Scientific Inc. Deferred Compensation Plan, as amended and restated January 1, 2024.*
21 Subsidiaries of the Registrant.
22 Subsidiary Issuer of Guaranteed Securities.
23.1 Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.
31.1 Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
31.2 Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
32.1 Certification of Chief Executive Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.**
32.2 Certification of Chief Financial Officer required by Exchange Act Rules 13a-14(b) and 15d-14(b), as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002.**
97 Clawback Policy
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL
document.
101.SCH XBRL Taxonomy Extension Schema Document.
101.CAL XBRL Taxonomy Calculation Linkbase Document.
101.DEF XBRL Taxonomy Definition Linkbase Document.
101.LAB XBRL Taxonomy Label Linkbase Document.
101.PRE XBRL Taxonomy Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
_______________________
*Indicates management contract or compensatory plan, contract or arrangement.
** Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be
incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.
Item 16. Form 10-K Summary
None.
78
-- 78 of 225 --
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its
behalf by the undersigned, thereunto duly authorized.
Date: February 22, 2024 THERMO FISHER SCIENTIFIC INC.
By: /s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
Registrant and in the capacities indicated, as of February 22, 2024.
By: /s/ Marc N. Casper By: /s/ Jennifer M. Johnson
Marc N. Casper Jennifer M. Johnson
Chairman, President and Chief Executive Officer Director
(Principal Executive Officer)
By: /s/ Stephen Williamson By: /s/ R. Alexandra Keith
Stephen Williamson R. Alexandra Keith
Senior Vice President and Chief Financial Officer Director
(Principal Financial Officer)
By: /s/ Joseph R. Holmes By: /s/ James C. Mullen
Joseph R. Holmes James C. Mullen
Vice President and Chief Accounting Officer Director
(Principal Accounting Officer)
By: /s/ Nelson J. Chai By: /s/ Lars R. Sørensen
Nelson J. Chai Lars R. Sørensen
Director Director
By: /s/ Ruby R. Chandy By: /s/ Debora L. Spar
Ruby R. Chandy Debora L. Spar
Director Director
By: /s/ C. Martin Harris By: /s/ Scott M. Sperling
C. Martin Harris Scott M. Sperling
Director Director
By: /s/ Tyler E. Jacks By: /s/ Dion J. Weisler
Tyler E. Jacks Dion J. Weisler
Director Director
79
-- 79 of 225 --
Exhibit 3.4
As amended and restated effective as of February 21, 2024
Thermo Fisher Scientific Inc.
BY-LAWS
TABLE OF CONTENTS
Title Page
ARTICLE I - STOCKHOLDERS 1
Section 1. Annual Meeting 1
Section 2. Special Meetings 1
Section 3. Notice of Meetings 3
Section 4. Quorum; Adjournments 4
Section 5. Voting; Proxies 4
Section 6. Inspectors of Elections 5
Section 7. Presiding Officer and Secretary 5
Section 8. List of Stockholders 6
Section 9. Advance Notice of Stockholder Nominations and Proposals 6
Section 10. Proxy Access 11
Section 11. Action Without Meeting 17
Section 12. Meeting by Remote Communication 17
Section 13. Delivery to the Corporation 18
ARTICLE II - DIRECTORS 18
Section 1. General Powers 18
Section 2. Number and Qualification 18
Section 3. Terms of Office 18
Section 4. Removal 18
Section 5. Vacancies 19
Section 6. Resignations 19
Section 7. Meetings 19
Section 8. Notice of Meetings 19
Section 9. Quorum 19
Section 10. Action at Meeting 19
Section 11. Action by Consent 20
Section 12. Meetings by Telephone Conference Call 20
Section 13. Compensation of Directors 20
Section 14. Committees 20
Section 15. Emergency Bylaws 21
i
-- 80 of 225 --
-- 81 of 225 --
Title Page
ARTICLE III - OFFICERS 21
Section 1. General Provisions; Qualification 21
Section 2. Election 21
Section 3. Tenure 21
Section 4. Resignation and Removal 21
Section 5. Vacancies 21
Section 6. The Chief Executive Officer 22
Section 7. The President 22
Section 8. Vice Presidents 22
Section 9. Chief Financial Officer 22
Section 10. General Counsel 22
Section 11. The Treasurer 22
Section 12. The Secretary 22
Section 13. Assistant Treasurers 23
Section 14. Assistant Secretaries 23
Section 15. Other Officers 23
Section 16. Delegation of Duties 23
Section 17. Salaries 23
ARTICLE IV - CAPITAL STOCK 23
Section 1. Shares of Stock 23
Section 2. Transfer of Shares of Stock 23
Section 3. Lost, Stolen or Destroyed Certificates 24
Section 4. Record Date 24
Section 5. Regulations 25
ARTICLE V - GENERAL PROVISIONS 25
Section 1. Fiscal Year 25
Section 2. Corporate Seal 25
Section 3. Waiver of Notice 25
Section 4. Voting of Securities 25
Section 5. Evidence of Authority 26
Section 6. Certificate of Incorporation 26
Section 7. Transactions with Interested Parties 26
Section 8. Severability 26
Section 9. Limitation on Stock Option Repricing 26
ARTICLE VI - AMENDMENTS 27
Section 1. By the Board of Directors 27
Section 2. By the Stockholders 27
-- 82 of 225 --
ii
-- 83 of 225 --
THERMO FISHER SCIENTIFIC INC.
BY-LAWS
ARTICLE I - STOCKHOLDERS
Section 1. Annual Meeting. The annual meeting of the stockholders, for the election of directors to succeed those whose
terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if
any, on such date, and at such time as the Board of Directors may each year fix. The Board of Directors may postpone, reschedule or
cancel any previously scheduled annual meeting.
Section 2. Special Meetings.
1. Except as otherwise provided in paragraph 2 of Section 2 of this Article I, special meetings of stockholders may be
called only by the Board of Directors, the Chairman of the Board of Directors, or the Chief Executive Officer. Business transacted at
any special meeting of stockholders called pursuant to this paragraph 1 of Section 2 of Article I shall be limited to matters relating to
the purpose or purposes stated in the notice of meeting.
2. A special meeting of stockholders shall be called by the Secretary upon written request (a “Special Meeting Request”) of
one or more holders of record representing not less than 15% of the outstanding shares of Common Stock of the Corporation (the
“Requisite Percentage”), provided that such shares have been “Owned” (as defined in paragraphs 7 and 8 of Section 10 of this
Article I) continuously by such holders for at least one year prior to the date of the Special Meeting Request (the “One Year Period”),
who have complied in full with the requirements set forth in these By-laws.
(i) A Special Meeting Request must be delivered to the attention of the Secretary at the principal executive offices
of the Corporation. A Special Meeting Request shall be valid only if it is signed and dated by each stockholder of record submitting
the Special Meeting Request and the beneficial owners, if any, on whose behalf the Special Meeting Request is being made, or such
stockholder’s or beneficial owner’s duly authorized agent (each, a “Requesting Stockholder”) collectively representing the Requisite
Percentage, and includes (A) a statement of the specific purpose(s) of the special meeting and the reasons for conducting such
business at the special meeting; (B) as to any director nominations proposed to be presented at the special meeting and any matter
(other than a director nomination) proposed to be conducted at the special meeting and as to each Requesting Stockholder, the
information, statements, representations, agreements and other documents that would be required to be set forth in or included with a
stockholder’s notice of a nomination pursuant to Section 9 of this Article I (including any nominee’s written consent to being named
in the Corporation’s proxy statement as a nominee and to serving as a director if elected) and/or a stockholder’s notice of business
proposed to be brought before a meeting pursuant to Section 9 of this Article I, as applicable; (C) a representation that a Requesting
Stockholder or a qualified representative (as defined in Section 9 of this Article I) thereof intends to appear in person or by proxy at
the special meeting to present the nomination(s) or business to be brought before the special meeting; (D) an agreement by each
Requesting Stockholder to notify the Corporation promptly
1
-- 84 of 225 --
in the event of any disposition prior to the date of the special meeting of shares of the Corporation owned beneficially or of record
and an acknowledgement that any such disposition shall be deemed to be a revocation of such Special Meeting Request with respect
to such disposed shares; and (E) documentary evidence that each Requesting Stockholder has Owned continuously for the One Year
Period the Requisite Percentage; provided, however, that if the Requesting Stockholders are not the beneficial owners of the shares
representing the Requisite Percentage, then to be valid, the Special Meeting Request must also include documentary evidence (or, if
not simultaneously provided with the Special Meeting Request, such documentary evidence must be delivered to the Secretary
within 10 days after the date on which the Special Meeting Request is delivered to the Secretary) that the beneficial owners on
whose behalf the Special Meeting Request is made beneficially have Owned the Requisite Percentage continuously for the One Year
Period. In addition, each Requesting Stockholder shall (x) further update and supplement the information provided in the Special
Meeting Request, if necessary, so that the information provided or required to be provided therein shall be true and correct as of the
record date for the special meeting and as of the date that is 10 business days prior to the special meeting or any adjournment or
postponement thereof, and such update and supplement shall be delivered to the Secretary at the principal executive offices of the
Corporation not later than five business days after the later of the record date for the meeting or the date notice of the record date is
first publicly disclosed in the case of the update and supplement required to be made as of the record date and not later than 10
business days prior to the date of the special meeting or any adjournment or postponement thereof in the case of the update and
supplement required to be made as of 10 business days prior to the special meeting or any adjournment or postponement thereof and
(y) promptly provide any other information reasonably requested by the Corporation.
(ii) A Special Meeting Request shall not be valid, and a special meeting requested by stockholders shall not be held,
if (A) the Special Meeting Request does not comply with this Section 2; (B) the Special Meeting Request relates to an item of
business that is not a proper subject for stockholder action under applicable law (as determined in good faith by the Board of
Directors); (C) the Special Meeting Request is delivered during the period commencing 90 days prior to the first anniversary of the
date of the immediately preceding annual meeting of stockholders and ending on the earlier of the date of the next annual meeting of
stockholders and the date that is 90 days after the first anniversary of the date of the immediately preceding annual meeting of
stockholders; (D) an identical or substantially similar item (as determined in good faith by the Board of Directors, a “Similar Item”),
other than the election of directors, was presented at an annual or special meeting of stockholders held not more than 12 months
before the Special Meeting Request is delivered; (E) a Similar Item was presented at an annual or special meeting of stockholders
held not more than 120 days before the Special Meeting Request is delivered (and, for purposes of this clause (E), the election of
directors shall be deemed to be a “Similar Item” with respect to all items of business involving the election or removal of directors,
changing the size of the Board of Directors and the filling of vacancies and/or newly created directorships resulting from any
increase in the authorized number of directors); (F) a Similar Item is included in the Corporation’s notice of meeting as an item of
business to be brought before an annual or special meeting of stockholders that has been called but not yet held or that is called for a
date within 90 days of the receipt by the Corporation of a Special Meeting Request; or (G) the Special Meeting Request was made in
a manner that involved a violation of Regulation 14A under the Exchange Act or other applicable law.
2
-- 85 of 225 --
(iii) Special meetings of stockholders called pursuant to this Section 2 shall be held at such place, if any, on such
date, and at such time as the Board of Directors shall fix; provided, however, that the special meeting shall not be held more than 90
days after receipt by the Corporation of a valid Special Meeting Request.
(iv) The Requesting Stockholders may revoke a Special Meeting Request by written revocation delivered to the
Secretary at the principal executive offices of the Corporation at any time prior to the special meeting. If, at any point after 60 days
of the first date on which a Special Meeting Request is delivered to the Corporation the unrevoked requests from Requesting
Stockholders (whether by specific written revocation or deemed revocation pursuant to clause (D) of paragraph 2(i) of this Section
2) represent in the aggregate less than the Requisite Percentage, the Board of Directors, in its discretion, may cancel the special
meeting.
(v) In determining whether a special meeting of stockholders has been requested by the Requesting Stockholders
representing in the aggregate at least the Requisite Percentage, multiple Special Meeting Requests delivered to the Secretary of the
Corporation will be considered together only if (A) each Special Meeting Request identifies substantially the same purpose or
purposes of the special meeting and substantially the same matters proposed to be acted on at the special meeting, in each case as
determined by the Board of Directors (which, if such purpose is the election or removal of directors, changing the size of the Board
of Directors and/or the filling of vacancies and/or newly created directorships resulting from any increase in the authorized number
of directors, will mean that the exact same person or persons are proposed for election or removal in each relevant Stockholder
Meeting Request), and (B) such Special Meeting Requests have been dated and delivered to the Secretary of the Corporation within
60 days of the first date on which a Special Meeting Request is delivered to the Corporation.
(vi) If none of the Requesting Stockholders appear or send a qualified representative (as defined in Section 9 of this
Article I) to present the nomination and/or business to be presented for consideration as specified in the Special Meeting Request,
the Corporation need not present such nomination and/or business for a vote at the special meeting, notwithstanding that proxies in
respect of such nomination and/or business may have been received by the Corporation.
(vii) Business transacted at any special meeting called pursuant to this paragraph 2 of Section 2 shall be limited to
(A) the purpose(s) stated in the valid Special Meeting Request received from the Requisite Percentage of record holders and (B) any
additional matters that the Board of Directors determines to include in the Corporation’s notice of the special meeting.
3. The Board of Directors may postpone, reschedule or cancel any previously scheduled special meeting.
Section 3. Notice of Meetings. Notice of the place, date, and time of all meetings of the stockholders and the means of
remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such
meeting shall be given, not less than ten (10) nor more than sixty (60) days before the date on which the meeting is to be held, to
each stockholder entitled to vote at such meeting, except as otherwise required by the Delaware General Corporation Law (meaning,
here and hereinafter, the General Corporation Law of the State of Delaware, as amended and in effect from time to time, the
“Delaware General Corporation Law”).
3
-- 86 of 225 --
Section 4. Quorum; Adjournments. At any meeting of the stockholders, the holders of a majority in voting power of all of
the shares of the stock entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if
any, authorized by the Board of Directors in its sole discretion, or represented by proxy, shall constitute a quorum for all purposes,
unless or except to the extent that the presence of a larger number may be required by the Certificate of Incorporation or the
Delaware General Corporation Law. Where a separate vote by a class or classes or series is required, a majority of the shares of such
class or classes or series present in person, present by means of remote communication in a manner, if any, authorized by the Board
of Directors in its sole discretion, or represented by proxy shall constitute a quorum entitled to take action with respect to that vote
on that matter. A quorum, once established at a meeting, shall not be broken by the withdrawal of enough votes to leave less than a
quorum.
Any meeting of stockholders may be adjourned from time to time to reconvene at any other time and to any other place at
which a meeting of stockholders may be held under these Bylaws by the presiding officer. When a meeting is adjourned to another
place or time (including an adjournment taken to address a technical failure to convene or continue a meeting using remote
communication), notice need not be given of the adjourned meeting if the place, if any, and time thereof and the means of remote
communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting
are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the
same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote
communication or (iii) set forth in the notice of meeting given in accordance with Section 3 hereof; provided, however, that if the
date of any adjourned meeting is more than thirty (30) days after the date for which the meeting was originally noticed, or if a new
record date is fixed for the adjourned meeting, notice of the place, if any, date, and time of the adjourned meeting and the means of
remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such
meeting shall be given in conformity herewith. At any adjourned meeting, any business may be transacted that could have been
transacted at the original meeting.
Section 5. Voting; Proxies. Each stockholder shall have one vote for each share of stock entitled to vote held of record by
such stockholder unless otherwise provided by the Delaware General Corporation Law or the Certificate of Incorporation. Each
stockholder of record entitled to vote at a meeting of stockholders, or to express consent or dissent to corporate action in writing
without a meeting, may vote or express such consent or dissent in person or may authorize another person or persons to vote or act
for the stockholder by proxy authorized by an instrument in writing or by a transmission permitted by law, delivered in accordance
with the procedure established for the meeting. No such proxy shall be voted or acted upon after three years from the date of its
execution, unless the proxy expressly provides for a longer period.
4
-- 87 of 225 --
When a quorum is present at any meeting, the affirmative vote of holders of a majority in voting power of the stock present
or represented and entitled to vote and voting affirmatively or negatively on a matter (or if there are two or more classes or series of
stock entitled to vote as separate classes, then in the case of each such class or series, the holders of a majority of the stock of that
class present or represented and voting affirmatively or negatively on a matter) shall constitute stockholder action on any matter to
be voted upon by the stockholders at such meeting, except when a different or minimum vote is required by the Delaware General
Corporation Law, the Certificate of Incorporation, these By-laws, the rules and regulations of any stock exchange applicable to the
Corporation, or any law or regulation application to the Corporation or its securities, in which case, such different or minimum vote
shall be the applicable vote on the matter. Except as may be otherwise required by the Certificate of Incorporation, a nominee for
director shall be elected to the Board of Directors if the votes cast for such nominee’s election exceed the votes cast against such
nominee’s election (with “abstentions” and “broker nonvotes” not counted as a vote cast either “for” or “against” that director’s
election), provided that if, on the tenth business day before the Corporation first mails its notice of meeting for such meeting to the
stockholders, the number of nominees exceeds the number of directors to be elected, the directors shall be elected by the vote of a
plurality of the shares represented in person or by proxy at any such meeting and entitled to vote on the election of directors. If
directors are to be elected by a plurality of the votes cast, stockholders shall not be permitted to vote against a nominee.
Section 6. Inspectors of Elections. The Corporation shall, in advance of any meeting of the stockholders, appoint one or
more inspectors to act at the meeting and make a written report thereof and perform the other duties of inspectors at meetings of
stockholders as set forth in the Delaware General Corporation Law. The Corporation may designate one or more persons as alternate
inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person
presiding at the meeting shall appoint one or more persons to act as inspector at the meeting. Each inspector, before entering the
discharge of the inspector’s duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and
according to the best of the inspector’s ability.
Section 7. Presiding Officer and Secretary. The Chairman of the Board, or in the Chairman’s absence, the Chief Executive
Officer, or in the Chief Executive Officer’s absence, the President, or in the President’s absence, the Chief Financial Officer, in such
order, or, in the absence of all of them, any person designated by the Board of the Directors, shall call meetings of the stockholders
to order, and shall act as presiding officer of such meeting. The Board of Directors may adopt by resolution such rules and
regulations for the conduct of the meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with such
rules and regulations as adopted by the Board of Directors, the presiding officer shall have the power to convene and (for any or no
reason) to recess or adjourn meetings to another place, if any, or time, to prescribe such rules, regulations and procedures and to do
all such acts as, in the judgment of such presiding officer, are appropriate for the proper conduct of the meeting. Such rules,
regulations or procedures, whether adopted by the Board of Directors or prescribed by the presiding officer, may include, without
limitation, the following: (i) the establishment of an agenda or order of business for the meeting; (ii) rules and procedures for
maintaining order at the meeting and the safety of those present; (iii) limitations on attendance at or participation in the meeting to
stockholders entitled to vote at the meeting, their duly authorized and constituted
5
-- 88 of 225 --
proxies or such other persons as the presiding officer shall determine; (iv) restrictions on entry to the meeting after the time fixed for
the commencement thereof; and (v) limitations on the time allotted to questions or comments by participants. The presiding officer,
in addition to making any other determinations that may be appropriate to the conduct of the meeting, shall, if the facts warrant,
determine and declare to the meeting that a matter or business was not properly brought before the meeting and if such presiding
officer should so determine, such presiding officer shall so declare to the meeting and any such matter or business not properly
brought before the meeting shall not be transacted or considered. Unless and to the extent determined by the Board of Directors or
the presiding officer, meetings of stockholders shall not be required to be held in accordance with the rules of parliamentary
procedure. The date and time of the opening and closing of the polls for each matter upon which the stockholders will vote at a
meeting shall be announced at the meeting. The Secretary of the Corporation, or in the Secretary’s absence, any Assistant Secretary,
shall act as the secretary at all meetings of the stockholders, but in the absence of the Secretary and any Assistant Secretary, the
presiding officer may appoint any person to act as secretary of the meeting.
Section 8. List of Stockholders. The Corporation shall prepare, at least 10 days before every meeting of stockholders, a
complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each
stockholder and the number of shares registered in the name of each stockholder. Such list shall be open to the examination of any
stockholder, for any purpose germane to the meeting for a period of 10 days ending on the day before the meeting date (i) on a
reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the
notice of meeting or (ii) during ordinary business hours at the principal place of business of the Corporation.
Section 9. Advance Notice of Stockholder Nominations and Proposals.
1. Nominations of persons for election to the Board of Directors and the proposal of business to be transacted by the
stockholders may be made at an annual meeting of stockholders only (a) pursuant to the Corporation’s notice with respect to such
meeting, (b) by or at the direction of the Board, (c) by any stockholder of record of the Corporation who was a stockholder of record
at the time of the giving of the notice provided for in the following paragraph, who is entitled to vote at the meeting and who has
complied with the notice procedures set forth in this Section 9 or (d) by an Eligible Stockholder (as defined in Section 10 of this
Article I) whose Stockholder Nominee (as defined in Section 10 of this Article I) is included in the Corporation’s proxy materials for
the relevant annual meeting of stockholders pursuant to Section 10 of this Article I.
2. For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to
clause (c) of the foregoing paragraph, (1) the stockholder must have given timely notice thereof in writing to the Secretary of the
Corporation, (2) such business must be a proper matter for stockholder action under the Delaware General Corporation Law, (3) if
the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, and/or the respective affiliates
and associates of, or others acting in concert with, such stockholder and such beneficial owner (each, a “Stockholder Associated
Person”), has provided the Corporation with a Solicitation Notice, as that term is defined in subclause (c)(iii) of this paragraph, such
stockholder, beneficial owner and/or Stockholder Associated Person must, in the case of a proposal, have delivered a proxy
statement and form of proxy to holders of at least the percentage of the Corporation’s voting shares required under the Delaware
General Corporation Law to carry any such proposal, or, in the case of a
6
-- 89 of 225 --
nomination or nominations, have delivered a proxy statement and form of proxy to holders of a percentage of the Corporation’s
voting shares reasonably believed by such stockholder, beneficial owner and/or Stockholder Associated Person to be sufficient to
elect the nominee or nominees proposed to be nominated by such stockholder or such beneficial owner, and must, in either case,
have included in such materials the Solicitation Notice, and (4) if no Solicitation Notice relating thereto has been timely provided
pursuant to this Section 9, the stockholder or beneficial owner proposing such business or nomination must not have solicited a
number of proxies or votes sufficient to have required the delivery of such a Solicitation Notice under this Section 9. To be timely, a
stockholder’s notice shall be delivered to the Secretary at the principal executive offices of the Corporation not less than 60 or more
than 75 days prior to the first anniversary (the “Anniversary”) of the date on which the Corporation first mailed its proxy materials
for the preceding year’s annual meeting of stockholders; provided, however, that if the date of the annual meeting is advanced more
than 30 days prior to or delayed (other than as a result of adjournment) by more than 30 days after the anniversary of the preceding
year’s annual meeting, notice by the stockholder to be timely must be so delivered not later than the close of business on the later of
(i) the 90th day prior to such annual meeting or (ii) the 10th day following the day on which public announcement of the date of such
meeting is first made. In no event shall the adjournment or postponement of an annual meeting (or the public announcement thereof)
commence a new time period (or extend any time period) for the giving of a stockholder’s notice as described above. The number of
nominees a stockholder may nominate for election at the annual meeting (or in the case of a stockholder giving the notice on behalf
of a beneficial owner, the number of nominees a stockholder may nominate for election at the annual meeting on behalf of such
beneficial owner) shall not exceed the number of directors to be elected at such annual meeting. Such stockholder’s notice shall set
forth (a) as to each person whom the stockholder proposes to nominate for election or reelection as a director all information relating
to such person as would be required to be disclosed in solicitations of proxies for the election of such nominees as directors pursuant
to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and such person’s written consent
to being named in the Corporation’s proxy statement as a nominee of the stockholder and to serve as a director if elected; (b) as to
any other business that the stockholder proposes to bring before the meeting, a brief description of such business, the text of the
proposal or business (including the exact text of any resolutions proposed for consideration and in the event that such business
includes a proposal to amend the By-laws, the exact text of the proposed amendment), the reasons for conducting such business at
the meeting and any material interest in such business of such stockholder, such beneficial owner, and/or any Stockholder Associated
Person; (c) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination is made (i) the
name and address of such stockholder, as they appear on the Corporation’s books, and of such beneficial owner, (ii) the class, series
and number of shares of the Corporation that are, directly or indirectly, owned beneficially and of record by such stockholder and
such beneficial owner, (iii) whether either such stockholder, beneficial owner and/or Stockholder Associated Person intends to
deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation’s
voting shares required under the Delaware General Corporation Law to carry the proposal or, in the case of a nomination or
nominations, a sufficient number of holders of the Corporation’s voting shares to elect such nominee or nominees (an affirmative
statement of such intent, a “Solicitation Notice”), (iv) a representation as to whether or not such stockholder, such beneficial owner
and/or any Stockholder Associated Person intends to solicit proxies in support of any director nominees other than the Corporation’s
nominees in accordance with Rule 14a-19 promulgated under the Exchange Act, and, where such stockholder, beneficial owner,
and/or Stockholder
7
-- 90 of 225 --
Associated Person intends to so solicit proxies, the notice and information required by Rule 14a-19(b) under the Exchange Act, and a
statement that such stockholder, beneficial owner, and/or Stockholder Associated Person has otherwise complied or will otherwise
comply with the requirements of Rule 14a-19 under the Exchange Act, (v) a description of any agreement, arrangement or
understanding with respect to the nomination or proposal between or among such stockholder, such beneficial owner, and/or any
Stockholder Associated Person, including, in the case of a nomination, the nominee, (vi) a description of any agreement,
arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, convertible securities,
stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of
the stockholder’s notice by, or on behalf of, such stockholder, such beneficial owners, and/or any Stockholder Associated Person,
whether or not such instrument or right shall be subject to settlement in underlying shares of capital stock of the Corporation, the
effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting
power of, such stockholder, such beneficial owner, and/or any Stockholder Associated Person, with respect to securities of the
Corporation, (vii) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such
meeting and intends to appear in person or by proxy at the meeting to propose such business or nomination, (viii) a representation
that such stockholder, such beneficial owner, and/or any Stockholder Associated Person has complied, and will comply, with all
applicable requirements of state law and the Exchange Act with respect to matters set forth in this Section 9 and (ix) any other
information relating to such stockholder, beneficial owner, and/or Stockholder Associated Person required to be disclosed in a proxy
statement or other filings required to be made in connection with solicitations of proxies for, as applicable, the proposal and/or for
the election of directors in an election contest pursuant to and in accordance with Section 14(a) of the Exchange Act and the rules
and regulations promulgated thereunder. The foregoing notice requirements of this paragraph 2 of Section 9 shall be deemed
satisfied by a stockholder with respect to business other than a nomination if the stockholder has notified the Corporation of his, her
or its intention to present a proposal at an annual meeting in compliance with applicable rules and regulations promulgated under the
Exchange Act and such stockholder’s proposal has been included in a proxy statement that has been prepared by the Corporation to
solicit proxies for such annual meeting. The Corporation may require any proposed nominee to furnish such other information as the
Corporation may reasonably require, to determine the eligibility of such proposed nominee to serve as a director of the Corporation.
3. Notwithstanding anything in the second sentence of the second paragraph of this Section 9 to the contrary, in the
event that the number of directors to be elected to the Board at the annual meeting is increased effective after the time period for
which nominations would otherwise be due under the second paragraph of this Section 9 and there is no public announcement
naming the nominees for additional directorships at least 70 days prior to the Anniversary, a stockholder’s notice required by this
By-law shall also be considered timely, but only with respect to nominees for the additional directorships, if it shall be delivered to
the Secretary at the principal executive offices of the Corporation not later than the close of business on the 10th day following the
day on which such public announcement is first made by the Corporation.
8
-- 91 of 225 --
4. Only persons nominated in accordance with the procedures set forth in this Section 9 or Section 10, as applicable,
shall be eligible to serve as directors and only such business shall be conducted at an annual meeting of stockholders as shall have
been brought before the meeting in accordance with the procedures set forth in this Section 9. The presiding officer of the meeting
(and, in advance of the meeting, the Board of Directors) shall have the power and the duty to determine whether a nomination or any
business proposed to be brought before the meeting has been made in accordance with the procedures set forth in these By-laws
(including whether the stockholder, beneficial owner and/or any Stockholder Associated Person did or did not solicit, as the case
may be, proxies or votes in support of such stockholder’s nominee in compliance with the representations with respect thereto
required by this Section 9), and, if any proposed nomination or business is not in compliance with these By-laws, to declare that such
defective proposed business or nomination shall not be presented for stockholder action at the meeting and shall be disregarded.
Notwithstanding the foregoing provisions of this Section 9, unless otherwise required by law, if the stockholder (or a qualified
representative of the stockholder) does not appear at the annual or special meeting of stockholders of the Corporation to present a
nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted,
notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Section 9 and
Section 10 of these By-laws, to be considered a qualified representative of the stockholder, a person must be a duly authorized
officer, manager or partner of such stockholder or must be authorized by a writing executed by such stockholder or an electronic
transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders and such person must
produce such writing or electronic transmission, or a reliable reproduction of the writing or electronic transmission, at the meeting of
stockholders.
5. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the
meeting pursuant to the Corporation’s notice of meeting. Nominations of persons for election to the Board may be made at a special
meeting of stockholders at which directors are to be elected pursuant to the Corporation’s notice of meeting (a) by or at the direction
of the Board or stockholders pursuant to Section 2 of this Article I or (b) provided that the Board or stockholders pursuant to Section
2 of this Article I have determined that directors shall be elected at such meeting, by any stockholder of record of the Corporation
who is a stockholder of record at the time of giving of notice provided for in this paragraph, who shall be entitled to vote at the
meeting and who complies with the procedures set forth in this Section 9, including, without limitation, the procedures regarding
Solicitation Notices. The proposal by stockholders of other business to be conducted at a special meeting of stockholders may be
made only in accordance with Section 2 of this Article I. The number of nominees a stockholder may nominate for election at the
special meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a
stockholder may nominate for election at the special meeting on behalf of such beneficial owner) shall not exceed the number of
directors to be elected at such special meeting. In the event the Corporation calls a special meeting of stockholders for the purpose of
electing one or more directors to the Board, nominations by stockholders of persons for election to such positions as specified in the
Corporation’s notice of meeting may be made at such a special meeting of stockholders if the stockholder’s notice required by
Section 9 shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business
on the later of the 90th day prior to such special
9
-- 92 of 225 --
meeting or the 10th day following the day on which the Corporation first makes a public announcement of the date of the special
meeting at which directors are to be elected. In no event shall the adjournment or postponement of a special meeting (or the public
announcement thereof) commence a new time period (or extend any time period) for the giving of a stockholder’s notice as
described above.
6. For purposes of this Section 9 and Section 10 of this Article I, “public announcement” shall mean disclosure in a
press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document
publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange
Act.
7. Notwithstanding the foregoing provisions of this Section 9, a stockholder shall also comply with all applicable
requirements of the Exchange Act and the rules and regulations thereunder with respect to matters set forth in this Section 9. Nothing
in this Section 9 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation’s proxy
statement pursuant to Rule 14a-8 under the Exchange Act.
8. Notwithstanding anything to the contrary in these By-laws, unless otherwise required by law, (1) no stockholder,
beneficial owner, and/or any Stockholder Associated Person shall solicit proxies in support of director nominees, other than the
Corporation’s nominees, unless such stockholder, beneficial owner, and/or Stockholder Associated Person has complied with Rule
14a-19(b) promulgated under the Exchange Act in connection with the solicitation of such proxies, including the requirement to
provide the Corporation with the notices required thereunder in a timely manner and (2) if any stockholder, beneficial owner, and/or
Stockholder Associated Person (A) provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act and (B)
subsequently fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) promulgated under the Exchange Act
or fails to timely provide reasonable evidence sufficient to satisfy the Corporation that such stockholder, beneficial owner, or
Stockholder Associated Person has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act in accordance
with the following sentence, then the nomination of each such director nominee shall be disregarded notwithstanding that proxies or
votes in respect of the election of such proposed nominees may have been received by the Corporation (which proxies and votes
shall be disregarded). If any stockholder, beneficial owner, and/or Stockholder Associated Person provides notice pursuant to Rule
14a-19(b) promulgated under the Exchange Act, such stockholder, beneficial owner, or Stockholder Associated Person shall deliver
to the Corporation, no later than five (5) business days prior to the applicable meeting, reasonable documentary evidence that such
person has met the requirements of Rule 14a-19 promulgated under the Exchange Act, including clause (a)(3) thereof, together with
a representation that such person has complied with the requirements of Rule 14a-19 promulgated under the Exchange Act.
9. Any person directly or indirectly soliciting proxies from stockholders of the Corporation must use a proxy card color
other than white, which shall be reserved for exclusive use by the Board of Directors.
10
-- 93 of 225 --
10. Unless the Corporation elects otherwise, a stockholder’s notice to the Corporation shall be in writing exclusively (and
not in an electronic transmission) and shall be delivered exclusively by hand (including, without limitation, overnight courier
service) or by certified or registered mail, return receipt requested, and the Corporation shall not be required to accept delivery of
any document not in such written form or so delivered.
Section 10. Proxy Access.
1. Subject to the provisions of this Section 10, the Corporation shall include in its proxy statement (including its form of
proxy) for an annual meeting of stockholders the name of any stockholder nominee for election to the Board of Directors submitted
pursuant to this Section 10 (each a “Stockholder Nominee”) provided (a) timely written notice of such Stockholder Nominee
satisfying this Section 10 (“Notice”) is delivered to the Corporation by or on behalf of a stockholder or stockholders that, at the time
the Notice is delivered, satisfy the ownership and other requirements of this Section 10 (such stockholder or stockholders, and any
person on whose behalf they are acting, the “Eligible Stockholder”), (b) the Eligible Stockholder expressly elects in writing at the
time of providing the Notice to have its nominee included in the Corporation’s proxy statement pursuant to this Section 10, and (c)
the Eligible Stockholder and the Stockholder Nominee otherwise satisfy the requirements of this Section 10 and the director
qualifications requirements set forth in the Corporation’s Corporate Governance Guidelines and any other document(s) setting forth
qualifications for directors.
2. To be timely, an Eligible Stockholder’s notice must be received in writing by the Secretary of the Corporation at the
principal executive offices of the Corporation not less than 120 days nor more than 150 days prior to the first anniversary of the
preceding year’s annual meeting; provided, however, that in the event that the date of the annual meeting is advanced by more than
30 days, or delayed (other than as a result of adjournment) by more than 60 days, from the first anniversary of the preceding year’s
annual meeting, or if no annual meeting was held in the preceding year, a stockholder’s notice must be so received not earlier than
the 150th day prior to such annual meeting and not later than the close of business on the later of (a) the 120th day prior to such
annual meeting and (b) the tenth day following the day on which notice of the date of such annual meeting was mailed or public
announcement (as defined in Section 9 of this Article I) of the date of such annual meeting was made, whichever first occurs. In no
event shall the adjournment or postponement of an annual meeting (or the public announcement thereof) commence a new time
period (or extend any time period) for the giving of an Eligible Stockholder’s notice as described above.
3. In addition to including the name of the Stockholder Nominee in the Corporation’s proxy statement for the annual
meeting, the Corporation also shall include (a) the information concerning the Stockholder Nominee and the Eligible Stockholder
that is required to be disclosed in the Corporation’s proxy statement pursuant to Section 14 of the Exchange Act and the rules and
regulations promulgated thereunder and (b) if the Eligible Stockholder so elects, a Statement (defined below) (collectively, the
“Required Information”). Nothing in this Section 10 shall limit the Corporation’s ability to solicit against and include in its proxy
statement its own statements relating to any Stockholder Nominee.
11
-- 94 of 225 --
4. The number of Stockholder Nominees (including Stockholder Nominees that were submitted by an Eligible
Stockholder for inclusion in the Corporation’s proxy statement pursuant to this Section 10 but either are subsequently withdrawn or
that the Board of Directors decides to nominate (the latter a “Board Nominee”)) appearing in the Corporation’s proxy statement with
respect to an annual meeting of stockholders shall not exceed the greater of (a) two or (b) 20% of the number of directors in office as
of the last day on which notice of a nomination may be received pursuant to this Section 10 (the “Final Proxy Access Nomination
Date”) or, if such amount is not a whole number, the closest whole number below 20% (such greater number the “Permitted
Number”); provided, however, that the Permitted Number shall be reduced by (i) the number of director candidates for which the
Corporation shall have received one or more valid notices that a stockholder intends to nominate director candidates at the annual
meeting of stockholders pursuant to Section 9 of this Article I; provided further, that in no event shall the Permitted Number be less
than one, (ii) any number of director candidates who will be included in the Corporation’s proxy materials with respect to the annual
meeting as an unopposed (by the Corporation) nominee pursuant to any agreement, arrangement or other understanding with any
stockholder or group of stockholders (other than any such agreement, arrangement or understanding entered into in connection with
an acquisition of shares of capital stock of the Corporation, by such stockholder or group of stockholders, from the Corporation);
provided, that in no event shall the Permitted Number be less than one, and (iii) any number of directors in office as of the
nomination deadline who were included in the Corporation’s proxy statement as a Stockholder Nominee for any of the two
preceding annual meetings and whom the Board of Directors decides to nominate for election to the Board of Directors. In the event
that one or more vacancies for any reason occurs on the Board of Directors at any time after the Final Proxy Access Nomination
Date and before the date of the applicable annual meeting of stockholders and the Board of Directors resolves to reduce the size of
the Board of Directors in connection therewith, the Permitted Number shall be calculated based on the number of directors in office
as so reduced.
5. In the event that the number of Stockholder Nominees submitted by Eligible Stockholders pursuant to this Section 10
exceeds the Permitted Number, each Eligible Stockholder shall select one Stockholder Nominee for inclusion in the Corporation’s
proxy statement until the Permitted Number is reached, going in order of the amount (greatest to least) of the Corporation’s capital
stock entitled to vote on the election of directors as disclosed in the Notice. If the Permitted Number is not reached after each
Eligible Stockholder has selected one Stockholder Nominee, this selection process shall continue as many times as necessary,
following the same order each time, until the Permitted Number is reached.
6. An Eligible Stockholder must have owned (as defined below) continuously for at least three years a number of shares
that represents 3% or more of the Corporation’s outstanding shares of capital stock entitled to vote in the election of directors (the
“Required Shares”) as of both the date the Notice is received by the Corporation in accordance with this Section 10 and the record
date for determining stockholders entitled to vote at the annual meeting and must continue to own the Required Shares through the
annual meeting date. For purposes of satisfying the ownership requirement under this Section 10, the shares of the Corporation’s
capital stock owned by one or more stockholders, or by the person or persons who own shares of the Corporation’s capital stock and
on whose behalf any stockholder is acting, may be aggregated, provided that (a) the number of stockholders and other persons whose
ownership of shares is aggregated for such purpose shall not exceed 20, (b) each
12
-- 95 of 225 --
stockholder or other person whose shares are aggregated shall have held such shares continuously for at least three years, and (c) a
group of two or more funds that are (i) under common management and investment control, (ii) under common management and
funded primarily by the same employer (or by a group of related employers that are under common control), or (iii) a “group of
investment companies,” as such term is defined in Section 12(d)(1)(G)(ii) of the Investment Company Act of 1940, as amended,
shall be treated as one stockholder or person for this purpose. Whenever an Eligible Stockholder consists of a group of stockholders
and/or other persons, any and all requirements and obligations for an Eligible Stockholder set forth in this Section 10 must be
satisfied by and as to each such stockholder or other person, except that shares may be aggregated to meet the Required Shares as
provided in this Section 10. With respect to any one particular annual meeting, no stockholder or other person may be a member of
more than one group of persons constituting an Eligible Stockholder under this Section 10.
7. For purposes of this Section 10, an Eligible Stockholder shall be deemed to “own” only those outstanding shares of
the Corporation’s capital stock as to which the person possesses both (a) the full voting and investment rights pertaining to the shares
and (b) the full economic interest in (including the opportunity for profit and risk of loss on) such shares; provided that the number
of shares calculated in accordance with clauses (a) and (b) shall not include any shares (x) sold by such person or any of its affiliates
in any transaction that has not been settled or closed, (y) borrowed by such person or any of its affiliates for any purposes or
purchased by such person or any of its affiliates pursuant to an agreement to resell, or (z) subject to any option, warrant, forward
contract, swap, contract of sale, other derivative or similar agreement entered into by such person or any of its affiliates, whether any
such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of outstanding shares of
the Corporation’s capital stock, in any such case which instrument or agreement has, or is intended to have, the purpose or effect of
(A) reducing in any manner, to any extent or at any time in the future, such person’s or affiliates’ full right to vote or direct the voting
of any such shares, and/or (B) hedging, offsetting or altering to any degree gain or loss arising from the full economic ownership of
such shares by such person or affiliate. A person shall “own” shares held in the name of a nominee or other intermediary so long as
the person retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full
economic interest in the shares.
8. A person’s ownership of shares shall be deemed to continue during any period in which (a) the person has loaned
such shares, provided that the person has the power to recall such loaned shares on five business days’ notice and provides a
representation that it will promptly recall, and promptly recalls, such loaned shares upon being notified that any of its Stockholder
Nominees will be included in the Corporation’s proxy statement, or (b) the person has delegated any voting power by means of a
proxy, power of attorney or other instrument or arrangement that is revocable at any time by the person. The terms “owned,”
“owning” and other variations of the word “own” shall have correlative meanings. For purposes of this Section 10, the term
“affiliate” shall have the meaning ascribed thereto in the regulations promulgated under the Exchange Act.
9. An Eligible Stockholder must provide with its Notice the following in writing to the Secretary: (a) one or more
written statements from the record holder of the shares (and from each intermediary through which the shares are or have been
held during the requisite three-year holding period) verifying that, as of a date within seven calendar days prior to the date the
Notice is received
13
-- 96 of 225 --
by the Corporation, the Eligible Stockholder owns, and has owned continuously for the preceding three years, the Required
Shares, and the Eligible Stockholder’s agreement to provide (i) within five business days after the record date for the annual
meeting, written statements from the record holder and intermediaries verifying the Eligible Stockholder’s continuous ownership
of the Required Shares through the record date and (ii) immediate notice if the Eligible Stockholder ceases to own any of the
Required Shares prior to the date of the applicable annual meeting of stockholders; (b) documentation satisfactory to the
Corporation demonstrating that a group of funds qualifies to be treated as one stockholder or person for purposes of this Section
10, if applicable; (c) a representation that the Eligible Stockholder (including each member of any group of stockholders and/or
persons that together is an Eligible Stockholder hereunder) (i) intends to continue to own the Required Shares through the date of
the annual meeting, (ii) acquired the Required Shares in the ordinary course of business and not with the intent to change or
influence control of the Corporation, and does not presently have such intent, (iii) has not nominated and will not nominate for
election to the Board of Directors at the annual meeting any person other than the Stockholder Nominee(s) being nominated
pursuant to this Section 10, (iv) has not engaged and will not engage in, and has not and will not be, a “participant” in another
person’s “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as
a director at the annual meeting other than its Stockholder Nominee(s) or a Board Nominee, (v) will not distribute to any
stockholder any form of proxy for the annual meeting other than the form distributed by the Corporation, and (vi) has provided
and will provide facts, statements and other information in all communications with the Corporation and its stockholders that are
or will be true and correct in all material respects and do not and will not omit to state a material fact necessary in order to make
the statements made, in light of the circumstances under which they were made, not misleading; (d) the written consent of each
Stockholder Nominee to be named in the Corporation’s proxy statement as a nominee and to serve as a director if elected; (e) a
copy of the Schedule 14N that has been filed with the Securities and Exchange Commission as required by Rule 14a-18 under the
Exchange Act; (f) the information required to be provided by Section 9 of this Article I, as applicable; (g) in the case of a
nomination by a group of stockholders that together is an Eligible Stockholder, the designation by all group members of one group
member that is authorized to act on behalf of all members of the nominating stockholder group with respect to the nomination and
matters related thereto, including withdrawal of the nomination; and (h) an undertaking that the Eligible Stockholder agrees to (i)
assume all liability stemming from any legal or regulatory violation arising out of the Eligible Stockholder’s communications with
the Corporation’s stockholders or out of the information that the Eligible Stockholder provides to the Corporation, (ii) indemnify
and hold harmless the Corporation and each of its directors, officers and employees individually against any liability, loss or
damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative,
against the Corporation or any of its directors, officers or employees in connection with the Eligible Stockholder’s nomination
and/or efforts to elect its Stockholder Nominee(s) pursuant to this Section 10, (iii) file with the Securities and Exchange
Commission any solicitation or other communication with the Corporation’s stockholders relating to the annual meeting at which
the Stockholder Nominee will be nominated, regardless of whether any such filing is required under Section 14 of the Exchange
Act and the rules and regulations promulgated thereunder or whether any exemption from filing is available for such solicitation or
other communication under Section 14 of the Exchange Act and the rules and regulations promulgated thereunder, and (iv) comply
with all other applicable laws, rules, regulations and listing standards with respect to any solicitation in connection with the annual
meeting.
14
-- 97 of 225 --
10. The Eligible Stockholder may include with its Notice, a written statement for inclusion in the Corporation’s proxy
statement for the annual meeting, not to exceed 500 words per Stockholder Nominee, in support of each Stockholder Nominee’s
candidacy (the “Statement”). Notwithstanding anything to the contrary contained in this Section 10, the Corporation may omit
from its proxy statement any information or Statement that it believes would violate any applicable law, rule, regulation or listing
standard.
11. Each Stockholder Nominee must (a) provide within five business days of the Corporation’s request an executed
agreement, in a form deemed satisfactory to the Corporation, that (i) the Stockholder Nominee has read and agrees to adhere to the
Corporation’s Corporate Governance Guidelines and all other Corporation policies and guidelines applicable to directors,
including with regard to securities trading, (ii) the Stockholder Nominee is not and will not become a party to (A) any agreement,
arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such
person, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not
been disclosed to the Corporation or (B) any Voting Commitment that could limit or interfere with such person’s ability to comply,
if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law, and (iii) the Stockholder
Nominee is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than
the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification (a “Compensation
Arrangement”) in connection with such person’s nomination or candidacy for director and/or service as a director that has not been
disclosed to the Corporation; (b) complete, sign and submit all questionnaires required of the Corporation’s Board of Directors
within five business days of receipt of each such questionnaire from the Corporation; and (c) provide within five business days of
the Corporation’s request such additional information as the Corporation determines may be necessary to permit the Board of
Directors to determine whether such Stockholder Nominee meets the requirements of this Section 10 and/or the Corporation’s
requirements with regard to director qualifications and policies and guidelines applicable to directors, including whether (i) such
Stockholder Nominee is independent under the listing standards of any U.S. exchange upon which the Corporation’s capital stock
is listed, any applicable rules of the Securities and Exchange Commission, and any publicly disclosed standards used by the Board
of Directors in determining and disclosing the independence of the directors (collectively, the “Independence Standards”), (ii)
such Stockholder Nominee has any direct or indirect relationship with the Corporation, and (iii) such Stockholder Nominee has
been subject to (A) any event specified in Item 401(f) of Regulation S-K under the Securities Act of 1933, as amended (the
“Securities Act”) or (B) any order of the type specified in Rule 506(d) of Regulation D under the Securities Act.
12. In the event that any information or communications provided by the Eligible Stockholder or Stockholder Nominee
to the Corporation or its stockholders ceases to be true and correct in any respect or omits a fact necessary to make the statements
made, in light of the circumstances under which they were made, not misleading, each Eligible Stockholder or Stockholder
Nominee, as the case may be, shall promptly notify the Secretary of any such inaccuracy or omission in such previously provided
information and of the information that is required to make such information or communication true and correct; it being
understood that
15
-- 98 of 225 --
providing any such notification shall not be deemed to cure any defect or limit the Corporation’s right to omit a Stockholder
Nominee from its proxy materials as provided in this Section 10.
13. The Corporation shall not be required to include, pursuant to this Section 10, a Stockholder Nominee in its proxy
statement (or, if the proxy statement has already been filed, to allow the nomination of a Stockholder Nominee, notwithstanding
that proxies in respect of such vote may have been received by the Corporation) (a) if the Eligible Stockholder who has nominated
such Stockholder Nominee has nominated for election to the Board of Directors at the annual meeting any person other than
pursuant to this Section 10, or has or is engaged in, or has been or is a “participant” in another person’s, “solicitation” within the
meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting
other than its Stockholder Nominee(s) or a Board Nominee, (b) who is not independent under the Independence Standards, (c)
whose election as a member of the Board of Directors would violate or cause the Corporation to be in violation of these By-laws,
the Corporation’s certificate of incorporation, the Corporation’s Corporate Governance Guidelines or other document setting forth
qualifications for directors, the listing standards of any U.S. exchange upon which the Corporation’s capital stock is listed, or any
applicable state or federal law, rule or regulation, (d) if the Stockholder Nominee is or becomes a party to any undisclosed or
prohibited Voting Commitment, (e) if the Stockholder Nominee is or becomes a party to any undisclosed Compensation
Arrangement, (f) who is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of
the Clayton Antitrust Act of 1914, (g) whose then-current or prior business or personal interests place such Stockholder Nominee
in a conflict of interest with the Corporation or any of its subsidiaries that would cause such Stockholder Nominee to violate any
fiduciary duties of directors established pursuant to Delaware law, including but not limited to the duty of loyalty and duty of care,
(h) who is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been
convicted in such a criminal proceeding within the past ten years, (i) who is subject to any order of the type specified in Rule
506(d) of Regulation D under the Securities Act, or (j) if such Stockholder Nominee or the applicable Eligible Stockholder shall
have provided information to the Corporation in respect of such nomination that was untrue in any material respect or omitted to
state a material fact necessary in order to make the statement made, in light of the circumstances under which they were made, not
misleading or shall have breached any of its or their agreements, representations, undertakings and/or obligations pursuant to this
Section 10.
14. Notwithstanding anything to the contrary set forth herein, if (a) the Stockholder Nominee and/or the applicable
Eligible Stockholder shall have breached its or their agreements, representations, undertakings and/or obligations pursuant to this
Section 10, as determined by the Board of Directors or the person presiding at the annual meeting, or (b) the Eligible Stockholder
(or a qualified representative thereof) does not appear at the annual meeting to present any nomination pursuant to this Section 10,
(x) the Board of Directors or the person presiding at the annual meeting shall be entitled to declare a nomination by an Eligible
Stockholder to be invalid, and such nomination shall be disregarded notwithstanding that proxies in respect of such vote may have
been received by the Corporation and (y) the Corporation shall not be required to include in its proxy statement any successor or
replacement nominee proposed by the applicable Eligible Stockholder or any other Eligible Stockholder.
16
-- 99 of 225 --
15. Any Stockholder Nominee who is included in the Corporation’s proxy statement for a particular annual meeting of
stockholders but either (a) withdraws from or becomes ineligible or unavailable for election at the annual meeting or (b) does not
receive a number of votes cast in favor of his or her election at least equal to 25% of the shares present in person or represented by
proxy at the annual meeting and entitled to vote on the Stockholder Nominee’s election, shall be ineligible to be included in the
Corporation’s proxy statement as a Stockholder Nominee pursuant to this Section 10 for the next two annual meetings of
stockholders following the annual meeting for which the Stockholder Nominee has been nominated for election. This Section 10
shall be the exclusive method for stockholders to include nominees for director election in the Corporation’s proxy materials,
except to the extent required by Rule 14a-19 under the Exchange Act.
Section 11. Action Without Meeting. Unless otherwise provided in the Certificate of Incorporation, any action required or
permitted to be taken by stockholders for or in connection with any corporate action may be taken without a meeting, without prior
notice and without a vote, if a consent or consents, setting forth the action so taken, shall be signed by the holders of outstanding
stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at
which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with Section
228 of the Delaware General Corporation Law. No consent shall be effective to take the corporate action referred to therein unless
consents signed by a number of stockholders sufficient to take such action are delivered to the Corporation in the manner specified
in this paragraph within sixty (60) days of the first date on which a consent is so delivered to the Corporation.
If action is taken by consent of stockholders and in accordance with the foregoing, there shall be filed with the records of the
meetings of stockholders such consent or consents.
If action is taken by less than unanimous consent of stockholders, prompt notice of the taking of such action without a
meeting shall be given to those who have not consented and a certificate signed and attested to by the Secretary of the Corporation
that such notice was given shall be filed with the records of the meetings of stockholders.
In the event that the action consented to is such as would have required the filing of a certificate under any provision of the
Delaware General Corporation Law, if such action had been voted upon by the stockholders at a meeting thereof, the certificate filed
under such provision shall state, in lieu of any statement required by such provision concerning a vote of stockholders, that consent
has been given under Section 228 of the Delaware General Corporation Law.
Section 12. Meetings by Remote Communication. If authorized by the Board of Directors, in its sole discretion, and
subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxy holders not physically
present at a meeting of stockholders may by means of remote communication, to the fullest extent permitted by law: (a) participate
in a meeting of stockholders, and (b) be deemed present in person and vote at a meeting of stockholders whether such meeting is to
be held at a designated place or solely by means of remote communication.
17
-- 100 of 225 --
Section 13. Delivery to the Corporation. Whenever Section 2, 9 or 10 of this Article I of these By-laws requires one or
more persons (including a record or beneficial owner of stock of the Corporation) to deliver a document or information to the
Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or
other document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission)
and shall be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered
mail, return receipt requested and the Corporation shall not be required to accept delivery of any document not in such written form
or so delivered. For the avoidance of doubt, with respect to any notice from any stockholder of record or beneficial owner of the
Corporation’s capital stock under the Certificate of Incorporation, these By-laws or the Delaware General Corporation Law, to the
fullest extent permitted by law, the Corporation expressly opts out of Section 116 of the Delaware General Corporation Law.
ARTICLE II - DIRECTORS
Section 1. General Powers. The business and affairs of the Corporation shall be managed by or under the direction of a
Board of Directors, who may exercise all of the powers of the Corporation except as otherwise provided by the Certificate of
Incorporation or the Delaware General Corporation Law. In the event of a vacancy in the Board of Directors, the remaining
directors, except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation Law, may exercise
the powers of the full Board of Directors until the vacancy is filled. The Board of Directors may appoint a Chairman of the Board.
The Chairman of the Board shall preside at all meetings of the Board of Directors and shall perform such duties and possess such
powers as are assigned to the Chairman by the Board of Directors.
Section 2. Number and Qualification. Except as otherwise required by the Certificate of Incorporation, the number of
directors that shall constitute the whole Board of Directors shall be determined by resolution of the Board of Directors, but in no
event shall be less than three (3). The number of directors may be increased at any time by resolution of the Board of Directors. The
number of directors may be decreased at any time and from time to time by a majority of the directors then in office (so long as a
quorum is present), but only to eliminate vacancies existing by reason of the death, resignation, removal or expiration of the term of
one or more directors. The Board of Directors shall be comprised of a majority of directors who are determined by the Board of
Directors to be independent directors as such term is defined by Section 303A(2) of the New York Stock Exchange Listed Company
Manual.
Section 3. Terms of Office. Each director shall be elected for a term expiring at the next annual meeting of stockholders
following such director’s election and shall remain in office until a successor is elected and qualified, or until such director’s earlier
death, resignation or removal; provided, however, that the foregoing shall not shorten the term of any incumbent director as of such
date.
Section 4. Removal. Except as otherwise provided by the Certificate of Incorporation or the Delaware General Corporation
Law, any one or more or all of the directors of the Corporation may be
18
-- 101 of 225 --
removed, with or without cause, by the holders of a majority of the voting power of the shares entitled to vote thereon.
Section 5. Vacancies. Except as otherwise required by the Certificate of Incorporation or the Delaware General Corporation
Law, any vacancy in the Board of Directors, however occurring, or any newly-created directorship resulting from an enlargement of
the size of the Board of Directors, shall be filled only by vote of a majority of the directors then in office, even if less than a quorum,
or by the sole remaining director and not by the stockholders. A director elected to fill a vacancy or a newly-created directorship
shall serve for a term expiring at the next annual meeting of stockholders following such director’s election, and shall remain in
office until the election and qualification of the director’s successor or the director’s earlier death, resignation or removal.
Section 6. Resignations. Any director may resign by delivering a resignation to the Corporation at its principal office or to
the Chief Executive Officer or Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some
other time or upon the happening of some other event.
Section 7. Meetings. Regular meetings of the Board of Directors may be held without notice at such time and place, either
within or without the State of Delaware, as shall be determined from time to time by the Board of Directors. A regular meeting of the
Board of Directors may be held without notice immediately after and at the same place as the annual meeting of stockholders.
Special meetings of the Board of Directors may be called by the Chairman of the Board, the Chief Executive Officer, a majority of
the total number of the whole Board of Directors, or by one director in the event that there is only a single director in office and may
be held at any time and place, within or without the State of Delaware, as specified by the person(s) calling the meeting.
Section 8. Notice of Meetings. No notice of the annual or other regular meetings of the Board of Directors need be given.
Notice of any special meeting of directors shall be given to each director by the Secretary. Notice to each director shall be duly given
by mailing the same not later than the second business day before the meeting, or by giving notice in person, by fax, by telephone, or
by any other electronic means not later than four hours before the meeting. No notice of a meeting need be given if all directors are
present in person. Any business may be transacted at any meeting of the Board of Directors, whether or not specified in a notice of
the meeting.
Section 9. Quorum. A majority of the total number of the whole Board of Directors shall constitute a quorum at all meetings
of the Board of Directors. In the absence of a quorum at any such meeting, a majority of the directors present may adjourn the
meeting from time to time to a different date, place, or time without further notice (or waiver of notice) other than announcement at
the meeting, until a quorum shall be present.
Section 10. Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, the vote of a
majority of the directors present shall be sufficient to take any action, unless a different vote is specified by the Delaware General
Corporation Law, the Certificate of Incorporation or these By-laws.
19
-- 102 of 225 --
Section 11. Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors or of
any committee of the Board of Directors may be taken without a meeting, if all members of the Board of Directors or committee, as
the case may be, consent to the action in writing or by electronic transmission. After an action is taken, the consent or consents
relating thereto shall be filed with the minutes of proceedings of the Board of Directors or committee in the same paper or electronic
form as the minutes are maintained.
Section 12. Meetings by Telephone Conference Call. Directors or any members of any committee designated by the
directors may participate in a meeting of the Board of Directors or such committee by means of conference telephone or other
communications equipment by means of which all persons participating in the meeting can hear each other, and participation by such
means shall constitute presence in person at such meeting.
Section 13. Compensation of Directors. Directors may be paid such compensation for their services and such
reimbursement for expenses of attendance at meetings of the Board of Directors or committees of the Board of Directors as the
Board of Directors or any committee to which the Board has delegated responsibility for establishing director compensation may
from time to time determine. No such payment shall preclude any director from serving the Corporation or any of its parent,
subsidiary, or affiliate corporations in any other capacity and receiving compensation for such service.
Section 14. Committees. The Board of Directors may designate one or more committees, each committee to consist of one
or more of the directors of the Corporation. In addition to other committees that the Board of Directors may designate from time to
time, the Board of Directors shall designate a Compensation Committee, an Audit Committee and a Nominating and Corporate
Governance Committee each of which shall be comprised only of directors of the Corporation who are determined by the Board of
Directors (i) to be “independent directors” as such term is defined by Section 303A(2) of the New York Stock Exchange Listed
Company Manual and (ii) with respect to members of the Audit Committee only, to also be “independent” as such term is defined by
Rule 10A-3(b)(1) of the Securities and Exchange Commission. The Board of Directors may designate one or more directors as
alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the
absence or disqualification of a member of a committee, the member or members of the committee present at any meeting and not
disqualified from voting, whether or not the member or members constitute a quorum, may unanimously appoint another member of
the Board of Directors to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the
extent provided in the resolution of the Board of Directors and subject to the provisions of the Delaware General Corporation Law,
shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of
the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it. Each such committee
shall keep minutes and make such reports as the Board of Directors may from time to time request. Except as the Board of Directors
may otherwise determine, any committee may make rules for the conduct of its business, but unless otherwise provided by the
directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in these By-laws for
the Board of Directors. A majority of the members of a committee shall constitute a quorum unless the committee consist of one or
two members, in which event, one member shall constitute a quorum. All matters shall be determined by a majority vote of the
committee members present assuming a quorum is present.
20
-- 103 of 225 --
Section 15. Emergency Bylaws. In the event of any emergency, disaster, catastrophe or other similar emergency condition of
a type described in Section 110(a) of the Delaware General Corporation Law (an “Emergency”), notwithstanding any different or
conflicting provisions in Delaware General Corporation Law, the Certificate of Incorporation or these By-laws, during such
Emergency:
1. Notice. A meeting of the Board of Directors or a committee thereof may be called by any director, the Chairman of the
Board, the Chief Executive Officer, the President or the Secretary by such means as, in the judgment of the person calling the
meeting, may be feasible at the time, and notice of any such meeting of the Board of Directors or any committee may be given, in
the judgment of the person calling the meeting, only to such directors as it may be feasible to reach at the time and by such means as
may be feasible at the time. Such notice shall be given at such time in advance of the meeting as, in the judgment of the person
calling the meeting, circumstances permit.
2. Quorum. The director or directors in attendance at a meeting called in accordance with Section 15 shall constitute a
quorum.
3. Liability. No officer, director or employee acting in accordance with this Section 15 shall be liable except for willful
misconduct. No amendment, repeal or change to this Section 15 shall modify the prior sentence with regard to actions taken prior to
the time of such amendment, repeal or change.
ARTICLE III - OFFICERS
Section 1. General Provisions; Qualification. The officers of the Corporation shall be a Chief Executive Officer, a
President, a Chief Financial Officer, a General Counsel, a Treasurer and a Secretary, and may include one or more Vice Presidents,
one or more Assistant Treasurers and one or more Assistant Secretaries and such other officers as the Board of Directors may deem
appropriate. Any two or more offices may be held by the same person.
Section 2. Election. Officers of the Corporation shall be elected annually by the Board of Directors.
Section 3. Tenure. Except as otherwise provided by the Delaware General Corporation Law, by the Certificate of
Incorporation or by these By-laws, each officer shall hold office until such officer’s successor is elected and qualified, unless a
different term is specified in the vote choosing or appointing such officer, or until such officer’s earlier death, resignation or removal.
Section 4. Resignation and Removal. Any officer may resign by delivering a resignation to the Corporation at its principal
office or to the Chief Executive Officer or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be
effective at some other time or upon the happening of some other event. Any officer may be removed at any time, with or without
cause by vote of the Board of Directors.
Section 5. Vacancies. The Board of Directors may at any time fill any vacancy occurring in any office for any reason. Each
such successor shall hold office for the unexpired term of such successor’s predecessor and until such successor’s successor is
elected and qualified, or until such successor’s earlier death, resignation or removal.
21
-- 104 of 225 --
Section 6. The Chief Executive Officer. The Chief Executive Officer shall be the principal executive officer of the
Corporation. Subject to the control of the Board of Directors, the Chief Executive Officer shall have general charge of the business
and affairs of the Corporation. The Chief Executive Officer shall employ and discharge employees and agents of the Corporation,
except such as shall hold their offices by appointment of the Board of Directors, but the Chief Executive Officer may delegate these
powers to other officers as to employees under their immediate supervision. The Chief Executive Officer shall have such other
powers and perform such other duties as may be prescribed by the Board of Directors.
Section 7. The President. The Board of Directors may appoint an officer of the Corporation to serve as the President of the
Corporation. The President shall perform such of the duties of the Chief Executive Officer of the Corporation on behalf of the
Corporation as may be assigned to the President from time to time by the Board of Directors or the Chief Executive Officer. In the
absence or inability of the Chief Executive Officer to act, the President shall have and possess all of the powers and discharge all of
the duties of the Chief Executive Officer, subject to the control of the Board of Directors.
Section 8. Vice Presidents. Each Vice President shall have such powers and perform such duties as the Board of Directors,
the Chief Executive Officer, or the President may from time to time prescribe.
Section 9. Chief Financial Officer. The Board of Directors shall appoint an officer to serve as the Chief Financial Officer of
the Corporation. The Chief Financial Officer shall be responsible for the Corporation’s public financial reporting obligations and
shall have such further powers and duties as are incident to the position of Chief Financial Officer, subject to the direction of the
Chief Executive Officer and the Board of Directors.
Section 10. General Counsel. The Board of Directors shall appoint an officer to serve as the General Counsel of the
Corporation. The General Counsel shall be the chief legal officer of the Corporation and shall be responsible for all legal affairs of
the Corporation, and shall have such further powers and duties as are incident to the position of General Counsel.
Section 11. The Treasurer. The Treasurer shall perform such duties and shall have such powers as may from time to time be
assigned to the Treasurer by the Board of Directors, the Chief Executive Officer or the Chief Financial Officer. In addition, subject to
the direction of the Board of Directors, the Treasurer shall perform such duties and have such powers as are incident to the office of
treasurer, including, without limitation, the duty and power to keep and be responsible for all funds and securities of the Corporation,
to deposit funds of the Corporation in depositories, to disburse such funds, to make proper accounts of such funds, and to render
statements of all such transactions and of the financial condition of the Corporation.
Section 12. The Secretary. The Secretary shall keep the minutes of all meetings of the Board of Directors and of the
stockholders and shall attend to the giving and serving of all notices of the Corporation.
22
-- 105 of 225 --
The Secretary shall have custody of the seal of the Corporation and shall affix the seal to all certificates of shares of stock of the
Corporation and to such other papers or documents as may be proper and, when the seal is so affixed, the Secretary shall attest the
same by the Secretary’s signature wherever required. The Secretary shall have charge of the stock certificate book, transfer book,
and stock ledger, and such other books and papers as the Board of Directors may direct. The Secretary shall, in general, perform all
the duties of secretary, subject to the control of the Board of Directors.
Section 13. Assistant Treasurers. In the absence or inability of the Treasurer to act, any Assistant Treasurer may perform all
the duties and exercise all of the powers of the Treasurer, subject to the control of the Board of Directors. An Assistant Treasurer
shall also perform such other duties as the Board of Directors, the Chief Executive Officer, or the Treasurer may from time to time
prescribe.
Section 14. Assistant Secretaries. In the absence or inability of the Secretary to act, any Assistant Secretary may perform all
the duties and exercise all the powers of the Secretary, subject to the control of the Board of Directors. An Assistant Secretary shall
also perform such other duties as the Board of Directors, the Chief Executive Officer, or the Secretary may from time to time
prescribe.
Section 15. Other Officers. Other officers shall perform such duties and have such powers as may from time to time be
assigned to them by the Board of Directors.
Section 16. Delegation of Duties. In case of the absence of any officer of the Corporation, or for any other reason that the
Board of Directors may deem sufficient, the Board of Directors may confer, for the time being, the powers or duties, or any of them,
of such officer upon any other officer, or upon any director.
Section 17. Salaries. Officers of the Corporation shall be entitled to such salaries, compensation, or reimbursement as shall
be fixed or allowed from time to time by the Board of Directors.
ARTICLE IV - CAPITAL STOCK
Section 1. Shares of Stock. The shares of capital stock of the Corporation shall be uncertificated and shall not be represented
by certificates, except to the extent as may be required by applicable law or as otherwise authorized by the Board of Directors. The
preceding sentence shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation.
Every holder of capital stock of the Corporation represented by certificates shall be entitled to have a certificate for shares of capital
stock of the Corporation signed by, or in the name of the Corporation by two authorized officers of the Corporation (it being
understood that each of the Chairman of the Board, the Vice-Chairman of the Board, the Chief Executive Officer, the President, any
Vice President, the Secretary, any Assistant Secretary, the Treasurer and any Assistant Treasurer shall be an authorized person for
these purposes), certifying the class and number of shares of record owned by such stockholder in the Corporation. Any or all of the
signatures may be a facsimile.
Section 2. Transfer of Shares of Stock. Stock of the Corporation shall be transferable in the manner prescribed by
applicable law and in these By-Laws. Transfers of stock shall be made on the books of the Corporation, and in the case of
certificated shares of stock, only by the person named in the certificate or by such person’s attorney lawfully constituted in writing
and upon the surrender of
23
-- 106 of 225 --
the certificate therefor, properly endorsed for transfer and payment of all necessary transfer taxes; or, in the case of uncertificated
shares of stock, upon receipt of proper transfer instructions from the registered holder of the shares or by such person’s attorney
lawfully constituted in writing, and upon payment of all necessary transfer taxes and compliance with appropriate procedures for
transferring shares in uncertificated form; provided, however, that such surrender and endorsement, compliance or payment of taxes
shall not be required in any case in which the officers of the Corporation shall determine to waive such requirement. No transfer of
stock shall be valid as against the Corporation for any purpose until it shall have been entered in the books of the Corporation by an
entry showing from and to whom transferred.
Section 3. Lost, Stolen or Destroyed Certificates. In the event of the loss, theft or destruction of any certificate of stock,
another may be issued in its place pursuant to such regulations as the Board of Directors or transfer agent may establish concerning
proof of such loss, theft, or destruction and concerning the giving of a satisfactory bond or bonds of indemnity.
Section 4. Record Date.
(a) In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of
stockholders, or to receive payment of any dividend or other distribution or allotment of any rights or to exercise any rights in
respect of any change, conversion, or exchange of stock or for the purpose of any other lawful action, the Board of Directors may,
except as otherwise required by the Delaware General Corporation Law, fix a record date, which record date shall not precede the
date on which the resolution fixing the record date is adopted and which record date shall not be more than sixty (60) nor less than
ten (10) days before the date of any meeting of stockholders, nor more than sixty (60) days prior to the time for such other action as
hereinbefore described; provided, however, that if no record date is fixed by the Board of Directors, the record date for determining
stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding
the day on which notice is given or, if notice is waived, at the close of business on the day next preceding the day on which the
meeting is held, and, for determining stockholders entitled to receive payment of any dividend or other distribution or allotment of
rights or to exercise any rights of change, conversion, or exchange of stock or for any other purpose, the record date shall be at the
close of business on the day on which the Board of Directors adopts a resolution relating thereto. A determination of stockholders of
record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however,
that the Board of Directors may fix a new record date for the adjourned meeting.
(b) In order that the Corporation may determine the stockholders entitled to consent to corporate action without a
meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing
the record date is adopted by the Board of Directors, and which date shall not be more than ten (10) days after the date upon which
the resolution fixing the record date is adopted by the Board of Directors. Any stockholder of record seeking to have the
stockholders authorize or take corporate action by consent shall, by written notice to the Secretary of the Corporation, request the
Board of Directors to fix a record date.
24
-- 107 of 225 --
The Board of Directors shall promptly, but in all events within ten (10) days after the date on which such a request is received by the
Secretary, adopt a resolution fixing the record date. If no record date has been fixed by the Board of Directors within ten (10) days of
the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action
without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a
consent setting forth the action taken or proposed to be taken is delivered to the Corporation in accordance with Section 228 of the
Delaware General Corporation Law. If no record date has been fixed by the Board of Directors and prior action by the Board of
Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action without a
meeting shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.
Section 5. Regulations. The issue, transfer, conversion and registration of shares of stock shall be governed by such other
regulations as the Board of Directors may establish.
ARTICLE V - GENERAL PROVISIONS
Section 1. Fiscal Year. Except as from time to time otherwise designated by the Board of Directors, the fiscal year of the
Corporation shall end on December 31.
Section 2. Corporate Seal. The corporate seal shall be in such form as may be approved by the Board of Directors. The
corporate seal may be altered from time to time by the Board.
Section 3. Waiver of Notice. Whenever any notice whatsoever is required to be given by the Delaware General Corporation
Law, by the Certificate of Incorporation or by these By-laws, a waiver of such notice given by the person entitled to such notice or
such person’s duly authorized attorney, whether before or after the time of the event for which notice is to be given shall be deemed
equivalent to the notice required to be given to such person. Neither the business nor the purpose of any meeting need be specified in
such a waiver. The appearance of such person at such meeting in person or by proxy, shall constitute waiver of notice except
attendance for the sole purpose of objecting at the beginning of the meeting to the timeliness or lack of notice.
Section 4. Voting of Securities. Unless otherwise provided by resolution adopted by the Board of Directors, the Chairman of
the Board, the President, any Vice President or the Secretary may from time to time appoint an attorney or attorneys or agent or
agents of the Corporation, in the name and on behalf of the Corporation, to cast the votes which the Corporation may be entitled to
cast as the holder of stock or other securities in any other corporation or other entity, any of whose stock or other securities may be
held by the Corporation, at meetings of the holders of the stock or other securities of such other corporation or other entity, or to
consent in any manner permitted under applicable law, in the name of the Corporation as such holder, to any action by such other
corporation or other entity, and may instruct the person or persons so appointed as to the manner of casting such votes or giving such
consents, and may execute or cause to be executed in the name and on behalf of the Corporation and under its corporate seal or
otherwise, all such proxies or other instruments as he or she may deem necessary or proper. Any of the rights set forth in this Section
4 which may be delegated to an attorney or agent may also be exercised directly by the Chairman of the Board, the President, any
Vice President or the Secretary.
25
-- 108 of 225 --
Section 5. Evidence of Authority. A certificate by the Secretary, or an Assistant Secretary as to any action taken by the
stockholders, directors, a committee or any officer or representative of the Corporation shall as to all persons who rely on the
certificate in good faith be conclusive evidence of such action.
Section 6. Certificate of Incorporation. All references in these By-laws to the Certificate of Incorporation shall be deemed
to refer to the Third Amended and Restated Certificate of Incorporation of the Corporation, as amended, restated and in effect from
time to time.
Section 7. Transactions with Interested Parties. No contract or transaction between the Corporation and one or more of the
directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which
one or more of the directors or officers are directors or officers, or have a financial interest, shall be void or voidable solely for this
reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or a committee
of the Board of Directors that authorizes the contract or transaction or solely because the interested directors’ votes are counted for
such purpose, if:
(1) The material facts as to the director’s or officer’s relationship or interest and as to the contract or
transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee
in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even
though the disinterested directors be less than a quorum;
(2) The material facts as to the director’s or officer’s relationship or interest and as to the contract or
transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is
specifically approved in good faith by vote of the stockholders; or
(3) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or
ratified, by the Board of Directors, a committee of the Board of Directors, or the stockholders.
Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of
Directors or of a committee that authorizes the contract or transaction.
Section 8. Severability. Any determination that any provision of these By-laws is for any reason inapplicable, illegal, or
ineffective shall not affect or invalidate any other provision of these By-laws.
Section 9. Limitation on Stock Option Repricing. No stock option granted to an officer or director of the Corporation shall,
after issuance, be repriced to a lower exercise price (other than adjustments for stock splits, stock dividends, spinoffs,
recapitalizations and like events), without the prior affirmative vote of the holders of a majority in voting power of the shares of
capital stock of the Corporation present at a stockholders meeting in person or by proxy and entitled to vote thereon.
26
-- 109 of 225 --
ARTICLE VI - AMENDMENTS
Section 1. By the Board of Directors. In furtherance and not in limitation of the powers conferred by the Delaware General
Corporation Law and the Certificate of Incorporation, the Board of Directors is expressly authorized to alter, amend or repeal any
provision of these By-laws or make new by-laws.
Section 2. By the Stockholders. The stockholders of the Corporation shall have the power to alter, amend or repeal any
provision of these By-laws or make new by-laws by affirmative vote of the holders of a majority in voting power of the shares of
capital stock of the Corporation issued and outstanding and entitled to vote, voting together as a single class.
27
-- 110 of 225 --
Exhibit 10.1
THERMO FISHER SCIENTIFIC INC.
DEFERRED COMPENSATION PLAN FOR DIRECTORS,
As amended and restated effective as of February 21, 2024
Section 1. Participation. Any director of Thermo Fisher Scientific Inc. (the “Company”) may elect to have such percentage as
he or she may specify of the fees otherwise payable to him or her deferred and paid to him or her as provided in this Plan. A director
who is also an employee of the Company or any subsidiary or parent of the Company shall not be eligible to participate in this Plan.
Each election to defer fees to be paid in any calendar year shall be made by notice in writing delivered to the Secretary of the
Company no later than December 31 of the preceding year, in such form as the Secretary shall designate, and each election shall be
applicable only with respect to fees earned during the calendar year designated in the form. The term “participant” as used herein
refers to any director who shall have made an election. No participant may defer the receipt of any fees to be earned after the date on
which he or she shall cease to be a director of the Company (the “deferral termination date”).
Section 2. Establishment of Deferred Compensation Accounts. There shall be established for each participant an account to
be designated as that participant’s deferred compensation account.
Section 3. Allocations to Deferred Compensation Accounts. There shall be allocated to each participant’s deferred
compensation account, as of the end of each quarter, an amount equal to his or her fees for that quarter which that participant shall
have elected to have deferred pursuant to Section 1.
Section 4. Stock Units and Stock Unit Accounts. All amounts allocated to a participant’s deferred compensation account
pursuant to Section 3 shall be converted, at the end of each quarter, into stock units by dividing the accumulated balance in the
deferred compensation account as of the end of that quarter by the last sale price per share of the Company’s common stock as
reported in The Wall Street Journal, for the last trading day of that quarter. The number of stock units, so determined, rounded to the
nearest one-hundredth of a share, shall be credited to a separate stock unit account to be established for the participant, and the
aggregate value thereof as of the last business day of that quarter shall be charged to the participant’s deferred compensation
account. No amounts credited to the participant’s deferred compensation account pursuant to Section 5 shall be converted into stock
units. Any such amount shall be distributed in cash as provided in Section 8.
Section 5. Cash Dividend Credits. Additional credits shall be made to a participant’s deferred compensation account, until all
distributions shall have been made from the participant’s stock unit account, in amounts equal to the cash dividends (or the fair
market value of dividends paid in property other than dividends payable in common stock of the Company) which the participant
would have received from time to time had he or she been the owner on the record dates for the payment of such dividends of the
number of shares of the Company’s common stock equal to the number of units in his or her stock unit account on those dates.
1
-- 111 of 225 --
Section 6. Stock Dividend Credits. Additional credits shall be made to a participant’s stock unit account, until all distributions
shall have been made from the participant’s stock unit account, of a number of units equal to the number of shares of the Company’s
common stock, rounded to the nearest one-hundredth share, which the participant would have received from time to time as stock
dividends had he or she been the owner on the record dates for the payments of such stock dividends of the number of units of the
Company’s common stock equal to the number of units credited to his or her stock unit account on those dates.
Section 7. Adjustments in the Event of Certain Transactions. In the event of a stock dividend, stock split or combination of
shares, or other distribution with respect to holders of Common Stock other than normal cash dividends, the number of units then
credited to a participant’s stock unit account shall be appropriately adjusted on the same basis. In the event of any recapitalization,
merger or consolidation involving the Company, any transaction in which the Company becomes a subsidiary of another entity, any
sale or other disposition of all or a substantial portion of the assets of the Company or any similar transaction, as determined by the
Board, the Board in its discretion may terminate the Plan pursuant to Section 11.
Section 8. Distribution of Stock and Cash After Participant’s Deferral Termination Date. When a participant’s deferral
termination date shall occur, the Company shall become obligated to make the distributions prescribed in the following paragraphs
(a) and (b).
(a) The Company shall distribute to the participant the number of shares of the common stock of the Company which
shall equal the total number of units accumulated in his or her stock unit account as of the close of the fiscal year in which the
participant’s deferral termination date occurs. Such distribution of stock shall be made in a single distribution within 60 days after
the close of the fiscal year in which the participant’s deferral termination date occurs. Distribution of stock made hereunder may be
made from shares of common stock held in the treasury and/or from shares of authorized but previously unissued shares of common
stock.
(b) The Company shall distribute to the participant sums in cash equal to the cash balance credited to his or her deferred
compensation account as of the close of the fiscal year in which his or her deferral termination date occurs. The cash distribution
shall be made on the same date as the distribution made pursuant to paragraph (a) above, and shall consist of the entire cash balance
credited to the participant’s deferred compensation account at the time of the distribution.
(c) If a participant’s deferral termination date shall occur by reason of his or her death or if he or she shall die after his or
her deferral termination date but prior to receipt of all distributions of stock and cash provided for in this Section 8, all stock and
cash remaining distributable hereunder shall be distributed to such beneficiary as the participant shall have designated in writing and
filed with the Secretary of the Company or, in the absence of designation, to the participant’s personal representative. Such
distributions shall be made in the same manner and at the same intervals as they would have been made to the participant had he or
she continued to live.
(d) A participant may change the time of payment of the distribution to be made
2
-- 112 of 225 --
under Section 8(a) by submitting an election form to the Secretary of the Company. Such election shall not take effect until at least
12 months after the date on which the election is made, the new distribution shall take place at least 5 years after the distribution date
that would otherwise been applicable, and the election must be made at least 12 months prior to such distribution date.
Section 9. Participant’s Rights Unsecured. The right of any participant to receive distributions under Section 8 shall be an
unsecured claim against the general assets of the Company. The Company may but shall not be obligated to acquire shares of its
outstanding common stock from time to time in anticipation of its obligation to make such distributions, but no participant shall have
any rights in or against any shares of stock so acquired by the Company. All such stock shall constitute general assets of the
Company and may be disposed of by the Company at such time and for such purposes as it may deem appropriate.
Section 10. Change in Control.
10.1 Impact of Event
In the event of a “Change in Control” as defined in Section 10.2, the Plan shall terminate and full distribution shall be made from all
participants’ deferred compensation accounts and stock unit accounts effective upon the Change of Control.
10.2 Definition of “Change in Control”
"Change in Control" shall mean the occurrence of a "change in the ownership," a "change in the effective control" or a "change in
the ownership of a substantial portion of the assets" of a corporation, as determined in accordance with this Section.
In order for an event described below to constitute a Change in Control with respect to a Participant, except as otherwise provided in
part (b)(ii) of this Section, the applicable event must relate to the corporation for which the Participant is providing services, the
corporation that is liable for payment of the Participant's Account Balance (or all corporations liable for payment if more than one),
as identified by the Committee in accordance with Treas. Reg. § 1.409A-3(i)(5)(ii)(A)(2), or such other corporation identified by the
Committee in accordance with Treas. Reg. § 1.409A-3(i)(5)(ii)(A)(3).
In determining whether an event shall be considered a "change in the ownership," a "change in the effective control" or a "change in
the ownership of a substantial portion of the assets" of a corporation, the following provisions shall apply:
(a) A "change in the ownership" of the applicable corporation shall occur on the date on which any one person, or more
than one person acting as a group, acquires ownership of stock of such corporation that, together with stock held by such person or
group, constitutes more than 50% of the total fair market value or total voting power of the stock of such corporation, as determined
in accordance with Treas. Reg. § 1.409A-3(i)(5)(v). If a person or group is considered either to own more than 50% of the total fair
market value or total voting power of the stock of such corporation, or to have effective control of such corporation within the
meaning
3
-- 113 of 225 --
of part (b) of this Section, and such person or group acquires additional stock of such corporation, the acquisition of additional stock
by such person or group shall not be considered to cause a "change in the ownership" of such corporation.
(b) A "change in the effective control" of the applicable corporation shall occur on either of the following dates:
(i) The date on which any one person, or more than one person acting as a group, acquires (or has acquired
during the 12-month period ending on the date of the most recent acquisition by such person or persons) ownership of
stock of such corporation possessing 40% or more of the total voting power of the stock of such corporation, as
determined in accordance with Treas. Reg. § 1.409A-3(i)(5)(vi). If a person or group is considered to possess 40% or
more of the total voting power of the stock of a corporation, and such person or group acquires additional stock of such
corporation, the acquisition of additional stock by such person or group shall not be considered to cause a "change in the
effective control" of such corporation; or
(ii) The date on which a majority of the members of the applicable corporation's board of directors is replaced
during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of
such corporation's board of directors before the date of the appointment or election, as determined in accordance with
Treas. Reg. § 1.409A-3(i)(5)(vi). In determining whether the event described in the preceding sentence has occurred, the
applicable corporation to which the event must relate shall only include a corporation identified in accordance with Treas.
Reg. § 1.409A-3(i)(5)(ii) for which no other corporation is a majority shareholder.
(c) A "change in the ownership of a substantial portion of the assets" of the applicable corporation shall occur on the date
on which any one person, or more than one person acting as a group, acquires (or has acquired during the 12-month period ending on
the date of the most recent acquisition by such person or persons) assets from the corporation that have a total gross fair market
value equal to or more than 40% of the total gross fair market value of all of the assets of the corporation immediately before such
acquisition or acquisitions, as determined in accordance with Treas. Reg. § 1.409A-3(i)(5)(vii). A transfer of assets shall not be
treated as a "change in the ownership of a substantial portion of the assets" when such transfer is made to an entity that is controlled
by the shareholders of the transferor corporation, as determined in accordance with Treas. Reg. § 1.409A-3(i)(5)(vii)(B).
Section 11. Amendment and Termination of the Plan. The Board of Directors of the Company may amend or terminate the
Plan at any time and from time to time, provided, however, that no amendment adversely affecting credits already made to any
participant’s deferred compensation account or stock unit account may be made without the consent of that participant or, if that
participant has died, that participant’s beneficiary. Upon termination of the Plan, the Company shall be obligated to distribute to the
participant the following as the Board of Directors of the Company, in its sole discretion, may determine: (i) the number of shares of
the common stock of the Company which shall equal the total number of units accumulated in the
4
-- 114 of 225 --
participant’s stock unit account as of the effective date of termination of the Plan and/or (ii) a sum in cash equal to the balance
credited to the participant’s deferred compensation account as of the effective date of termination of the Plan.
Section 12. Section 409A. This Plan is intended to comply with all applicable law, including Code Section 409A of the Internal
Revenue Code and related Treasury guidance and regulations, and shall be operated and interpreted in accordance with this
intention.
5
-- 115 of 225 --
Exhibit 10.49
Thermo Fisher Scienti ic Inc.
Deferred Compensation Plan
Amended & Restated Effective January 1, 2024
IMPORTANT NOTE
This document has not been approved by the Department of Labor, Internal Revenue Service, or any other governmental entity. An
adopting Employer must determine whether the Plan is subject to the federal securities laws and the securities laws of the various
states. An adopting Employer may not rely on this document to ensure any particular tax consequences or to ensure that the Plan is
“unfunded and maintained primarily for the purpose of providing deferred compensation to a select group of management or highly
compensated employees” under Title I of the Employee Retirement Income Security Act of 1974, as amended, with respect to the
Employer’s particular situation. FMR LLC, its af iliates and employees cannot provide you with legal advice in connection with the
execution of this document. This document should be reviewed by the Employer’s attorney prior to execution.
-- 116 of 225 --
Table of Contents
Preamble 1
Article 1 - General 1-1
1.1. Plan 1-1
1.2. Effective Dates 1-1
1.3. Amounts Not Subject to Code Section 409A 1-1
Article 2 - De initions 2-1
2.1. Account 2-1
2.2. Administrator 2-1
2.3. Adoption Agreement 2-1
2.4. Bene iciary 2-1
2.5. Board or Board of Directors 2-1
2.6. Bonus 2-1
2.7. Change in Control 2-1
2.8. Code 2-1
2.9. Committee 2-1
2.10. Compensation 2-1
2.11. Director 2-2
2.12. Disability 2-2
2.13. Eligible Employee 2-2
2.14. Employer 2-2
2.15. ERISA 2-2
2.16. Identi ication Date 2-2
2.17. Key Employee 2-2
2.18. Match-Eligible Compensation 2-2
2.19. Participant 2-2
2.20. Plan 2-2
2.21. Plan Sponsor 2-2
2.22. Plan Year 2-2
2.23. Related Employer 2-3
2.24. Retirement 2-3
2.25. Separation from Service 2-3
2.26. Unforeseeable Emergency 2-4
2.27. Valuation Date 2-4
2.28. Years of Service 2-4
Article 3 - Participation 3-1
3.1. Participation 3-1
3.2. Termination of Participation 3-1
TOC-i
-- 117 of 225 --
Article 4 - Participant Elections 4-1
4.1. Deferral Agreement 4-1
4.2. Amount of Deferral 4-1
4.3. Timing of Election to Defer 4-1
4.4. Election of Payment Schedule and Form of Payment 4-2
Article 5 - Employer Contributions 5-1
5.1. Matching Contributions 5-1
5.2. Other Contributions 5-1
Article 6 - Accounts and Credits 6-1
6.1. Establishment of Account 6-1
6.2. Credits to Account 6-1
Article 7 - Investment of Contributions 7-1
7.1. Investment Options 7-1
7.2. Adjustment of Accounts 7-1
Article 8 - Right to Bene its 8-1
8.1. Vesting 8-1
8.2. Death 8-1
8.3. Disability 8-1
Article 9 - Distribution of Bene its 9-1
9.1. Amount of Bene its 9-1
9.2. Method and Timing of Distributions 9-1
9.3. Unforeseeable Emergency 9-1
9.4. Payment Election Overrides 9-2
9.5. Cashouts of Amounts Not Exceeding Stated Limit 9-2
9.6. Required Delay in Payment (Including to Key Employees) 9-2
9.7. Change in Control 9-3
9.8. Permissible Delays in Payment 9-5
9.9. Permitted Acceleration of Payment 9-5
Article 10 - Amendment and Termination 10-1
10.1. Amendment by Plan Sponsor 10-1
10.2. Plan Termination Following Change in Control or Corporate Dissolution 10-1
10.3. Other Plan Terminations 10-1
Article 11 - The Trust 11-1
11.1. Establishment of Trust 11-1
11.2. Trust 11-1
11.3. Investment of Trust Funds 11-1
Article 12 - Plan Administration 12-1
12.1. Powers and Responsibilities of the Administrator 12-1
12.2. Claims and Review Procedures 12-2
TOC-ii
-- 118 of 225 --
12.3. Plan Administrative Costs 12-6
Article 13 - Miscellaneous 13-1
13.1. Unsecured General Creditor of the Employer 13-1
13.2. Employer’s Liability 13-1
13.3. Limitation of Rights 13-1
13.4. Anti-Assignment 13-1
13.5. Facility of Payment 13-2
13.6. Notices 13-2
13.7. Tax Withholding 13-2
13.8. Indemni ication 13-2
13.9. Successors 13-3
13.10. Lost Participant or Bene iciaries 13-3
13.11. Headings 13-3
13.12. Invalid or Unenforceable Provisions 13-3
13.13. Disclaimer 13-3
13.14. Governing Law 13-3
TOC-iii
-- 119 of 225 --
Preamble
The Plan is intended to be a “plan which is unfunded and is maintained by an employer primarily for the purpose of providing deferred
compensation for a select group of management or highly compensated employees” within the meaning of Sections 201(2), 301(a)(3)
and 401(a)(1) of the Employee Retirement Income Security Act of 1974, as amended, or an “excess bene it plan” within the meaning of
Section 3(36) of the Employee Retirement Income Security Act of 1974, as amended, or a combination of both. The Plan is further
intended to conform with the requirements of Internal Revenue Code Section 409A and the inal regulations issued thereunder and shall
be interpreted, implemented and administered in a manner consistent therewith.
Preamble 1
-- 120 of 225 --
Article 1 - General
1.1. Plan
The Plan will be referred to by the name speci ied in the Adoption Agreement.
1.2. Effective Dates
(a) Original Effective Date. The Original Effective Date is the date as of which the Plan was initially adopted.
(b) Amendment Effective Date. The Amendment Effective Date is the date speci ied in the Adoption Agreement as of which
the Plan is amended and restated. Except as otherwise provided in the Adoption Agreement, all amounts deferred under
the Plan prior to the Amendment Effective Date shall be governed by the terms of the Plan as in effect on the day before
the Amendment Effective Date.
(c) Special Effective Date. A Special Effective Date may apply to any given provision if so speci ied in Appendix A of the
Adoption Agreement. A Special Effective Date will control over the Original Effective Date or Amendment Effective Date,
whichever is applicable, with respect to such provision of the Plan.
1.3. Amounts Not Subject to Code Section 409A
Except as otherwise indicated by the Plan Sponsor in Section 1.01 of the Adoption Agreement, amounts deferred before January
1, 2005 that are earned and vested on December 31, 2004 will be separately accounted for and administered in accordance with
the terms of the Plan as in effect on December 31, 2004.
Article 1-1
-- 121 of 225 --
Article 2 - De initions
Wherever used herein, the following terms have the meanings set forth below, unless a different meaning is clearly required by the
context:
2.1. Account
“Account” means an account and any subaccounts established for the purpose of recording amounts credited on behalf of a
Participant and any earnings, expenses, gains, losses or distributions included thereon. The Account shall be a bookkeeping entry
only and shall be utilized solely as a device for the measurement and determination of the amounts to be paid to a Participant or
to the Participant’s Bene iciary pursuant to the Plan.
2.2 Administrator
“Administrator” means the person or persons designated by the Plan Sponsor in Section 1.05 of the Adoption Agreement to be
responsible for the administration of the Plan. If no Administrator is designated in the Adoption Agreement, the Administrator is
the Plan Sponsor.
2.3 Adoption Agreement
“Adoption Agreement” means the agreement adopted by the Plan Sponsor that establishes the Plan.
2.4 Bene iciary
“Bene iciary” means the persons, trusts, estates or other entities entitled under Section 8.2 to receive bene its under the Plan
upon the death of a Participant. The Participant’s spouse, if living, otherwise the Participant’s estate, shall be the Bene iciary if:
(i) the Participant has failed to properly designate a Bene iciary or (ii) all designated Bene iciaries have predeceased the
Participant.
2.5 Board or Board of Directors
“Board” or “Board of Directors” means the Board of Directors of the Plan Sponsor.
2.6. Bonus
“Bonus” means an amount of incentive remuneration payable by the Employer to a Participant.
2.7. Change in Control
“Change in Control” means the occurrence of an event involving the Plan Sponsor that is described in Section 9.7.
2.8. Code
“Code” means the Internal Revenue Code of 1986, as amended.
2.9. Committee
“Committee” means the Compensation Committee of the Board or such other committee as the Board may appoint from time to
time.
2.10. Compensation
“Compensation” has the meaning speci ied in Section 3.01 of the Adoption Agreement.
Article 2-1
-- 122 of 225 --
2.11. Director
“Director” means a non-employee member of the Board.
2.12. Disability
“Disability” means that a Participant is disabled as de ined in Section 6.01(i) of the Adoption Agreement.
2.13. Eligible Employee
“Eligible Employee” means an employee of the Employer who satis ies the requirements in Section 2.01 of the Adoption
Agreement.
2.14. Employer
“Employer” means the Plan Sponsor and any other Related Employer that is listed in Section 1.04 of the Adoption Agreement and
which is authorized by the Plan Sponsor to participate in and, in fact, does adopt the Plan.
2.15. ERISA
“ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
2.16. Identi ication Date
“Identi ication Date” means the date as of which Key Employees are determined which is speci ied in Section 1.06 of the
Adoption Agreement.
2.17. Key Employee
“Key Employee” means an employee who satis ies the conditions set forth in Section 9.6.
2.18. Match-Eligible Compensation
Match-Eligible Compensation for a given Plan Year means a Participant's Compensation that is in excess of the amount of
Compensation treated as "compensation" for the applicable plan year under the Thermo Fisher Scienti ic Inc. 401(k) Retirement
Plan. Match-Eligible Compensation includes a Participant's Compensation that is in excess of the IRS limit on covered
compensation for quali ied plans established in Code Section 401 (a)(17) in effect for that Plan Year and also includes any
amount of a Participant's Compensation that was reduced below the Code Section 401(a)(17) limit for purposes of applying the
Company match in the Company sponsored 401(k) plan due to deferrals in this Plan.
2.19. Participant
“Participant” means an Eligible Employee who commences participation in the Plan in accordance with Article 3.
2.20. Plan
“Plan” means the unfunded plan of deferred compensation set forth herein, including the Adoption Agreement and any trust
agreement, as adopted by the Plan Sponsor, and as amended from time to time.
2.21. Plan Sponsor
“Plan Sponsor” means the entity identi ied in Section 1.03 of the Adoption Agreement or any successor by merger, consolidation
or otherwise.
2.22. Plan Year
“Plan Year” means the period identi ied in Section 1.02 of the Adoption Agreement.
Article 2-2
-- 123 of 225 --
2.23. Related Employer
“Related Employer” means the Plan Sponsor and (a) any corporation that is a member of a controlled group of corporations as
de ined in Code Section 414(b) that includes the Plan Sponsor and (b) any trade or business that is under common control as
de ined in Code Section 414(c) that includes the Plan Sponsor.
2.24. Retirement
“Retirement” has the meaning speci ied in 6.01(f) of the Adoption Agreement.
2.25. Separation from Service
“Separation from Service” means the date that the Participant dies, retires or otherwise has a termination of employment with
respect to all entities comprising the Related Employer. A Separation from Service does not occur if the Participant is on military
leave, sick leave or other bona ide leave of absence if the period of leave does not exceed six months or such longer period
during which the Participant’s right to re-employment is provided by statute or contract. If the period of leave exceeds six
months and the Participant’s right to re-employment is not provided either by statute or contract, a Separation from Service will
be deemed to have occurred on the irst day following the six-month period. If the period of leave is due to any medically
determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous
period of not less than six months, where the impairment causes the Participant to be unable to perform the duties of his or her
position of employment or any substantially similar position of employment, a 29 month period of absence may be substituted
for the six month period.
Whether a termination of employment has occurred is based on whether the facts and circumstances indicate that the Related
Employer and the Participant reasonably anticipated that no further services would be performed after a certain date or that the
level of bona ide services the Participant would perform after such date (whether as an employee or as an independent
contractor) would permanently decrease to no more than 20 percent of the average level of bona ide services performed
(whether as an employee or an independent contractor) over the immediately preceding 36 month period (or the full period of
services to the Related Employer if the employee has been providing services to the Related Employer for less than 36 months).
An independent contractor is considered to have experienced a Separation from Service with the Related Employer upon the
expiration of the contract (or, in the case of more than one contract, all contracts) under which services are performed for the
Related Employer if the expiration constitutes a good-faith and complete termination of the contractual relationship.
If a Participant provides services as both an employee and an independent contractor of the Related Employer, the Participant
must separate from service both as an employee and as an independent contractor to be treated as having incurred a Separation
from Service. If a Participant ceases providing services as an independent contractor and begins providing services as an
employee, or ceases providing services as an employee and begins providing services as an independent contractor, the
Participant will not be considered to have experienced a Separation from Service until the Participant has ceased providing
services in both capacities.
If a Participant provides services both as an employee and as a member of the Board of Directors of a corporate Related
Employer (or an analogous position with respect to a noncorporate Related Employer), the services provided as a Director are
not taken into account in determining whether the Participant has incurred a Separation from Service as an employee for
purposes of a nonquali ied deferred compensation plan in which the Participant participates as an employee that is not
aggregated under Code Section 409A with any plan in which the Participant participates as a Director.
Article 2-3
-- 124 of 225 --
For purposes of determining whether a Separation from Service has occurred, the Related Employer means the Related Employer
as de ined in Section 2.22 of the Plan, except that in applying Code Sections 1563(a)(1), (2) and (3) for purposes of determining
whether another organization is a Related Employer of the Plan Sponsor under Code Section 414(b), and in applying Treas. Reg.
§ 1.414(c)-2 for purposes of determining whether another organization is a Related Employer of the Plan Sponsor under Code
Section 414(c), "at least 50 percent" shall be used instead of "at least 80 percent" each place it appears in those Sections. The
Plan Sponsor speci ically reserves the right to determine whether a sale or other disposition of substantial assets to an unrelated
party constitutes a Separation from Service with respect to a Participant providing services to the seller immediately prior to the
transaction and providing services to the buyer after the transaction.
All determinations of whether a Separation from Service has occurred will be made in a manner consistent with Code Section
409A and the inal regulations thereunder.
2.26. Unforeseeable Emergency
“Unforeseeable Emergency” means a severe inancial hardship of the Participant resulting from an illness or accident of the
Participant, the Participant’s spouse, the Participant’s Bene iciary or the Participant’s dependent (as de ined in Code Section 152,
without regard to Code Section 152(b)(1), (b)(2) and (d)(1)(B)); loss of the Participant’s property due to casualty; or other
similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant. The
types of events which may qualify as an Unforeseeable Emergency may be limited by the Plan Sponsor.
2.27. Valuation Date
“Valuation Date” means each business day of the Plan Year that the New York Stock Exchange is open.
2.28. Years of Service
“Years of Service” means each one-year period for which the Participant receives service credit in accordance with the provisions
of Section 7.01(d) of the Adoption Agreement.
Article 2-4
-- 125 of 225 --
Article 3 - Participation
3.1. Participation
The Participants in the Plan shall be those Eligible Employees of the Employer who satisfy the requirements of Section 2.01 of
the Adoption Agreement.
3.2 Termination of Participation
The Administrator may terminate a Participant’s participation in the Plan in a manner consistent with Code Section 409A. If the
Employer terminates a Participant’s participation before the Participant experiences a Separation from Service, the Participant’s
vested Accounts shall be paid in accordance with the provisions of Article 9.
Article 3-1
-- 126 of 225 --
Article 4 - Participant Elections
4.1. Deferral Agreement
If permitted by the Plan Sponsor in accordance with Section 4.01 of the Adoption Agreement, each Eligible Employee may elect to
defer his or her Compensation within the meaning of Section 3.01 of the Adoption Agreement by executing, in writing or
electronically, a deferral agreement in accordance with rules and procedures established by the Administrator and the provisions
of this Article 4.
A new deferral agreement must be timely executed for each Plan Year during which the Eligible Employee desires to defer
Compensation. An Eligible Employee who does not timely execute a deferral agreement shall be deemed to have elected zero
deferrals of Compensation for such Plan Year.
A deferral agreement may be changed or revoked during the period speci ied by the Administrator. Except as provided in Section
9.3, a deferral agreement becomes irrevocable at the close of the speci ied period.
The Plan Sponsor may modify any deferral agreement prior to the date the election becomes irrevocable under the rules of
Section 4.3.
4.2. Amount of Deferral
An Eligible Employee may elect to defer Compensation in any amount permitted by Section 4.01(a) of the Adoption Agreement.
4.3. Timing of Election to Defer
Each Eligible Employee who desires to defer Compensation otherwise payable during a Plan Year must execute a deferral
agreement within the period preceding the Plan Year during which the Compensation is earned that is speci ied by the
Administrator. Each Eligible Employee who desires to defer Compensation that is a Bonus must execute a deferral agreement
within the period preceding the Plan Year during which the Bonus is earned that is speci ied by the Administrator, except that if
the Bonus can be treated as performance based compensation as described in Code Section 409A(a)(4)(B)(iii), the deferral
agreement may be executed within the period speci ied by the Administrator, which period, in no event, shall end after the date
which is six months prior to the end of the period during which the Bonus is earned, provided the Participant has performed
services continuously from the later of the beginning of the performance period or the date the performance criteria are
established through the date the Participant executed the deferral agreement and provided further that the compensation has
not yet become ‘readily ascertainable’ within the meaning of Treas. Reg. § 1.409A-2(a)(8). Compensation that meets the
de inition of a "short-term deferral" described in Treas. Reg. § 1.409A-1(b)(4) may be deferred in accordance with the rules of
Section 9.2, applied as if the date the substantial risk of forfeiture lapses is the date payments were originally scheduled to
commence, provided, however, that the provisions requiring the delay of the payment date for a minimum period of 60 months
from the originally scheduled date of payment shall not apply to payments attributable to a change in control (as de ined in
Treas. Reg. § 1.409A- 3(i)(5)). In addition, if the Compensation quali ies as ‘ iscal year compensation’ within the meaning of
Treas. Reg. § 1.409A-2(a)(6), the deferral agreement may be made not later than the end of the Employer’s taxable year
immediately preceding the irst taxable year of the Employer in which any services are performed for which such Compensation
is payable.
Article 4-1
-- 127 of 225 --
Except as otherwise provided below, an employee who is classi ied or designated as an Eligible Employee during a Plan Year may
elect to defer Compensation otherwise payable during the remainder of such Plan Year in accordance with the rules of this
Section 4.3 by executing a deferral agreement within the thirty (30)-day period beginning on the date the employee is classi ied
or designated as an Eligible Employee, if permitted by Section 4.01(b)(ii) of the Adoption Agreement. If Compensation is based
on a speci ied performance period that begins before the Eligible Employee or Director executes his or her deferral agreement,
the election will be deemed to apply to the portion of such Compensation equal to the total amount of Compensation for the
performance period multiplied by the ratio of the number of days remaining in the performance period after the election
becomes irrevocable and effective over the total number of days in the performance period. The rules of this paragraph shall not
apply unless the Eligible Employee can be treated as initially eligible in accordance with Treas. Reg. § 1.409A-2(a)(7).
4.4. Election of Payment Schedule and Form of Payment
All elections of a payment schedule and a form of payment will be made in accordance with rules and procedures established by
the Administrator and the provisions of this Section 4.4.
(a) If the Plan Sponsor has elected to permit annual distribution elections in accordance with Section 6.01(h) of the Adoption
Agreement the following rules apply. At the time an Eligible Employee completes a deferral agreement, the Eligible
Employee must elect a distribution event (which includes a speci ied time) and a form of payment for the Compensation
subject to the deferral agreement from among the options the Plan Sponsor has made available for this purpose and
which are speci ied in 6.01(b) of the Adoption Agreement. Prior to the time required by Treas. Reg. § 1.409A-2, the
Eligible Employee shall elect a distribution event (which includes a speci ied time) and a form of payment for any
Employer contributions that may be credited to the Participant’s Account during the Plan Year. If an Eligible Employee
fails to elect a distribution event, he or she shall be deemed to have elected Separation from Service as the distribution
event. If he or she fails to elect a form of payment, he or she shall be deemed to have elected a lump sum form of payment.
(b) If the Plan Sponsor has elected not to permit annual distribution elections in accordance with Section 6.01(h) of the
Adoption Agreement the following rules apply. At the time an Eligible Employee irst completes a deferral agreement but
in no event later than the time required by Treas. Reg. § 1.409A-2, the Eligible Employee must elect a distribution event
(which includes a speci ied time) and a form of payment for amounts credited to his or her Account from among the
options the Plan Sponsor has made available for this purpose and which are speci ied in Section 6.01(b) of the Adoption
Agreement. If an Eligible Employee fails to elect a distribution event, he or she shall be deemed to have elected
Separation from Service in the distribution event. If the Participant fails to elect a form of payment, he or she shall be
deemed to have elected a lump sum form of payment.
Article 4-2
-- 128 of 225 --
Article 5 - Employer Contributions
5.1. Matching Contributions
If elected by the Plan Sponsor in Section 5.01(a) of the Adoption Agreement, the Employer will credit the Participant’s Account
with a matching contribution determined in accordance with the formula speci ied in Section 5.01(a) of the Adoption Agreement.
The matching contribution will be treated as allocated to the Participant’s Account at the time speci ied in Section 5.01(a)(iii) of
the Adoption Agreement.
5.1. Other Contributions
If elected by the Plan Sponsor in Section 5.01(b) of the Adoption Agreement, the Employer will credit the Participant’s Account
with a contribution or contributions determined in accordance with the formula or method speci ied in Section 5.01(b) of the
Adoption Agreement. These contributions will be treated as allocated to the Participant’s Account at the time speci ied in Section
5.01(b)(iii) of the Adoption Agreement.
Article 5-1
-- 129 of 225 --
Article 6 - Accounts and Credits
6.1. Establishment of Account
For accounting and computational purposes only, the Administrator will establish and maintain an Account on behalf of each
Participant which will re lect the credits made pursuant to Section 6.2, distributions or withdrawals, along with the earnings,
expenses, gains and losses allocated thereto, attributable to the hypothetical investments made with the amounts in the Account
as provided in Article 7. The Administrator may establish and maintain such other records and accounts, as it decides in its
discretion to be reasonably required or appropriate to discharge its duties under the Plan.
6.2. Credits to Account
A Participant’s Account will be credited for each Plan Year with the amount of his or her elective deferrals under Section 4.1 at
the time the amount subject to the deferral election would otherwise have been payable to the Participant and the amount of
Employer contributions, if any, treated as allocated on his or her behalf under Article 5.
Article 6-1
-- 130 of 225 --
Article 7 - Investment of Contributions
7.2. Investment Options
The amount credited to each Account shall be treated as invested in the investment options designated for this purpose by the
Administrator.
7.2. Adjustment of Accounts
The amount credited to each Account shall be adjusted for hypothetical investment earnings, expenses, gains or losses in an
amount equal to the earnings, expenses, gains or losses attributable to the investment options selected by the party designated in
Section 9.01 of the Adoption Agreement from among the investment options provided in Section 7.1. If permitted by Section 9.01
of the Adoption Agreement, a Participant (or the Participant’s Bene iciary after the death of the Participant) may, in accordance
with rules and procedures established by the Administrator, select the investments from among the options provided in Section
7.1 to be used for the purpose of calculating future hypothetical investment adjustments to the Account or to future credits to the
Account under Section 6.2 effective as of the Valuation Date coincident with or next following notice to the Administrator. Each
Account shall be adjusted as of each Valuation Date to re lect: (a) the hypothetical earnings, expenses, gains and losses described
above; (b) amounts credited pursuant to Section 6.2; and (c) distributions or withdrawals. In addition, each Account may be
adjusted for its allocable share of the hypothetical costs and expenses associated with the maintenance of the hypothetical
investments provided in Section 7.1.
Article 7-1
-- 131 of 225 --
Article 8 - Right to Bene its
8.1. Vesting
A Participant, at all times, has a 100% nonforfeitable interest in the amounts credited to his or her Account attributable to his or
her elective deferrals made in accordance with Section 4.1.
A Participant’s right to the amounts credited to his or her Account attributable to Employer contributions made in accordance
with Article 5 shall be determined in accordance with the relevant schedule and provisions in Section 7.01 of the Adoption
Agreement. Upon a Separation from Service and after application of the provisions of Section 7.01 of the Adoption Agreement,
the Participant shall forfeit the nonvested portion of his or her Account.
8.2. Death
The Plan Sponsor may elect to accelerate vesting upon the death of the Participant in accordance with Section 7.01(c) of the
Adoption Agreement and/or to accelerate distributions upon death in accordance with Section 6.01(b) or Section 6.01(d) of the
Adoption Agreement. If the Plan Sponsor does not elect to accelerate distributions upon death in accordance with Section
6.01(b) or Section 6.01(d) of the Adoption Agreement, the vested amount credited to the Participant’s Account will be paid in
accordance with the provisions of Article 9.
A Participant may designate a Bene iciary or Bene iciaries, or change any prior designation of Bene iciary or Bene iciaries in
accordance with rules and procedures established by the Administrator. Whenever a Participant designates a new Bene iciary, all
former Bene iciary designations by such Participant shall be revoked automatically. If a Participant and the Participant’s spouse
divorce, any designations of the spouse as Bene iciary shall become null and void. The former spouse shall be treated as the
Bene iciary under the Plan only if after the divorce is inal, the Participant expressly re-designates the former spouse as the
Participant’s Bene iciary.
A copy of the death notice or other suf icient documentation must be iled with and approved by the Administrator.
8.3. Disability
If the Plan Sponsor has elected to accelerate vesting upon the occurrence of a Disability in accordance with Section 7.01(c) of the
Adoption Agreement and/or to permit distributions upon Disability in accordance with Section 6.01(b) or Section 6.01(d) of the
Adoption Agreement, the determination of whether a Participant has incurred a Disability shall be based on the de inition of
Disability in Section 6.01(i) of the Adoption Agreement and in a manner consistent with the requirements of Code Section 409A.
Article 8-1
-- 132 of 225 --
Article 9 - Distribution of Bene its
9.1. Amount of Bene its
The vested amount credited to a Participant’s Account as determined under Articles 6, 7 and 8 shall determine and constitute the
basis for the value of bene its payable to the Participant under the Plan.
9.2. Method and Timing of Distributions
Except as otherwise provided in this Article 9, distributions under the Plan shall be made in accordance with the elections made
or deemed made by the Participant under Article 4. Subject to the provisions of Section 9.6 requiring a six-month delay for
certain distributions, payments following a distribution event described in Section 6.01(b) shall commence at the time speci ied
in Section 6.01(a) and 6.01(b) of the Adoption Agreement. If permitted by Section 6.01(g) of the Adoption Agreement, a
Participant may elect, at least twelve months before a scheduled distribution event, to delay the payment date for a minimum
period of sixty months from the originally scheduled date of payment, provided the election does not take effect for at least
twelve months from the date on which the election is made. The distribution election change must be made in accordance with
procedures and rules established by the Administrator. The Participant may, at the same time the date of payment is deferred,
change the form of payment but such change in the form of payment may not effect an acceleration of payment in violation of
Code Section 409A or the provisions of Treas. Reg. § 1.409A-2(b). For purposes of this Section 9.2, a series of installment
payments is always treated as a single payment and not as a series of separate payments.
Payments made on the payment date speci ied in the Plan, or on a later date within the same taxable year of the Participant or
Bene iciary, or, if later, by the ifteenth (15th) day of the third (3 ) calendar month following the payment date speci ied in the
Plan shall be treated as having been made on the payment date; provided, however, that the Participant or Bene iciary is not
permitted, directly or indirectly, to designate the taxable year of the payment. In addition, payments made no earlier than thirty
(30) days before the designated payment date will likewise be treated as having been made on the payment date so long as the
Participant or Bene iciary is not permitted, directly or indirectly, to designate the taxable year of the payment. The foregoing
shall be administered in compliance with the provisions of Treas. Reg. § l.409A- 3(d), which may authorize other instances in
which payments made after the payment date shall be treated as having been made on the payment date.
9.3. Unforeseeable Emergency
A Participant may request a distribution of all or any portion of his or her vested Account due to an Unforeseeable Emergency if
the Plan Sponsor has elected to permit Unforeseeable Emergency withdrawals under Section 8.01(a) of the Adoption Agreement.
The request must be in writing and must be submitted to the Administrator along with evidence that the circumstances
constitute an Unforeseeable Emergency. The Administrator has the discretion to require whatever evidence it deems necessary
to determine whether a distribution is warranted, and may require the Participant to certify that the need cannot be met from
other sources reasonably available to the Participant. Whether a Participant has incurred an Unforeseeable Emergency will be
determined by the Administrator on the basis of the relevant facts and circumstances in its sole discretion, but, in no event, will
an Unforeseeable Emergency be deemed to exist if the hardship can be relieved: (a) through reimbursement or compensation by
insurance or otherwise, (b) by liquidation of the Participant’s assets to the extent such liquidation would not itself cause severe
inancial hardship or (c) by cessation of deferrals under the Plan. A distribution due to an Unforeseeable Emergency must be
limited to the amount reasonably necessary to satisfy the emergency need, taking into account the additional compensation that
is available to the Participant as the result of any cancellation of deferrals under the Plan, and may include any amounts
necessary to pay any federal, state, foreign or local income taxes and penalties reasonably anticipated to result from the
distribution. The distribution will be made in the
rd
Article 9-1
-- 133 of 225 --
form of a single lump sum cash payment. If permitted by Section 8.01(b) of the Adoption Agreement, a Participant’s deferral
elections for the remainder of the Plan Year may be cancelled upon a withdrawal due to an Unforeseeable Emergency. If the
payment of all or any portion of the Participant’s vested Account is being delayed in accordance with Section 9.6 at the time he or
she experiences an Unforeseeable Emergency, the amount being delayed shall not be subject to the provisions of this Section 9.3
until the expiration of the six month period of delay required by Section 9.6.
9.4. Payment Election Overrides
If the Plan Sponsor has elected one or more payment election overrides in accordance with Section 6.01(d) of the Adoption
Agreement, the following provisions apply. Upon the occurrence of the irst event selected by the Plan Sponsor, the remaining
vested amount credited to the Participant’s Account shall be paid in the form designated to the Participant or his or her
Bene iciary regardless of whether the Participant had made different elections of time and/or form of payment or whether the
Participant was receiving installment payments at the time of the event.
9.5. Cashouts of Amounts Not Exceeding Stated Limit
If the vested amount credited to the Participant’s Account does not exceed the limit established for this purpose by the Plan
Sponsor in Section 6.01(e) of the Adoption Agreement at the time he or she incurs a Separation from Service for any reason, the
Employer shall distribute such amount to the Participant at the time speci ied in Section 6.01(a) of the Adoption Agreement in a
single lump sum cash payment following such Separation from Service regardless of whether the Participant had made different
elections of time or form of payment as to the vested amount credited to his or her Account or whether the Participant was
receiving installments at the time of such termination. A Participant’s Account, for purposes of this Section 9.5, shall include any
amounts described in Section 1.3.
9.6. Required Delay in Payment (Including to Key Employees)
Except as otherwise provided in this Section 9.6, a distribution made on account of Separation from Service to any Participant
(including to any Participant who is a Key Employee as of the date of his or her Separation from Service) shall not be made before
the date which is six months after the Separation from Service.
The six-month delay does not apply to payments described in Section 9.9(a), (b) or (d) or to payments that occur after the death
of the Participant. If the payment of all or any portion of the Participant’s vested Account is being delayed in accordance with this
Section 9.6 at the time he or she incurs a Disability which would otherwise require a distribution under the terms of the Plan, no
amount shall be paid until the expiration of the six month period of delay required by this Section 9.6.
Article 9-2
-- 134 of 225 --
9.7. Change in Control
If the Plan Sponsor has elected to permit distributions upon a Change in Control, the following provisions shall apply. A
distribution made upon a Change in Control will be made at the time speci ied in Section 6.01(a) of the Adoption Agreement in
the form elected by the Participant in accordance with the procedures described in Article 4. Alternatively, if the Plan Sponsor
has elected in accordance with Section 11.02 of the Adoption Agreement to require distributions upon a Change in Control, the
Participant’s remaining vested Account shall be paid to the Participant or the Participant’s Bene iciary at the time speci ied in
Section 6.01(a) of the Adoption Agreement as a single lump sum payment. A Change in Control, for purposes of the Plan, will
occur upon a change in the ownership of the Plan Sponsor, a change in the effective control of the Plan Sponsor or a change in the
ownership of a substantial portion of the assets of the Plan Sponsor, but only if elected by the Plan Sponsor in Section 11.03 of
the Adoption Agreement. The Plan Sponsor, for this purpose, includes any corporation identi ied in this Section 9.7. However, an
event constitutes a Change in Control with respect to a Participant only if the Participant performs services for the Plan Sponsor
at the time of the Change in Control, or the Participant's relationship to the Plan Sponsor otherwise satis ies the requirements of
Treas. Reg. § 1.409A-3(i)(5)(ii). All distributions made in accordance with this Section 9.7 are subject to the provisions of Section
9.6.
If a Participant continues to make deferrals in accordance with Article 4 after he or she has received a distribution due to a
Change in Control, the residual amount payable to the Participant shall be paid at the time and in the form speci ied in the
elections he or she makes in accordance with Article 4 or upon his or her death or Disability as provided in Article 8.
Whether a Change in Control has occurred will be determined by the Administrator in accordance with the rules and de initions
set forth in this Section 9.7. The determination as to the occurrence of a Change in Control shall be based on objective facts and in
accordance with the requirements of Code Section 409A. A distribution to the Participant will be treated as occurring upon a
Change in Control if the Plan Sponsor terminates the Plan in accordance with Section 10.2 and distributes the Participant’s
bene its within twelve (12) months of a Change in Control as provided in Section 10.3.
(a) Relevant Corporations. To constitute a Change in Control for purposes of the Plan, the event must relate to: (i) the
corporation for whom the Participant is performing services at the time of the Change in Control, (ii) the corporation that
is liable for the payment of the Participant’s bene its under the Plan (or all corporations liable if more than one
corporation is liable) but only if either the deferred compensation is attributable to the performance of services by the
Participant for such corporation (or corporations) or there is a bona ide business purpose for such corporation (or
corporations) to be liable for such payment and, in either case, no signi icant purpose of making such corporation (or
corporations) liable for such payment is the avoidance of federal income tax, or (iii) a corporation that is a majority
shareholder of a corporation identi ied in (i) or (ii), or any corporation in a chain of corporations in which each
corporation is a majority shareholder of another corporation in the chain, ending in a corporation identi ied in (i) or (ii).
A majority shareholder is de ined as a shareholder owning more than ifty percent (50%) of the total fair market value
and voting power of such corporation.
(b) Stock Ownership. Code Section 318(a) applies for purposes of determining stock ownership. Stock underlying a vested
option is considered owned by the individual who owns the vested option (and the stock underlying an unvested option
is not considered owned by the individual who holds the unvested option). If, however, a vested option is exercisable for
stock that is not substantially vested (as de ined by Treas. Reg. § 1.83-3(b) and (j)) the stock underlying the option is not
treated as owned by the individual who holds the option.
(c) Change in the Ownership of a Corporation. A change in the ownership of a corporation occurs on the date that any one
person, or more than one person acting
Article 9-3
-- 135 of 225 --
as a group, acquires ownership of stock of the corporation that, together with stock held by such person or group,
constitutes more than ifty percent (50%) of the total fair market value or total voting power of the stock of such
corporation. If any one person or more than one person acting as a group is considered to own more than ifty percent
(50%) of the total fair market value or total voting power of the stock of a corporation, the acquisition of additional stock
by the same person or persons is not considered to cause a change in the ownership of the corporation (or to cause a
change in the effective control of the corporation as discussed below in Section 9.7(d)). An increase in the percentage of
stock owned by any one person, or persons acting as a group, as a result of a transaction in which the corporation
acquires its stock in exchange for property will be treated as an acquisition of stock. Section 9.7(c) applies only when
there is a transfer of stock of a corporation (or issuance of stock of a corporation) and stock in such corporation remains
outstanding after the transaction. For purposes of this Section 9.7(c), persons will not be considered to be acting as a
group solely because they purchase or own stock of the same corporation at the same time or as a result of a public
offering. Persons will, however, be considered to be acting as a group if they are owners of a corporation that enters into a
merger, consolidation, purchase or acquisition of stock or similar business transaction with the corporation. If a person,
including an entity, owns stock in both corporations that enter into a merger, consolidation, purchase or acquisition of
stock or similar transaction, such shareholder is considered to be acting as a group with other shareholders in a
corporation only with respect to ownership in that corporation prior to the transaction giving rise to the change and not
with respect to the ownership interest in the other corporation.
(d) Change in the Effective Control of a Corporation. A change in the effective control of a corporation occurs on the date that
either (i) any one person, or more than one person acting as a group, acquires (or has acquired during the twelve month-
period ending on the date of the most recent acquisition by such person or persons) ownership of stock of the
corporation possessing forty percent (40%) or more of the total voting power of the stock of such corporation or (ii) a
majority of members of the corporation’s Board of Directors is replaced during any twelve month period by Directors
whose appointment or election is not endorsed by a majority of the members of the corporation’s Board of Directors
prior to the date of the appointment or election, provided that for purposes of this paragraph (ii), the term corporation
refers solely to the relevant corporation identi ied in Section 9.7(a) for which no other corporation is a majority
shareholder for purposes of Section 9.7(a). In the absence of an event described in Section 9.7(d)(i) or (ii), a change in
the effective control of a corporation will not have occurred. A change in effective control may also occur in any
transaction in which either of the two corporations involved in the transaction has a change in the ownership of such
corporation as described in Section 9.7(c) or a change in the ownership of a substantial portion of the assets of such
corporation as described in Section 9.7(e). If any one person, or more than one person acting as a group, is considered to
effectively control a corporation within the meaning of this Section 9.7(d), the acquisition of additional control of the
corporation by the same person or persons is not considered to cause a change in the effective control of the corporation
or to cause a change in the ownership of the corporation within the meaning of Section 9.7(c). For purposes of this
Section 9.7(d), persons will or will not be considered to be acting as a group in accordance with rules similar to those set
forth in Section 9.7(c) with the following exception. If a person, including an entity, owns stock in both corporations that
enter into a merger, consolidation, purchase or acquisition of stock or similar transaction, such shareholder is considered
to be acting as a group with other shareholders in a corporation only with respect to the ownership in that corporation
prior to the transaction giving rise to the change and not with respect to the ownership interest in the other corporation.
Article 9-4
-- 136 of 225 --
(e) Change in the Ownership of a Substantial Portion of a Corporation’s Assets. A change in the ownership of a substantial
portion of a corporation’s assets occurs on the date that any one person, or more than one person acting as a group (as
determined in accordance with rules similar to those set forth in Section 9.7(d)), acquires (or has acquired during the
twelve month period ending on the date of the most recent acquisition by such person or persons) assets from the
corporation that have a total gross fair market value equal to or more than forty percent (40%) of the total gross fair
market value of all of the assets of the corporation immediately prior to such acquisition or acquisitions. For this purpose,
gross fair market value means the value of the assets of the corporation or the value of the assets being disposed of
determined without regard to any liabilities associated with such assets. There is no Change in Control event under this
Section 9.7(e) when there is a transfer to an entity that is controlled by the shareholders of the transferring corporation
immediately after the transfer. A transfer of assets by a corporation is not treated as a change in ownership of such assets
if the assets are transferred to (i) a shareholder of the corporation (immediately before the asset transfer) in exchange for
or with respect to its stock, (ii) an entity, ifty percent (50%) or more of the total value or voting power of which is
owned, directly or indirectly, by the corporation, (iii) a person, or more than one person acting as a group, that owns,
directly or indirectly, ifty percent (50%) or more of the total value or voting power of all the outstanding stock of the
corporation, or (iv) an entity, at least ifty (50%) of the total value or voting power of which is owned, directly or
indirectly, by a person described in Section 9.7(e)(iii). For purposes of the foregoing, and except as otherwise provided, a
person’s status is determined immediately after the transfer of assets.
Article 9-5
-- 137 of 225 --
9.8. Permissible Delays in Payment
Distributions may be delayed beyond the date payment would otherwise occur in accordance with the provisions of Articles 8
and 9, provided such delay would be permitted by the provisions of Treas. Reg. § 1.409A-2(b)(7), including the following events
(as long as the Employer treats all payments to similarly situated Participants on a reasonably consistent basis):
(a) The Employer may delay payment if it reasonably anticipates that its deduction with respect to such payment would be
limited or eliminated by the application of Code Section 162(m). Payment must be made during the Participant’s irst
taxable year in which the Employer reasonably anticipates, or should reasonably anticipate, that if the payment is made
during such year the deduction of such payment will not be barred by the application of Code Section 162(m) or during
the period beginning with the Participant’s Separation from Service and ending on the later of the last day of the
Employer’s taxable year in which the Participant separates from service or the 15 day of the third month following the
Participant’s Separation from Service. If a scheduled payment to a Participant is delayed in accordance with this Section
9.8(a), all scheduled payments to the Participant that could be delayed in accordance with this Section 9.8(a) will also be
delayed.
(b) The Employer may also delay payment if it reasonably anticipates that the making of the payment will violate federal
securities laws or other applicable laws provided payment is made at the earliest date on which the Employer reasonably
anticipates that the making of the payment will not cause such violation.
(c) The Employer reserves the right to amend the Plan to provide for a delay in payment upon such other events and
conditions as the Secretary of the Treasury may prescribe in generally applicable guidance published in the Internal
Revenue Bulletin.
9.9. Permitted Acceleration of Payment
The Employer may permit acceleration of the time or schedule of any payment or amount scheduled to be paid pursuant to a
payment under the Plan provided such acceleration would be permitted by the provisions of Treas. Reg. § 1.409A-3(j)(4),
including the following events:
(a) Domestic Relations Order. A payment may be accelerated if such payment is made to an alternate payee pursuant to and
following the receipt and quali ication of a domestic relations order as de ined in Code Section 414(p).
(b) Compliance with Ethics Agreement and Legal Requirements. A payment may be accelerated as may be necessary to
comply with ethics agreements with the federal government or as may be reasonably necessary to avoid the violation of
federal, state, local or foreign ethics law or con licts of laws, in accordance with the requirements of Code Section 409A.
(c) De Minimis Amounts. A payment may be accelerated if (i) the amount of the payment is not greater than the applicable
dollar amount under Code Section 402(g)(1)(B) and (ii) at the time the payment is made, the amount constitutes the
Participant’s entire interest under the Plan and all other plans that are aggregated with the Plan under Treas. Reg. §
1.409A-1(c)(2).
(d) FICA Tax. A payment may be accelerated to the extent required to pay the Federal Insurance Contributions Act tax
imposed under Code Sections 3101, 3121(a) and 3121(v)(2) of the Code with respect to compensation deferred under
the Plan (the “FICA Amount”). Additionally, a payment may be accelerated to pay the income tax on wages imposed under
Code Section 3401 of the Code on the FICA Amount and to pay the additional income tax at source on wages attributable
to the pyramiding
th
Article 9-6
-- 138 of 225 --
Code Section 3401 wages and taxes. The total payment under this subsection (d) may not exceed the aggregate of the
FICA Amount and the income tax withholding related to the FICA Amount.
(e) Section 409A Additional Tax. A payment may be accelerated if the Plan fails to meet the requirements of Code Section
409A; provided that such payment may not exceed the amount required to be included in income as a result of the failure
to comply with the requirements of Code Section 409A.
(f) Offset. A payment may be accelerated in the Employer’s discretion as satisfaction of a debt of the Participant to the
Employer, where such debt is incurred in the ordinary course of the service relationship between the Participant and the
Employer, the entire amount of the reduction in any of the Employer’s taxable years does not exceed $5,000 and the
reduction is made at the same time and in the same amount as the debt otherwise would have been due and collected
from the Participant.
(g) Other Events. A payment may be accelerated in the Administrator’s discretion in connection with such other events and
conditions as permitted by Code Section 409A.
Article 9-7
-- 139 of 225 --
Article 10 - Amendment and Termination
10.1. Amendment by Plan Sponsor
The Plan Sponsor reserves the right to amend the Plan (for itself and each Employer) through action of its Board of Directors or
other authorized person or body. No amendment can directly or indirectly deprive any current or former Participant or
Bene iciary of all or any portion of his or her Account which had accrued and vested prior to the amendment.
10.2. Plan Termination Following Change in Control or Corporate Dissolution
If so elected by the Plan Sponsor in 11.01 of the Adoption Agreement, the Plan Sponsor reserves the right to terminate the Plan
and distribute all amounts credited to all Participant Accounts within the 30 days preceding or the twelve months following a
Change in Control as determined in accordance with the rules set forth in Section 9.7 through action of its Board of Directors or
other authorized person or body. For this purpose, the Plan will be treated as terminated only if all agreements, methods,
programs and other arrangements sponsored by the Related Employer immediately after the Change in Control which are
treated as a single plan under Treas. Reg. § 1.409A-1(c)(2) are also terminated so that all Participants under the Plan and all
similar arrangements are required to receive all amounts deferred under the terminated arrangements within twelve months of
the date the Plan Sponsor irrevocably takes all necessary action to terminate the arrangements. In addition, the Plan Sponsor
reserves the right to terminate the Plan within twelve months of a corporate dissolution taxed under Code Section 331 or with
the approval of a bankruptcy court pursuant to Section 503(b)(1)(A) of Title 11of the United States Code provided that amounts
deferred under the Plan are included in the gross incomes of Participants in the latest of (a) the calendar year in which the
termination and liquidation occurs, (b) the irst calendar year in which the amount is no longer subject to a substantial risk of
forfeiture or (c) the irst calendar year in which payment is administratively practicable.
10.3. Other Plan Terminations
The Plan Sponsor retains the discretion to terminate the Plan through action of its Board of Directors or other authorized person
or body if (a) all arrangements sponsored by the Plan Sponsor that would be aggregated with any terminated arrangement under
Code Section 409A and Treas. Reg. § 1.409A-1(c)(2) are terminated, (b) no payments other than payments that would be payable
under the terms of the arrangements if the termination had not occurred are made within twelve months of the termination of
the arrangements, (c) all payments are made within twenty-four months of the date the Plan Sponsor takes all necessary action
to irrevocably terminate and liquidate the arrangements, (d) the Plan Sponsor does not adopt a new arrangement that would be
aggregated with any terminated arrangement under Code Section 409A and the regulations thereunder at any time within the
three year period following the date of termination of the arrangement and (e) the termination does not occur proximate to a
downturn in the inancial health of the Plan Sponsor. The Plan Sponsor also reserves the right to amend the Plan to provide that
termination of the Plan will occur under such conditions and events as may be prescribed by the Secretary of the Treasury in
generally applicable guidance published in the Internal Revenue Bulletin.
Article 10-1
-- 140 of 225 --
Article 11 - The Trust
11.1. Establishment of Trust
The Plan Sponsor may but is not required to establish a trust to hold amounts which the Plan Sponsor may contribute from time
to time to correspond to some or all amounts credited to Participants under Section 6.2. In the event that the Plan Sponsor
wishes to establish a trust to provide a source of funds for the payment of Plan bene its, any such trust shall be constructed to
constitute an unfunded arrangement that does not affect the status of the Plan as an unfunded plan for purposes of Title I of
ERISA and the Code. If the Plan Sponsor elects to establish a trust in accordance with Section 10.01 of the Adoption Agreement,
the provisions of Sections 11.2 and 11.3 shall become operative.
11.2. Trust
Any trust established by the Plan Sponsor shall be between the Plan Sponsor and a trustee pursuant to a separate written
agreement under which assets are held, administered and managed, subject to the claims of the Plan Sponsor’s creditors in the
event of the Plan Sponsor’s insolvency. The Plan Sponsor must notify the trustee in the event of a bankruptcy or insolvency.
11.3. Investment of Trust Funds
Any amounts contributed to the trust by the Plan Sponsor shall be invested by the trustee in accordance with the provisions of
the trust and the instructions of the Administrator. Trust investments need not re lect the hypothetical investments selected by
Participants under Section 7.1 for the purpose of adjusting Accounts and the earnings or investment results of the trust need not
affect the hypothetical investment adjustments to Participant Accounts under the Plan.
Article 11-1
-- 141 of 225 --
Article 12 - Plan Administration
12.1. Powers and Responsibilities of the Administrator
The Administrator has the full power and the full responsibility to administer the Plan in all of its details, subject, however, to the
applicable requirements of ERISA. The Administrator’s powers and responsibilities include, but are not limited to, the following:
(a) To make and enforce such rules and procedures as it deems necessary or proper for the ef icient administration of the
Plan;
(b) To interpret the Plan, its interpretation thereof to be inal, except as provided in Section 12.2, on all persons claiming
bene its under the Plan;
(c) To decide all questions concerning the Plan and the eligibility of any person to participate in the Plan;
(d) To administer the claims and review procedures speci ied in Section 12.2;
(e) To compute the amount of bene its which will be payable to any Participant, former Participant or Bene iciary in
accordance with the provisions of the Plan;
(f) To determine the person or persons to whom such bene its will be paid;
(g) To authorize the payment of bene its;
(h) To make corrections and recover the overpayment of any bene its;
(i) To comply with the reporting and disclosure requirements of Part 1 of Subtitle B of Title I of ERISA;
(j) To appoint such agents, counsel, accountants and consultants as may be required to assist in administering the Plan;
(k) To sever from the Plan or any deferral agreement any provision or exercise of a right that otherwise would result in a
violation of Code Section 409A; and
(l) By written instrument, to allocate and delegate its responsibilities, including the formation of an administrative
committee to administer the Plan.
Within one hundred and twenty (120) days following a Change in Control, the individuals who comprised the Committee (as
de ined in the Adoption Agreement) immediately prior to the Change in Control (whether or not such individuals are members of
the Committee following the Change in Control) may, by written consent of the majority of such individuals, appoint an
independent third party administrator to perform any or all of the Plan Sponsor's duties as Administrator as described in this
Section, including, without limitation, the power to determine any questions arising in connection with the administration or
interpretation of the Plan and the power to make bene it entitlement determinations. Upon and after the effective date of such
appointment, (i) the Plan Sponsor must pay all reasonable administrative expenses and fees of such new administrator and (ii)
such new administrator may only be terminated with the written consent of the majority of Participants with an Account balance
in the Plan as of the date of such proposed termination.
The decision or action of the Plan Sponsor, or in the event of a Change in Control and actions pursuant to any new administrator,
in respect of any question arising out of or in connection with the administration, interpretation and application of the Plan and
the rules and regulations thereunder shall be inal and conclusive and binding upon all persons having any interest in the Plan.
Article 12-1
-- 142 of 225 --
12.2. Claims and Review Procedures
(a) Claims Procedure. If any person believes he or she is being denied any rights or bene its under the Plan, such person may
ile a claim in writing with the Administrator. Notice of a claim for payments shall be delivered to the Administrator
within 90 days of the latest date upon which the payment could have been timely made in accordance with the terms of
the Plan and Code Section 409A, and if not paid, such person must ile a claim under this Article 12 not later than 180
days after such latest date.
If any such claim is wholly or partially denied, the Administrator will notify such person of its decision in writing. Such
noti ication will contain (i) speci ic reasons for the denial, (ii) speci ic reference to pertinent Plan provisions, (iii) a
description of any additional material or information necessary for such person to perfect such claim and an explanation
of why such material or information is necessary and (iv) a description of the Plan’s review procedures and the time
limits applicable to such procedures, including a statement of the person’s right to bring a civil action under Section
502(a) of ERISA following an adverse decision on review. If the claim involves a Disability, the denial must also include (i)
a statement that the Administrator will provide to such person, upon request and free of charge, a copy of any internal
rule, guideline, protocol or other similar criterion that was relied upon in making the decision and (ii) a discussion of the
decision, including an explanation of the basis for disagreeing with or not following (a) the views of health care
professionals treating such person or vocational professionals who evaluated such person that were presented by such
person to the Plan, (b) the views of medical or vocational experts whose advice was obtained on behalf of the Plan in
connection with the adverse bene it determination, regardless of whether the advice was relied on in making the
determination or (c) a disability determination regarding such person made by the Social Security Administration that
was presented by such person to the Plan.
Such noti ication will be given within 90 days (45 days in the case of a claim regarding Disability) after the claim is
received by the Administrator. The Administrator may extend the period for providing the noti ication by 90 days (30
days in the case of a claim regarding Disability, which may be extended an additional 30 days) if special circumstances
require an extension of time for processing the claim and if written notice of such extension, the circumstances requiring
the extension and the date by which the Administrator expects to make a decision is given to such person within the
initial 90 day period (45 day period in the case of a claim regarding Disability). Further, in the case of a claim regarding
Disability, if the Administrator determines that a decision cannot be made within the irst extension period due to
matters beyond the control of the Administrator, the Administrator may extend the period for providing the noti ication
by an additional 30 days if written notice of such extension, the circumstances requiring the extension, the date by which
the Administrator expects to make a decision, the speci ic standards on which such entitlement to a bene it is based, the
unresolved issues that prevent a decision on the claim and any additional information needed to resolve those issues is
given to such person within the initial 30-day extension. Such person will be provided a minimum of 45 days to submit
any necessary additional information to the Administrator. In the event that a 30-day extension is necessary due to such
person’s failure to submit information necessary to decide a claim, the period for furnishing a notice of decision shall be
tolled from the date on which the notice of the extension is sent to such person until the earlier of the date such person
responds to the request for additional information or the response deadline. If such noti ication is not given within the
proper period, the claim will be considered denied as of the last day of such period and such person may request a review
of his or her claim.
(b) Review Procedure. Within 60 days (180 days in the case of a claim regarding Disability) after the date on which a person
receives a written noti ication of
Article 12-2
-- 143 of 225 --
complete or partial denial of claim (or, if written noti ication is not provided, within 60 days (180 days in the case of a
claim regarding Disability) of the date denial is considered to have occurred), such person (or his or her duly authorized
representative) may ile a written request with the Administrator (but in the case of a claim regarding Disability, the
Committee exclusive of the person who made the initial adverse decision or such person’s subordinate) for a review of
his or her denied claim. If such person timely requests a review of the denied claim, such person may review, upon
request and free of charge, copies of all documents, records and other information relevant to the denial and may submit
written comments, documents, records and other information relevant to the claim to the Committee . All written
comments, document, records and other information shall be considered “relevant” if the information (i) was relied upon
in making a bene its determination, (ii) was submitted, considered or generated in the course of making a bene its
decision regardless of whether it was relied upon to make the decision or (iii) demonstrates compliance with
administrative processes and safeguards established for making bene it decisions. The Committee may, in its sole
discretion and if it deems appropriate or necessary, decide to hold a hearing with respect to the claim appeal.
The Committee will take into account comments, documents, records and other information submitted by the person
relating to the claim without regard to whether such information was submitted or considered in the initial bene it
determination. In the case of a claim regarding Disability, the Committee will (i) not afford deference to the initial denial
of the claim, (ii) consult a medical professional who has appropriate training and experience in the ield of medicine
relating to such person’s Disability and who was neither consulted as part of the initial denial nor is the subordinate of
such individual and (iii) identify the medical or vocational experts whose advice was obtained with respect to the initial
bene it denial, without regard to whether the advice was relied upon in making the decision.
The Committee will notify such person of its decision in writing. Such noti ication will be written in a manner calculated
to be understood by such person and will contain (i) speci ic reasons for the decision, (ii) speci ic references to pertinent
Plan provisions, (iii) a statement that the person is entitled to receive, upon request and free of charge, reasonable access
to and copies of all documents, records or other information relevant (as de ined above) to such person’s claim and (iv) a
statement describing any voluntary appeals procedures offered by the Plan and a statement of such person’s right to
bring a civil action under Section 502(a) of ERISA following an adverse decision on review. In the case of a claim
regarding Disability, the noti ication will also contain a statement that the Committee will provide, upon request and free
of charge, (i) any internal rule, guideline, protocol or other similar criterion relied upon in making the decision, (ii) any
medical opinion relied upon to make the decision, (iii) the required statement under Section 2560.503-1(i)(5)(iii) of the
Department of Labor regulations and (iv) a discussion of the decision, including an explanation of the basis for
disagreeing with or not following (a) the views of health care professionals treating such person, or vocational
professionals who evaluated such person, that were presented by such person to the Plan, (b) the views of medical or
vocational experts whose advice was obtained on behalf of the Plan in connection with the appeal of the adverse bene it
determination, regardless of whether the advice was relied upon in making the determination or (c) a disability
determination regarding such person made by the Social Security Administration that was presented by such person to
the Plan.
The decision on review will be made within 60 days (45 days in the case of a claim regarding Disability) following receipt
of the appeal. The Committee may extend the period for making the decision on review by 60 days (45 days in the case of
a claim regarding Disability) if special circumstances require an extension of time for processing the request such as an
election by the Committee to hold a hearing, and if written notice of such extension, the circumstances requiring the
extension and the date by which the Committee expects to make a decision is given to such person
Article 12-3
-- 144 of 225 --
within the initial 60-day period (45 days in the case of a claim regarding Disability). If the decision on review is not made
within such period, the claim will be considered denied.
Before issuing any decision with respect to a claim involving Disability, the Committee will provide to the person, free of
charge, the following information as soon as possible and suf iciently in advance of the date on which the response is
required to be provided to the person to allow the person a reasonable opportunity to respond prior to the due date of
the response:
(i) Any new or additional evidence considered, relied upon, or generated by the Committee or other person making
the decision; and
(ii) A new or additional rationale if the decision will be based on that rationale.
(c) Review Procedure Upon Change in Control. Upon a Change in Control, the Committee, as constituted immediately prior to
such Change in Control, shall continue to act as the Committee. Upon such Change in Control, the Plan Sponsor may not
remove any member of the Committee but may replace resigning members if 2/3rds of the members of the Committee, as
constituted immediately prior to such Change in Control, and a majority of Participants and Bene iciaries with Account
balances consent to the replacement. The Committee shall have the exclusive authority at the appeals stage to interpret
the terms of the Plan and resolve appeals under the claims procedures.
(d) Exhaustion of Claims Procedures and Right to Bring Legal Claim. A claimant may not bring any legal action, including
commencement of any arbitration, relating to a claim for bene its under the Plan unless and until the claimant has
followed the claims procedures under the Plan and exhausted his or her administrative remedies under such claims
procedures. No such action at law or equity shall be brought more than one year after the Committee’s af irmation of a
denial of a claim, or, if no appeal is iled by the applicable appeals deadline, 12 months following the appeals deadline.
If a Participant or Bene iciary prevails in a legal proceeding brought under the Plan to enforce the rights of such
Participant or any other similarly situated Participant or Bene iciary, in whole or in part, the Plan Sponsor shall
reimburse such Participant or Bene iciary for all reasonable legal costs, expenses, attorneys' fees and such other
reasonable liabilities incurred as a result of such proceedings. If the legal proceeding is brought in connection with a
Change in Control, or a "change in control" as de ined in a trust described in Section 11.1 (if applicable), the Participant
or Bene iciary may ile a claim directly with the trustee for reimbursement of such costs, expenses and fees. For purposes
of the preceding sentence, the amount of the claim shall be treated as if it were an addition to the Participant's or
Bene iciary's Account balance.
(e) Discretion of Committee. All interpretations, determinations and decisions of the Committee with respect to any claim
shall be made in its sole discretion, and shall be inal and conclusive.
(f) Arbitration. If, prior to a Change in Control, any claim or controversy between the Plan Sponsor and a Participant or
Bene iciary is not resolved through the claims procedure set forth in this Article 12, such claim shall be submitted to and
resolved exclusively by expedited binding arbitration by a single arbitrator. Arbitration shall be conducted in accordance
with the following procedures.
The complaining party shall promptly send written notice to the other party identifying the matter in dispute and the
proposed remedy. Following the giving of such notice, the parties shall meet and attempt in good faith to resolve the
matter. In the event the parties are unable to resolve the matter within 21 days, the parties
Article 12-4
-- 145 of 225 --
shall meet and attempt in good faith to select a single arbitrator acceptable to both parties. If a single arbitrator is not
selected by mutual consent within ten business days following the giving of the written notice of dispute, an arbitrator
shall be selected from a list of nine persons each of whom shall be an attorney who is either engaged in the active practice
of law or a recognized arbitrator and who, in either event, is experienced in serving as an arbitrator in disputes between
employers and employees, which list shall be provided by the main of ice of either Judicial Arbitration and Mediation
Services, Inc. (“JAMS”), the American Arbitration Association ("AAA") or the Federal Mediation and Conciliation Service. If,
within three business days of the parties' receipt of such list, the parties are unable to agree on an arbitrator from the list,
then the parties shall each strike names alternatively from the list, with the irst to strike being determined by the lip of a
coin. After each party has had four strikes, the remaining name on the list shall be the arbitrator. If such person is unable
to serve for any reason, the parties shall repeat this process until an arbitrator is selected.
Unless the parties agree otherwise, within 60 days of the selection of the arbitrator, a hearing shall be conducted before
such arbitrator at a time and a place agreed upon by the parties. In the event the parties are unable to agree upon the
time or place of the arbitration, the time and place shall be designated by the arbitrator after consultation with the
parties. Within 30 days of the conclusion of the arbitration hearing, the arbitrator shall issue an award, accompanied by a
written decision explaining the basis for the arbitrator's award.
In any arbitration hereunder, the Plan Sponsor shall pay all administrative fees of the arbitration and all fees of the
arbitrator. Each party shall pay its own attorneys’ fees, cost and expenses, unless the arbitrator orders otherwise. The
prevailing party in such arbitration, as determined by the arbitrator, and in any enforcement or other court proceedings,
shall be entitled, to the extent permitted by law, to reimbursement from the other party for all of the prevailing party’s
costs (including but not limited to the arbitrator’s compensation), expenses and attorneys’ fees. The arbitrator shall have
no authority to add to or to modify this Plan, shall apply all applicable law and shall have no lesser and no greater
remedial authority than would a court of law resolving the same claim or controversy. The arbitrator shall, upon an
appropriate motion, dismiss any claim without an evidentiary hearing if the party bringing the motion establishes that it
would be entitled to summary judgment if the matter had been pursued in court litigation.
The parties shall be entitled to discovery as follows: Each party may take no more than three depositions. The Plan
Sponsor may depose the Participant or Bene iciary plus two other witnesses, and the Participant or Bene iciary may
depose the Plan Sponsor, pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, plus two other witnesses.
Each party may make such reasonable document discovery requests as are allowed in the discretion of the arbitrator.
The decision of the arbitrator shall be inal, binding, and non-appealable, and may be enforced as a inal judgment in any
court of competent jurisdiction.
This arbitration provision of the Plan shall extend to claims against any parent, subsidiary or af iliate of each party, and,
when acting within such capacity, any of icer, director, shareholder, Participant, Bene iciary or agent of any party or of any
of the above and shall apply as well to claims arising out of state and federal statutes and local ordinances as well as to
claims arising under the common law or under this Plan.
Notwithstanding the foregoing, and unless otherwise agreed between the parties, either party may apply to a court for
provisional relief, including a temporary restraining order or preliminary injunction, on the grounds that the arbitration
award to which the applicant may be entitled may be rendered ineffectual without provisional relief.
Article 12-5
-- 146 of 225 --
Any arbitration hereunder shall be conducted in accordance with the Federal Arbitration Act, provided, however, that, in
the event of any inconsistency between the rules and procedures of the Act and the terms of this Plan, the terms of this
Plan shall prevail.
If any of the provisions of this Section are determined to be unlawful or otherwise unenforceable, in the whole part, such
determination shall not affect the validity of the remainder of this Section and this Section shall be reformed to the extent
necessary to carry out its provisions to the greatest extent possible and to insure that the resolution of all con licts
between the parties, including those arising out of statutory claims, shall be resolved by neutral, binding arbitration. If a
court should ind that the provisions of this Section are not absolutely binding, then the parties intend any arbitration
decision and award to be fully admissible in evidence in any subsequent action, given great weight by any inder of fact
and treated as determinative to the maximum extent permitted by law.
The parties do not agree to arbitrate any putative class action or any other representative action. The parties agree to
arbitrate only the claims(s) of a single Participant or Bene iciary.
(g) Arbitration Upon Change in Control. If, upon the occurrence of a Change in Control, any dispute, controversy or claim
arises between a Participant or Bene iciary and the Plan Sponsor out of or relating to or concerning the provisions of the
Plan, such dispute, controversy or claim shall be inally settled by a court of competent jurisdiction which,
notwithstanding any other provision of the Plan, shall apply a de novo standard of review to any determination made by
the Plan Sponsor or the Committee.
12.3. Plan Administrative Costs
All reasonable costs and expenses (including legal, accounting and employee communication fees) incurred by the Administrator
in administering the Plan shall be paid by the Plan to the extent not paid by the Employer.
Article 12-6
-- 147 of 225 --
Article 13 - Miscellaneous
13.1. Unsecured General Creditor of the Employer
Participants and their Bene iciaries, heirs, successors and assigns shall have no legal or equitable rights, interests or claims in
any property or assets of the Employer. For purposes of the payment of bene its under the Plan, any and all of the Employer’s
assets shall be, and shall remain, the general, unpledged, unrestricted assets of the Employer. Each Employer's obligation under
the Plan shall be merely that of an unfunded and unsecured promise to pay money in the future.
13.2. Employer’s Liability
Each Employer’s liability for the payment of bene its under the Plan shall be de ined only by the Plan and by the deferral
agreements entered into between a Participant and the Employer. An Employer shall have no obligation or liability to a
Participant under the Plan except as provided by the Plan and a deferral agreement or agreements. An Employer shall have no
liability to Participants employed by other Employers.
13.3. Limitation of Rights
Neither the establishment of the Plan, nor any amendment thereof, nor the creation of any fund or account, nor the payment of
any bene its, will be construed as giving to the Participant or any other person any legal or equitable right against the Employer,
the Plan or the Administrator, except as provided herein; and in no event will the terms of employment or service of the
Participant be modi ied or in any way affected hereby.
13.4. Anti-Assignment
Except as may be necessary to ful ill a domestic relations order within the meaning of Code Section 414(p), none of the bene its
or rights of a Participant or any Bene iciary of a Participant shall be subject to the claim of any creditor. In particular, to the fullest
extent permitted by law, all such bene its and rights shall be free from attachment, garnishment or any other legal or equitable
process available to any creditor of the Participant and his or her Bene iciary. Neither the Participant nor his or her Bene iciary
shall have the right to alienate, anticipate, commute, pledge, encumber or assign any of the payments which he or she may expect
to receive, contingently or otherwise, under the Plan, except the right to designate a Bene iciary to receive death bene its
provided hereunder. Notwithstanding the preceding, the bene it payable from a Participant’s Account may be reduced, at the
discretion of the Administrator, to satisfy any debt or liability to the Employer.
However, the Employer may assign any or all of its liabilities under this Plan in connection with any restructuring,
recapitalization, sale of assets or other similar transactions affecting the Employer without the consent of the Participant.
Article 13-1
-- 148 of 225 --
13.5. Facility of Payment
If the Administrator determines, on the basis of medical reports or other evidence satisfactory to the Administrator, that the
recipient of any bene it payments under the Plan is incapable of handling his or her affairs by reason of minority, illness, in irmity
or other incapacity, the Administrator may direct the Employer to disburse such payments (i) to the legal guardian, or if none, to
a parent of a minor payee with whom the payee maintains his or her residence or (ii) to the conservator or, if none, to the person
having custody of an incompetent payee. The receipt by such person or institution of any such payments therefore, and any such
payment to the extent thereof, shall discharge the liability of the Employer, the Plan and the Administrator for the payment of
bene its hereunder to such recipient.
13.6. Notices
Any notice or other communication to the Employer or Administrator in connection with the Plan shall be deemed delivered in
writing, in person, or through such electronic means as is established by the Employer or Administrator. Notice shall be deemed
given as of the date it is actually delivered or, in the case delivery is made by mail, as of the date shown on the postmark on the
receipt for registration or certi ication. Written transmission shall be addressed to the Plan Sponsor at the address speci ied in
Section 1.03 of the Adoption Agreement.
Any notice or iling required or permitted to be given to a Participant under this Plan shall be suf icient if in writing or hand-
delivered or sent by mail to the last known address of the Participant.
13.7. Tax Withholding
If the Employer concludes that tax is owing with respect to any deferral or payment hereunder, the Employer shall withhold such
amounts from any payments due the Participant or from amounts deferred, as permitted by law, or otherwise make appropriate
arrangements with the Participant or his or her Bene iciary for satisfaction of such obligation. Tax, for purposes of this Section
13.7 means any federal, state, local or any other governmental income tax, employment or payroll tax, excise tax or any other tax
or assessment owing with respect to amounts deferred, any earnings thereon and any payments made to Participants under the
Plan.
13.8. Indemni ication
(a) Each Indemnitee (as de ined in Section 13.8(d)) shall be indemni ied and held harmless by the Employer for all actions
taken by him or her and for all failures to take action (regardless of the date of any such action or failure to take action) in
connection with the operation and administration of the Plan, to the fullest extent permitted by the law of the jurisdiction
in which the Employer is incorporated and to the extent that the claim, ine or penalty, expense or liability is not paid for
by liability insurance purchased or paid for by the Employer, against all claims, ines and penalties, expenses and
liabilities (including, without limitation, reasonable attorneys’ fees) reasonably incurred or suffered by the Indemnitee.
No indemni ication pursuant to this Section shall be made, however, in any case where (1) the act or failure to act are due
to gross negligence or willful misconduct or (2) for any such amount incurred through any settlement or compromise of
any action unless the Employer consents in writing to such settlement or compromise.
(b) Indemni ication pursuant to this Section shall continue as to an Indemnitee who has ceased to be such and shall inure to
the bene it of his or her heirs, executors and administrators. The Employer agrees that the undertakings made in this
Section shall be binding on its successors or assigns and shall survive the termination, amendment or restatement of the
Plan.
Article 13-2
-- 149 of 225 --
(c) The foregoing right to indemni ication shall be in addition to such other rights as the Indemnitee may enjoy as a matter of
law or by reason of insurance coverage of any kind and is in addition to and not in lieu of any rights to indemni ication to
which the Indemnitee may be entitled pursuant to the by-laws of the Employer.
(d) “Indemnitee” shall mean each person serving as an Administrator (or any other person who is an employee, Director,
agent, organization or of icer of the Employer) to whom or to which are delegated duties, responsibilities and authority
under the Plan or otherwise with respect to administration of the Plan.
13.9. Successors
The provisions of the Plan shall bind and inure to the bene it of the Plan Sponsor, the Employer and their successors and assigns
and the Participant and the Participant’s designated Bene iciaries.
13.10. Lost Participant or Bene iciaries
Any Participant or Bene iciary who is entitled to a bene it from the Plan has the duty to keep the Employer advised of his or her
current mailing address. If bene it payments are returned to the Plan or are not presented for payment after a reasonable
amount of time, the Employer shall presume that the payee is missing. The Employer, after making such efforts as in its discretion
it deems reasonable and appropriate to locate the payee, shall stop payment on any uncashed checks and may discontinue
making future payments until contact with the payee is restored.
13.11. Headings
The headings of Sections are included solely for convenience of reference, and if there is any con lict between such headings and
the text of this Plan, the text shall control.
13.12. Invalid or Unenforceable Provisions
If any provision of this Plan shall be held invalid or unenforceable, such invalidity or unenforceability shall not affect any other
provisions hereof and the Employer may elect in its sole discretion to construe such invalid or unenforceable provisions in a
manner that conforms to applicable law or as if such provisions, to the extent invalid or unenforceable, had not been included.
13.13. Disclaimer
It is the Plan Sponsor’s intention that the Plan comply with the requirements of Code Section 409A. Neither the Plan Sponsor nor
the Employer shall have any liability to any Participant should any provision of the Plan fail to satisfy the requirements of Code
Section 409A.
13.14. Governing Law
The Plan will be construed, administered and enforced according to the laws of the State speci ied by the Plan Sponsor in Section
12.01 of the Adoption Agreement.
Article 13-3
-- 150 of 225 --
Thermo Fisher Scienti ic Inc.
Deferred Compensation Plan
Adoption Agreement
-- 151 of 225 --
Table of Contents
1.01 Preamble 1
1.02 Plan 1
1.03 Plan Sponsor 2
1.04 Employer 2
1.05 Administrator 2
1.06 Key Employee Determination Dates 3
2.01 Participation 4
3.01 Compensation 5
3.02 Bonuses 6
4.01 Participant Contributions 7
5.01 Employer Contributions 9
6.01 Distributions 12
7.01 Vesting 18
8.01 Unforeseeable Emergency 22
9.01 Investment Decisions 23
10.01 Trust 24
11.01 Termination Upon Change In Control 25
11.02 Automatic Distribution Upon Change In Control 25
11.03 Change In Control 25
12.01 Governing State Law 26
i
-- 152 of 225 --
Adoption Agreement
1.01 Preamble
By the execution of this Adoption Agreement the Plan Sponsor hereby [complete (a) or (b)]
(1) ☐ adopts a new plan as of [month, day, year]
(2) ☒ amends and restates its existing plan as of January 1, 2024 which is the Amendment Effective Date. All amounts
deferred under the Plan prior to the Amendment Effective Date shall be governed by the terms of the Plan as in effect on
the day before the Amendment Effective Date.
Originally effective November 1, 2001; Amounts deferred under the Plan prior to January 1, 2005 that were vested as
of December 31, 2004 shall be subject to the provisions of the Plan as in effect on October 3, 2004.
Previously Amended & Restated effective January 1, 2009 and executed on January 27, 2009 for amounts deferred on
or after January 1, 2005; and previously Restated effective January 1, 2020 with subsequent First Amendment
effective January 1, 2022 and Second Amendment effective March 1, 2023.
Pre-409A Grandfathering: ☒ Yes ☐ No
By executing this Adoption Agreement, the Plan Sponsor (as de ined below) has adopted the Plan (as de ined below) consisting
of the Basic Plan Document along with this Adoption Agreement (and any exhibits or scheduled attached hereto). The Plan
Sponsor, by completing this Adoption Agreement has made the speci ic choices regarding plan design as set forth in the Adoption
Agreement together with the detailed additional provisions set out in the Basic Plan Document. All capitalized terms used in this
Adoption Agreement have the same meaning given in the Basic Plan Document.
1.02 Plan
Plan Name: Thermo Fisher Scienti ic Inc. Deferred Compensation Plan
Plan Year: Calendar Year (1/1 – 12/31)
1
-- 153 of 225 --
1.03 Plan Sponsor
Name: Thermo Fisher Scienti ic Inc. (also referred to herein as the “Company”)
Address: 168 3 Avenue, Waltham MA 02451
Phone #: 781-622-1000
EIN #: 04-2209186
Fiscal Year: Calendar Year (1/1 – 12/31)
Is stock of the Plan Sponsor, any Employer or any Related Employer publicly traded on an established securities market? ☒
Yes ☐ No
1.04 Employer
The following entities have been authorized by the Plan Sponsor to participate in and have adopted the Plan [insert “Not
Applicable” if none have been authorized]:
Entity Publicly Traded on Est. Securities Market
Yes No
Not Applicable ☐ ☐
☐ ☐
1.05 Administrator
The Plan Sponsor has designated the following party or parties to be responsible for the administration of the Plan:
Name: Thermo Fisher Scienti ic Inc. Management Pension Committee (the “Committee”)
Address: 168 3 Avenue, Waltham MA 02451
Note: The Administrator is the person or persons designated by the Plan Sponsor to be responsible for the administration of the
Plan. Neither Fidelity Employer Services Company nor any other Fidelity af iliate can be the Administrator.
rd
rd
2
-- 154 of 225 --
1.06 Key Employee Determination Dates
Key Employee identi ication will not be applicable given distribution events other than those based on Speci ied Date or
Speci ied Age, Death, Disability, or Change in Control will be treated as not having occurred for six (6) months (i.e., 6-month delay
applies to all Participants. The remainder of this section is retained for information purposes only.
The Employer has designated [month, day, year] as the Identi ication Date for purposes of determining Key Employees.
In the absence of a designation, the Identi ication Date is December 31.
The Employer has designated [month, day, year] as the effective date for purposes of applying the six month delay in
distributions to Key Employees.
In the absence of a designation, the effective date is the irst day of the fourth month following the Identi ication Date.
3
-- 155 of 225 --
2.01 Participation
(a) ☒ Employees [complete (i), (ii) or (iii)]
(i) ☐ Eligible Employees are selected by the Employer.
(ii) ☒ Eligible Employees are those employees of the Employer who satisfy the following criteria:
Eligible Employee means a member of a "select group of management or highly
compensated employees" of the Company within the meaning of Sections 201(2),
30l(a)(3) and 401 (a)(l) of ERISA, as determined by the Committee from time to
time in its sole discretion. Employees become Eligible Employees upon
noti ication by the Company of their eligibility to become Participants in the Plan.
An Eligible Employee becomes a Participant upon the earlier to occur of: (i) the
noti ication of eligibility to participate and the timely submission of a deferral
agreement on which an election to make a deferral is made; or (ii) a credit of a
Company contribution.
Further, a Participant shall become eligible to earn Matching Contributions under
the Plan when they become eligible to earn matching contributions in the Thermo
Fisher Scienti ic Inc. 401(k) Retirement Plan (without consideration of any
limitations imposed by the Code).
(iii) ☐ Employees are not eligible to participate.
4
-- 156 of 225 --
3.01 Compensation
For purposes of determining Participant contributions under Article 4 and Employer contributions under Article 5,
Compensation shall be de ined in the following manner [complete (a) or (b) and select (c) and/or (d), if applicable]:
(a) ☒ Compensation is de ined as:
Compensation means the amount paid in the year of the deferral as the Participant's base
salary, bonus and such other remuneration for services rendered as an employee (if any)
approved by the Company as Compensation that may be deferred under this Plan.
Compensation shall not include any Compensation that has been previously deferred under
this Plan or any other arrangement subject to Code Section 409A. The Company has the
authority to determine the payroll practices under which Compensation subject to a deferral
agreement will be deducted from a Participant's Compensation.
“Match-Eligible Compensation” for a given Plan Year means a Participant's Compensation that
is in excess of the amount of Compensation treated as "compensation" for the applicable plan
year under the Thermo Fisher Scienti ic Inc. 401(k) Retirement Plan. Match-Eligible
Compensation includes a Participant's Compensation that is in excess of the Internal Revenue
Service (“IRS”) limit on covered compensation for quali ied plans established in Code Section
401(a)(17) in effect for that Plan Year and also includes any amount of a Participant's
Compensation that was reduced below the Code Section 401(a)(17) limit for purposes of
applying the Company match in the Company sponsored 401(k) plan due to deferrals in this
Plan.
(b) ☐ Compensation as de ined in [insert name of quali ied plan] without regard to the limitation in Section 401(a)
(17) of the Code for such Plan Year.
(c) ☐ Compensation shall, for all Plan purposes, be limited to $ .
(d) ☐ Not Applicable.
5
-- 157 of 225 --
3.02 Bonuses
Compensation, as de ined in Section 3.01 of the Adoption Agreement, includes the following type of bonuses that will be the
subject of a separate deferral election:
Type
[Will be treated as]
Performance Based Compensation
Yes No
Annual Incentive Plan (AIP) ☒ ☐
☐ ☐
☐ ☐
☐ ☐
☐ ☐
☐ Not Applicable.
6
-- 158 of 225 --
4.01 Participant Contributions
If Participant contributions are permitted, complete (a) and (b). Otherwise complete (c).
(a) Amount of Deferrals
A Participant may elect within the period speci ied in Section 4.01(b) of the Adoption Agreement to defer the following
amounts of remuneration. For each type of remuneration listed, complete “dollar amount” and/or “percentage amount”.
(i) Compensation other than Bonuses [do not complete if you complete (iii)]
Type of Remuneration
Dollar Amount % Amount Increment
Min Max Min Max
Base Salary 1% 75% 1%
Match-Eligible
Compensation 6% 6% N/A
Note: The increment is required to determine the permissible deferral amounts. For example, a minimum of 0% and
maximum of 20% with a 5% increment would allow an individual to defer 0%, 5%, 10%, 15% or 20%.
(ii) Bonuses [do not complete if you complete (iii)]
Type of Bonus
Dollar Amount % Amount Increment
Min Max Min Max
Annual Incentive Plan 1% 75% 1%
Note: (If Match-Eligible Compensation is elected by Participant in Section 4.01(a)(i) and (ii) for deferral, Participants
are prohibited from making separate base salary or Annual Incentive Plan bonus elections and vice versa (i.e.,
Participants may only defer Match-Eligible Compensation or separate base salary and/or Annual Incentive Plan).
(iii) Compensation [do not complete if you completed (i) and (ii)]
Type of Remuneration Dollar Amount % Amount
Increment Min Max Min Max
7
-- 159 of 225 --
(b) Election Period
(i) Performance Based Compensation
A special election period
☐ Does
☒ Does Not
apply to each eligible type of performance based compensation referenced in Section 3.02 of the Adoption
Agreement.
The special election period, if applicable, will be determined by the Employer.
(ii) Newly Eligible Participants
An employee who is classi ied or designated as an Eligible Employee during a Plan Year
☒ May
☐ May Not
elect to defer Compensation earned during the remainder of the Plan Year by completing a deferral agreement within
the 30 day period beginning on the date he or she is eligible to participate in the Plan.
The special election period, if applicable, will be determined by the Employer.
(c) No Participant Contributions
☐ Participant contributions are not permitted under the Plan.
8
-- 160 of 225 --
5.01 Employer Contributions
If Employer contributions are permitted, complete (a) and/or (b). Otherwise complete (c).
(a) Matching Contributions
(i) Amount
For each Plan Year, the Employer shall make a matching contribution on behalf of each Participant who defers
Compensation for the Plan Year and satis ies the requirements of Section 5.01(a)(ii) of the Adoption
Agreement equal to [complete the ones that are applicable]:
(A) ☐ [insert percentage]% of the Compensation the Participant has elected to defer for the Plan Year
(B) ☐ An amount determined by the Employer in its sole discretion
(C) ☐ Matching contributions for each Participant shall be limited to $ and/or [insert percentage]% of
Compensation
(D) ☒ Other:
In each Plan Year, with respect to each Participant determined eligible
for the Plan, the Plan Sponsor shall make a matching contribution equal
to 100% of the irst six percent (6%) of Match-Eligible Compensation
that such Participant elected to defer for that Plan Year.
(E) ☐ Not Applicable [Proceed to Section 5.01(b)]
(ii) Eligibility for matching contribution
A Participant who defers Compensation for the Plan Year shall receive an allocation of matching contributions
determined in accordance with Section 5.01(a)(i) provided he or she satis ies the following requirements [complete
the ones that are applicable]:
(A) ☐ Describe requirements:
9
-- 161 of 225 --
(B) ☒ Is selected by the Employer in its sole discretion to receive an allocation of matching contributions
(C) ☐ No requirements
(iii) Time of Allocation
Matching contributions, if made, shall be treated as allocated [select one]:
(A) ☐ As of the last day of the Plan Year
(B) ☒ At such times as the Employer shall determine in its sole discretion
(C) ☐ At the time the Compensation on account of which the matching contribution is being made would
otherwise have been paid to the Participant
(D) ☐ Other:
(b) Other Contributions
(i) Amount
The Employer shall make a contribution on behalf of each Participant who satis ies the requirements of Section
5.01(b)(ii) equal to [complete the ones that are applicable]:
(A) ☐ An amount equal to [insert percentage]% of the Participant’s Compensation
(B) ☒ An amount determined by the Employer in its sole discretion
(C) ☐ Contributions for each Participant shall be limited to $
10
-- 162 of 225 --
(D) ☐ Other:
(E) ☐ Not Applicable [Proceed to Section 6.01]
(ii) Eligibility for Other Contribution
A Participant shall receive an allocation of other Employer contributions determined in accordance with Section
5.01(b)(i) for the Plan Year if he or she satis ies the following requirements [complete the one that is applicable]:
(A) ☐ Describe requirements:
(B) ☒ Is selected by the Employer in its sole discretion to receive an allocation of other Employer
contributions
(C) ☐ No requirements
(iii) Time of Allocation
Employer contributions, if made, shall be treated as allocated [select one]:
(A) ☐ As of the last day of the Plan Year
(B) ☒ At such times or times as the Employer shall determine in its sole discretion
(C) ☐ Other:
(c) No Employer Contributions
☐ Employer contributions are not permitted under the Plan.
11
-- 163 of 225 --
6.01 Distributions
The timing and form of payment of distributions made from the Participant’s vested Account shall be made in accordance with
the elections made in this Section 6.01 of the Adoption Agreement except when Section 9.6 of the Plan requires a six month delay
for certain distributions to Key Employees of publicly traded companies.
(a) Timing of Distributions
(i) All distributions shall commence in accordance with the following [choose one]:
(A) ☐ As soon as administratively feasible following the distribution event but in no event later than the
time prescribed by Treas. Reg. Sec. 1.409A-3(d).
(B) ☒ Monthly on the irst business day of the month.
(C) ☐ Annually on speci ied month and day [insert month and day]
(D) ☐ Calendar quarter on speci ied month and day [insert month and day] [insert numerical quarter 1, 2,
3, or 4]
(ii) The timing of distributions as determined in Section 6.01(a)(i) shall be modi ied by the adoption of:
(A) ☒ Event Delay – Distribution events other than those based on Speci ied Date or Speci ied Age, Death,
Disability, or Change in Control will be treated as not having occurred for six (6) months
(B) ☐ Hold Until Next Year – Distribution events other than those based on Speci ied Date or Speci ied Age
will be treated as not having occurred for twelve months from the date of the event if payment pursuant
to Section 6.01(a)(i) will thereby occur in the next calendar year or on the irst payment date in the next
calendar year in all other cases
(C) ☐ Immediate Processing – The timing method selected by the Plan Sponsor under Section 6.01(a)(i)
shall be overridden for the following distribution events [insert events]:
(D) ☐ Not applicable
12
-- 164 of 225 --
(b) Distribution Events
(i) Participant Contributions under Section 4.01(a)
Participants may elect the following payment events and the associated form or forms of payment. If multiple events
for each year are selected, the earliest to occur will trigger payment. For installments, insert the range of available
periods (e.g., 5-15) or insert the periods available (e.g., 5, 7, 9).
Lump Sum Installments
(A) ☒ Speci ied Date (MM/YYYY) ☒ 2-5 years
(B) ☐ Speci ied Age ☐ years
(C) ☒ Separation from Service ☒
2-15 years; (25
years with respect
to contributions to
the Plan made
prior to 1/1/2022)
(D) ☐ Separation from Service plus 6 months ☐ years
(E) ☐ Separation from Service plus ___ months [not to
exceed ___ months] ☐ years
(F) ☐ Retirement ☐ years
(G) ☐ Retirement plus 6 months ☐ years
(H) ☐ Retirement plus 12 months ☐ years
(I) ☐ Disability ☐ years
(J) ☐ Death ☐ years
(K) ☒Change in Control** ☒ 2-15 years
** Change in Control bene it only available to amounts deferred under Compensation Deferral Agreements that became irrevocable prior to
October 1, 2019 for those Participants who have elected prior to October 1, 2019 to receive a Change in Control Bene it and shall be paid
within ninety (90) days following the date upon which the Change in Control occurred,
The minimum deferral period for Speci ied Date or Speci ied Age event shall be 2 year(s).
13
-- 165 of 225 --
Installments may be paid [select each that applies]
☐ Monthly
☐ Quarterly
☐ Semi-Annually
☒ Annually
(ii) Employer Contributions under Section 5.01(a) and (b).
Participants may elect the following payment events and the associated form or forms of payment. If multiple events
for each year are selected, the earliest to occur will trigger payment. For installments, insert the range of available
periods (e.g., 5-15) or insert the periods available (e.g., 5, 7, 9).
Lump Sum Installments
(A) ☐ Speci ied Date (MM/YYYY) ☐ years
(B) ☐ Speci ied Age ☐ years
(C) ☒ Separation from Service ☒ 2-15 years
(D) ☐ Separation from Service plus 6 months ☐ years
(E) ☐ Separation from Service plus ___ months [not to
exceed ___ months] ☐ years
(F) ☐ Retirement ☐ years
(G) ☐ Retirement plus 6 months ☐ years
(H) ☐ Retirement plus 12 months ☐ years
(I) ☐ Disability ☐ years
(J) ☐ Death ☐ years
(K) ☐ Change in Control ☐ years
14
-- 166 of 225 --
The minimum deferral period for Speci ied Date or Speci ied Age event shall be Not Applicable year(s).
Installments may be paid [select each that applies]
☐ Monthly
☐ Quarterly
☐ Semi-Annually
☒ Annually
(c) Speci ied Date and Speci ied Age elections may not extend beyond age Not Applicable.
(d) Payment Election Override
Payment of the remaining vested balance of the Participant’s Account will automatically occur at the time speci ied in
Section 6.01(a) of the Adoption Agreement in the form indicated upon the earliest to occur of the following events [check
each event that applies and for each event include only a single form of payment]:
Events Form of Payment
Lump Sum Installments
☒ Separation from Service/Change in Control** ☒
** Upon a Separation from Service or, with respect to any Participant who has elected (prior to October 1, 2019) a
Change in Control bene it pursuant to Section 6.01(b), upon a Change in Control, the unpaid balance of a Speci ied
Date account shall be paid as follows: (i) Speci ied Date payments that have commenced (i.e. in “pay status) shall
continue to be paid separately; and (ii) Speci ied Date payments that have not commenced shall be paid in accordance
with the form of payment applicable to the Separation from Service or Change in Control Bene it, as applicable.
If such bene it is payable in a single lump sum, the unpaid balance of all Speci ied Date Accounts (including those in
pay status) will be paid in a lump sum."
☐ Separation from Service before Retirement ☐
☒ Separation from Service within 24 months following a Change in
Control ☒
☒ Death ☒
☐ Disability ☐
☐ Not Applicable ☐
15
-- 167 of 225 --
(e) Involuntary Cashouts
☒ If the Participant’s vested Account at the time of his or her Separation from Service does not exceed the applicable
dollar amount under Code Section 402(g)(1)(B), distribution of the vested Account shall automatically be made in the
form of a single lump sum in accordance with Section 9.5 of the Plan.
☐ There are no involuntary cashouts.
(f) Retirement
☐ Retirement shall be de ined as a Separation from Service that occurs on or after the Participant [insert description of
requirements]:
☒ No special de inition of Retirement applies.
(g) Distribution Election Change
A Participant
☒ Shall
☐ Shall Not
be permitted to modify a scheduled distribution date and/or payment option in accordance with Section 9.2 of the Plan.
The Plan Sponsor, in its sole and absolute discretion, reserves the right to limit the number of times a Participant may be
permitted to modify distribution elections.
Administratively, allowable distribution events will be modi ied to re lect all options necessary to ful ill the distribution
change election provision.
16
-- 168 of 225 --
(h) Frequency of Elections
The Plan Sponsor
☒ Has
☐ Has Not
elected to permit annual elections of a time and form of payment for amounts deferred under the Plan. If a single election of
a time and/or form of payment is required, the Participant will make such election at the time he or she irst completes a
deferral agreement which, in all cases, will be no later than the time required by Reg. Sec. 1.409A-2.
(i) Disability
For Purposes of Section 2.11 of the Plan, Disability shall be de ined as
☐ Total disability as determined by the Social Security Administration or the Railroad Retirement Board.
☐ As determined by the Employer’s long term disability insurance policy.
☐ As follows [insert description of requirements]:
☒ Not applicable.
17
-- 169 of 225 --
7.01 Vesting
(a) Matching Contributions
The Participant’s vested interest in the amount credited to his or her Account attributable to matching contributions shall
be based on the following schedule:
☒ Years of Service Vesting %
0 100% [insert “100” if there is immediate vesting]
1 %
2 %
3 %
4 %
5 %
6 %
7 %
8 %
9 %
☐ Other:
☐ Class year vesting applies:
☐ Not applicable.
18
-- 170 of 225 --
(b) Other Employer Contributions
The Participant’s vested interest in the amount credited to his or her Account attributable to Employer contributions other
than matching contributions shall be based on the following schedule:
☐ Years of Service Vesting %
0 % [insert “100” if there is immediate vesting]
1 %
2 %
3 %
4 %
5 %
6 %
7 %
8 %
9 %
☒ Other:
Vesting determined by the Employer in its sole discretion at the time the contribution is made.
☐ Class year vesting applies:
☐ Not applicable.
(c) Acceleration of Vesting
The Participant’s vested interest in his or her Account will automatically be 100% upon the occurrence of the following
events [select the ones that are applicable]:
19
-- 171 of 225 --
(i) ☒ Death.
(ii) ☐ Disability.
(iii) ☐ Change in Control.
(iv) ☐ Eligibility for Retirement.
(v) ☒ Other:
The Plan Sponsor may, at any time, in its sole discretion, increase a Participant's
vested interest in a Plan Sponsor discretionary contribution.
(vi) ☐ Not applicable.
(d) Years of Service
(i) A Participant’s Years of Service shall include all service performed for the Employer and
☐ Shall
☐ Shall Not
include service performed for the Related Employer.
20
-- 172 of 225 --
(ii) Years of Service shall also include service performed for the following entities:
(iii) Years of Service shall be determined in accordance with [select one]:
(A) ☐ The elapsed time method in Treas. Reg. Sec. 1.410(a)-7
(B) ☐ The general method in DOL Reg. Sec. 2530.200b-1 through b-4
(C) ☐ Participant’s Years of Service credited under:
[insert name of plan]
(D) ☐ Other:
(iv) ☒ Not applicable.
21
-- 173 of 225 --
8.01 Unforeseeable Emergency
(a) A withdrawal due to an Unforeseeable Emergency as de ined in Section 2.24:
☒ Will
☐ Will Not [if Unforeseeable Emergency withdrawals are not permitted, proceed to Section 9.01]
be allowed.
(b) Upon (i) a withdrawal due to an Unforeseeable Emergency, or (ii) during periods in which the Participant is unable to
perform the duties of his or her position or any substantially similar position due to a mental or physical impairment that
can be expected to result in death or last for a continuous period of at least six (6) months, provided cancellation occurs by
the later of the end of the taxable year of the Participant or the ifteenth (15 ) day of the third (3 ) month following the
date the Participant incurs the Disability (as de ined here), a Participant’s deferral election for the remainder of the Plan
Year:
☒ May
☐ Will Not
be cancelled. If cancellation occurs, the Participant may resume participation in accordance with Article 4 of the Plan.
th rd
22
-- 174 of 225 --
9.01 Investment Decisions
Investment decisions regarding the hypothetical amounts credited to a Participant’s Account shall be made by [select one]:
(a) ☒ The Participant or his or her Bene iciary
(b) ☐ The Employer
23
-- 175 of 225 --
10.01 Trust
The Employer [select one]:
☒ Does
☐ Does Not
intend to establish a trust as provided in Article 11 of the Plan.
24
-- 176 of 225 --
11.01 Termination Upon Change In Control
The Plan Sponsor
☒ Reserves
☐ Does Not Reserves
the right to terminate the Plan and distribute all vested amounts credited to Participant Accounts upon a Change in Control as
described in Section 9.7.
11.02 Automatic Distribution Upon Change In Control
Distribution of the remaining vested balance of each Participant’s Account
☐ Shall
☒ Shall Not
automatically be paid as a lump sum payment upon the occurrence of a Change in Control as provided in Section 9.7.
11.03 Change In Control
A Change in Control for Plan purposes includes the following [select each de inition that applies]:
(a) ☒ A change in the ownership of the Employer as described in Section 9.7(c) of the Plan.
(b) ☒ A change in the effective control of the Employer as described in Section 9.7(d) of the Plan.
(c) ☒ A change in the ownership of a substantial portion of the assets of the Employer as described in Section 9.7(e) of
the Plan.
(d) ☐ Not Applicable.
25
-- 177 of 225 --
12.01 Governing State Law
The laws of Massachusetts shall apply in the administration of the Plan to the extent not preempted by ERISA.
26
-- 178 of 225 --
The Plan Sponsor has caused this Adoption Agreement to be executed this 20 day of December, 2023.
Plan Sponsor: Thermo Fisher Scienti ic Inc.
By: /s/ Lisa P. Britt
Title: SVP & Chief Human Resources Officer
27
-- 179 of 225 --
Exhibit 21
THERMO FISHER SCIENTIFIC INC.
NAME STATE OR JURISDICTION OF
ORGANIZATION
0972792 B.C. LTD Canada
236 Perinton Parkway, LLC New York
27 Forge Parkway LLC Delaware
Abgene Inc. Delaware
Abgene Limited England
ABII 2 Limited England
ACI Holdings Inc. New York
Acoustic Cytometry Systems, Inc. Delaware
AcroMetrix LLC California
Acros Organics BV Belgium
Acurian, Inc. Delaware
Advanced Biotechnologies Limited England
Advanced Scientifics International, Inc. Pennsylvania
Advanced Scientifics, Inc. Pennsylvania
Affymetrix Biotech Shanghai Ltd China
Affymetrix Japan K.K. Japan
Affymetrix UK Ltd England
Affymetrix, Inc Delaware
Alchematrix LLC Delaware
Alchematrix, Inc. Delaware
Alfa Aesar (China) Chemical Co. Ltd. China
Alfa Aesar (Hong Kong) Limited Hong Kong
Allergon AB Sweden
Ambion, Inc. Delaware
APBI Finance Corporation Delaware
Apogent Finance Company Delaware
Apogent Holding Company Delaware
Apogent Technologies Inc. Wisconsin
Apogent Transition Corp. Delaware
Apogent U.K. Limited England
Applied Bioscience International, LLC Delaware
Applied Biosystems B.V. Netherlands
1
-- 180 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Applied Biosystems de Mexico S. de R.L. de C.V. Mexico
Applied Biosystems International Inc. Delaware
Applied Biosystems Taiwan LLC Delaware
Applied Biosystems Trading (Shanghai) Company Ltd. China
Applied Biosystems, LLC Delaware
Applied Scientific Corporation California
App-Tek International Pty Ltd Australia
ARG Services LLC Delaware
ASPEX Corporation Pennsylvania
ATP, LLC North Carolina
Avances Cientificos de Mexico, S. de R.L. de C.V. Mexico
Avocado Research Chemicals Limited England
B.R.A.H.M.S. Biotech GmbH Germany
B.R.A.H.M.S. GmbH Germany
B.R.A.H.M.S. UK Ltd England
BAC BV Netherlands
BAC IP BV Netherlands
Barnstead Thermolyne LLC Delaware
Beijing Phadia Diagnostics Co Ltd China
Bender MedSystems GmbH Austria
Biochemical Sciences LLC Delaware
Bio-Sciences Ltd Ireland
BioTrove Corporation Delaware
BioTrove International, Inc. Delaware
BmT GmbH Laborprodukte Germany
Brammer Bio Holding Company, LLC Delaware
Brammer Bio MA, LLC Delaware
Brammer Bio, LLC Delaware
Bumi-Sans Sendirian Berhad Malaysia
CAC Limited England
Capitol Scientific Products, Inc. New York
Capitol Vial, Inc. Alabama
2
-- 181 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
CB Diagnostics AB Sweden
CB Diagnostics Holding AB Sweden
CB Diagnostics I AB Sweden
CCBR (Beijing) Company Limited China
Cellomics, Inc. Delaware
CellzDirect, Inc. Delaware
Center for Clinical and Basic Research A/S Denmark
CEPH International Corporation Puerto Rico
Cezanne S.A.S. France
Chase Scientific Glass, Inc. Wisconsin
CHK Holdings Inc. Delaware
Chromacol Limited England
Clinical Technology Centre (International) Limited England
Clinical Technology Centre (Ireland) Limited Ireland
Clintrak Clinical Labeling Services, LLC Delaware
Clintrak Pharmaceutical Services, LLC Delaware
Cohesive Technologies (UK) Limited England
Cohesive Technologies Inc. Delaware
Columbia Diagnostics, Inc. Delaware
Combinati Incorporated Delaware
Compass NeuroHealth, LLC Florida
Compass Research, LLC Florida
Compendia Bioscience, Inc. Michigan
Comtest Limited England
Consolidated Technologies, Inc. Wisconsin
Consultores Fisher Scientific Chile Ltd Chile
Core Informatics UK Ltd. England
Core Informatics, LLC Connecticut
CorEvitas, LLC Delaware
Corrona Intermediate Holdings, Inc. Delaware
Corrona UK Holdings Limited England
CTPS LLC Delaware
3
-- 182 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
DCG Systems G.K. Japan
D-finitive Technologies, Inc. South Carolina
Diagnostix Ltd. Canada
Dionex (Switzerland) AG Switzerland
Dionex (UK) Limited England
Dionex Austria GmbH Austria
Dionex Benelux B.V. Netherlands
Dionex Canada Ltd. Canada
Dionex China Limited Hong Kong
Dionex Corporation Delaware
Dionex Denmark A/S Denmark
Dionex Holding GmbH Germany
Dionex I, LLC Delaware
Dionex S.A. France
Dionex S.p.A. Italy
Dionex Softron GmbH Germany
Dionex Sweden AB Sweden
Distribution Solutions International, Inc. Michigan
Doe & Ingalls Investors, Inc. Delaware
Doe & Ingalls Limited Ireland
Doe & Ingalls Management, LLC Delaware
Doe & Ingalls of California Operating LLC North Carolina
Doe & Ingalls of Florida Operating LLC Florida
Doe & Ingalls of Maryland Operating LLC North Carolina
Doe & Ingalls of Massachusetts Operating LLC North Carolina
Doe & Ingalls of North Carolina Operating LLC North Carolina
Doe & Ingalls Properties II, LLC North Carolina
Doe & Ingalls Properties, LLC North Carolina
Doublecape Holding Limited England
Doublecape Limited England
DPI Newco LLC Delaware
Drakeside Real Estate Holding Company LLC Delaware
4
-- 183 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
DSM Pharmaceutical Products, Inc. Delaware
Duke Scientific Corporation California
Dynal Biotech Beijing Limited China
Eagle Holding Company II, LLC Delaware
eBioscience SAS France
eBioscience, Ltd England
EGS Gauging Ltd. England
EGS Gauging Technical Services Company Delaware
EP Scientific Products LLC Delaware
Epsom Glass Industries Limited England
Erie (GC) Holding Limited England
Erie Finance 1 Limited England
Erie Finance 2 Limited England
Erie Finance Holding Limited England
Erie Finance Limited England
Erie Finance LLC Delaware
Erie GC Holding LLC Delaware
Erie GC Limited England
Erie LP Holding LLC Delaware
Erie Luxembourg LLC Delaware
Erie N10 LLC Delaware
Erie N2 LLC Delaware
Erie N2 UK Limited England
Erie Scientific Company of Puerto Rico Delaware
Erie Scientific Hungary Ipari és Szolgáltató Kft Hungary
Erie Scientific LLC Delaware
Erie U.K. Limited England
Erie UK 1 Limited England
Erie UK 1 LLC Delaware
Erie UK 2 Limited England
Erie UK 3 Limited England
Erie UK 4 Limited England
5
-- 184 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Erie UK 5 Limited England
Erie UK 6 Limited England
Erie UK Holding Company Delaware
Erie UK Senior Holding Limited England
Erie US II LLC Delaware
Erie US III LLC Delaware
European Laboratory Holdings Limited Ireland
Eutech Instruments Pte Ltd. Singapore
Ever Ready Thermometer Co., Inc. Wisconsin
Evidera Access Consulting Ltd England
Evidera Holdings Ltd England
Evidera Ltd England
Evidera, Inc. Delaware
Excel PharmaStudies Inc. Cayman Islands
FB2 Blocker, LLC Delaware
FEI Asia Pacific Co., Ltd. China
FEI Australia Pty Ltd Australia
FEI Company Oregon
FEI Company Japan Ltd. Japan
FEI Company of USA (S.E.A.) Pte Ltd. Singapore
FEI CPD B.V. Netherlands
FEI Deutschland GmbH Germany
FEI EFA International Pte. Ltd. Singapore
FEI EFA, Inc. Delaware
FEI Electron Optics B.V. Netherlands
FEI Electron Optics International B.V. Netherlands
FEI Europe B.V. Netherlands
FEI France SAS France
FEI Hong Kong Company Limited Hong Kong
FEI Houston, Inc. Delaware
FEI Italia Srl Italy
FEI Korea Ltd. Korea
6
-- 185 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
FEI Melbourne Pty Ltd. Australia
FEI Microscopy Solutions Ltd Israel
FEI SAS France
FEI Saudi Arabia LLC Saudi Arabia
FEI Technologies, Inc. Oregon
FEI Technology de Mexico S.A. de C.V. Mexico
FEI Trading (Shanghai) Co., Ltd. China
FEI UK Limited England
Fermentas China Co., Ltd China
Fermentas Inc. Maryland
FHP LLC Delaware
Fiberlite Centrifuge LLC Delaware
Finesse Scientific Equipment (Shanghai) Co., Ltd. China
Finesse Solutions, Inc. Delaware
Fisher Alder S. de R.L. de C.V. Mexico
Fisher Bermuda Holdings Limited Bermuda
Fisher Bioblock Holding II SNC France
Fisher BioPharma Services (India) Private Limited India
Fisher BioSciences Japan G.K. Japan
Fisher BioServices Inc. Virginia
Fisher Bioservices Netherlands B.V. Netherlands
Fisher Canada Holding ULC 1 Canada
Fisher Canada Holding ULC 2 Canada
Fisher Canada Holding ULC 3 Canada
Fisher Clinical Logistics LLC Delaware
Fisher Clinical Services (Beijing) Co., Ltd. China
Fisher Clinical Services (Bristol), LLC Delaware
Fisher Clinical Services (Colombia) LLC Delaware
Fisher Clinical Services (Korea) Co., Ltd Korea
Fisher Clinical Services (Mexico) LLC Delaware
Fisher Clinical Services (Peru) LLC Delaware
Fisher Clinical Services (Suzhou) Co., Ltd. China
7
-- 186 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Fisher Clinical Services Colombia S.A.S. Colombia
Fisher Clinical Services GmbH Germany
Fisher Clinical Services GmbH Switzerland
Fisher Clinical Services Inc. Pennsylvania
Fisher Clinical Services Japan K.K. Japan
Fisher Clinical Services Latin America S.R.L. Argentina
Fisher Clinical Services Limited Liability Company Russia
Fisher Clinical Services Mexico, S. de R.L. de C.V. Mexico
Fisher Clinical Services Peru S.R.L Peru
Fisher Clinical Services Pte Ltd. Singapore
Fisher Clinical Services Rheinfelden GmbH Germany
Fisher Clinical Services U.K. Limited England
Fisher CLP Holding Limited Partnership Canada
Fisher Emergo B.V. Netherlands
Fisher Hamilton China Inc. Delaware
Fisher Hamilton Mexico LLC Delaware
Fisher Internet Minority Holdings L.L.C. Delaware
Fisher Luxembourg Danish Holdings SARL Luxembourg
Fisher Manufacturing (Malaysia) Sdn Bhd Malaysia
Fisher Maybridge Holdings Limited England
Fisher Mexico, S. de R.L. de C.V. Mexico
Fisher Scientific (Austria) GmbH Austria
Fisher Scientific (Hong Kong) Limited Hong Kong
Fisher Scientific (M) Sdn Bhd Malaysia
Fisher Scientific (SEA) Pte. Ltd. Singapore
Fisher Scientific A/S Norway
Fisher Scientific AG Switzerland
Fisher Scientific Australia Pty Limited Australia
Fisher Scientific Biotech Line ApS Denmark
Fisher Scientific Brazil Inc. Delaware
Fisher Scientific Central America Inc. Delaware
Fisher Scientific Chile Inc. Delaware
8
-- 187 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Fisher Scientific Colombia Inc. Delaware
Fisher Scientific Company Canada
Fisher Scientific Company L.L.C. Delaware
Fisher Scientific Costa Rica Sociedad de Responsabilidad Limitada Costa Rica
Fisher Scientific de Mexico S.A. Mexico
Fisher Scientific Europe Holdings B.V. Netherlands
Fisher Scientific Germany Beteiligungs GmbH Germany
Fisher Scientific GmbH Germany
Fisher Scientific GTF AB Sweden
Fisher Scientific Holding Company LLC Delaware
Fisher Scientific Holding HK Limited Hong Kong
Fisher Scientific Holding U.K., Limited England
Fisher Scientific Holdings (S) Pte Ltd Singapore
Fisher Scientific International LLC Delaware
Fisher Scientific Investments (Cayman), Ltd. Cayman Islands
Fisher Scientific Ireland Investments Unlimited Ireland
Fisher Scientific Ireland Limited Ireland
Fisher Scientific Japan, Ltd. Japan
Fisher Scientific Jersey Island Limited Jersey
Fisher Scientific Korea Ltd Korea
Fisher Scientific Latin America Inc. Delaware
Fisher Scientific Luxembourg S.a.r.l. Luxembourg
Fisher Scientific Mexicana, S. de R.L. de C.V. Mexico
Fisher Scientific Mexico Inc. Delaware
Fisher Scientific Middle East and Africa Inc. Delaware
Fisher Scientific Norway AS Norway
Fisher Scientific Operating Company Delaware
Fisher Scientific Oxoid Holdings Ltd. England
Fisher Scientific Oy Finland
Fisher Scientific Pte. Ltd. Singapore
Fisher Scientific S.A.S. France
Fisher Scientific S.L. Spain
9
-- 188 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Fisher Scientific SRL Belgium
Fisher Scientific The Hague II B.V. Netherlands
Fisher Scientific The Hague III B.V. Netherlands
Fisher Scientific The Hague V B.V. Netherlands
Fisher Scientific U.K., Limited England
Fisher Scientific UK Holding Company 2 England
Fisher Scientific UK Holding Company Limited England
Fisher Scientific Venezuela Inc. Delaware
Fisher Scientific Worldwide (Shanghai) Co., Ltd. China
Fisher Scientific Worldwide Holdings I C.V. Netherlands
Fisher Scientific Worldwide Inc. Delaware
Fisher Scientific, spol. S.r.o Czech Republic
Fisher Scientific, Unipessoal, Lda. Portugal
Fisher Servicios Clinicos (Chile) LLC Delaware
Fisher Servicios Clinicos Chile Ltda Chile
Fisher Worldwide Gene Distribution SPV Cayman Islands
Fisher WWD Holding L.L.C. Delaware
FRC Holding Inc., V Delaware
FS Casa Rocas Holdings LLC Delaware
FS Mexicana Holdings LLC Delaware
FSI Receivables Company LLC Delaware
FSII Sweden Holdings AB Sweden
FSII Sweden Holdings I AB Sweden
FSII Sweden Holdings II AB Sweden
FSIR Holdings (UK) Limited England
FSIR Holdings (US) Inc. Delaware
FSUK Holdings Limited England
FSWH Company LLC Delaware
FSWH I LLC Delaware
FSWH II LLC Delaware
FSWH International Holdings LLC Delaware
Fuji Partnership Japan
10
-- 189 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
G & M Procter Limited Scotland
G V Instruments Limited England
General Scientific Company Sdn Bhd (M) Malaysia
Ginkgo Parc SA Belgium
Gold Cattle Standard Testing Labs, Inc. Texas
Golden West Indemnity Company Limited Bermuda
Goring Kerr Detection Limited England
Greenbird Limited Cyprus
GV Instruments Inc Delaware
Hangar 215, Inc. Delaware
Health iQ Limited England
HealthUnlocked Holdings Limited England
Helmet Securities Limited England
Henogen SRL Belgium
HighChem s.r.o. Slovakia
Hybaid Limited England
HyClone International Trade (Tianjin) Co., Ltd China
I.Q. (BIO) Limited England
Indigo Merger Subsidiary Inc. Delaware
Inel Inc. Delaware
Inel SAS France
InnaPhase Limited England
IntegenX Ltd England
IntegenX, Inc. California
Intrinsic BioProbes, Inc. Arizona
Invitrogen (Shanghai) Investment Co., Ltd. China
Invitrogen Argentina SA Argentina
Invitrogen BioServices India Private Limited India
Invitrogen Europe Limited Scotland
Invitrogen Finance Corporation Delaware
Invitrogen Holdings Limited Scotland
Invitrogen Holdings LLC Delaware
11
-- 190 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Invitrogen Hong Kong Limited Hong Kong
Invitrogen IP Holdings, Inc. Delaware
Invitrogen Trading (Shanghai) Co., Ltd. China
Ion Torrent Systems, Inc. Delaware
Jaguar (Barbados) Finance SRL Barbados
Jaguar Holding Company I, LLC Delaware
Jaguar Holding Company II Delaware
Jouan Limited England
Jouan LLC Delaware
Kendro Containment & Services Limited England
Kendro Laboratory Products Ltd England
Kettlebrook Insurance Co. ltd. Hawaii
Kyle Jordan Investments LLC Delaware
Lab-Chrom-Pack LLC New York
Lab-Line Instruments, Inc. Delaware
Labomex MBP, S. de R. L. De C.V. Mexico
Laboratoire Service International - L.S.I France
Laboratory Management Systems, Inc. Delaware
Laboratory Specialties Proprietary Ltd. South Africa
LambTrack Limited England
La-Pha-Pack GmbH Germany
Laser Analytical Systems, Inc. California
Liberty Lane Investment LLC Delaware
Liberty Lane Real Estate Holding Company LLC Delaware
Life Sciences International Holdings BV Netherlands
Life Sciences International Limited England
Life Sciences International LLC Delaware
Life Technologies AS Norway
Life Technologies BPD UK Limited England
Life Technologies Brasil Comercio e Industria de Produtos para Biotecnologia Ltda Brazil
Life Technologies Chile SpA Chile
Life Technologies Clinical Services Lab, Inc. Delaware
12
-- 191 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Life Technologies Co., Ltd. Taiwan
Life Technologies Corporation Delaware
Life Technologies Czech Republic s.r.o. Czech Republic
Life Technologies Europe B.V. Netherlands
Life Technologies Finance Ltd. Scotland
Life Technologies GmbH Germany
Life Technologies Holdings PTE Ltd. Singapore
Life Technologies Inc. Canada
Life Technologies Japan Ltd. Japan
Life Technologies Limited Scotland
Life Technologies Limited Hong Kong
Life Technologies Magyarorszag Kft Hungary
Life Technologies Norway Investments US LLC Delaware
Life Technologies Polska Sp z.o.o. Poland
Life Technologies s.r.o Slovakia
Life Technologies SA Spain
Life Technologies SAS France
Limited Liability Company Contract Research Organisation Innopharm Ukraine
Limited Liability Company PPD Development (Smolensk) Russia
LLC PPD Ukraine Ukraine
Loftus Furnace Company Pennsylvania
Lomb Scientific (Aust) Pty Limited Australia
LTC Tech South Africa PTY Ltd. South Africa
Marketbase International Limited Hong Kong
MarqMetrix, Inc Washington
Matrix MicroScience Inc. Delaware
Matrix Microscience Limited England
Matrix Technologies Corporation Limited England
Matrix Technologies LLC Delaware
Maybridge Chemical Holdings Limited England
Maybridge Limited England
Medical Analysis Systems International, Inc. California
13
-- 192 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Medical Analysis Systems, Inc. Delaware
Medical Centre Synexus Sofia EOOD Bulgaria
Medical Diagnostics Systems, Inc. California
MediciGroup, Inc. Pennsylvania
Medimix Latam Pesquisa de Mercado Ltda Brazil
Mesa Biotech LLC Delaware
Metavac LLC Delaware
Microgenics B.V. & Co. KG Germany
Microgenics Corporation Delaware
MLS ACQ, Inc. Delaware
Molecular BioProducts, Inc. California
Molecular Probes, Inc. Oregon
Molecular Transfer, Inc. Delaware
Nalge Nunc International (Monterrey) LLC Delaware
Nalge Nunc International Corporation Delaware
NanoDrop Technologies LLC Delaware
NAPCO, Inc. Connecticut
National Scientific Company Wisconsin
Navaho Acquisition Corp. Delaware
NERL Diagnostics LLC Wisconsin
NeuroHealth, Inc. Florida
New FS Holdings Inc. Delaware
NewcoGen PE, LLC Delaware
Niton Asia Limited Hong Kong
NovaWave Technologies, Inc. California
Nunc A/S Denmark
Odyssey Holdings Corporation Delaware
Odyssey Holdings LLC Delaware
Odyssey Luxembourg IP Holdings 1 S.à r.l. Luxembourg
Odyssey Luxembourg IP Holdings 2 S.à r.l. Luxembourg
Odyssey Venture Corporation Delaware
Oncomine India Private Limited India
14
-- 193 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Oncomine K.K. Japan
Oncomine Limited England
Oncomine LLC Delaware
Oncomine Molecular Inc. Delaware
Oncomine Molecular, S.L Spain
Oncomine Pte. Ltd Singapore
Oncomine S.r.l Italy
Oncomine ULC Canada
One Lambda, Inc California
Onix Holdings Limited England
ONIX Systems Inc. Delaware
Optimal Research, LLC Maryland
Orion Acquisition AB Sweden
Owl Separation Systems LLC Wisconsin
Oxoid (ELY) Limited England
Oxoid 2000 Limited England
Oxoid Australia Pty. Limited Australia
Oxoid Company Canada
Oxoid Deutschland GmbH Germany
Oxoid Holding SAS France
Oxoid Holdings Limited England
Oxoid Inc. Delaware
Oxoid International Limited England
Oxoid Investments GmbH Germany
Oxoid Limited England
Oxoid Limited Ireland
Oxoid NV Belgium
Oxoid Pension Trustees Limited England
Oxoid Senior Holdings Limited England
Oxoid UKH LLC Delaware
Pacific Rim Far East Industries LLC Delaware
Pacific Rim Investment, LLC Delaware
15
-- 194 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Panomics, L.L.C. California
Pasteur U.S. Corporation Delaware
Patheon API Inc. South Carolina
Patheon API Manufacturing Inc. South Carolina
Patheon API Services Inc. South Carolina
Patheon Austria GmbH & Co. KG Austria
Patheon B.V. Netherlands
Patheon Banner U.S. Holdings Inc. Delaware
Patheon Biologics (NJ) LLC Delaware
Patheon Biologics Australia Pty Ltd Australia
Patheon Biologics B.V. Netherlands
Patheon Biologics LLC Delaware
Patheon Calculus Merger LLC Delaware
Patheon Development Services Inc. Delaware
Patheon France SAS France
Patheon Holdings B.V. Netherlands
Patheon Holdings I B.V. Netherlands
Patheon Holdings II B.V. Netherlands
Patheon Holdings SAS France
Patheon I B.V. Netherlands
Patheon I Holding GmbH Austria
Patheon Inc. Canada
Patheon Italia S.p.A. Italy
Patheon KK Japan
Patheon Life Science Products International GmbH Austria
Patheon Logistics Switzerland GmbH Switzerland
Patheon Manufacturing Services LLC Delaware
Patheon Pharmaceuticals Inc. Delaware
Patheon Pharmaceuticals Services Inc. Delaware
Patheon Puerto Rico Acquisitions Corporation Puerto Rico
Patheon Puerto Rico, Inc. Puerto Rico
Patheon Regensburg GmbH Germany
16
-- 195 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Patheon Softgels B.V. Netherlands
Patheon Softgels Inc. Delaware
Patheon U.S. Holdings Inc. Delaware
Patheon U.S. Holdings LLC Delaware
Patheon UK Limited England
Patheon UK Pension Trustees Limited England
PAX – DSI Acquisition LLC Delaware
Pelican Acquisition Corporation Delaware
PeproTech Asia Ltd Israel
PeproTech BioTech (Suzhou) Co., Ltd. China
PeproTech EC Ltd. England
PeproTech France France
PeproTech GmbH Germany
PeproTech Korea Korea
PeproTech, Inc. New Jersey
Perbio Science (Canada) Company Canada
Perbio Science AB Sweden
Perbio Science France SAS France
Perbio Science International Netherlands B.V. Netherlands
Perbio Science Sweden Holdings AB Sweden
Perbio Science UK Limited England
Perbio Science, Inc. Delaware
Percivia LLC Delaware
Phadia AB Sweden
Phadia Diagnosticos Ltda Brazil
Phadia GmbH Germany
Phadia Holding AB Sweden
Phadia International Holdings LP England
Phadia International LLC Delaware
Phadia Real Property AB Sweden
Phadia s.r.o. Czech Republic
Phadia Taiwan Inc. Taiwan
17
-- 196 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Phadia US Inc. Delaware
Phadia US Market Holdings LLC Delaware
Pharmacaps Mexicana S.A. de C.V. Mexico
Pharmaceutical Product Development South Africa (Proprietary) Ltd South Africa
Pharmaceutical Product Development Spain SL Spain
Pharmaceutical Product Development, LLC Delaware
Pharmaco Investments, Inc. Delaware
PharmaFluidics NV Belgium
Phitonex, Inc. North Carolina
picoSpin, LLC Colorado
Pierce Biotechnology, Inc. Delaware
Pierce Milwaukee Holding Corp. Delaware
Pierce Milwaukee, Inc. Delaware
Power Sweden Holdings I AB Sweden
Power Sweden Holdings II AB Sweden
PPD (Netherlands) B.V. Netherlands
PPD (Netherlands) LLC Delaware
PPD Aeronautics Corporation Delaware
PPD Aeronautics, LLC North Carolina
PPD Argentina S.A. Argentina
PPD Australia Pty Limited Australia
PPD Bulgaria EOOD Bulgaria
PPD Canada Canada
PPD Colombia S.A.S Colombia
PPD CT Investments LLP England
PPD Czech Republic S.R.O. Czech Republic
PPD Development (HK) Limited Hong Kong
PPD Development (S) Pte. Ltd. Singapore
PPD Development (Thailand) Co., Ltd. Thailand
PPD Development Ireland Limited Ireland
PPD Development, L.P. Delaware
PPD do Brasil- Suporte a Pesquisa Clinica Ltd Brazil
18
-- 197 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
PPD France SAS France
PPD Germany GmbH Germany
PPD Germany GmbH & Co. KG Germany
PPD Global Central Labs (S) Pte. Ltd. Singapore
PPD Global Central Labs BV Belgium
PPD Global Central Labs, LLC Kentucky
PPD Global Ltd. England
PPD GP, LLC Delaware
PPD Holdings, LLC Delaware
PPD Hrvatska d.o.o. Croatia
PPD Hungary Research and Development Ltd. Hungary
PPD International Holdings (UK) Ltd England
PPD International Holdings GmbH Germany
PPD International Holdings, Inc. y Compania Limitada Chile
PPD International Holdings, LLC Delaware
PPD International Investments Limited England
PPD Investigator Services, LLC Delaware
PPD Italy S.r.l Italy
PPD Laboratories (Suzhou) Co., Ltd. China
PPD Latvia SIA Latvia
PPD Mexico S.A. de C.V. Mexico
PPD Netherlands International LLC Delaware
PPD Peru S.A.C. Peru
PPD Pharmaceutical Development (Beijing) Co., Ltd. China
PPD Pharmaceutical Development India Private Limited India
PPD Pharmaceutical Development Japan K.K. Japan
PPD Pharmaceutical Development Philippines Corp. Philippines
PPD Pharmaceutical Development Vietnam Company Limited Vietnam
PPD Poland Sp.Z o.o. Poland
PPD Romania SRL Romania
PPD Scandinavia AB Sweden
PPD Serbia D.O.O. Beograd Serbia
19
-- 198 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
PPD Services, Inc. North Carolina
PPD Slovak Republic s.r.o. Slovak Republic
PPD Switzerland GmbH Switzerland
PPD UK Holdings Limited England
PPD Vaccines and Biologics, LLC Pennsylvania
PPD, Inc. Delaware
PPD-SNBL K.K. Japan
Pregistry Holdings Limited England
Pregistry, LLC Delaware
Princeton Gamma-Tech Instruments LLC Delaware
Prionics France SAS France
Prionics Lelystad B.V. Netherlands
Prionics USA Inc. Delaware
Priority Air Express Pte. Ltd. Singapore
Priority Air Express UK Limited England
Priority Air Express, LLC Delaware
Priority Air Holdings Corp Delaware
Proxeon Biosystems ApS Denmark
Quebec B.V. Netherlands
Quebec Court B.V. Netherlands
Remel Europe Limited England
Remel Inc. Wisconsin
REP GBP I-B Blocker, Inc. Delaware
River Ventures, LLC North Carolina
Robbins Scientific LLC California
Robocon Labor- und Industrieroboter Gesellschaft m.b.H Austria
S.C.I. du 10 rue Dugay Trouin France
Samco Scientific (Monterrey) LLC Delaware
Samco Scientific LLC Delaware
Saroph Sweden AB Sweden
Schantz Road LLC Pennsylvania
SCI Inno 92 France
20
-- 199 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Seradyn Inc. Delaware
Shanghai Life Technologies Biotechnology Co. Limited China
Shanghai Thermo Fisher (C-I) Trading Co. Ltd China
Shanghai Thermo Fisher (S) Trading Co. Ltd China
Shorecloud Corporation Philippines
Southern Trials (Pty) Ltd. South Africa
Specialty (SMI) Inc. California
Spectra-Physics AB Sweden
Spectra-Physics Holdings Limited England
Spectra-Physics Holdings USA, LLC Delaware
Staten Island Cogeneration Corporation New York
STC Bio Manufacturing, Inc. Illinois
Sterilin Limited England
Stokes Bio Ltd. Ireland
SwissAnalytic Group GmbH Switzerland
Synexus Bulgaria EOOD Bulgaria
Synexus Clinical Research Acquisitions Limited England
Synexus Clinical Research GmbH Germany
Synexus Clinical Research Limited England
Synexus Clinical Research Midco No1 Limited England
Synexus Clinical Research South Africa (Pty) Limited South Africa
Synexus Clinical Research Topco Limited England
Synexus Clinical Research US, Inc. Arizona
Synexus Compass, Inc. (fmr. Synarc Inc.) Delaware
Synexus Czech s.r.o. Czech Republic
Synexus Limited England
Synexus Magyarorszg Egszsggyi Szolgltat Korltolt Felelssg Trsasg Hungary
Synexus Polska Sp. Z o.o Poland
Synexus Ukraine Limited Liability Company Ukraine
SystemLink, Inc. Virginia
Systems Manufacturing Corporation Delaware
TBS Howard Hill LLC Vermont
21
-- 200 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Technology Design Solutions Pty Ltd Australia
TFLP LLC Delaware
TFS (Barbados) I Srl Barbados
TFS Brammer Holding Corporation Delaware
TFS Breda B.V. Netherlands
TFS FEI Holding LLC Delaware
TFS Group Holding I LLC Delaware
TFS Group Holding II LLC Delaware
TFS Group Holdings III LLC Delaware
TFS Group Holdings IV LLC Delaware
TFS Life Holding LLC Delaware
TFS LLC Massachusetts
TFS Singapore HK Limited Hong Kong
TFS Venture Holdings I LLC Delaware
TFS Venture Holdings III S.C.S. Luxembourg
The Binding Site Benelux BV Belgium
The Binding Site Brasil Comercio De Produtos Para Laboratorio Ltda. Brazil
The Binding Site Corporation Limited England
The Binding Site Denmark ApS Denmark
The Binding Site France SAS France
The Binding Site GmbH Germany
The Binding Site Group (Shanghai) Trading Co., Ltd. China
The Binding Site Group Limited England
The Binding Site Group Limited Jordan
The Binding Site Holding GmbH Germany
The Binding Site Holding Inc. Delaware
The Binding Site Ireland Limited Ireland
The Binding Site KK Japan
The Binding Site Limited New Zealand
The Binding Site Portugal, Specialist Protein Company, Unip Lda Portugal
The Binding Site Pte Ltd. Singapore
The Binding Site Pty Limited Australia
22
-- 201 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
The Binding Site S. de R.L. de C.V. Mexico
The Binding Site S.r.l. Italy
The Binding Site s.r.o. Czech Republic
The Binding Site Spain (Specialist Protein Company) S.L. Spain
The Binding Site VT, Inc. Vermont
The Binding Site, Inc. California
The Compass Clinic, LLC Florida
The Nettleton Gate Limited England
The Thermo Fisher Scientific Phambili Trust South Africa
Thermedics Detection de Argentina S.R.L Argentina
Thermo Asset Management Services Inc. Delaware
Thermo BioAnalysis Limited England
Thermo BioAnalysis LLC Delaware
Thermo BioSciences Holdings LLC Delaware
Thermo Cambridge Limited England
Thermo Cayman Holdings Ltd. Cayman Islands
Thermo CIDTEC Inc. New York
Thermo CN Luxembourg LLC Delaware
Thermo Corporation Delaware
Thermo CRS Holdings Ltd. Canada
Thermo CRS Ltd. Canada
Thermo Detection de Mexico S. de R.L. de C.V. Mexico
Thermo DMA Inc. Texas
Thermo Eberline Holdings I LLC Delaware
Thermo Eberline Holdings II LLC Delaware
Thermo Eberline LLC Delaware
Thermo EGS Gauging LLC Delaware
Thermo Electron (Calgary) Limited Canada
Thermo Electron (Chile) S.p.A. Chile
Thermo Electron (Karlsruhe) GmbH Germany
Thermo Electron (Management Services) Limited England
Thermo Electron (Proprietary) Limited South Africa
23
-- 202 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Electron A/S Denmark
Thermo Electron Australia Pty Limited Australia
Thermo Electron Export Inc. Barbados
Thermo Electron Holdings SAS France
Thermo Electron Industries France
Thermo Electron LED GmbH Germany
Thermo Electron LED S.A.S. France
Thermo Electron Limited England
Thermo Electron Manufacturing Limited England
Thermo Electron Metallurgical Services, Inc. Texas
Thermo Electron North America LLC Delaware
Thermo Electron Pension Trust GmbH Germany
Thermo Electron Puerto Rico, Inc. Puerto Rico
Thermo Electron SAS France
Thermo Electron Scientific Instruments LLC Delaware
Thermo Electron Sweden AB Sweden
Thermo Electron Sweden Forvaltning AB Sweden
Thermo Electron Weighing & Inspection Limited England
Thermo Environmental Instruments LLC California
Thermo Finland Holdings MT1 B.V. Netherlands
Thermo Finland Holdings MT2 B.V. Netherlands
Thermo Finnigan LLC Delaware
Thermo Fisher (Cayman) Holdings I Ltd. Cayman Islands
Thermo Fisher (Cayman) Holdings II Ltd. Cayman Islands
Thermo Fisher (China) Analytical Ltd. China
Thermo Fisher (CN) Luxembourg Holding S.a.r.l.
[Domesticated in the State of Delaware under the name of Thermo Fisher (CN) Luxembourg Holding
S.a.r.l. LLC]
Luxembourg
Thermo Fisher (CN) Luxembourg S.a.r.l. Luxembourg
Thermo Fisher (CN) Malta Holdings Limited Malta
Thermo Fisher (CN-I) Luxembourg LLC Delaware
Thermo Fisher (CN-II) Luxembourg LLC Delaware
Thermo Fisher (FEI) Ireland Ltd Ireland
Thermo Fisher (Gibraltar) II Limited Gibraltar
24
-- 203 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher (Gibraltar) Limited Gibraltar
Thermo Fisher (Heysham) Limited England
Thermo Fisher (Kandel) GmbH Germany
Thermo Fisher Biopharma Services (Hangzhou) Ltd. China
Thermo Fisher Biopharma Services Pte. Ltd. Singapore
Thermo Fisher Bioprocessing Research and Development (Shanghai) Co., Ltd. China
Thermo Fisher China Business Trust China
Thermo Fisher CHK Holding LLC Delaware
Thermo Fisher Clinical Switzerland Holding LLC Delaware
Thermo Fisher CM II LLC Delaware
Thermo Fisher Detection Mexico LLC Delaware
Thermo Fisher Diagnostics (Ireland) Limited Ireland
Thermo Fisher Diagnostics AB Sweden
Thermo Fisher Diagnostics AG Switzerland
Thermo Fisher Diagnostics Aps Denmark
Thermo Fisher Diagnostics AS Norway
Thermo Fisher Diagnostics Austria GmbH Austria
Thermo Fisher Diagnostics B.V. Netherlands
Thermo Fisher Diagnostics CZ s.r.o. Czech Republic
Thermo Fisher Diagnostics GmbH Germany
Thermo Fisher Diagnostics K.K. Japan
Thermo Fisher Diagnostics Limited England
Thermo Fisher Diagnostics NV Belgium
Thermo Fisher Diagnostics Oy Finland
Thermo Fisher Diagnostics S.p.A. Italy
Thermo Fisher Diagnostics SAS France
Thermo Fisher Diagnostics sp. z o.o Poland
Thermo Fisher Diagnostics, S.L.U. Spain
Thermo Fisher Diagnostics, Sociedade Unipessoal Lda Portugal
Thermo Fisher Electronic Technology Research and Development (Shanghai) Co., Ltd China
Thermo Fisher Eurobonds Ltd. Cayman Islands
Thermo Fisher Financial Services B.V. Netherlands
25
-- 204 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Financial Services Inc. Delaware
Thermo Fisher German Holdings LLC Delaware
Thermo Fisher Germany B.V. Netherlands
Thermo Fisher GP LLC Delaware
Thermo Fisher India Holding B.V. Netherlands
Thermo Fisher Insurance Holdings Inc. Delaware
Thermo Fisher Insurance Holdings LLC Delaware
Thermo Fisher Investments (Cayman) LLC Delaware
Thermo Fisher Investments (Cayman) Ltd. Cayman Islands
Thermo Fisher Israel Ltd. Israel
Thermo Fisher Project Cyprus LLC Delaware
Thermo Fisher RE I Corporation Delaware
Thermo Fisher RE II Corporation Delaware
Thermo Fisher Scientific (Asheville) LLC Delaware
Thermo Fisher Scientific (Breda) Holding BV Netherlands
Thermo Fisher Scientific (Bremen) GmbH Germany
Thermo Fisher Scientific (Cayman) LLC Delaware
Thermo Fisher Scientific (CH EQ) LLC Delaware
Thermo Fisher Scientific (CH) 1 LLC Delaware
Thermo Fisher Scientific (CH) 2 LLC Delaware
Thermo Fisher Scientific (China) Co., Ltd. China
Thermo Fisher Scientific (China) Holding Limited England
Thermo Fisher Scientific (China-HK) Holding Limited Hong Kong
Thermo Fisher Scientific (CP1) Limited England
Thermo Fisher Scientific (CP2) Limited England
Thermo Fisher Scientific (DE) Holding S.a.r.l. Luxembourg
Thermo Fisher Scientific (DPI) Limited Partnership Canada
Thermo Fisher Scientific (Ecublens) SARL Switzerland
Thermo Fisher Scientific (FCS) Holding LLC Delaware
Thermo Fisher Scientific (Finance I) B.V. Netherlands
Thermo Fisher Scientific (Finance I) S.a.r.l. Luxembourg
Thermo Fisher Scientific (Finance II) S.a.r.l. Luxembourg
26
-- 205 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific (Finance III) LLC Delaware
Thermo Fisher Scientific (Finance III) S.a.r.l. Luxembourg
Thermo Fisher Scientific (Fuji) LLC Delaware
Thermo Fisher Scientific (Guangzhou) Biotechnology Co., Ltd. China
Thermo Fisher Scientific (Guangzhou) Co., Ltd China
Thermo Fisher Scientific (Holding II) B.V. & Co. KG Germany
Thermo Fisher Scientific (Hong Kong) Limited Hong Kong
Thermo Fisher Scientific (IVGN) B.V. Netherlands
Thermo Fisher Scientific (IVGN) Holding LLC Delaware
Thermo Fisher Scientific (IVGN) Limited Hong Kong
Thermo Fisher Scientific (IVGN) Luxembourg S.a.r.l. Luxembourg
Thermo Fisher Scientific (Johannesburg) (Proprietary) Limited South Africa
Thermo Fisher Scientific (Luxembourg) II Holdings S.a.r.l. Luxembourg
Thermo Fisher Scientific (Luxembourg) II S.a.r.l. Luxembourg
Thermo Fisher Scientific (Mexico City) LLC Delaware
Thermo Fisher Scientific (Milwaukee) LLC Delaware
Thermo Fisher Scientific (Mississauga) Inc. Canada
Thermo Fisher Scientific (Monterrey), S. De R.L. De C.V. Mexico
Thermo Fisher Scientific (NK) LLC Delaware
Thermo Fisher Scientific (OLI) 1 Limited England
Thermo Fisher Scientific (OLI) 2 Limited England
Thermo Fisher Scientific (OLI) 3 Limited England
Thermo Fisher Scientific (OLI) 3 LLC Delaware
Thermo Fisher Scientific (OLI) Limited England
Thermo Fisher Scientific (OLI) LLC Delaware
Thermo Fisher Scientific (OLI) LP Canada
Thermo Fisher Scientific (OLI) UK Limited England
Thermo Fisher Scientific (Panama) B.V. Netherlands
Thermo Fisher Scientific (Panama) Dutch LLC Delaware
Thermo Fisher Scientific (Panama) II B.V. Netherlands
Thermo Fisher Scientific (PN) UK Limited Partnership England
Thermo Fisher Scientific (PN) UK LLC Delaware
27
-- 206 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific (PN1) UK Ltd England
Thermo Fisher Scientific (PN-I) SRL Barbados
Thermo Fisher Scientific (PN-II) SRL Barbados
Thermo Fisher Scientific (PN-III) SRL Barbados
Thermo Fisher Scientific (Praha) s.r.o. Czech Republic
Thermo Fisher Scientific (Real Estate 1) GmbH & Co. KG Germany
Thermo Fisher Scientific (Real Estate 1) S.a.r.l. Luxembourg
Thermo Fisher Scientific (Schweiz) AG Switzerland
Thermo Fisher Scientific (Shanghai) Instruments Co., Ltd. China
Thermo Fisher Scientific (Shanghai) Management Co., Ltd. China
Thermo Fisher Scientific (Shanghai) Supply Chain Management Co., Ltd China
Thermo Fisher Scientific (Suzhou) Instruments Co., Ltd China
Thermo Fisher Scientific (Suzhou) Research and Development Co., Ltd. China
Thermo Fisher Scientific (Thailand) Co., Ltd. Thailand
Thermo Fisher Scientific Africa Proprietary Ltd South Africa
Thermo Fisher Scientific AL-1 LLC Delaware
Thermo Fisher Scientific Aquasensors LLC Delaware
Thermo Fisher Scientific Asset Management 1 GmbH Germany
Thermo Fisher Scientific Asset Management 2 GmbH Germany
Thermo Fisher Scientific AU C.V. Netherlands
Thermo Fisher Scientific AU II Limited England
Thermo Fisher Scientific AU Limited England
Thermo Fisher Scientific AU LLC Delaware
Thermo Fisher Scientific Australia Pty Ltd Australia
Thermo Fisher Scientific B.V. Netherlands
Thermo Fisher Scientific Baltics UAB Lithuania
Thermo Fisher Scientific Beteiligungsverwaltungs GmbH Germany
Thermo Fisher Scientific BHK (I) Limited Hong Kong
Thermo Fisher Scientific BHK (II) Limited Hong Kong
Thermo Fisher Scientific Biosciences Corp. Canada
Thermo Fisher Scientific Blade I Limited England
Thermo Fisher Scientific Blade II Limited England
28
-- 207 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific Blade III Limited England
Thermo Fisher Scientific Blade IV Limited England
Thermo Fisher Scientific Blade V Limited England
Thermo Fisher Scientific Blade VI Limited England
Thermo Fisher Scientific Blade VII Limited England
Thermo Fisher Scientific BLG Limited England
Thermo Fisher Scientific Brahms LLC Delaware
Thermo Fisher Scientific Brasil Instrumentos de Processo Ltda. Brazil
Thermo Fisher Scientific Brasil Serviços de Logística Ltda Brazil
Thermo Fisher Scientific Brno s.r.o. Czech Republic
Thermo Fisher Scientific Brussels BV Belgium
Thermo Fisher Scientific BV Belgium
Thermo Fisher Scientific C.F. GmbH Germany
Thermo Fisher Scientific C.V. Netherlands
Thermo Fisher Scientific Canada Financing 1 ULC Canada
Thermo Fisher Scientific Canada Financing 2 ULC Canada
Thermo Fisher Scientific Canada Holdings LLC Delaware
Thermo Fisher Scientific Cayman Investments LLC Delaware
Thermo Fisher Scientific Chemicals Inc. Delaware
Thermo Fisher Scientific China (C-I) LLC Delaware
Thermo Fisher Scientific China (S) LLC Delaware
Thermo Fisher Scientific China Holdings I B.V. Netherlands
Thermo Fisher Scientific China Holdings II B.V. Netherlands
Thermo Fisher Scientific China Holdings III B.V. Netherlands
Thermo Fisher Scientific China Holdings IV B.V. Netherlands
Thermo Fisher Scientific CHK Senior Holdings LLC Delaware
Thermo Fisher Scientific CHN Holding Limited England
Thermo Fisher Scientific Chromatography Holdings Aps Denmark
Thermo Fisher Scientific Chromatography Holdings S.à r.l. Luxembourg
Thermo Fisher Scientific Clinical Services Ireland Limited Ireland
Thermo Fisher Scientific CMN LLC Delaware
Thermo Fisher Scientific CN Holding LLC Delaware
29
-- 208 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific Colombia S.A.S. Colombia
Thermo Fisher Scientific Cork Ltd Ireland
Thermo Fisher Scientific Cyprus I Ltd Cayman Islands
Thermo Fisher Scientific Cyprus II Ltd Cayman Islands
Thermo Fisher Scientific Cyprus III Ltd Cayman Islands
Thermo Fisher Scientific Denmark Senior Holdings ApS Denmark
Thermo Fisher Scientific Dutch Holdings B.V. Netherlands
Thermo Fisher Scientific Dutch Holdings II B.V. Netherlands
Thermo Fisher Scientific Dutch Senior Holdings B.V. Netherlands
Thermo Fisher Scientific eCommerce Solutions, LLC Delaware
Thermo Fisher Scientific EMEA Limited Ireland
Thermo Fisher Scientific Erie 1 Financing (Barbados) SRL Barbados
Thermo Fisher Scientific Erie Financing (Barbados) SRL Barbados
Thermo Fisher Scientific Erie Financing S.a r.l Luxembourg
Thermo Fisher Scientific Falcon Senior Holdings Inc. Delaware
Thermo Fisher Scientific FCS Limited England
Thermo Fisher Scientific FCS Switzerland Holdings GmbH Switzerland
Thermo Fisher Scientific Flagship I LLC Delaware
Thermo Fisher Scientific Flagship II LLC Delaware
Thermo Fisher Scientific FLC B.V. Netherlands
Thermo Fisher Scientific FLC Hong Kong Limited Hong Kong
Thermo Fisher Scientific FLC II B.V.
[Domesticated in the State of Delaware under the name of Thermo Fisher Scientific FLC II B.V.] Netherlands
Thermo Fisher Scientific FLC LLC Delaware
Thermo Fisher Scientific FSIR Financing (Barbados) SRL Barbados
Thermo Fisher Scientific FSIR Financing S.a.r.l. Luxembourg
Thermo Fisher Scientific FSIR Holdings (UK) Financing Limited England
Thermo Fisher Scientific FSUKHCO Financing (Barbados) SRL Barbados
Thermo Fisher Scientific GCL Limited England
Thermo Fisher Scientific GCL LLC Delaware
Thermo Fisher Scientific GCL2 Limited Delaware
Thermo Fisher Scientific GENEART GmbH Germany
Thermo Fisher Scientific Germany BV & Co. KG Germany
30
-- 209 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific GmbH Germany
Thermo Fisher Scientific Holdings (Cayman) I Cayman Islands
Thermo Fisher Scientific Holdings (Cayman) II Cayman Islands
Thermo Fisher Scientific Holdings Europe Limited England
Thermo Fisher Scientific HR Services Mexico, S. de R.L. de C.V. Mexico
Thermo Fisher Scientific India Holding LLC Delaware
Thermo Fisher Scientific India Pvt Ltd India
Thermo Fisher Scientific Investments (Luxembourg) II S.a.r.l. Luxembourg
Thermo Fisher Scientific Investments (Luxembourg) S.a.r.l. Luxembourg
Thermo Fisher Scientific Investments (Sweden) II LLC Delaware
Thermo Fisher Scientific Investments (Sweden) S.a.r.l. Luxembourg
Thermo Fisher Scientific Invitrogen Financing (Barbados) SRL Barbados
Thermo Fisher Scientific Invitrogen Holding 2 LLC Delaware
Thermo Fisher Scientific IT Services GmbH Germany
Thermo Fisher Scientific Japan 1 LLC Delaware
Thermo Fisher Scientific Japan 2 LLC Delaware
Thermo Fisher Scientific Japan Holdings I B.V. Netherlands
Thermo Fisher Scientific Japan Holdings I LLC Delaware
Thermo Fisher Scientific Japan Holdings I LP Delaware
Thermo Fisher Scientific Japan Holdings II B.V. Netherlands
Thermo Fisher Scientific Japan Holdings II LLC Delaware
Thermo Fisher Scientific Japan Holdings II LP Delaware
Thermo Fisher Scientific Japan Holdings III B.V. Netherlands
Thermo Fisher Scientific Japan Holdings III LLC Delaware
Thermo Fisher Scientific Japan Holdings IV LLC Delaware
Thermo Fisher Scientific Japan Holdings V LLC Delaware
Thermo Fisher Scientific K.K. Japan
Thermo Fisher Scientific Korea Ltd. Korea
Thermo Fisher Scientific Life Canada Holding ULC Canada
Thermo Fisher Scientific Life Financing (Barbados) SRL Barbados
Thermo Fisher Scientific Life Financing (Cayman) Cayman Islands
Thermo Fisher Scientific Life Financing 2 Limited England
31
-- 210 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific Life Financing Limited England
Thermo Fisher Scientific Life Holding MRP LLC Delaware
Thermo Fisher Scientific Life Holdings 1 Limited England
Thermo Fisher Scientific Life Holdings 2 Limited England
Thermo Fisher Scientific Life Holdings III C.V. LLC Delaware
Thermo Fisher Scientific Life Holdings Limited England
Thermo Fisher Scientific Life International Holdings II LP England
Thermo Fisher Scientific Life Investments II S.à r.l. Luxembourg
Thermo Fisher Scientific Life Investments IV S.a.r.l Luxembourg
Thermo Fisher Scientific Life Investments US Financing I LLC Delaware
Thermo Fisher Scientific Life Investments US Financing II LLC Delaware
Thermo Fisher Scientific Life Sciences COE Corporation Delaware
Thermo Fisher Scientific Life Senior Holdings MRP LLC Delaware
Thermo Fisher Scientific Life Senior Holdings, Inc. Delaware
Thermo Fisher Scientific Life Tech Korea Holdings LLC Delaware
Thermo Fisher Scientific Life Technologies Enterprise Holding Limited England
Thermo Fisher Scientific Life Technologies Investment I LLC Delaware
Thermo Fisher Scientific Life Technologies Investment II LLC Delaware
Thermo Fisher Scientific Life Technologies Investment UK I Limited England
Thermo Fisher Scientific Life Technologies Investment UK II Limited England
Thermo Fisher Scientific Life Technologies Israel Investment I Limited England
Thermo Fisher Scientific Life Technologies Israel Investment II Limited England
Thermo Fisher Scientific Life Technologies Luxembourg Holding LLC Delaware
Thermo Fisher Scientific Life UK Holdings 2 LP England
Thermo Fisher Scientific Life UK Holdings LP England
Thermo Fisher Scientific LSI Financing (Barbados) SRL Barbados
Thermo Fisher Scientific Luxembourg Enterprise Holdings S.à r.l. Luxembourg
Thermo Fisher Scientific Luxembourg German Holdings S.a.r.l. Luxembourg
Thermo Fisher Scientific Luxembourg Life Technologies UK Holding S.à r.l Luxembourg
Thermo Fisher Scientific Luxembourg Sweden Holdings I S.à r.l Luxembourg
Thermo Fisher Scientific Luxembourg Sweden Holdings II S.à r.l. Luxembourg
Thermo Fisher Scientific Luxembourg Venture Holdings I S.a.r.l. Luxembourg
32
-- 211 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific Luxembourg Venture Holdings II S.a.r.l. Luxembourg
Thermo Fisher Scientific Malaysia Sdn. Bhd. Malaysia
Thermo Fisher Scientific Matrix Holding Limited England
Thermo Fisher Scientific Messtechnik GmbH Germany
Thermo Fisher Scientific Middle East Holdings Inc. Delaware
Thermo Fisher Scientific Milano Srl Italy
Thermo Fisher Scientific MRP 1 LLC Delaware
Thermo Fisher Scientific New Zealand Holdings New Zealand
Thermo Fisher Scientific New Zealand Limited New Zealand
Thermo Fisher Scientific NHK Limited Hong Kong
Thermo Fisher Scientific Norway Holdings AS Norway
Thermo Fisher Scientific Norway Senior Holding AS Norway
Thermo Fisher Scientific Norway US Investments LLC Delaware
Thermo Fisher Scientific Odyssey Financing (Barbados) SRL Barbados
Thermo Fisher Scientific Odyssey Holding LLC Delaware
Thermo Fisher Scientific Odyssey Holdings Limited England
Thermo Fisher Scientific One Limited England
Thermo Fisher Scientific Operating Company LLC Delaware
Thermo Fisher Scientific Oy Finland
Thermo Fisher Scientific Pakistan (Private) Limited Pakistan
Thermo Fisher Scientific Panama I Cayman Ltd Cayman Islands
Thermo Fisher Scientific Peprotech Holding LLC Delaware
Thermo Fisher Scientific Peru S.R.L. Peru
Thermo Fisher Scientific PN LLC Delaware
Thermo Fisher Scientific PN2 (Luxembourg) S.à.r.l Luxembourg
Thermo Fisher Scientific PN2 C.V Netherlands
Thermo Fisher Scientific PN2 LLC Delaware
Thermo Fisher Scientific PNM Limited Liability Partnership England
Thermo Fisher Scientific PNM S.a.r.l Luxembourg
Thermo Fisher Scientific Powder Finance LLC Delaware
Thermo Fisher Scientific Powder Financing 2 LLC Delaware
Thermo Fisher Scientific Powder Holdings 4 LLC Delaware
33
-- 212 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific Powder Holdings I Cayman Islands
Thermo Fisher Scientific Powder Holdings II Cayman Islands
Thermo Fisher Scientific Powder Holdings III Cayman Islands
Thermo Fisher Scientific Powder Holdings IV Cayman Islands
Thermo Fisher Scientific Powder LLC Delaware
Thermo Fisher Scientific Powder SRL Barbados
Thermo Fisher Scientific Powder UK Holdings Limited England
Thermo Fisher Scientific Powder UK Senior Holdings Limited England
Thermo Fisher Scientific Powder US Holdings Corp. Delaware
Thermo Fisher Scientific Powder US Holdings Limited England
Thermo Fisher Scientific PPD (OLI) LLC Delaware
Thermo Fisher Scientific PRB S.a.r.l. Luxembourg
Thermo Fisher Scientific PSG Corporation Delaware
Thermo Fisher Scientific Pte. Ltd. Singapore
Thermo Fisher Scientific Re Ltd. Bermuda
Thermo Fisher Scientific Remel Luxembourg S.a.r.l. Luxembourg
Thermo Fisher Scientific Senior Financing LLC Delaware
Thermo Fisher Scientific Senior Holdings Australia LLC Delaware
Thermo Fisher Scientific Senior Holdings LP Canada
Thermo Fisher Scientific Singapore Holdings LLC Delaware
Thermo Fisher Scientific SL Spain
Thermo Fisher Scientific Solutions LLC Korea
Thermo Fisher Scientific South Africa Proprietary Ltd South Africa
Thermo Fisher Scientific SpA Italy
Thermo Fisher Scientific Spectra S.a.r.l. Luxembourg
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg I S.à r.l. Luxembourg
Thermo Fisher Scientific Spectra-Physics Holdings Luxembourg II S.à r.l. Luxembourg
Thermo Fisher Scientific Sweden 2 LLC Delaware
Thermo Fisher Scientific Sweden Holdings LLC Delaware
Thermo Fisher Scientific Sweden Holdings S.a.r.l Luxembourg
Thermo Fisher Scientific Switzerland B.V. Netherlands
Thermo Fisher Scientific Taiwan Co., Ltd. Taiwan
34
-- 213 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Fisher Scientific TDI 2 S.a.r.l. Luxembourg
Thermo Fisher Scientific TDI S.a.r.l Luxembourg
Thermo Fisher Scientific TR Limited Hong Kong
Thermo Fisher Scientific TX LLC Texas
Thermo Fisher Scientific UK Holding Company Financing Limited England
Thermo Fisher Scientific US 1 LLC Delaware
Thermo Fisher Scientific Vector Holdings 2 LLC Delaware
Thermo Fisher Scientific Vector Holdings LLC Delaware
Thermo Fisher Scientific Vector Holdings UAB Lithuania
Thermo Fisher Scientific Vector Senior Holdings I UAB Lithuania
Thermo Fisher Scientific Vector Senior Holdings II UAB Lithuania
Thermo Fisher Scientific West Palm Holdings LLC Delaware
Thermo Fisher Scientific Wissenschaftliche Geräte GmbH Austria
Thermo Fisher Scientific Worldwide Investments (Cayman) Cayman Islands
Thermo Fisher Scientific Worldwide Investments (Luxembourg) S.a.r.l. Luxembourg
Thermo Fisher Scientific Worldwide Investments LLC Delaware
Thermo Fisher Senior Canada Holdings LLC Delaware
Thermo Fisher TDI Holding LLC Delaware
Thermo FLC LP Delaware
Thermo Foundation, Inc. Massachusetts
Thermo Gamma-Metrics Holdings Pty Ltd. Australia
Thermo Gamma-Metrics LLC Delaware
Thermo Gamma-Metrics Pty Ltd Australia
Thermo Holding European Operations LLC Delaware
Thermo Hypersil-Keystone LLC Delaware
Thermo Instrument Controls de Mexico, S.A. de C.V. Mexico
Thermo Kevex X-Ray LLC Delaware
Thermo Keytek LLC Delaware
Thermo LabSystems Inc. Massachusetts
Thermo Life Science International Trading (Tianjin) Co., Ltd. China
Thermo Life Sciences AB Sweden
Thermo Luxembourg Holding S.a.r.l.
[Domesticated in the State of Delaware under the name of Thermo Luxembourg Holding LLC]
Luxembourg
35
-- 214 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo Luxembourg S.a.r.l. Luxembourg
Thermo Luxembourg U.S. S.a.r.l. Luxembourg
Thermo Measuretech Canada Inc. Canada
Thermo MF Physics LLC Delaware
Thermo Neslab LLC New Hampshire
Thermo Onix Limited England
Thermo Optek Limited England
Thermo Orion Inc. Massachusetts
Thermo Patheon Holdings LLC Delaware
Thermo Portable Holdings LLC Delaware
Thermo Power Corporation Massachusetts
Thermo Process Instruments GP, LLC Delaware
Thermo Process Instruments, L.P. Texas
Thermo Projects Limited England
Thermo Ramsey Italia S.r.l. Italy
Thermo Ramsey LLC Massachusetts
Thermo Ramsey S.A. Spain
Thermo Re, Ltd. Bermuda
Thermo Scientific Microbiology Pte Ltd. Singapore
Thermo Scientific Microbiology Sdn Bhd Malaysia
Thermo Scientific Portable Analytical Instruments Inc. Delaware
Thermo Scientific Services, Inc. California
Thermo Securities Corporation Delaware
Thermo Sentron Canada Inc. Canada
Thermo Services (Hungary) Kft Hungary
Thermo Suomi Holding B.V. Netherlands
Thermo TLH (UK) Limited England
Thermo TLH L.P. Delaware
Thermo TLH Luxembourg S.a.r.l. Luxembourg
Thermo Trace Pty Ltd. Australia
Thermo USC I LLC Delaware
Thermo USC II LLC Delaware
36
-- 215 of 225 --
NAME STATE OR JURISDICTION OF
ORGANIZATION
Thermo-Fisher Biochemical Product (Beijing) Co., Ltd. China
ThermoLase LLC Delaware
TK Partnership (aka Silent Partnership Japan
TMOI Inc. Delaware
TPI Real Estate Holdings LLC Delaware
Trek Diagnostic Systems LLC Delaware
Trek Diagnostic Systems Ltd. England
Trek Holding Company II Ltd. England
Trek Holding Company Ltd. England
Trex Medical Corporation Delaware
TSP Holdings I LLC Delaware
TWX, LLC Massachusetts
United Diagnostics, Inc. Delaware
USB Corporation Ohio
Vestrum Health Inc. Canada
Vestrum Health, LLC Delaware
VG Systems Limited England
Westover Scientific, Inc. Washington
Wildcat Acquisition Holdings (UK) Limited England
-- 216 of 225 --
Exhibit 22
Subsidiary Issuer of Guaranteed Securities
Thermo Fisher Scientific Inc. (the “Registrant”) is the guarantor of the senior secured registered notes listed below issued by Thermo Fisher Scientific
(Finance I) B.V., a wholly-owned finance subsidiary of the Registrant.
Thermo Fisher Scientific (Finance I) B.V.
0.800% Senior Notes due 2030
1.125% Senior Notes due 2033
1.625% Senior Notes due 2041
2.000% Senior Notes due 2051
0.000% Senior Notes due 2025
37
-- 217 of 225 --
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-263034) and Form S-8 (Nos. 033-51189, 033-54347,
333-188846, 333-220231, 333-261548, 333-272173, and 333-275438) of Thermo Fisher Scientific Inc. of our report dated February 22, 2024 relating to the
financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 22, 2024
-- 218 of 225 --
Exhibit 31.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Marc N. Casper, certify that:
1. I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: February 22, 2024
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
-- 219 of 225 --
Exhibit 31.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen Williamson, certify that:
1. I have reviewed this Annual Report on Form 10-K of Thermo Fisher Scientific Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal
quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the
registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely
to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over
financial reporting.
Date: February 22, 2024
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer
-- 220 of 225 --
Exhibit 32.1
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2023 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Marc N. Casper, Chairman, President and Chief Executive
Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 22, 2024
/s/ Marc N. Casper
Marc N. Casper
Chairman, President and Chief Executive Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and
will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
-- 221 of 225 --
Exhibit 32.2
THERMO FISHER SCIENTIFIC INC.
CERTIFICATION REQUIRED BY EXCHANGE ACT RULES 13a-14(b) and 15d-14(b),
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Thermo Fisher Scientific Inc. (the “Company”) for the period ended December 31, 2023 as filed
with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Stephen Williamson, Senior Vice President and Chief
Financial Officer of the Company, hereby certifies, pursuant to Securities Exchange Act of 1934 Rules 13a-14(b) and 15d-14(b), that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: February 22, 2024
/s/ Stephen Williamson
Stephen Williamson
Senior Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Thermo Fisher Scientific Inc. and
will be retained by Thermo Fisher Scientific Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
-- 222 of 225 --
Exhibit 97
Policies & Procedures
EFFECTIVE DATE: October 2, 2023
Title: CLAWBACK POLICY Supersedes: February 25, 2019 Total Pages: 3
POLICY
This Clawback Policy (this “Policy”), relates to the Company’s right to recover compensation previously paid to specified employees
in certain circumstances, including the recovery of Erroneously Awarded Compensation (as defined below) in accordance with
Section 303A.14 of the New York Stock Exchange (“NYSE”) Listed Company Manual (“Section 303A.14”), which implements Rule
10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (collectively, the “Applicable Rules”). This
Policy is effective as of October 2, 2023 (the “Effective Date”).
This Policy is applicable to current or former Executive Officers (as defined in 16a-1(f) under the Exchange Act), and such other
employees of the Company as may be determined from time to time by the Compensation Committee of the Board of Directors (the
“Committee”).
In the event the Company is required, on or after the Effective Date, to prepare an Accounting Restatement, the Company will use
reasonable efforts to recover reasonably promptly from each Covered Person, any Erroneously Awarded Compensation that was
Received by such Covered Person from the Company during the three completed fiscal years immediately preceding the date on
which the Company is required to prepare an Accounting Restatement (or such other period as may be required by Applicable
Rules in the event of a change in the Company’s fiscal year).
This Policy does not apply to Incentive-Based Compensation that was Received before the Effective Date. With respect to any
Covered Person, this Policy does not apply to Incentive--Based Compensation that was Received by such Covered Person before
beginning service as an Executive Officer.
INTERPRETATION AND ADMINISTRATION
This Policy will be interpreted in a manner that is consistent with the Applicable Rules and any other applicable law and this Policy
will otherwise be interpreted in the business judgment of the Committee. All decisions and interpretations of the Committee will be
final and binding; provided that such decisions must be consistent with the Applicable Rules.
The Company is not required to recover Erroneously Awarded Compensation under this Policy if a determination is made by the
Committee that either (A) after the Company has made and documented a reasonable attempt to recover such Erroneously
Awarded Compensation, the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be
recovered or (B) recovery of such Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement
plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)
(13) or 411(a) of the Internal Revenue Code and regulations thereunder.
-- 223 of 225 --
The Company will not indemnify any Covered Person against the loss of Erroneously Awarded Compensation and will not pay or
reimburse any Covered Person for the purchase of a third-party insurance policy to fund potential recovery obligations.
The Committee will determine the appropriate means of any recovery of Erroneously Awarded Compensation under this Policy,
which may vary between Covered Persons or based on the nature of the applicable Incentive-Based Compensation. Such recovery
may involve, establishing a deferred repayment plan, setting off against current or future compensation otherwise payable to the
Covered Person, or other appropriate means.
The Company may have other rights or remedies available to the Company under any agreement with a Covered Person (such as
an equity award agreement) or applicable law, and nothing in this Policy will limit the Company’s right to pursue these rights or
remedies.
DEFINITIONS
“Accounting Restatement” means a requirement that the Company prepare an accounting restatement due to the material
noncompliance of the Company with any financial reporting requirement under the U.S. federal securities laws, including any
required accounting restatement to correct an error in previously issued financial statements that is material to the previously
issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left
uncorrected in the current period. Changes to the Company’s financial statements that do not represent error corrections are not an
Accounting Restatement, including: (A) retrospective application of a change in accounting principle; (B) retrospective revision to
reportable segment information due to a change in the structure of the Company’s internal organization; (C) retrospective
reclassification due to a discontinued operation; (D) retrospective application of a change in reporting entity, such as from a
reorganization of entities under common control; and (E) retrospective revision for stock splits, reverse stock splits, stock dividends
or other changes in capital structure.
“Covered Person” means a person who served as an Executive Officer (and any other employee of the Company as may be
determined from time to time by the Committee as subject to this Policy) at any time during the performance period for the
applicable Incentive-Based Compensation.
“Erroneously Awarded Compensation” means the amount of Incentive-Based Compensation that was Received that exceeds
the amount of Incentive-Based Compensation that otherwise would have been Received had the amount of Incentive-Based
Compensation been determined based on the restated amounts, computed without regard to any taxes paid by the Covered
Person or by the Company on the Covered Person’s behalf. For Incentive-Based Compensation based on stock price or total
shareholder return (“TSR”), where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation
directly from the information in an Accounting Restatement, the amount of Erroneously Awarded Compensation will be based on a
reasonable estimate by the Committee of the effect of the Accounting Restatement on the stock price or TSR upon which the
Incentive-Based Compensation was Received.
“Incentive-Based Compensation” means any compensation that is granted, earned, or vested based wholly or in part upon the
attainment of (A) measures that are determined and presented in accordance with the accounting principles used in preparing the
Company’s financial statements, and any measures that are derived wholly or in part from such measures (whether or not such
measures are presented within the Company’s financial statements or included in a filing made with the U.S. Securities and
Exchange Commission), (B) stock price and (C) TSR.
2
-- 224 of 225 --
Incentive-Based Compensation is deemed to be “Received” in the Company’s fiscal period during which the financial reporting
measure specified in the applicable Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-
Based Compensation occurs after the end of that period or is subject to additional time-based vesting requirements.
3
-- 225 of 225 --